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Autontibodies  to  a  wide  variety  of  antigens  are  associated  with  systemic  lupus 
erythematosus  (SLE)  and the Antiphospholipid  Syndrome (APS).  Previous  studies 
have demonstrated the importance of somatic mutations and  arginine  residues  in 
the  complementarity  determining  regions  (CDRs)  of  pathogenic  anti-dsDNA  and 
antiphospholipid  antibodies.  This  thesis  describes  the  study  of  two  human 
monoclonal  IgG  antibodies,  B3  (anti-DNA)  and  IS4  (antiphospholipid)  that were 
derived  from  a  patient  with  active  SLE  and  primary  APS  respectively.  I  have 
demonstrated  in-vitro expression  and  mutagenesis  of B3  and  IS4  and  used  this 
expression  system to  investigate the importance of the arginine  residues  in  B3VH  
and IS4Vh. The mutant heavy chains, as well  as the wild-type VH  were expressed 
with  different  light  chains  and  the  resulting  antibodies  assessed  for  binding  to 
nucleosomes,  alpha-actinin,  cardiolipin  (CL),  phosphatidylserine  (PS),  beta-2- 
glycoprotein I (p2 GPI), and the N-terminal domain of p2 GPI (Domain I) using direct 
binding assays.
The  results  obtained  have  shown  that the  presence of arginine at  position  53  in 
B3Vh  was  essential  but  not  sufficient  for  binding  to  dsDNA  and  nucleosomes. 
Conversely,  the presence of this arginine  reduced  binding to  alpha-actinin,  p2 GPI 
and Domain I of fcGPI. The fact that the arginine to serine substitution at position 
53 in  B3Vh significantly alters binding of B3 to different clinically relevant antigens, 
but in opposite directions implies that this arginine residue plays a critical role in the 
affinity  maturation  of the antibody  B3.  Furthermore,  of  four  arginine  residues  in 
IS4Vh CDR3 substituted to serine, two at positions 100 and lOOg reduced binding to 
all  antigens,  while  two  at  positions  96  and  97  reduced  binding  to  p2 GPI  but 
increased  or decreased  binding  to  CL  and  PS.  Only  one  H/L  chain  combination 
bound  neutral  phospholipid  and  none  bound  dsDNA;  hence,  these  effects  are 
particularly  relevant to antigens important in APS. Therefore,  my findings suggest 
that these four arginine residues have developed as a  result of somatic mutations 
driven by an antigen containing both phospholipid and foGPI. These results extend 
our knowledge of the structure-function  relationship of human anti-DNA and anti­
phospholipid antibodies and aid in our understanding of how these antibodies lead 
to  pathogenicity and what we need to target in  the future for possible therapies.
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V |_  Variable domain of light chain
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One letter codes and three letter codes
Amino acid Letter code Three letter code
Alanine A GCT, GCC, GCA, GCG
Arginine R CGT, CGC, CGA, CGG, AGA, AGG
Asparagine N AAT, AAC
Aspartic acid D GAT, GAC
Cysteine C TGT, TGC
Glutamic acid E GAA, GAG
Glutamine Q CAA, CAG
Glycine G GGT, GGC, GGA, GGG
Histidine H CAT, CAC
Isoleucine I ATT, ATC, ATA
Leucine L CTT, CTC, CTA, CTG, TTA, TTG
Lysine K AAA, AAG
Methionine M ATG
Phenylalanine F TTT, TTC
Proline P CCT, CCC, CCA, CCG
Serine S TCT, TCC, TCA, TCG, AGT, AGC
Threonine T ACT, ACC, ACA, ACG
Tryptophan W TGG
Tyrosine Y TAT, TAC
Valine V GTT, GTC, GTA, GTG
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CHAPTER ONE.
INTRODUCTION
1.1  The immune system
1.1.1 Components of immunity
Immunity  is  the  body's  capability  to  repel  foreign  substances  and  cells.  The 
nonspecific component, innate immunity, is the first line of defense and consists of a 
set of disease-resistance mechanisms that are not specific to a particular pathogen. 
Nonspecific  responses  block the  entry  and  spread  of  disease-causing  agents.  In 
contrast,  the  highly  specific component,  adaptive  immunity,  is the second  line of 
defense and is adapted to an individual threat therefore displaying a high degree of 
specificity as well as the remarkable properties of "memory". Antibody-mediated and 
cell-mediated  responses are the two types  of specific  response (Roitt and  Delves, 
2002).  Unfortunately,  when  the  target  of  the  immune  response  becomes  self­
antigen,  as opposed  to foreign  antigen,  these components of the  immune  system 
may be unable to remove the antigen completely,  resulting in a sustained  immune 
response,  chronic  inflammation  and  self-tissue  damage  as  seen  in  autoimmunity. 
Autoimmune diseases are classified as organ-specific - affecting a  single organ,  or 
systemic - affecting multiple organ systems.
1.1.2 Cells of the immune system
The immune system is composed of many interdependent cell types with specialised 
functions that collectively  protect  the  body from  bacterial,  parasitic,  fungal,  viral 
infections  and  from  the  growth  of  tumor  cells.  An  effective  immune  response 
involves two major groups of cells:  lymphocytes, which arise in the bone marrow (B 
cells and T cells) and antigen-presenting cells.
1.1.2.1  B cells
The human body makes millions of different types of B cells each day, and each type 
has a unique receptor protein  [referred to as the B cell  receptor or immunoglobulin
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(Ig) or antibody] on its membrane that will  bind to one particular antigen. A mature 
B cell  leaves the bone marrow expressing  membrane-bound Ig of the IgM and IgD 
class  with  a  single  antigenic  specificity.  These  naive  B  cells,  which  have  not 
encountered antigen are circulating  in the blood and  lymph and are carried to the 
secondary lymphoid organs, most notably the spleen and  lymph  nodes. Once the B 
cell  encounters its cognate antigen, the cell  proliferates  by clonal expansion and  it 
can further differentiate to generate a population of antibody-secreting plasma cells 
and memory cells. The B cell can either directly become one of these cell types or go 
through an  intermediate differentiation step, the germinal center reaction,  in  which 
the B cell will hypermutate the variable (V) region of the antibody and possibly class 
switch. Only 10% of the potential  B cells reach maturity and exit the bone marrow. 
In the absence of antigen-induced activation, naive B cells in the periphery die within 
a few days (Goldsby et al., 2000, Janeway et al., 2001).
Plasma cells secrete antibodies, which effect the destruction of antigens by binding 
to them  and  making them  easier targets for  phagocytes.  Most  live only for a few 
days, do not express membrane bound antibody but instead produce large amounts 
of the antibody in secreted form.  Memory B cells are formed specific to the antigen 
encountered during the primary immune response and are able to live much  longer 
(Dorner  and  Radbruch,  2005).  These  cells  can  respond  quickly  upon  second 
exposure to the antigen for which they are specific, therefore expressing membrane 
bound antibody with the same specificity as their parent cell  (Goldsby et al.,  2000, 
Janeway et al., 2001).
1.1.2.2T cells
T  lymphocytes  are  usually  divided  into  two  major  subsets  that  are  functionally 
different. Both types of T cells can be found throughout the body. They often depend 
on  the secondary  lymphoid  organs (the  lymph  nodes  and  spleen)  as  sites  where 
activation occurs, but they are also found in other tissues of the body, most evidently 
the liver, lung, blood, and intestinal and reproductive tracts.
The two types of T cells are distinguished by the presence on their surface of one or 
the other of two glycoproteins designated CD4 and CD8. The T helper subset,  also 
called the CD4+ T cell, co-ordinates immune regulation. The main function of the T 
helper  cell  is  to  augment  or  potentiate  immune  responses  by  the  secretion  of 
specialised factors that activate other white blood cells to fight off infection. CD4+ T
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cells bind an epitope consisting of an antigen fragment lying in the groove of a class 
II  histocompatibility molecule. CD4+ T cells are essential for both the cell-mediated 
and antibody-mediated branches of the immune system. The T helper (Th) cells may 
be  subdivided  according  to  their  cytokine  secretion  profile.  Thl  cells  secrete 
interleukin  IL-2,  IL-3  and gamma  interferon  IFN-y  that  play  a  central  part  in  cell 
mediated immunity and acute allograft rejection.  In the cell-mediated immunity, the 
Thl  cells  bind  to  antigen  presented  by  antigen-presenting  cells  (APCs)  like 
phagocytic macrophages and dendritic cells. The T cells then  release cytokines that 
attract other cells. The Th2 cells secrete interleukin (IL)-4, IL-5, IL-6, IL-9 and IL-10, 
which  enhance  antibody  production.  The  Th2  cells  participate  in  the  antibody- 
mediated immunity where they bind to antigen presented by B cells. The result is the 
development  of clones  of  plasma  cells  secreting  antibodies  against the  antigenic 
material (Roitt and Delves, 2002).
The other important type of T cell is called the T cytotoxic (Tc) subset or CD8+ T cell. 
These cells are important in directly killing certain tumor cells, viral-infected cells and 
sometimes parasites. The Tc cells are also important in down-regulation of immune 
responses.  Under the influence of Th-derived cytokines, a Tc cell that recognises an 
antigen-Major  Histocompatibility Complex (MHC)  Class  I  molecule  proliferates  and 
differentiates  into  a  cytotoxic T  lymphocyte  (CTL)  which  does  not  secrete  many 
cytokines and  instead  exhibits cytotoxic activity.  The CTL has a  crucial  function  in 
monitoring  the  cells  of the  body  and  eliminating  any virus-infected  cells,  tumour 
cells, or cells of a foreign tissue graft (Goldsby et al., 2000, Janeway et al., 2001).
1.1.2.3  Antigen Presenting Cells
Macrophages  are  important  in  the  regulation  of  immune  responses.  They  are 
referred  to  as  antigen-presenting  cells  (APC)  because they  identify,  pick  up  and 
ingest foreign  materials and  present these antigens to  other cells  of the  immune 
system notably T cells and B cells. This action  is one of the important first steps in 
the  initiation  of an  immune  response.  Stimulated  macrophages  exhibit  increased 
levels  of  phagocytosis  and  are also  secretory.  These cells  are  part  of the  innate 
response.  Unlike T and  B cells, they do not contain any antigen specific receptors. 
Macrophages continuously phagocytose self-proteins and cells in their vicinity, during 
normal tissue  repair and  aging  (e.g.  old  red  blood cells).  All of these  proteins are 
degraded and presented with  MHC-Class II molecules. These self-proteins however,
do  not  fully  activate  T  cells,  because  in  the  absence  of  infection,  macrophages
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express  low levels  of MHC-II, and  almost no co-stimulator  (B7).  B7  molecules are 
members  of the  Ig  superfamily;  they  have  a  single  V-like  domain  and  a  single 
constant (C)-like domain. They are constitutively expressed  on  dendritic  cells  and 
induced on  activated  macrophages and activated  B cells.  In  the case of infection, 
however,  macrophages posses certain types of receptors that recognise differential 
carbohydrate patterns on foreign cells. They also have receptors for specific bacterial 
products such as LPS (endotoxin). These receptors, called Toll-like receptors (TLRs), 
are transmembrane proteins that serve as a key part of the innate immune system 
and  are also  able to  stimulate activation  of the adaptive  immune  system,  linking 
innate  and  acquired  immune  responses.  TLRs are  considered  pattern  recognition 
receptors (PRRs),  binding to pathogen-associated  molecular patterns (PAMPs) small 
molecular  sequences  consistently  found  on  pathogens.  Their  function  is  the 
recognition  of  pathogens  and  the  activation  of  immune  cell  responses  directed 
against those pathogens.  Macrophages are therefore stimulated to up-regulate MHC- 
II and  B7,  providing these cells with  strong  antigen  presentation  properties. They 
also start to secrete cytokines that aid in their functions (IL-1, 6, 8,  12 and TNFa). It 
is  at this  point  that  antigen  presentation  by  MHC  Class  II  will  activate Th  cells 
(Goldsby et al., 2000, Janeway et al., 2001).
Dendritic  cells,  which  also  originate  in  the  bone  marrow,  function  as  antigen 
presenting  cells.  These cells can  be classified  by their  location  either  in  skin  and 
mucous membranes, in the lymphoid organs such as the thymus,  lymph nodes and 
spleen, or in the bloodstream and other organs of the body. They capture antigen or 
bring  it to the lymphoid organs where an immune response is initiated. These cells 
continuously express high levels of both MHC class II molecules and co-stimulatory 
B7.  For this  reason,  they are  more potent than  macrophages and  B cells,  both  of 
which  need to  be activated  before they can function as APCs.  After recognition  of 
foreign  particles,  dendritic  cells  migrate  into the  blood  or  lymph  and  circulate  to 
various  lymphoid  organs,  where  they  present  the  antigen  to  T  lymphocytes 
(Peakman and Vergani, 1997).
1.1.3  The role of antibodies in the immune system
The  first  insights  into  the  mechanism  of  immunity  and  the  first  description  of 
antibodies were provided in  1890 by the experimental work of Emil von Behring and 
Shibasaburo Kitasato.  Antibodies are specialised  proteins produced  by plasma cells
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that  circulate  in  the  blood  recognising  and  binding  to  foreign  proteins, 
microorganisms or toxins in order to neutralise them. They are also known as Igs.
1.1.3.1  Antibody structure and function
The  basic antibody  structural  unit made of amino  acids  contains four  polypeptide 
chains (Figure  1.1). There are two heavy (H) chains (MW 50,000-70,000) and two 
light (L) chains (MW 25,000). Disulphide bonds connect each H chain to its partner L 
chain, and connect the two H chains. When individual Ig molecules of the same type 
are  compared,  some  portions  of  the  molecule  are  identical  while  others  are 
extremely variable. The V parts are the N-terminal domains of both  H and  L chains 
and  are  called  V  regions  (VH   and  VL ).  The  remainder of the  H  and  L  chains  are 
identical in all molecules of the same class and are called C regions (Ch1-Ch3 and Q.) 
(Roitt and Delves, 2002).
V  regions  form  the  antigen-binding  sites.  Antibodies  as  a  group  can  bind  many 
different antigens because there are many different kinds of V domains. The antigen- 
binding site is formed from the V domains of one H chain and one L chain. Within an 
Ig molecule, two H chains are always identical, as are the two L chains, so each Ig 
unit  has two  identical  binding  sites.  Antigen  and  antibody are  both  sterically  and 
chemically  complementary  with  the  interacting  surfaces  forming  multiple  bonds. 
Antigens are often  macromolecules and an antibody therefore binds to only a small 
portion  of  an  antigen's  surface,  an  epitope  or  antigenic  determinant.  A  large, 
complex, antigen  such  as a  protein  has many epitopes.  When the  immune system 
reacts to  an antigen,  although  each  individual  Ig  molecule  is epitope-specific,  the 
population  of antibodies  produced will  bind to  many different epitopes.  Since each 
distinct  type  of  antibody  is  produced  by  a  different  clone  of  plasma  cells,  this 
response  is termed  a  polyclonal  response.  Not all epitopes  provide equally strong 
stimuli,  and antibodies to a few  immunodominant epitopes  may constitute most of 
the antibodies formed. Dominant epitopes are typically present in many copies (Roitt 
et al., 1996).
Most  of  the  amino  acid  differences  among  antibodies  fall  within  areas  called 
complementarity-determining regions (CDRs), and it is these CDRs, on both L and H 
chains, that constitute the antigen-binding  site of the Ig  molecule.  Each V domain 
has  3  CDRs  (Chothia  et  al.,  1989).  The  remainder  of  the  V  regions  is  largely 
composed of p-sheets and comprises the framework regions (FRs), which are more
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conserved and perform a structural  role, to hold the CDRs in  place (Wu and  Kabat, 
1970).  When  antibody  V  region  sequences  are  compared,  CDRs  are  much  more 
different than FRs.  Because of this difference the CDRs are also called hypervariable 
regions. CDRs of both VH  and VL  make up the antigen-binding site and they are held 
in  place  by  interactions  between  them  and  between  their associated  ChI  and  Q. 
domains.
There are five different classes of antibodies, with distinct biological properties.  Each 
class  has a  H chain with a different amino acid sequence. The five  Ig  classes are 
designated IgA, IgG, IgM, IgE and IgD and the five types of H chains are designated 
by  the  corresponding  lowercase  Greek  letter,  a, y,  \i,  e,  and  6.  There  are  two 
different kinds of L chain designated k and X and either type of L chain can associate 
with any H chain. In humans 60% of the L chains are k  and 40% are X. IgG has four 
subclasses (IgGl, IgG2, IgG3, IgG4) and IgA has two subclasses (IgAl, IgA2).
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Figure 1.1 Schematic diagram of the structure of an IgG molecule
Immunoglobulin  molecules  consist  of  two  identical  heavy  chains  (50  KD  each)  and  two 
identical  light  chains  (25  KD  each),  which  are  linked  by  disulphide  bridges.  The  heavy 
chains comprise four domains and the  light chains each  have two domains.  Three of the 
heavy  chain  domains  (CH1,  Ch2  &  Ch3)  are constant  in  all  antibodies of the  same  isotype 
and one (VH )  is highly variable between  individual antibody molecules.  The light chain  has 
one constant  (Q.)  and  one variable  (VL )  domain.  The variable domains,  and  in  particular 
the  hypervariable  regions  (termed  complementarity  determining  regions,  CDRs),  of  the 
amino terminal  domains (N-terminus)  of both the heavy and  light chains form the antigen 
binding  site of the  antibody.  The  carboxyl  terminal  domains  (C-terminus)  of the  heavy 
chains form  the  Fc  (crystallisable fragment)  region,  this  region  determines the  isotype of 
the antibody molecule and controls the antibody's effector functions.
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1.1.3.3  Autoimmunity and autoantibodies
Unfortunately, there are there are situations in which the immune system ceases to 
recognise  one  or  more  of the  body's  normal  constituents  as "self," creates "self 
binding" or autoantibodies, and starts to attack its own cells, tissues, and/or organs, 
causing inflammation and damage. The causes of this mistake are varied and are not 
completely  understood.  These  misdirected  immune  responses  are  referred  to  as 
autoimmunity,  which  can  be demonstrated  by the presence of autoantibodies or T 
lymphocytes reactive with host antigens (Roitt et al., 1996).
It is thought that some autoantibody  production  is due to a genetic predisposition 
combined  with  an  environmental  trigger  (such  as  a  viral  illness  or  a  prolonged 
exposure to certain toxic chemicals). There is however generally not a direct genetic 
link.  While families  may  be  prone to  develop  autoimmune  conditions,  individual 
family members may have different autoimmune disorders, or may never develop a 
"full-blown" autoimmune condition.  It is  likely that there  may also  be a  hormonal 
component as many autoimmune conditions are much more prevalent in women.
The type of autoimmune disease that occurs and the amount of destruction done to 
the body depends on which systems or organs are targeted  by the autoantibodies, 
and  how  strongly.  Disorders  caused  by  organ  specific autoantibodies,  those  that 
primarily target a single organ, are often the easiest to diagnose as they frequently 
present  with  organ  related  symptoms.  Examples  of  organ-specific  autoimmune 
disorders  are  insulin-dependent  diabetes  (Type  I)  which  affects  the  pancreas, 
Hashimoto's thyroiditis and Graves' disease which affect the thyroid gland, pernicious 
anemia which affects the absorption of vitamin B12, Addison's disease which affects 
the adrenal glands, and chronic active hepatitis which affects the liver. Disorders due 
to systemic autoantibodies can be much  more difficult to diagnose.  Symptoms may 
include: joint pain, fatigue, fever, rashes, cold or allergy-type symptoms, weight loss, 
and  muscular weakness.  Even  if they are due to a  particular systemic autoimmune 
condition, the symptoms will vary from person to person, vary over time, vary with 
organ involvement, and they may decrease or flare unexpectedly.  Examples of non­
organ  specific  autoimmune  disorders  are  rheumatoid  arthritis,  systemic  lupus 
erythematosus (SLE) and the Antiphospholipid syndrome (APS) (Roitt et al.,  1996). 
SLE and APS will be discussed more extensively later in this chapter.
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Autoantibodies  found  in  SLE  and  APS  patients  tend  to  differ  from  natural 
autoantibodies found in healthy individuals in that they are generally IgG isotype and 
have a high affinity for particular autoantigens.  In  healthy individuals however,  low 
titres of low affinity autoantibodies are part of the normal B cell repertoire (Peeva et 
al. 2002). These natural autoantibodies resemble the antibodies of a primary immune 
response  in that they are primarily IgM and exhibit polyreactive binding to a wide 
variety of both autoantigens and foreign antigens.  Natural autoantibodies are mainly 
germline encoded and some germline autoantibody genes are used in the absence of 
an autoimmune disease.  Some autoantibodies  might actually  be the  precursors to 
pathogenic  autoantibodies  in  SLE.  Shlomchik  et  al.,  (1987)  suggested  that 
pathogenic  autoantibodies  arise  by  the  somatic  mutation  of genes  that  encode 
protective autoantibodies.
1.1.3.3  Monoclonal Antibodies
Monoclonal  antibody  (mAb) technology allows the production  of large amounts of 
homogenous pure antibodies. A myeloma is a tumor of the bone marrow that can be 
adapted to grow permanently in cell culture.  When  myeloma cells were fused  with 
antibody-producing  mammalian spleen cells,  it was found that the resulting  hybrid 
cells,  or  hybridomas,  produced  large amounts of mAb (Kohler and  Milstein,  1975). 
This product of cell fusion combined the desired qualities of the two different types 
of cells:  the ability to grow continually, and the ability to produce large amounts of 
pure antibody. These antibodies are called monoclonal because they come from only 
one type of cell, the hybridoma cell;  antibodies produced  by conventional methods, 
on the other hand, are derived from preparations containing many kinds of cells, and 
hence are called polyclonal.  Because selected hybrid cells produce only one specific 
antibody,  they  are  more  pure  than  the  polyclonal  antibodies.  mAbs  are  useful 
because they allow us to study autoimmune rheumatic diseases such as SLE.
1.2  What is Systemic Lupus Erythematosus?
SLE  is a  complex,  heterogeneous autoimmune  rheumatic disease characterised  by 
the production of antibodies to components of the cell nucleus in association with a 
diverse array  of clinical  manifestations.  It  is  a  disabling  disease and the  primary 
pathological  findings  in  patients  involve  widespread  inflammation,  vasculitis  and 
immune complex deposition. Virtually every organ and/or system of the body may be
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involved although the skin, joints, kidneys, lungs and the central nervous system are 
most commonly affected. The term "lupus erythematosus" was first used in  1852 by 
Cazenave and  Calausit (Amital  et al.,  1999,  Morrow et al.,  1999)  and  its  systemic 
nature has been accepted for the past 100 years (Isenberg et al., 1997).
Lupus is found worldwide. The incidence rate of SLE in the UK is approximately four 
cases per 105  people every year (Johnson et al.,  1995). Like many other autoimmune 
diseases, women are more commonly affected than men and the age of onset is, on 
average,  between  20 and 40 years (Alarcbn-Segovia et al.,  1999).  It is much  more 
common  among  black females  in the UK,  the West Indies,  and  the  United  States 
(Nived  and  Sturfelt,  1997).  Although  lupus  is  widely  regarded  as  a  serious  and 
potentially fatal disease, the overall  probability of survival  in  patients with  SLE has 
improved dramatically over the  last few decades.  Whereas earlier studies  in  1955 
showed  a  survival  rate of less than  50%  in  5 years  reports from the last decade 
revealed that over 90% of patients with SLE survive for 10 years (Abu-Shakra et al., 
2004). The exact cause of SLE is not known.  However it is clearly a  multi-factorial 
disease influenced by genetic, hormonal and environmental factors.
1.2.1 Aetiology of Systemic Lupus Erythematosus
1.2.1.1 The Genetics of SLE
The  exact  aetiology  of  SLE  remains  elusive.  There  is  however  clearly  a  genetic 
component  to  disease  susceptibility  in  SLE.  The  disease  shows  a  strong  familial 
aggregation, with a much higher frequency among first-degree relatives of patients. 
Moreover,  in  extended  families,  SLE  may  co-exist  with  other  organ  specific 
autoimmune diseases such as haemolytic anaemia and thyroiditis. The concordance 
of the disease in  monozygotic twins is approximately 25% compared with dizygotic 
which is about 2% (Pisetsky and Drayton, 1997, Deapen et al.,  1992). Therefore, the 
increased  risk  of  developing  the  disease  in  siblings  of  SLE  patients  reflects  a 
polygenic inheritance of the disease.
Multiple genes contribute to disease susceptibility and SLE is believed to result from 
the effects of a number of gene interactions. For instance, patients with homozygous 
deficiencies of the early components of complement are at risk of developing an SLE- 
like disease. The genes of the MHC - also known in humans as the Human Leukocyte 
Antigen System A (HLA)- have been most extensively studied for their contribution in
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SLE. An  increased frequency of HLA-DR2 and  DR3  has been  reported in Caucasian 
SLE patients (Eroglu and Kohler,  2002, Jonsen et al.,  2004).  However it is possible 
that some individuals may possess all these genes but still not develop SLE.  Further 
aspects on the genetics of SLE are dicussed in section 1.2.4.1.
1.2.1.2 Hormonal Factors in SLE
SLE  is  predominantly a  female disease,  affecting  women  during  the  child-bearing 
years. Females are commonly affected up to ten times more than males. It has been 
demonstrated  that  in  both  sexes,  low  endogenous  oestrogen  concentrations  are 
protective and  in males, low androgen values increase risk. Oestrogen can act as a 
potent disease stimulator in lupus-prone mice (Carlsten et al.,  1990, Roubinian et al., 
1979). In addition, there is evidence from mouse models that androgens may have a 
protective effect (Lucas et al.,  1985,  Roubinian  et al.,  1979).  These  observations 
suggest a role for sex hormones in disease predisposition.
1.2.1.3 Environmental Factors in SLE
Various viruses have been implicated in the aetiology of SLE and Epstein-Barr virus 
(EBV) is the most popular candidate.  Infection with  EBV results in the production of 
the viral  protein  Epstein-Barr virus  nuclear antigen-1  (EBNA-1),  antibodies against 
which cross-react with lupus-associated autoantigens, including Ro, Sm B/B', and Sm 
Dl, in lupus patients (Poole et al., 2006).
Photosensitivity  is  a  common  presenting  symptom  of  SLE.  Ultraviolet  (UV)  light 
exposure provokes an abnormal cutaneous reaction and also initiation or activation 
of systemic flare in susceptible individuals (Millard and Hawk,  2001).  UV irradiation 
induces apoptosis of human keratinocytes and changes the subcellular location of the 
ribonucleoprotein  autoantigens  targeted  in  SLE  (Ro,  La,  small  nuclear 
ribonucleoproteins)  (Casciola-Rosen  et  al.,  1994).  These  antigens  stained  in  a 
punctate  pattern  at the cell  surface of irradiated  cells,  a  site  at which  they were 
never  present  in  unirradiated  cells.  Little  is  known  about  other  possible 
environmental or occupational exposures in relation to SLE disease risk.
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1.2.2  Clinical Features of Systemic Lupus Erythematosus
SLE  can  cause a  wide variety  of clinical  manifestations.  The American  College of 
Rheumatology (ACR) has designated a set of criteria (Table 1.1) to aid the diagnosis 
of SLE (Tan et al.,  1982, Hochberg,  1997). To be classified as having SLE, a patient 
must  either  have  consecutively,  or  concurrently,  satisfied  four  or  more  of  these 
criteria.  Dermatological  problems such as the classic butterfly  rash found over the 
bridge  of the  nose and  malar  bones,  alopecia,  vasculitic  skin  lesions,  buccal  and 
nasal  ulceration  are  very  frequent  and  are  present  in  up  to  85%  of  patients 
(Isenberg and  Horsefall,  1998).  Many of these skin  lesions are photosensitive thus 
sun  protection  forms  an  important  part of  management of  SLE.  Musculoskeletal 
problems are also a common feature of lupus and these include arthralgia  (about 
90% of patients) as well as myalgia, muscle weakness and tenderness.  In advanced 
disease,  almost any system  in the body  may  be involved, with  renal, cerebral  and 
pulmonary  manifestations  being  most  dangerous.  Significant  renal  disease  will 
develop in approximately 30% of SLE patients.
Patients with  SLE appear to  be at  high  risk for coronary artery  disease  (Jonsson, 
1989, Rahman et al.,  1999). The pericardium, myocardium and endocardium may all 
be  affected.  Chest  pain  that  increases  with  respiration  and  breathlessness  are 
common  symptoms  in  SLE.  Infections  of the  respiratory and  urinary  systems  are 
frequent and difficult to distinguish from  flares of lupus activity (Edworthy,  2001). 
Normocytic anaemia is present in up to 70% of SLE patients and a Coombs'  positive 
haemolytic anaemia in  10% of patients.  Leucopenia and lymphopenia are the most 
frequent abnormalities of the white blood cell count found in SLE patients (Morrow et 
al.,  1999).  Vascular  lesions  as  well  as  cutaneous  vasculitis,  ulcers  and  digital 
gangrene are also well recognised in SLE patients. Abdominal  pain  is found  in  10 -  
20% of the patients, the causes of which range from mild non-specific gastroenteritis 
to  life  threatening  mesenteric  vasculitis.  Hepatomegaly  and/or  persistent  liver 
function  test  abnormalities  as  well  as  splenomegaly  are  found  in  up to  10%  of 
patients but pancreatitis is less common (Morrow et al., 1999).
The clinical manifestations of SLE are fundamentally the same in children and adults. 
SLE can  be fatal  with  the  most frequent cases of death  divided  equally  between 
infections  (due  to  use  of  immunosuppressive  drug  treatments),  cardiovascular 
disease and cancer (Cervera et al.,  1999). The disease is characterised  by cycles of 
relapse  and  remission  due  to  the  disease  activity  fluctuating  over  time  between
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organs and tissues involved (Morrow et al.,  1999). Flares of the disease may require 
drug  treatment  with  non-steroidal  anti-inflammatory  drugs,  antimalarials, 
corticosteroids  and  immunosuppressive  agents.  Hydrochloroquine  sulphate  has  a 
place in the management of SLE because of its low record of toxicity and its potential 
role in  lowering cholesterol (Hodis et al.,  1993).  Severe organ involvement, such as 
nephritis or vasculitis,  requires treatment with a combination of corticosteroids and 
either  azathioprine  or  cyclophosphamide.  Cyclophosphamide,  azathioprine  and 
methotrexate,  as  well  as  more  recent  immunosuppressive  agents  such  as 
mycophenolate (MMF) -see below- may be used to treat more severe forms of SLE 
(such  as  renal,  cerebral and  haematological  manifestations).  However, they  inhibit 
the  inflammatory  immune  response  non-specifically  and  are  therefore  associated 
with  a  host  of  unpleasant  side  effects  that  may  require  further  therapeutic 
intervention.  For  instance,  corticosteroids  are  associated  with  weight  gain, 
osteoporosis and diabetes and cyclophosphamide is associated with  bladder toxicity 
and infertility.
Because  of  the  side  effects  from  the  treatments  listed  above  and  the  limited 
prevention  measures  available,  there  is  a  continuing  need  to  increase  our 
understanding of the pathogenesis of the disease. A number of new treatments for 
SLE are now  being  introduced  and these  have been  developed  owing to a  better 
understanding of the  immunology of the disease.  New  immunosuppressive agents 
include  MMF  [reviewed  in  (Isenberg  and  Rahman,  2006)].  MMF  is the  prodrug  of 
mycophenolic  acid,  which  inhibits  the  enzyme  inosine-5'-monophosphate 
dehydrogenase,  resulting  in  inhibition of purine synthesis,  lymphocyte proliferation 
and  T-cell-dependent  antibody  responses.  MMF  is  as  effective  as  intravenous 
cyclophoshamide  for  the  treatment  of  lupus  nephritis  and  other  major  SLE 
manifestations.  It is also associated with fewer side effects than cyclophosphamide 
and  does  not seem  to cause infertility (Contreras et al.,  2004).  B-cell  depletion  is 
another approach for treating patients with SLE. The treatment incorporates the use 
of two infusions each of methylprednisolone, cyclophosphamide and rituximab. This 
approach  results  in  significant  clinical  improvement  and  normalises  two  of  the 
biomarkers (CD20 and CD22) that reflect disease activity. Thus,  it can  lower anti- 
dsDNA  antibody  levels.  Although  manifestations  of  SLE  in  the  major  organs  or 
systems  involved  can  improve  with  this treatment,  some  of the  clinical  features 
return with the return of B cells (Leandro et al., 2005, Looney et al., 2004).
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Additionally, therapies directed at the T cell-APC interaction are being  investigated. 
The  use  of  the  fusion  protein  CTLAa-Ig,  which  blocks  the  binding  of  the 
costimulatory B7 molecules expressed on APCs with CD28 on activated T cells, seems 
promising.  Anticytokine therapy  is also  under  investigation.  Infliximab,  a  chimeric 
mAb,  has high affinity for TNF and neutralises its activity.  In an open-label study of 
infliximab  in  six  patients  with  SLE,  Smolen  and  colleagues  have  demonstrated 
significant clinical improvement (Aringer et al., 2004). Another approach that targets 
cytokines  has  been  the development of  B  lymphocyte  stimulating  protein  (BLyS) 
antagonists.  Complement therapy  is  also  an  attractive  approach.  Eculizumab  is  a 
humanised  mAb that exerts  its effects  by  blocking the generation  of the terminal 
complement  component  C5a  and  C5b-9.  Early  human  studies  indicate  that  this 
molecule  is  safe  and  well  tolerated  (Rother  et  al.,  2004).  The  new  therapeutic 
approaches  described  above  have  shown  promise  in  early  studies  however  large 
clinical trials are awaited.
1.2.3  Immunopathogenesis of Systemic Lupus Erythematosus
1.2.3.1  Autoantibodies in SLE
The  central  immunological  disturbance  in  patients  with  SLE  is  autoantibody 
production.  These  antibodies  are directed  at  several  self  molecules  found  in  the 
nucleus, cytoplasm, and  cell  surface,  in  addition to soluble molecules such  as IgG 
and coagulation factors. It is now almost 50 years since the discovery of anti-nuclear 
and anti-DNA antibodies in the serum of patients with lupus. Antibodies to DNA were 
first isolated by four different groups in  1957 (Ceppellini et al.,  1957,  Robbins et al., 
1957,  Miescher  and  Strassle,  1957,  Seligmann,  1957).  A  broad  spectrum  of 
autoantibodies was identified in patients with SLE over the next two decades.
Antinudear antibodies (ANA) are present in more than 95% of patients, making the 
ANA test the most sensitive test for lupus.  However, ANA are not specific,  because 
they  can  be  detected  in  a  variety  of  autoimmune,  rheumatic,  and  infectious 
conditions.  Moreover, ANA can  be detected  in  normal  individuals,  especially  in  the 
elderly. However, the absence of ANA makes the diagnosis of lupus much less likely, 
although  still  possible.  ANA  are  most  commonly  detected  using  the  indirect 
immunofluorescent technique on a tissue culture cell substrate.
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Anti-double stranded  DNA (dsDNA) and  anti-Sm antibodies are unique to  patients 
with SLE. In fact, their presence is included in the classification criteria of SLE (Table 
1.1). The Sm antigen is designated as a small nuclear ribonucleoprotein (snRNP) and 
is composed of a unique set of uridine rich RNA molecules bound to a group of core 
proteins associated with  the  RNA  molecules.  Anti-Sm  antibodies  react with  snRNP 
core  proteins.  Antibodies  to  both  denatured/single-stranded  (ssDNA)  and  native/ 
dsDNA  are  often  present  in  SLE  patients,  however the  latter  notably  of the  IgG 
isotype  are  more  strongly  associated  with  the  renal  pathology  (Okamura  et  al.,
1993).  Other autoantibodies have been associated with SLE and are summarised in 
Table  1.2.  Anti-dsDNA  autoantibodies  will  be  discussed  in  more  detail  in  section
1.2.4.  Arbuckle at el., (2003) studied 130 patients with SLE and showed that at least 
one SLE autoantibody was present in  115 patients before diagnosis. They proposed 
that there is a  progressive accumulation of specific autoantibodies before the onset 
of SLE, while patients are still asymptomatic (Arbuckle et al., 2003).
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1. Malar rash (butterfly rash)
2. Discoid rash (erythematosus raised patches)
3. Photosensitivity (skin rash to sunlight)
4. Oral ulcers
5. Arthritis (involving two or more peripheral joints)
6. Serositis (a) Pleuritis
(b) Pericarditis
7. Renal disorder (a) Proteinuria
(b) Cellular casts
8. Neurological disorder (a) Seizures
(b) Psychosis
9. Haematological disorder (a) Haemolytic anaemia
(b) Leucopaenia
(c) Lymphopaenia
(d) Thrombocytopenia
10. Immunological disorder (a) Positive for lupus anticoagulant
(b) Raised anti-native DNA/ Anti-Sm antibody binding
(c) Abnormal serum level of IgG or IgM anti-cardiolipin antibodies Anti-Sm antibody
(d) False-positive serological test for syphilis, present for at least six months
11. Anti-nuclear antibody in raised titre
Table 1.1  The American College of Rheumatology criteria for the diagnosis of SLE 
Adapted from Tan et al., (1982) and updated Hochberg, (1997)Antibody Specificity Prevalence (%)
Antibodies to cell nucleus components Anti-nuclear antibodies >90
Anti-dsDNA antibodies 40-90
Anti-ssDNA antibodies up tp 70
Anti-ssRNA antibodies (including anti-poly A, - 
poly C, -poly I, -poly U)
“
Anti-ssRNA antibodies (including anti-poly-rU, - 
poly-rA)
~
Anti-poly (ADP-ribose) antibodies -
Anti-histone antibodies 30-80
Anti-ribonucleoprotein antibodies 20-35
Anti-Sm antibodies 5-30
Anti-SS-A(Ro) antibodies 30-40
Anti-SS-B(La) antibodies 10-15
Antibodies to cytoplasmic antigens Heat Shock proteins 5-50
Antibodies to cell membranes Lymphocytotoxic antibodies -
Anti-neurone antibodies -
Anti-erythrocyte antibodies -
Anti-platelet antibodies -
Anti-phospholipid antibodies (cardiolipin) 20-50
Antibodies to serum components Anticoagulants (lupus anticoagulant) 10-20
Antiglobulins (rheumatoid factor) 25
Clq 20-45
Table 1.2  Autoantibodies found in SLE and the approximate prevalence detectable in the serum of patients
Adapted from Morrow et al., (1999).Chapter One Introduction
1.2.3.2  The role of complement in SLE
The complement system consists of a  large number of proteins,  some of which are 
soluble  plasma  constituents  and  others  cell  membrane  proteins.  A  main  task  of 
complement  components  is  to  stop  the  invasion  of  the  body  by  microbes  and 
membrane complement proteins act as  receptors.  The complement molecules coat 
the  microorganism  and  the  cell  takes  up  the  whole  complement-microorganism 
complex, a process called opsonization. The complement system is not only involved 
in killing of invasive pathogens, but also contains important regulators and activators 
of several  humoral  and  cellular  immune functions  (Bohana-Kashtan  et al.,  2004). 
Regulators  of  complement  activation  protect  self-tissue  from  damage  (Walport, 
2001a,  Walport,  2001b).  The actions  of complement  involve activation  of one  of 
three pathways, all generating C3 convertase:  the classical pathway, the mannose- 
binding lectin (MBL) pathway and the alternative pathway.
Complement has  both  beneficial and  harmful  roles  in the  pathogenesis of SLE.  On 
the one hand, patients with SLE present with decreased complement levels and with 
complement  deposition  in  inflamed  tissues,  suggestive  of  a  damaging  role  of 
complement  in  the  effector  phase  of  disease.  On  the  other  hand,  homozygous 
deficiency of any of the classical  pathway  proteins  is strongly associated  with  the 
development of SLE. The classical pathway is mainly initiated by interaction of Clq 
with  antibodies  (IgG  and  IgM)  in  immune complexes  and  is the  main  effector of 
antibody-mediated immunity (Sturfelt and Truedsson, 2005).
Complement  is  strongly  activated  in  patients  with  SLE.  Deposits  of  C3,  C4,  and 
associated  complement  proteins  can  be easily detected  in  biopsies from  inflamed 
tissues from  patients with  SLE (Manderson et al.,  2004).  Complement activity and 
classical  pathway  protein  levels  are  generally  reduced  (especially  Cl,  C4  and  C2 
levels)  in  relation  to  disease  activity  and  increase  following  treatment  (Walport, 
2002).  The  initial  cause  of  complement  activation  in  SLE  is  thought  to  be  the 
formation of high levels of immune complexes that, in turn, activate complement via 
the  classical  pathway.  Disease  activity  however,  as  well  as  the  presence  of 
autoantibodies  directed  against  complement  proteins  (anti-Clq  antibodies)  may 
influence the degree of reduction of levels of complement components (Manderson 
et al., 2004).
37ChaDter One Introduction
Inherited  complement deficiencies are  rare but when  they occur these  individuals 
may develop a form of SLE. Complement deficiencies may be partial (heterozygous) 
or complete (homozygous). In recent years, evidence has emerged that homozygous 
deficiency of any of the early components of the classical  pathway of complement 
activation  (Clq,  Clr,  Cls, C4, and  C2)  predisposes to the development of SLE.  In 
fact, these deficiencies are the strongest susceptibility factors for the development of 
SLE identified up to now in humans (Manderson et al., 2004). There is an association 
of  disease  prevalence  and  severity  within  the  classical  pathway,  with  patients 
deficient in one of Cl-complex proteins exhibiting the strongest prevalence (>80%) 
and  the  most  severe  disease,  followed  in  turn  by  C4  and  C2-deficient patients 
(Pickering and Walport, 2000).
Several  mouse  strains  have  been  generated  with  classical  pathway  complement 
deficiencies and have provided important insights into the pathogenesis of SLE. The 
genes for Clq, C4 and C3 have been successfully targeted in mice, and these mouse 
strains  showed  a  hierarchy  of  disease  susceptibility  similar  to  that  observed  in 
humans.  Clq  has  been  shown  to  bind  directly  to  apoptotic  blebs  and  apoptotic 
bodies are found in the glomeruli of the Clq deficient mice (Korb and Ahearn,  1997) 
(Taylor et al., 2000). A recent study performed by Trouw and colleagues in MRLy/pr 
mice has shown that anti-Clq antibodies were present in the sera and deposited  in 
the  kidney  (Trouw et al.,  2004).  Gene-targeted Clq-deficient mice have also been 
shown to  develop a  syndrome  reminiscent of SLE with  antinuclear autoantibodies 
and  proliferative glomerulonephritis (Mitchell  et al.,  2002,  Botto  et  al.,  1998).  In 
another study by Paul et al., (2002)  using C4-deficient mice,  higher levels of anti- 
dsDNA  antibodies  developed  compared  to  C4  sufficient  littermate  controls.  At  3 
months of age, females with and without C4 have equivalent levels of DNA binding. 
By 6 months however, anti-dsDNA antibodies of the IgM isotype are elevated in C47' 
females compared to C4+/+ controls and by 9 months IgG anti-dsDNA antibodies also 
increase (Paul  et al.,  2002).  Furthermore,  they observed  that the  kidneys of C47' 
mice had glomerular immune complexes. Hence, these findings demonstrate that C4 
normally helps prevent early stages of autoimmune disease and that C4 deficiency 
predisposes to abnormal regulation of autoreactive B cells.
The levels of complement receptors, CR1 and CR2, are also altered in patients with 
SLE.  CR1  expressed  on  peripheral  B  cells,  erythrocytes,  monocytes  and 
macrophages,  binds and clears activated  complement components  (C3b,  iC3b and
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C4b) and their associated immune complexes.  Walport and  Lachmann, (1988) have 
described  decreased  expression  of  CR1  on  erythrocytes  and  peripheral  blood 
leukocytes in  patients with SLE and have shown that levels correlated with disease 
activity.  CR2  is  expressed  on  B-cells  and  follicular  dendritic  cells.  Furthermore, 
Tolnay  and  Tsokos,  (1998)  have  shown  that  MRL//pr mice deficient in  CR2  have 
more severe disease.
1.2.3.3  The role of apoptosis in SLE
Apoptosis,  or  programmed  cell  death,  is  a  process  that  leads  to  the  ordered 
destruction  of  cells,  avoiding  the  release  of  intracellular  contents  into  the 
extracellular  microenvironment,  where they  have a  powerful  inflammatory  effect. 
During apoptosis intracellular structures,  including the nucleus, are broken down via 
certain  pathways by specific enzymes.  Casciola-Rosen  et al.,  (1994) demonstrated 
that  these  intracellular  components  often  make  up  the  spectrum  of  target 
autoantigens in lupus (for example, nucleosomal DNA, Ro, La and RNP particles) and 
cluster in  blebs on the surface of apoptotic cells enabling them to be presented as 
antigen. These observations provide a  possible connection  between  apoptosis and 
SLE.
Under  normal  circumstances,  apoptotic cells are engulfed  by  macrophages  in  the 
early  phase of apoptotic cell  death  without  inducing  inflammation  or the  immune 
response.  Recent  studies  have  shown  that  the  clearance  of  apoptotic  cells  by 
macrophages  in  patients  with  SLE  is  impaired  (Herrmann  et  al.,  1998).  This 
impairment has generated much interest in recent years, with defective clearance of 
apoptotic fragments summarised as the 'waste disposal hypothesis' (Walport, 2001a, 
Walport,  2001b).  An  early  suggestion  that defective  clearance  of  apoptotic  cells 
might  predispose to  SLE came from the observations of those who observed  that 
Clq-null  mice develop SLE-like autoimmunity in the presence of defective clearance 
of apoptotic cells (Botto and  Walport,  2002).  These  mice show  glomerulonephritis 
with deposits of immune complexes and apoptotic cells in the glomeruli (Botto et al., 
1998). Interestingly, Clq binds to apoptotic cells, and human serum depleted of Clq 
does not allow efficient uptake of apoptotic cells by macrophages (Korb and Ahearn, 
1997, Taylor et al., 2000).
Cocca et al., (2002) have also illustrated that the clearance of apoptotic cells may be 
slowed  in  patients  with  SLE.  They  showed  that  a  murine  autoantibody  can  bind
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directly  to  blebs  on  apoptotic  cells,  due  to  the  presence  of certain  ligands,  and 
consequently prevent another molecule, annexin V from  recognising  ligands on the 
surface and  binding. Their results suggest that if autoantibody binding can  prevent 
annexin V from  binding then  it is  possible that autoantibody binding to  blebs may 
slow apoptotic cell  clearance further when  other molecules recognising factors on 
surface of apoptotic cells such  as phagocytes and complement are prevented from 
reaching their receptors and aiding apoptotic cell removal.
A number of studies with animal models support the role of apoptosis in SLE.  Fas is a 
43-kDa glycoprotein molecule which is involved in inducing apoptosis in both B and T 
lymphocytes. One of the pathways which leads to apoptosis involves Fas (CD95) and 
Fas  ligand  (FasL).  MRL//pr  mice  are  characterised  by  the  presence  of  the 
lymphoproliferation  (Ipt)  gene,  which  is  associated  with  defective  Fas  (CD95) 
receptors on the surface of lymphocytes (Suzuki et al.,  1998). In the murine MRL//pr 
model  of  SLE,  the  Ipr mutation  results  in  defective transcription  of the gene that 
codes  for the  Fas  protein  (Singh,  1995).  MRL  mice which  carry the  homozygous 
recessive  Ipr  mutation  develop  a  lupus-like  disease  characterised  by  high  IgG 
autoantibody  levels  and  immune complex-mediated  glomerulonephritis.  Takahashi 
and  colleagues  reported that Gld/gld  mice,  characterised  by a  mutation  in the Fas 
ligand  (FasL)  gene  leading  to  a  non-functional  FasL  molecule,  also  developed 
lymphoproliferation,  hypergammaglobulinaemia,  and  Ig  deposits  in  the  kidneys 
(Takahashi  et  al.,  1994).  Bcl-2  is  a  proto-oncogene,  which  exerts  a  regulatory 
function  during  development  and  maintenance  of  adult  tissue,  by  preventing 
apoptosis in specific cell types.  Evidence has demonstrated that mice transgenic for 
overexpression  of  bcl-2 develop  prolonged  B  cell  survival  and  other features  in 
common  with  SLE  patients  [reviewed  in  Morrow  et al.,  (1999)].  Therefore,  these 
animal  models suggest that these molecules,  which  play critical  roles in apoptosis, 
may play a role in the pathogenesis of SLE.
The impaired clearance mechanisms for these apoptotic materials seen  in  patients 
with  SLE,  may  predispose  individuals  to  the  development  of  antibodies  against 
nucleosomes,  which  contain  materials  such  as  histones  and  dsDNA.  Radic  et  al.,
(2004)  have  shown  that  autoantibodies  specific  for  the  nucleosome  core  or  its 
molecular components selectively precipitated a complex of core histones and  DNA 
from the cytosol at four hours after induction of apoptosis. Their results  indicate a 
direct role for nucleosomes in the execution of apoptosis, clearance of apoptotic cells
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and  regulation  of  anti-nuclear  autoantibody  production  (Radic  et  al.,  2004). 
Therefore, as the experimental  evidence discussed above suggests,  the release of 
nucleosomes from the nucleus and their exposure at the cell surface is important in 
the pathogenesis of SLE.  The  role of nucleosomes  is further discussed  in  section
1.2.5.
1.2.3.4  Cellular dysfunction: The role of B cells and T cells in SLE
SLE is characterised by abnormalities of the immune system that involve B cells and 
T cells.  B cell activation is abnormal in patients with SLE. The precise role of B cells 
in systemic autoimmunity is incompletely understood. Although B cells are necessary 
for  expression  of disease,  it  is  unclear whether autoantibody  production,  antigen 
presentation,  and  other  B cell  functions  are  required  for the complete  pathologic 
phenotype.  The  number  of  B  cells  at  all  stages  of activation  is  increased  in  the 
peripheral  blood  of  patients  with  active  SLE  (Klinman  et al.,  1991).  Autoantibody 
secretion  is not the only  role of B cells  in  patients with  SLE.  B cells are extremely 
efficient antigen presenting cells for antigens taken up specifically through the B cell 
receptor (Ig receptor). Although B cells are necessary for expression of disease,  it is 
unclear  whether  autoantibody  production,  antigen  presentation,  and  other  B  cell 
functions are required for the complete pathologic phenotype. To address this issue, 
Chan et al. (1999) analysed the individual contributions of circulating antibodies and 
B cells using MRiyipr mice that expressed a  mutant transgene encoding surface Ig, 
but  which  did  not  permit  the  secretion  of  circulating  Ig.  These  mice  developed 
nephritis, characterised by cellular infiltration within the kidney, indicating that B cells 
themselves,  without soluble autoantibody production,  exert a  pathogenic role. The 
results  indicated  that,  independent  of  serum  autoantibody,  functional  B  cells 
expressing  surface  Ig  are  essential  for  disease  expression,  either  by  serving  as 
antigen-presenting cells for antigen-specific, autoreactive T cells, or by contributing 
directly to local  inflammation (Chan et al.,  1999). New evidence for the strength of 
the role of B cells in disease development comes from a recent preliminary study of 
B-cell depletion therapy (involving  Rituximab and cyclophosphamide) in 24 patients 
with  SLE  resistant  to  conventional  therapies.  The  results  showed  a  beneficial 
response in  the majority of treated  patients  (Leandro et al.,  2002).  There  is also 
evidence  that  B  cells  in  patients  with  SLE  are  more  sensitive  to  the  stimulatory 
effects of cytokines such  as IL-6 and  it appears that are more prone to polyclonal 
activation by antigens and cytokines (Linker-Israeli et al., 1991).
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Abnormalities  in  T  cell  function  are  also  evident  in  patients  with  SLE.  T  cell 
abnormalities are crucial in the pathogenesis of the disease because T cells regulate 
B cell function and the production of most antibodies is T-cell dependent. The total 
number of peripheral blood T cells is usually reduced and experiments have shown 
that the early events of T cell activation are defective in patients with SLE compared 
with  controls  (Fernandez-Gutierrez  et  al.,  1998).  In  patients  with  SLE  there  is 
generally an exaggerated activity of CD4+ T helper cells and diminished function of 
CD8+ T suppressor cells.  This effect is accompanied by reduced antibody-dependent 
cytotoxicity and imbalanced cytokine production. Due to the loss of effective CD8+ T 
cells,  B cell  clones  produce autoantibodies directed against an  array of intra-  and 
extracellular autoantigens (Kammer et al.,  2002). T lymphocytopenia  is common  in 
patients with SLE, especially of cells bearing the CD8+  phenotype. Studies in  lupus- 
prone  mouse  models  and  patients  with  SLE  suggest  that  T  cell  dysfunction  is 
primarily  caused  by  multiple  biochemical  defects  in  T  cell  signalling  pathways 
(Kammer et al., 2002).
Nucleosome-specific  T  helper  (Th)  cells  provide  CD4+-c!ass  II-restricted  help  to 
nephritogenic ANA-producing  B cells  in  lupus.  The  autoimmune Th  cells  of  lupus 
were cloned from (SWR X NZB)Fi (SNFO  mice with  lupus nephritis, as well as from 
nephritic patients with SLE (Mohan et al.,  1993).  In the SNFi model, representative 
pathogenic  autoantibody-inducing  Th  clones  rapidly  induce  immune-deposit 
glomerulonephritis.  Approximately  50%  of such  pathogenic Th  clones  respond  to 
nucleosomal antigens and  nucleosome-specific T cells are detectable in  SNFi  mice. 
Thus,  nucleosomes are  primary  immunogens that  initiate the  cognate  interaction 
between the pathogenic Th and B cells of lupus. However, the lupus Th cells do not 
respond  when  components of the  nucleosome,  such  as free  DNA or  histones,  are 
individually  presented  by APCs  (Kaliyaperumal  et al.,  1996).  Thus  critical  peptide 
epitopes  for  the  pathogenic  Th  cells  are  probably  protected  during  uptake  and 
processing of the native nucleosome particle as a whole. Kaliyaperumal et al. (1996) 
synthesised  peptides  spanning  all  four  core  histones  in  the  nucleosome  and  the 
nucleosome-specific,  pathogenic autoantibody-inducing  Th  clones  were tested  for 
response  to  these  synthetic  peptides.  The  authors  reported  that  the  peptide 
autoepitopes triggered the pathogenic Th cells of SNFi  lupus mice in vivo to induce 
the development of severe lupus nephritis and stimulated the production of Th 1-type 
cytokines,  consistent  with  IgG2a,  IgG2b,  and  IgG3  being  the  isotypes  of 
nephritogenic autoantibodies  induced  in the  lupus  mice.  Interestingly,  the Th  cell
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epitopes overlapped with regions in histones that contain B cell epitopes targeted by 
autoantibodies,  as  well  as  the  sites  where  histones  contact  with  DNA  in  the 
nucleosome (Kaliyaperumal et al., 1996).
1.2.3.5  The role of cytokines in SLE
Cytokines are low-molecular-weight regulatory proteins or glycoproteins secreted  by 
white  blood  cells and  various other cells  in  the body  in  response to a  number of 
stimuli. They play an essential role in moulding the quality of an immune response to 
foreign or self-antigens.  Many cytokines have been  implicated  in  regulating disease 
activity and  in the involvement of different organs  in  patients with SLE (Kirou and 
Crow,  1999).  There  is  however  a  significant  body  of  data  only  for  IL-6,  IL-10, 
interferon-a  (INFa)  and  tumour  necrosis  factor-a (TNFa).  Cytokine  production  in 
patients with SLE differs from both healthy controls and patients with other diseases 
such  as  rheumatoid  arthritis  (RA)  but  also  changes  with  different  disease 
phenotypes.  For example,  IL-6 seems to  be  increased  in the cerebrospinal fluid of 
patients with central nervous system involvement in SLE but not in patients with SLE 
who lack neurological symptoms (Dean et al., 2000).
A recent study performed by Mathian et al., (2005) indicated that IFNa is involved in 
pathogenesis of SLE. The authors showed that in vivo adenovector-mediated delivery 
of  murine  IFN-a  resulted  in  preautoimmune  (New  Zealand  Black  (NZB)  x  New 
Zealand White (NZW))Fi [(NZB/W)Fi], but not in normal, mice, in a rapid and severe 
disease with all  characteristics of SLE.  Anti-dsDNA antibodies appeared as soon  as 
day  10  after  initiation  of  IFNa  treatment.  Proteinuria  and  death  caused  by 
glomerulonephritis occurred  in all treated mice within,  respectively, approximately 9 
and approximately  18 week, at a time when all untreated  (NZB/W)Fi did  not show 
any sign of disease (Mathian et al., 2005). Serum levels of IFNa are elevated in SLE 
patients,  and gene expression  profiling of peripheral  blood cells using  microarrays 
showed that most lupus cases demonstrate an upregulation of IFN-responsive genes 
(Bennett et al.,  2003,  Baechler et al.,  2003).  Of interest, these authors found that 
the IFN gene 'signature' correlates with more severe disease.
Jacob  et  al.,  (1988),  used  an  (NZB/W)Fi  hybrid  mouse  model  with  a  severe 
autoimmune  disease  similar to  SLE  in  humans  to  study  the  role  of TNFa.  They 
presented evidence that the TNFa  gene  could  be involved  in  the  pathogenesis of
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lupus nephritis in (NZB/W)Fi mice and replacement therapy with recombinant TNFa 
induced a significant delay in the development of the nephritis (Jacob and McDevitt, 
1988). IL-10 both inhibits Thl responses and is a potent cofactor for B cell survival, 
proliferation, differentiation, and Ig secretion, therefore it may play a potential role in 
the pathogenesis of SLE (Beebe et al., 2002). SLE patients produce abnormally high 
levels of IL-10 (Lacki  et al.,  1997) and  results obtained  by another group  indicate 
that serum IL-10 values reflect SLE disease activity suggesting that overexpression of 
IL-10  might play a  pathogenic role  in  SLE (Houssiau et al.,  1995).  To explore the 
consequences of IL-10 neutralization in (NZB/W)Fi mice, animals were injected with 
anti-IL-10 antibodies from  birth  until  8-10  months (Ishida  et al.,  1994). Anti-IL-10 
treatment  substantially  delayed  onset  of  autoimmunity  in  (NZB/W)Fi  mice  as 
monitored  either  by  overall  survival,  or  by  development  of  proteinuria, 
glomerulonephritis, or autoantibodies. Survival at 9 months was increased from 10 to 
80%  in anti-IL-10-treated  mice relative to Ig  isotype-treated controls (Ishida et al.,
1994).  Furthermore,  another  group  reported  IL-10  antagonist  administration  to 
humans  and  showed  that the  use  of  IL-10  antagonists  may  be  beneficial  in  the 
management of SLE (Llorente et al., 2000).
Anti-TNFa therapy is slightly more complicated because of TNFa's dual physiological 
roles;  it  is  a  proinflammatory  cytokine  but  has  also  been  proposed  to  be  an 
immunoregulatory  molecule that can  alter the  balance of T regulatory cells.  Anti- 
TNFa therapy is effective for the majority of autoimmune patients with  RA with end 
organ destruction due to inflammation, but can worsen or induce autoimmunity for a 
significant minority of these patients (Kodama et al., 2005). This finding is consistent 
with  numerous  animal  and  human  studies  showing  that  reducing  TNFa  activity 
aggravates  or  initiates  certain  forms  of autoimmunity.  Anti-TNFa  in  humans  can 
promote production of anti-DNA antibodies (Ehrenstein et al.,  1993b).  Kodama et al.,
(2005)  presented  a  mechanistically  based  hypothesis  that TNFa  holds  potential 
therapeutic  value  because  of  its  demonstrated  capacity  in  animal  models  of 
autoimmunity to selectively kill, by apoptosis, autoreactive (pathogenic) T cells but 
not normal cells. To investigate the safety of therapeutic TNFa blockade, 6 patients 
with  active SLE were given four 300-mg doses of infliximab, a chimeric anti-TNFa 
antibody (Aringer et al.,  2004).  The authors  proposed that anti-TNF therapy could 
suppress the local tissue destruction in SLE. Infliximab did not lead to adverse events 
related  to  an  increase  in  SLE  activity,  although  autoantibodies  to  dsDNA  and 
cardiolipin (CL) increased.  However, this study was small and was limited to patients
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with  nephritis  or  arthritis  and  low-to-moderate  overall  disease  activity.  Thus,  to 
sufficiently address the potential  value of TNF-blocking therapy  in  SLE,  larger and 
controlled clinical trials are necessary.
1.2.4  The role of anti-dsDNA autoantibodies
1.2.4.1  Origin of pathogenic anti-dsDNA antibodies
Autoantibodies that bind  dsDNA have generated  the  most  interest since they  are 
believed to be most closely involved with the pathogenesis of SLE (Isenberg,  1997). 
Even though they are among the most specific autoantibodies in lupus, they are not 
particularly sensitive because they may be transiently present and found  in 60-80% 
of lupus patients at some point in their disease course (Hahn,  1998).  Anti-dsDNA 
antibodies are very rare in other conditions but anti-ssDNA antibodies can  be found 
in  some  cases  of autoimmune  hepatitis  and  infections  including  syphilis,  parasitic 
infections, and bacterial endocarditis (Sawalha and Harley, 2004).
Anti-DNA  antibodies  differ  in  their  properties,  including  isotype,  ability  to  fix 
complement,  and  capacity  to  bind  to  the  glomeruli  causing  pathogenicity.  Only 
certain  types  of  anti-DNA  antibodies  are  pathogenic  (Hahn,  1998).  The  most 
remarkable feature  of  high-affinity  anti-dsDNA  IgG  antibodies  is  that  they  are 
frequently  linked to glomerulonephritis and widely  suspected to  be  responsible for 
kidney damage in many lupus patients (Putterman et al.,  1997). Complement fixation 
may  be  essential  for  tissue  damage;  thus  IgGl  and  IgG3  subclasses,  which  fix 
complement, are enriched in pathogenic antibodies (Hahn, 1998).
Okamura  et al.,  (1993)  studied the correlation  between  renal  histology  and  class 
specific  (IgG and  IgM)  antibodies to dsDNA and  ssDNA  by  ELISA in  40  untreated 
patients with SLE. The levels of IgG antibodies to dsDNA were significantly higher in 
patients with World  Health Organisation class IV nephritis (Hochberg  et al.,  1992), 
indicating more severe renal disease, than in those with class I, class II, or class III 
nephritis. IgG antibodies to ssDNA were higher in patients with class IV than in those 
with class II nephritis. IgG antibodies to dsDNA showed a close correlation with the 
renal histological activity score whereas IgG antibodies to ssDNA showed only a weak 
correlation.  IgM antibodies to dsDNA and to ssDNA were not correlated  with  renal 
histological features (Okamura et al., 1993).
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Cationic  charge  gives  an  antibody  to  dsDNA  a  pathogenic  advantage.  Extensive 
studies  in  murine  models  of  lupus  nephritis  have  shown  that  cationic  anti-DNA 
autoantibodies  have  nephritogenic  potential.  Suzuki  et  al.,  (1993)  investigated 
whether  cationic  anti-DNA  antibodies  of  IgG  class  are  also  produced  in  vivo  in 
patients with active lupus nephritis. They have shown that the highly cationic anti- 
dsDNA antibodies  of IgG  class  were  prominent  in  the  patients  with  active  lupus 
nephritis. The cationic anti-DNA antibodies bound to heparan sulphate (HS)f a major 
glycosaminoglycan in the glomerular basement membrane (GBM), much better than 
neutral  anti-DNA  antibodies.  The  results  suggest  that  the  cationic  anti-DNA 
autoantibodies may play a certain role in the development of lupus nephritis (Suzuki 
etal., 1993).
A  variety  of  methods  for  detecting  anti-dsDNA  antibodies  have  been  described. 
Immunofluorescence  of  the  haemoflagellate  of  Crithidia  luciliae  is  generally 
considered  to  be  the  cheapest  and  most  specific  test  (Hahn,  1998).  The  high 
specificity of the test relates to the pure circular dsDNA in the kinetoplast (with no no 
histones  or  single  stranded  DNA  in  its  structure)  (Isenberg, 2004).  The  enzyme- 
linked  immunosorbent  assay  (ELISA)  for  antibodies  to  DNA  is  widely  available, 
relatively easy to perform and therefore, very popular among many laboratories.  In 
this assay, plastic wells in a microtiter plate are coated with dsDNA and test serum is 
added.  IgG antibodies bound to the dsDNA are detected by adding enzyme-labeled 
anti-human IgG followed by substrate, which changes colour when acted on  by the 
enzyme.  In  the  Farr  assay,  radiolabeled  DNA  is  incubated  with  serum,  and  the 
DNA-anti-DNA complexes are precipitated  with ammonium  sulfate or polyethylene 
glycol (Hahn,  1998).  This  is a very accurate method  of assessing  dsDNA antibody 
levels and most likely to predict the occurrence of disease flares, particularly flares of 
glomerulonephritis (ter Borg et al., 1990).
Several  mechanisms  can  lead  to  the  production  of  antibodies  to  dsDNA.  These 
antibodies are part of the normal repertoire of natural autoantibodies, most of which 
are  low-affinity  IgM  antibodies  that  react  weakly  with  several  self-antigens 
(Putterman et al.,  1997). However, natural antibodies can undergo an isotype switch 
(from  IgM to IgG)- see section  1.4.4- and therefore  increase their  potential  to  be 
pathogenic. High-affinity IgG antibodies to dsDNA, can also be produced by somatic 
mutations in the encoding Ig genes (discussed in more detail in section 1.4).
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Antibodies to dsDNA can  be induced  in  mice by stimulation with  antigens, such as 
bacterial  DNA or cell-wall  phospholipids (PLs);  or by  DNA and  proteins complexes. 
These induced antibodies have been found to be deposited  in the glomeruli, where 
damage may result. Bacterial DNA has been shown to be much more antigenic than 
mammalian  DNA.  Bacterial  DNA  contains  unmethylated  CpG  motifs,  which  are 
immunostimulatory and more common in bacterial DNA than in mammalian DNA and 
can  elicit  cytokine  production  and  polyclonal  B  cell  activation  (Pisetsky,  1996). 
Immunisation  of  BALB/c  mice with  ssDNA from  Escherichia  coli (E.coh)  induced a 
significant anti-DNA  response that  included  antibodies  resembling  lupus anti-DNA 
antibodies  in  their  binding  properties,  although  lacking  specificity for  mammalian 
dsDNA (Gilkeson et al.,  1993).  DNA may also be presented to T cells in association 
with foreign proteins or peptides. Anti-DNA antibodies have been induced in normal, 
nonautoimmune mice by  immunisation  with complexes formed with a  DNA-binding 
peptide,  Fusl,  and  native,  B form,  mammalian  DNA (Krishnan  and  Marion,  1993). 
Fusl  is  a  27-amino  acid  peptide  from  the  internal  domain  of a  ubiquitin  fusion 
protein from  Trypanosoma cruzi. From a single BALB/c mouse immunised with Fusl- 
DNA,  six monoclonal anti-DNA antibodies were produced that shared specificity and 
V  region  structural  similarity  with  monoclonal  anti-DNA  antibodies  derived  from 
autoimmune  (NZB/W)Fi  mice  (Krishnan  and  Marion,  1993).  Polyomavirus 
transcription factor T antigen can induce anti-DNA antibodies in mice and antibodies 
recognizing  dsDNA  were  confined  to  patients  with  frequent  polyomavirus 
reactivations (Rekvig et al.,  1997).  In these cases,  it is believed that immunogenic 
immune  complexes  are  formed  between  the  host  chromatin  (packages  of 
nucleosomes  connected  by  DNA  linkers) and  the  DNA-binding  large T antigen  of 
polyomavirus.
The ability to make antibodies to dsDNA depends in part on genetic susceptibility. In 
the  NZB/W-related  NZM2410  lupus-prone  strain,  Wakeland  and  colleagues  have 
identified  the genomic  positions  of three  recessive  loci  (5/ei, Ste2,  and  Sle3 on 
chromosomes one, four,  and seven,  respectively) that are strongly associated  with 
SLE-susceptibiIity  (glomerulonephritis  and  anti-dsDNA  autoantibody  production) 
(Morel et al.,  1994). Although linkage analyses have provided information about the 
number  and  locations  of  susceptibility  genes  in  lupus-prone  strains,  they  have 
supplied little information about the nature of the component phenotypes each locus 
contributes and how they interact to produce the immunopathology characteristic of 
the  susceptible  parental  strains.  To  address  this  issue,  Wakeland  and  colleagues
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adopted a congenic dissection approach (Wakeland et al.,  1997). The basic principle 
of this approach is to convert a polygenic system into a series of monogenic systems 
in  individual  congenic  strains,  each  carrying  a  single  susceptibility  interval  on  a 
resistant genetic background (mouse strain C57BL/6 [B6]). Two strains are congenic 
if  they  are  genetically  identical  and  differ  only  at  a  single  genetic  locus.  Any 
phenotypic differences that can be detected between congenic strains are related to 
the genetic locus that distinguishes the  strains.  The authors  have  produced  three 
congenic strains B6.NZMS/el,  B6.NZMS/e2,  B6.NZMS/e3. Slel  mediates the  loss  of 
tolerance to  nuclear antigens;  Sle2 lowers the activation threshold of B ceils;  and 
Sle3 mediates  a  dysregulation  of CD4+  T  cells.  However,  these  S/e loci  are  not 
sufficient individually to mediate fatal  lupus nephritis and disease liability increased 
with  the  number  of  susceptibility  loci,  suggesting  that  significant  penetrance  of 
disease would  require two or more  loci  (Morel et al.,  2000).  Morel  and  colleagues 
reported that Slel in combination with either Sle2 or Sle3 as a B6-bicongenic strain 
develop  severe  humoral  autoimmunity  with  moderately  penetrant  fatal 
glomerulonephritis leading to kidney failure whilst other locus combinations without 
Slel  failed  to  mediate  fatal  disease  (Morel  et  al.,  2000).  The tricongenic  strain 
resulted  in  fully  penetrant,  fatal  glomerulonephritis.  Therefore  these  loci  are 
sufficient to  reconstitute  a  fully  penetrant  SLE  phenotype  in  these  mice.  These 
results are believed to be relevant to human SLE since these susceptibility loci are 
syntenic with regions found in human chromosomes. Moreover, several groups have 
completed linkage analyses in data sets from families containing  multiple members 
affected with SLE.  Results have identified chromosomal  regions exhibiting evidence 
for significant linkage to SLE and  have been confirmed  using  independent cohorts 
(lq23,  lq25-31,  lq41-42,  2q35-37,  4pl6-15.2,  6pll-21,  12q24,  and  16ql2), 
suggesting the high  likelihood of the presence of one or multiple SLE susceptibility 
genes at each locus [reviewed in (Shen and Tsao, 2004)].
1.2.4.2  The role of antibodies to DNA in the pathogenesis of disease
Anti-DNA antibodies can  be isolated from glomerular eluates of patients with active 
lupus  nephritis  and  can  induce  nephritis  in  normal  and  severe  combined 
immunodeficient mice (Vlahakos et al.,  1992, Ehrenstein et al.,  1995).  However, the 
correlation between anti-DNA antibodies and lupus nephritis is not absolute because 
some  patients with  active  nephritis are negative for anti-DNA antibodies,  whereas 
some  patients  with  persistent  high  titres  of  anti-DNA  may  not  show  renal 
involvement (Mok and Lau, 2003).
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Different  mechanisms  for  how  anti-DNA  antibodies  induce  nephritis  have  been 
proposed. These follow two main, non-mutually exclusive directions. The first theory 
of  pathogenesis  is  that  circulating  antibody-antigen  complexes  are  postulated  to 
deposit  in  the GBM,  forming  a  site for subsequent inflammatory  responses.  Anti- 
dsDNA-nucleosomal  DNA complexes get passively trapped via  interactions between 
the positively charged  cationic  N-terminus of the core histones and the negatively 
charged  HS  in  the  glomeruli  (Fournie,  1988,  Rekvig  et  al.,  2004,  Lefkowith  and 
Gilkeson,  1996,  Kramers  et al.,  1994).  Apoptotic  blebs  are  important  in  antigen 
presentation, and are believed to be the source of nucleosomal material involved in 
the formation  of these  immune complexes.  On the other hand,  there  is also  new 
support for  the  alternative  theory  of  pathogenesis  that  a  subset  of  anti-dsDNA 
antibodies  cross-reacts  with  a  non-nucleosomal  antigen  in  the  kidney,  thereby 
leading to tissue damage. This will be discussed futher in section I.2.4.3.
Anti-dsDNA antibodies penetrate living cells, even to the nucleus,  and  bind various 
intracellular  constituents.  Alarcon-Segovia  and  colleagues  reported  that  anti-DNA 
antibodies could enter living cells and interact with their intracellular target (Alarcon- 
Segovia  and  Llorente,  1983).  Subsequent  work  from  other  investigators  has 
confirmed these initial observations, and a mechanism of intracellular penetration of 
anti-dsDNA antibodies into living cells was suggested for the pathogenicity of anti- 
dsDNA autoantibodies (Yanase et al.,  1997). Cellular entry was found to be initiated 
by the binding of the nuclear localising anti-DNA antibodies to myosin  1, a  110-kDa 
cell  surface  receptor.  Myosin  1  is  expressed  on  the  surfaces  of  many  cell  types. 
Recent evidence suggests that within the cytoplasm, myosin  1 forms a complex with 
DNase I (Yanase et al.,  1997). Therefore internalization of anti-DNA antibodies by 
myosin 1 places them in proximity to DNase I, with the potential to interfere with the 
activity  of  the  enzyme  within  the  cell  (such  as  apoptosis).  Other  researchers 
suggested that antibody penetration depends on  binding to an extracellular  matrix 
protein  in  the  presence of DNA or a  membrane determinant  precisely  resembling 
DNA (Zack et al.,  1996).  It thus appears that a  subset of cross-reactive anti-DNA 
antibodies  might exert their  pathogenic effect  by cellular  penetration  and  nuclear 
localization (Madaio and Yanase, 1998).
Interestingly,  anti-dsDNA antibodies  have various effects  on  a  number of cellular 
cytokines, providing another feature that can explain their potential pathogenic effect 
in  lupus patients. Cellular interactions with anti-dsDNA antibodies have been shown
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to  be associated with  upreguiated  expression of IL-1,  IL-6,  IL-8,  and transforming 
growth factor-p (TGF-p) in supernatants of lupus Ig treated cells. IL-1, IL-6, IL-8 and 
TGF-p were determined in cultured human umbilical vein endothelial cells (HUVECs), 
incubated  with  control  IgG,  anti-dsDNA,  or  IgG  from  the  same  lupus  patients 
depleted of anti-dsDNA by affinity chromatography (Neng Lai et al.,  1996, Lai et al., 
1997).  Compared  with  control  IgG,  there  was  a  significant  increase  of  IL-1  in 
endothelial  cells (ECs)  incubated  with  anti-dsDNA.  IL-1  and  IL-6 were significantly 
elevated in ECs incubated with anti-dsDNA, compared with those incubated with anti- 
dsDNA-depleted-IgG  (Neng  Lai  et  al.,  1996).  Furthermore,  compared  with  either 
control IgG or anti-dsDNA-depleted-IgG, ECs incubated with anti-dsDNA-containing- 
IgG expressed higher levels of IL-8 and TGF-p (Lai et al., 1997).
In many patients with SLE,  increased renal disease activity is associated with  rising 
titres  of anti-DNA antibodies,  while  prophylactic treatment  of serologically  active 
patients with corticosteroids significantly reduces the number of subsequent disease 
flares,  contributing  to the suspicion that anti-dsDNA is a  specificity that  is  closely 
allied  with  clinical  disease.  Bootsma  and  colleagues  investigated  whether  giving 
prednisone when a rise in anti-dsDNA occurs can prevent these relapses (Bootsma et 
al.,  1995). They showed that treatment with prednisone as soon as a significant rise 
in anti-dsDNA occurs prevents relapse in most cases. However, doubling of the level 
of anti-dsDNA was taken  as  sufficient to trigger an  increase in  steroid  dose.  This 
doubling could occur within the normal range or only just outside of it.  In addition, 
the  potential  serious  complications of this  study cannot be  ignored.  The  patients 
were on high doses of steroid so much of the time that they had  many side effects 
such as weight gain and hypertension and made this treatment unattractive for many 
patients.  Furthermore, Alarcon-Segovia  and colleagues have recently reported that 
LJP 394,  an  immunomodulating  agent designed to  specifically downregulate  anti- 
dsDNA  producing  B  cells,  prolonged  the  time  to  renal  flare  and  decreased  the 
number of renal flares in a subgroup of lupus patients (Alarcon-Segovia et al., 2003). 
However, UP 394 was not significantly better than placebo when the whole group of 
patients in the trial is considered.
1.2.4.3  Cross-reactivity of anti-DNA antibodies with renal antigens
Nephritogenic anti-DNA antibodies may be polyreactive. Phosphodiester groups occur 
in  both  polynucleotides  and  PLs,  which  can  account  for  the  ability  of  some
monoclonal  and  serum  derived  lupus  autoantibodies  to  bind  to  both  species  of
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molecules. Therefore, the cross-reactivity of anti-DNA antibodies with CL and other 
negatively charged  PLs suggested that anti-DNA antibodies  might react with  renal 
tissue antigens that share epitopes with DNA (Shoenfeld et al.,  1983).  Furthermore, 
proteins  that  form  a  major  structural  component  of  glomerular  podocytes  and 
mesangial cells, such as laminin and a-actinin are known to play a prominent role in 
the pathogenesis of several experimental glomerulopathies.
Laminin  is  a  major non-collagenous  protein  constituent of the GBM.  Sabbaga  and 
colleagues reported that the interaction of a  murine monoclonal anti-DNA antibody 
with  extracellular glomerular antigens was found to  be due to the  binding of this 
antibody to laminin (Sabbaga et al.,  1989). In addition, this interaction was specific, 
since  it  was  inhibited  by  laminin,  dsDNA  and  ssDNA  in  solution.  Therefore,  the 
authors concluded that the polyreactivity of the anti-DNA antibody that confers to it 
the capacity to bind laminin, may account for its ability to form immune deposits by 
binding directly to non-DNA glomerular antigens. In addition, Amital and colleagues 
have  analyzed  the  fine  specificity  of the  interaction  of  pathogenic  murine  lupus 
autoantibodies with  laminin and found that pathogenic murine lupus autoantibodies 
react with  a 21-mer peptide located  in the globular part of the a-chain of laminin. 
Furthermore,  they  have shown that immunisation  of young  lupus-prone  mice with 
this peptide accelerated renal disease (Amital et al., 2005).
Mostoslavsky and colleagues investigated a panel of anti-DNA, anti-histone and anti- 
nucleosome mAb derived from  lupus-prone NZB/W or MRI_//pr mice for their in vivo 
pathogenicity,  using the RAG-1-deficient mouse model  (Mostoslavsky et al.,  2001). 
They  have  shown  in  this  model  a  group  of  anti-DNA,  but  not  anti-histone  or 
antinucleosome mAb were strongly pathogenic and could  be distinguished from the 
nonpathogenic  mAb  by  their  cross-reaction  with  a  ~100-kDa  glomerular  protein, 
identified  by mass spectrometry and Edman degradation as a-actinin. a-actinin  is a 
cross-reactive  target  for  pathogenic  anti-dsDNA  antibodies  in  renal  tissue,  and 
antigen expression and accessibility may contribute to the susceptibility of particular 
strains of mice to anti-dsDNA antibody-induced nephritis.
Deocharan and colleagues studied  R4A, a  pathogenic anti-DNA antibody and found 
that this antibody bound to and immunoprecipitated a  100-kDa protein identified as 
a-actinin from mesangial cell  lysates (Deocharan et al., 2002). This finding was not 
the case for a nonpathogenic mutant of R4A. The authors observed that binding was
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more apparent using  MRLJlpr than  nonautoimmune  BALB/c  mesangial  cell  lysates, 
suggesting that antigen expression  in the kidney plays a  role in anti-DNA antibody 
binding to renal tissue.  Furthermore, sera and  kidney eluates from lupus mice with 
active nephritis displayed  high titers of anti-a-actinin antibodies. The nature of the 
anti-DNA-reactive epitope in a-actinin is not known, a-actinin is a dimer composed of 
two  100-kDa  monomers that are arranged  in an antiparallel manner to form a rod­
shaped  molecule,  in which there  is a  high density of acidic residues with  negative 
electrostatic potential. This structure could potentially constitute a structural mimic to 
the  sugar-phosphate  backbone  of  the  DNA  double  helix.  Two  groups  have 
investigated  the differences  between  a  pathogenic and  non-pathogenic  subset  of 
anti-DNA  antibodies  and  whether  a  particular  antigen  was  involved  in  SLE 
pathogenesis.
What I  have discussed  so far are the findings of studies carried  out using  murine 
anti-DNA  mAbs,  which  suggest that  pathogenic anti-dsDNA  antibodies  cross-react 
with a-actinin.  To further elucidate the  nature of DNA/a-actinin cross-reactivity  in 
human lupus and to directly study the pathogenic potential of these antibodies, our 
group recently studied  binding to a-actinin  in  humans (Mason et al.,  2004).  Two 
human  mAbs  (RH14  and  B3),  which  cause  proteinuria  in  severe  combined 
immunodeficiency  mice  (SCID)  mice  bound  strongly to  a-actinin  in  ELISA,  while 
nonpathogenic DIL-6  bound very weakly.  Serum  samples from  patients  with  SLE 
were also tested,  a-actinin  binding  was found to be significantly higher in  patients 
than  in  healthy controls. A greater proportion of anti-dsDNA IgG-binding antibodies 
purified from patients with  renal disease bound to a-actinin than did those purified 
from the sera of patients without renal disease. The results published by our group 
support the findings of previous studies using murine anti-DNA mAbs, which suggest 
that some pathogenic anti-dsDNA antibodies cross-react with a-actinin.
The  question  regarding  which  glomerular  structures  (a-actinin,  nucleosomes,  or 
others) are recognised  by nephritogenic anti-dsDNA antibodies is still controversial. 
In a recent study, Kalaaji et al., (2006) determined which glomerular structures are 
recognised by monoclonal and in vivo bound nephritogenic antibodies. They analyzed 
sera  from  patients  with  lupus  nephritis,  from  random  ANA-positive  patients,  and 
paired antibodies from  sera  and  kidney eluates from  nephritic (NZB/W)Fi  mice for 
activity  against  proteins  identified  by  monoclonal  nephritogenic  antibodies,  and 
against  a-actinin,  dsDNA,  nucleosomes,  histone  HI,  HS,  DNase  I,  and  type  IV
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collagen.  Anti-a-actinin  antibodies  were  observed  In  human  and  murine  lupus 
nephritis sera and in sera from patients without SLE and were not detected in kidney 
eluates from nephritic mice. Antibodies to dsDNA and histone HI were detected in all 
eluates.  Western  blot analyses  revealed  that  nephritogenic anti-dsDNA antibodies 
recognised  histone  HI.  Competitive ELISA demonstrated  that nephritogenic  mAbs, 
and  dominant antibodies eluted from  nephritic  kidneys,  cross-reacted  with  dsDNA 
and HI. Immunoelectron  microscopic analysis of nephritic (NZB/W)Fi mouse kidneys 
revealed  that  antibodies  eluted  from  kidneys,  but  not  anti-a-actinin  antibodies, 
bound  to  distinct  nephritis-associated  electron-dense  structures  linked  to  GBMs 
(Kalaaji  et  al.,  2006).  From  their  experiments  it  seems  that  cross-reactive  anti- 
dsDNA/anti-histone  HI  antibodies  are central  among those deposited  in  nephritic 
glomeruli.
Zhao  and  colleagues  analyzed  the  reactivity  and  pathogenicity  of  monoclonal 
autoantibodies derived from  lupus patients with and without renal disease (Zhao et 
al., 2005). They have extensively characterised a panel of 10 IgM anti-dsDNA/anti-a- 
actinin  antibodies  that  was  generated  by  Epstein-Barr  virus  transformation  of 
lymphocytes from  patients with SLE and have shown that all anti-dsDNA antibodies 
isolated also bound a-actinin and cross-reactive antibodies bound to mesangial cells 
and to isolated glomeruli.  In addition the authors reported that binding to glomeruli 
was not inhibited by DNase treatment, but could be inhibited by a-actinin.
1.2.5  The role of nucleosomes in SLE
1.2.5.1  The nudeosome stucture
There  is  strong  evidence to  suggest that nucleosomes  are  important  in  both  the 
development of pathogenic antibodies in SLE and the interaction of these antibodies 
with tissues. The nucleosome is the fundamental unit of chromatin and consists of a 
core particle composed of an octamer of two copies each of histones H2A, H2B, H3, 
and H4, around which is wrapped round approximately 146 basepairs (bp) of helical 
DNA (Figure 1.2). Histones in the core associate among themselves primarily through 
their globular domains, while their basic amino-terminal segments are external and 
interact with DNA on the surface of the nucleosome.  Histone HI associates through 
its globular domain with the nucleosome core particle at the entry and exit points of 
the DNA strands to form a full nucleosome. The molecular weight of a  nucleosome 
particle  is  262-kDa  with  a  molar  ratio  protein/DNA  =  1.  This  highly  conserved
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structure occurs every 200±40 bp throughout all eukaryotic genomes.  Interestingly, 
chromatin  breakdown and  DNA fragmentation are common events in apoptotic cell 
death.  Linker DNA, which is accessible, is degraded by nuclear endonucleases upon 
activation in order to produce mono- and oligo-nucleosomes. Apoptotic cells are then 
an  important source of  nucleosomes.  In  physiological  conditions,  these apoptotic 
cells  are  recognised  and  engulfed  by  phagocytes  to  prevent  any  release  of  cell 
constituents in the extracellular environment.  Experimental  evidence suggests that 
SLE  patients  and  lupus  mice  have  been  shown  to  undergo  increased  rate  of 
apoptosis,  leading  to  an  increased  nucleosome  release  (apoptosis  is  very 
controversial since reduced apoptosis also mediates pathogenesis of SLE-discussed in 
more detail in section 1.2.3.3).
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DNA  H I  Histone
Nucleosome
Core of 8  Histone  molecules 
(2 molecules each of H2A, H2B, H3 and H4)
Figure 1.2 Diagramatic representation of the structure of a nucleosome
A  nucleosome consists  of an octameric  histone core,  containing two  molecules 
each  of H2A,  H2B,  H3 and  H4,  surrounded  by two turns of the  DNA  helix.  HI 
binds to the nucleosome where DNA enters and leaves the nucleosome.
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1.2.5.2  The role of anti-nucleosome reactivity in the pathogenesis of SLE
Free  nucleosomes  have  been  found  in  the sera  of  lupus  patients and  lupus  mice 
(Rumore  and  Steinman,  1990).  Interestingly,  a  positive  correlation  was  found 
between the presence of circulating nucleosomes in patients and the development of 
renal  and  neurological  manifestations  (Williams  et  al.,  2001).  Moreover,  anti- 
nucleosome  autoantibodies  as  well  as  autoreactive  Th  lymphocytes  specific  for 
nucleosomes  are  found  in  lupus  patients  (Datta,  1998).  Anti-nucleosome 
autoantibodies  are  actually  detected  very  early  during  the  disease  (before  anti- 
dsDNA and anti-histone antibodies) and are potentially nephritogenic in  lupus  mice 
(Amoura  et  al.,  1994).  Mohan  and  colleagues  have  reported  that  nucleosomes 
injected  into  young  SNF1  lupus  mice  increase  anti-dsDNA  and  anti-nucleosome 
autoantibody production and accelerate the disease (Mohan et al.,  1993).  All these 
reports support the hypothesis that nucleosome is a main lupus autoantigen and that 
circulating nucleosomes play a key role in lupus development. Importantly, the level 
of  circulating  anti-nucleosome  autoantibody  is  correlated  with  disease  activity  in 
humans.
Anti-nucleosome antibodies are  believed  to  be pathogenic in the form  of immune 
complexes which deposit in  kidneys,  causing  inflammation and tissue damage and 
also lead to activation of the complement system. Several mechanisms might explain 
the binding of anti-nucleosome antibodies to kidney cells, either directly or indirectly 
if  nucleosomes  are  "planted"  in  the  glomerular  tissue  due  to  its  affinity  for 
extracellular components where nucleosomes work as bridges.
In the direct-binding mechanism of anti-nucleosome antibodies to kidney cells, these 
antibodies  might  cross-react  with  non-nucleosomal  kidney  antigens,  as  it  was 
demonstrated for anti-dsDNA antibodies and cross-reaction with  a-actinin,  which  I 
have discussed above (Mostoslavsky et al., 2001). In the case of the indirect binding 
via  a  "planted  antigen",  nucleosome/anti-nucleosome  or  nucleosome/anti-DNA 
immune  complexes  have  been  shown  to  deposit  in  kidneys,  onto  the  GBM  (van 
Bruggen et al.,  1997). The sugar-phosphate backbone of DNA is negatively charged 
therefore  DNA  itself  is  unlikely  to  be  deposited  in  the  GBM  due to  repulsion  by 
similarly charged  molecules. The GBM also carries a strong  negative charge due to 
the  presence  of  glycosaminoglycan  side  chains,  particularly  HS.  Kramers  and 
colleagues demonstrated that for both monoclonal  murine antibodies and polyclonal 
human antibodies, both DNA binding and ability to cause nephritis could be reduced
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by purification under conditions in which antibody-nucleosome complexes dissociate 
(Kramers et al.,  1994). They suggested that the cause of renal damage was not the 
antibody itself but an antibody-nucleosome complex. The authors  investigated this 
using a rat kidney model.  Following renal perfusion of antibody,  no binding to the 
GBM was seen whereas  infusion of antibody complexed to nucleosome  resulted  in 
binding. Therefore the hypothesis is that the positively charged histones bind to the 
negatively charged HS in the GBM whilst the DNA part of the nucleosomes is bound 
by anti-DNA antibodies.  Thus nucleosomes  may act as a  bridge between  anti-DNA 
antibodies and the negatively charged HS in the GBM.
About 30% of SLE patients have no anti-dsDNA antibodies. Among these patients, 
about 65% are positive for anti-nucleosome antibodies (Amoura et al.,  2000b).  In 
this  study,  the  authors  have  shown  that  IgG  anti-nucleosome  antibodies  are 
significantly  increased  in  SLE.  Importantly,  IgG  anti-nucleosome  antibodies  were 
detected  in  both active and  inactive SLE  in contrast to IgG anti-dsDNA antibodies, 
which  were  nearly exclusively detected  in  active  patients.  This finding  shows that 
anti-nucleosome  maybe  more  important  in  some  people  than  others.  Moreover, 
active disease was marked  by a  unique increase in  IgG3 anti-nucleosome antibody 
levels during  SLE flares (Amoura  et al.,  2000a). This increase was also associated 
with  active  nephritis.  In  my  opinion,  clinical  studies  analysing  only  anti-DNA 
antibodies  ignore anti-nucleosome  antibodies,  which  can  be  important  in  disease 
diagnosis and activity assessment in patients negative for anti-DNA antibodies.
1.3 What is The Antiphospholipid Syndrome?
In  1983,  it was  recognised  that  in  patients  with  SLE the  presence  of  circulating 
antiphospholipid  antibodies  (aPL),  notably  lupus  anticoagulant  (LA)  and  anti-CL 
antibodies  (aCL),  was  associated  with  thrombosis,  pregnancy  complications  and 
thrombocytopenia (Hughes,  1983).  This association  was  later termed  APS  (Harris, 
1987). During the last 23 years, there has been enormous progress in the knowledge 
of different aspects of APS, but still a substantial number of questions, mainly about 
pathogenic mechanisms and treatment, remain unanswered.
1.3.1  Criteria for classification and diagnosis of the APS
By definition,  a  diagnosis of APS  requires  persistent  presence of  medium  to  high 
levels  of aCL  (IgG  or  IgM  isotype),  presence of  LA or  both.  A  recent consensus
57Chaoter One Introduction
provides simplified criteria for the diagnosis of APS (Table 1.3) (Wilson et al.,  1999, 
Miyakis et al.,  2006).  A  patient with  APS  must  meet at  least one of two  clinical 
criteria  and  at  least  one  of  two  laboratory  criteria.  APS  is  divided  into  several 
categories.  "Primary" APS  occurs  in  patients  without clinical  evidence  of another 
autoimmune disease,  whereas "secondary" APS occurs in association  with  another 
autoimmune disease.  SLE  is by far the  most common  disease with which the APS 
occurs. A minority of patients with APS present with  multiple simultaneous vascular 
occlusions throughout the body, often resulting in death. This acute and devastating 
syndrome,  termed "catastrophic" APS,  is defined  by the clinical  involvement of at 
least  three  different  organ  systems  over  a  period  of  days  or  weeks  with 
histopathological evidence of multiple occlusions of large or particularly small vessels 
(Asherson,  1998). The classification criteria have helped to focus research but have 
their  limitations  since they do  not  include some clinical  manifestations  associated 
with APS such as cardiac valve disease and cerebral ischemia. aPL are found among 
young, apparently healthy control subjects at a  prevalence of 1.5% to 5% for both 
aCL and LA . The prevalence of aPL increases with age and is much higher among 
patients with SLE, with figures ranging from  12-30% for aCL and  15-34% for the LA 
(Cervera et al.,  1993). APS has been shown to develop in up to 50-70% of patients 
with SLE who are aPL positive (Petri, 2000). However, many healthy individuals have 
laboratory evidence of aPL without clinical consequences.
1.3.2  Clinical Features of the APS
Thrombosis within the venous or arterial circulation  is a  major and  most common 
clinical manifestation of this syndrome (Table 1.4). Any size of vessel of any organ 
may be affected. In the venous circulation, deep or superficial vein thrombosis of the 
legs is  particularly common occurring in  31 to 55% of patients with the syndrome, 
half of whom  also  have  pulmonary emboli  (Asherson  et al.,  1989,  Cervera et al., 
2002).  Arterial thromboses are less common than  venous thromboses and  involve 
the brain in up to 50% of cases, presenting as transient ischemic attacks or strokes 
(7 to  13%) (Cervera et al.,  2002).  Other anatomic sites for arterial thrombosis are 
the  heart  (25%),  causing  coronary occlusion,  and  the eye,  kidney and  peripheral 
arteries (25%). Thrombocytopenia, present in up to half of the patients with APS, is 
a  prominent  manifestation  of  the  condition  and  occasionally  patients  can  also 
develop a form of haemolytic anaemia (6 to 20%  patients).  A skin  rash  known  as 
livedo reticularis,  whose severity varies enormously from a confined area of skin to 
large  parts  of the  arms  or  legs,  is  a  recognised  prominent  complication  of  the
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syndrome (occurs in  11 to 22% of patients) (Cervera et al., 2002). These lesions are 
characterised by thrombi in the intradermal vessels.
A particularly striking feature of PAPS is the development of recurrent, spontaneous 
fetal  loss. The risk of pregnancy loss in women with aPL is greatest from the 10th 
week of gestation onward (fetal period) (Wilson, 2001). This finding is in contrast to 
pregnancy loss in the general  population, which is most frequent during the first 9 
weeks of gestation (Morrow et al.,  1999). There is also evidence that women  with 
aPL  have  an  increased  risk  of  giving  birth  to  a  premature  infant  because  of 
pregnancy-associated  hypertension  and  uteroplacental  insufficiency  (Lima  et  al.,
1996). It has also been proposed that aPL may also impair trophoblast invasion and 
hormone production  (Di Simone et al.,  2000). The prevalence of pregnancy loss in 
patients with aPL has not yet been established, however, in aPL-positive patients, the 
risk of pregnancy loss is directly related to the levels of aPL, mainly aCL IgG isotype. 
According  to  a  cohort  study  of  1000  patients,  the  most  common  obstetric 
complications  in  the  mother  were  preeclampsia  (9.5%  of  pregnant  women), 
eclampsia (4.4%), and placental abruption (2.0%) (Cervera et al., 2002).
Treatment  decisions  for  the  APS  fall  into  four  main  categories:  prophylaxis, 
prevention  of further thromboses of large vessels,  treatment of acute thrombotic 
microangiopathy and  management of recurrent fetal  loss.  Many clinicians  use low 
dose aspirin in  patients with no history of thrombosis but persistently high IgG aPL 
and/or  positive  LA.  The  immediate  management of arterial  or venous thrombotic 
events follows standard  methods of anticoagulation using  heparin  initially, followed 
by  warfarin.  Anticoagulation  should  be  balanced  against the  risks,  particularly  of 
major  haemorrhage.  Options  for  the  management  of  pregnancy  in  aPL  positive 
patients include low dose aspirin or anticoagulation with subcutaneous low molecular 
weight heparin. In patients known to have aPL, it is generally wise to avoid exposure 
to other procoagulant factors such as oral contraceptives. Improvement in treatment 
awaits  the  further  elucidation  of  pathogenic  mechanisms  (Ruiz-Irastorza  and 
Khamashta, 2005).
59C
h
a
p
t
e
r
 
O
n
e
 
 
 
 
 
I
n
t
r
o
d
u
c
t
i
o
n
Vascular thrombosis
a) One or more clinical episodes of arterial, venous or small-vessel thrombosis in any tissue or organ AND
b) Thrombosis confirmed by imaging or Doppler studies or histopathology, with the exception of superficial venous thrombosis AND
c) For histopathological confirmation, thrombosis present without significant evidence of inflammation in the vessel wall.
Pregnancy morbidity
a) One or more unexplained deaths of a  morphologically normal foetus at or beyond the  10th week of gestation, with  normal foetal 
morphology documented by ultrasound or by direct examination of the foetus OR
b) One or more premature births of a  morphologically  normal  neonate at or before the 34th week of gestation  because of severe 
placental insufficiency OR
c) Three or  more unexplained  consecutive spontaneous abortions  before the  10th week of gestation,  with  maternal,  anatomic or 
hormonal abnormalities and paternal and maternal chromosomal causes excluded.
Laboratory criteria
a) Anti-cardiolipin antibody of IgG and/or IgM isotype in blood, present in medium or high titre on at least two occasions at least 12 
weeks apart, measured by standard ELISA for (3 2-Glycoprotein I dependent anti-cardiolipin antibodies OR
b) Lupus anticoagulant present in plasma on two or more occasions at least six weeks apart, detected according to the guidelines of 
the international Society on Thrombosis and Haemostasis OR
c) Anti-p2  glycoprotein-I antibody of IgG and/or IgM isotype in serum or plasma, present on two or more occasions, at least 12 weeks 
apart, measured by a standardised ELISA, according to recommended procedures
Table 1.3 Preliminary classification criteria for the Antiphospholipid Syndrome (Wilson et al., 1999, Miyakis et al., 2006)ORGAN SYSTEM PRIMARY PATHOGENIC PROCESS
Arterial Thrombosis of the aorta or axillary, carotid, hepatic, mesenteric, pancreatic, splenic artery
Cardiac Angina, myocardial infarction, valvular abnormalities, atherosclerosis
Cutaneous Superficial thrombophlebitis, splinter hemorrhages, leg ulcers, Livedo reticularis, purpura
Endocrine Adrenal infarction, necrosis of the pituitary gland
Gastrointestinal Hepatic infarction, intestinal infarction, splenic infarction, ascites
Haematologic Thrombocytopenia, haemolytic anaemia
Miscellaneous Perforation of the nasal septum or avascular necrosis of bone
Neurologic Transient ischaemic attack, stroke, seizures, multi-infarct dementia, encephalopathy, migraines, 
cerebral venous thrombosis
Obstetrical Pregnancy loss, intrauterine growth retardation, uteroplacental insufficiency
Opthalmologic Thrombosis of the retinal artery, thrombosis of the retinal vein
Pulmonary Pulmonary emboli, pulmonary hypertension, pulmonary arterial thrombosis, alveolar hemorrhage
Renal Thrombosis of the renal vein, thrombosis of the renal artery, renal infarction, hypertension, acute 
renal failure, chronic renal failure, proteinuria, haematuria
Venous Deep venous thrombosis of the legs or thrombosis of the adrenal, hepatic, mesenteric, or splenic vein
Table 1.4 Clinical manifestations of the Antiphospholipid Syndrome (Levine et al., 2002)Chaoter One Introduction
1.3.3  Antiphospholipid Antibodies
1.3.3.1  Detection of clinically relevant aPL
aPL are Igs of IgG, IgM, and IgA isotypes that target PLs and/or PL-binding plasma 
proteins. There are two broad categories of PLs. The neutrally charged  PLs include 
phosphatidyl ethanolamine,  phosphatidyl choline (PC) and  platelet-activating factor. 
Negatively  charged  PL  include  phosphatidyl  glycerol,  phosphatidyl  serine  (PS), 
phosphatidic acid, phosphatidyl inositol, and CL (Morrow et al., 1999).
aPL, notably the LA antibodies, aCL antibodies, and anti-fr-Glycoprotein I (faGPI) are 
the serological  hallmarks of APS and the  most-useful determinations for screening 
patients (Levine et al., 2002).  Division into these subgroups is broadly based on the 
method  of detection.  aPL  are  detected  by  coagulation  assays  that  indicate  the 
inhibition  of  PL-dependent  coagulation  reactions  and  by  immunoassays  that  use 
solid-phase PLs and protein cofactors as antigenic targets. In general, LA antibodies 
are more specific for APS, whereas aCL antibodies are more sensitive (Levine et al., 
2002).  Therefore,  the  most  sensitive  test  for  aPL  detection  is  a  solid-phase 
immunoassay for aCL which was initially introduced in  1983 (Harris et al., 1983). IgG 
and IgM are the isotypes usually measured and they are expressed in GPL and MPL 
international  units  (IU),  respectively.  However,  there  is  no  definitive  association 
between specific clinical manifestations and particular subgroups of aPL. Therefore, 
multiple tests for aPL should be performed, since patients may be negative according 
to one tests yet positive according to another. There are 30% of patients with only 
LA or aCL,  therefore to identify all  patients with aPL both  LA and  aCL have to  be 
measured (Cuadrado and Lopez-Pedrera, 2003). The anti-faGPI assay shows higher 
specificity than aCL for APS diagnosis. In 3-10% of APS patients, anti-p2 GPI may be 
the only test positive (Miyakis et al., 2006).
aPL  can  occur  in  patients  with  a  variety of  infectious  or  neoplastic  conditions  or 
patients exposed to certain  medications.  However, these antibodies usually are not 
related  to  the  clinical  manifestations  of  the  APS  and  are  different  from  those 
generated in patients with the syndrome. They are not associated with an increased 
risk of thrombosis  and  bind  to  both  neutral  and  anionic  PL  (Hunt et al.,  1992). 
Several  groups have reported that the predominant reactivity is against a complex 
formed  by  CL  and  serum  PL-binding  proteins  ("cofactors")  rather than  reactivity 
against CL per se (Ordi et al.,  1993, Galli et al.,  1990, McNeil et al.,  1990). aPL have
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been  shown  to  be directed  against a  variety  of other  PL  binding  serum  proteins 
which include protein C, protein S and prothrombin (PT) (Bevers et al., 1991, Oosting 
et al.,  1993). The most commonly studied however is p2 GPI, which associates with 
negatively  charged  PLs  through  charge  interactions.  In  contrast  to  antibodies 
generated  in  patients with APS, which  recognise p2 GPI  on  PL-binding  proteins and 
thus are referred to as being cofactor-dependent, the aPL that occur in patients with 
infections generally recognise PL epitopes and bind directly to negatively charged PLs 
themselves. This phenomenon distinguishes "non-pathogenic" and "pathogenic" aPL.
McNeil  and  colleagues  purified  aPL that exhibit  binding  in  a  CL  ELISA.  However, 
these  highly  purified  aPL did  not  bind  to the CL when  assayed  by a  modified  CL 
ELISA in which the blocking agent did not contain bovine serum, nor did they bind to 
PL affinity columns  (McNeil  et al.,  1990).  Binding to the  PL antigen  only  occured 
when  normal  human  plasma,  human  serum,  or  bovine  serum  was  present, 
suggesting that the binding of aPL to CL requires the presence of a serum cofactor. 
Using sequential PL affinity, gel-filtration, and ion-exchange chromatography, McNeil 
and  colleagues  purified  this  cofactor  to  homogeneity  and  have  shown  that  the 
binding  of aPL to CL  requires the  presence of this  cofactor  in  a  dose-dependent 
manner.  Using  N-terminal  region sequence analysis of the  molecule they  identified 
the cofactor as p2 GPI (McNeil et al.,  1990). Their findings indicate that the presence 
of p2 GPI is required for some antibody-PL interaction, suggesting that bound  (32 GPI 
forms the antigen to which aPL are directed.
Ordi  and  colleagues  used  a  similar  approach,  a  standard  ELISA  method  and  a 
modified  ELISA to study four groups of patients  (Group  1-  patients with  aCL and 
autoimmune disease [SLE and PAPS]; Group 2- patients with aCL, no symptoms and 
no  underlying  infection  or autoimmune  disease;  Group  3-  patients  with  aCL  and 
infectious diseases  [syphilis,  leprosy,  HIV  infection  and Q fever];  Group 4- control 
group). They observed that 19 of 20 samples from patients in Group 1  had cofactor 
dependence in aCL activity and  17 of 19 samples from patients in Group 3 had aCL 
activity,  which  was  independent  of the  presence  of the  cofactor.  Three  of four 
patients in Group 2 had cofactor independent aCL and one had cofactor dependent 
aCL activity.  None of the samples from the control group had aCL.  In addition, the 
authors have shown that aCL related clinical manifestations (thrombosis) depend on 
the presence of cofactor dependent aCL and not on cofactor independent aCL (Ordi 
et al.,  1993).  Absence of cofactor dependency  however was  shown  with  the  IgM
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APS-derived antibodies,  HVA2 and  HLC9. These antibodies presented  polyreactivity 
to several PLs- CL,  PS,  phosphatidyl ethanolamine,  phospatidyl inositol and PC- but 
not to p2 GPI (Buschmann et al., 2005).
Forastiero et al., (2005) assessed the contribution of antibodies to p2 GPI and  PT to 
the thrombotic risk in a cohort of 194 patients with  persistent LA and/or aCL.  IgG 
anti-frGPI  and  anti-PT  antibodies  were  associated  with  an  increased  risk  of 
thrombosis.  Patients testing positive for anti-faGPI  had a  higher rate of thrombosis 
than  did  antiphospholipid  patients  without  anti-p2 GPI.  Similarly,  a  higher  rate  of 
thrombosis  was  found  in  patients  with  positive  anti-PT  compared  with  patients 
without anti-PT (Forastiero et al., 2005).
1.3.3.2  The role of aPL in the APS
Unlike  anti-dsDNA  antibodies,  aPL  do  not form  immune  deposits  in  the  affected 
tissues and rarely produce significant amounts of inflammation.  aPL exhibit multiple 
effects because of the many biological processes that involve PLs and PL membranes 
hence it is difficult to determine whether these are clinically relevant.  However, the 
major features of APS arise from thrombosis.  No single mechanism  is accepted as 
the main cause of thrombosis in APS. The fact that thrombosis in APS is episodic and 
localized suggests that the presence of high  levels of aPL alone are not enough to 
trigger it. Any proposed aPL-mediated effects that are based on in vitro studies must 
be assessed  in vivo in animal  models and clinical  studies to evaluate significance. 
Evidence accumulated from animal models of the APS, where different groups induce 
the APS in normal mice by both the passive transfer of aPL and active immunisation 
with aPL or p2 GPI, indicate that aPL can play a role in the development of thrombosis 
and pregnancy loss [reviewed in (Radway-Bright et al., 1999)].
There are few models of the thrombosis found  in  patients with APS.  Pierangeli and 
colleagues (Pierangeli et al.,  1994,  Pierangeli et al.,  1996) have developed a  novel 
mouse model  of induced venous thrombosis to study the role of autoantibodies  in 
thrombus formation. To  determine whether Igs from  patients with the APS  play a 
role in thrombosis, the authors passively immunised groups mice,  intraperitoneally, 
either with Igs (IgG, IgM and IgA) purified from patients with the APS or with Igs of 
the  same  isotype from  healthy  controls.  Each  animal  was  anesthetised  and  the 
femoral vein  minimally mobilised and subjected to a  standardised  "pinch"  injury to
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induce  thrombosis.  The  vessel  was  transilluminated  and  clot  formation  and 
dissolution  were  visualised.  The  authors  noted  that  in  eight  out  of  nine  Ig 
preparations  from  patients  with  APS  there  was  a  significant  increase  in  mean 
thrombus  area  and  a  significant  delay  in  mean  thrombus  disappearance  time 
compared to mice that received  Ig from healthy people (Pierangeli et al.,  1994).  In 
addition,  Pierangeli  and  colleagues  compared  the  effects  on  thrombus  formation 
produced by separate groups of mice injected with affinity-purified IgG or IgM aCL or 
with  normal  Igs  of  the  same  isotype  to  determine  whether  aCL  are  involved 
(Pierangeli et al.,  1996). They have observed that mean  thrombus area and  mean 
disappearance times were again  significantly  increased  in  all  four groups  injected 
with affinity-purified aCL antibodies. This study was the first to show that aCL of IgG, 
IgM and IgA isotypes may play a  role in thrombosis  in vivo. The drawback of this 
work however, is that not all aPL can mediate this effect in the model and the pinch 
injury used in this model provides a second stimulus for the cause of thrombosis.
In a  later study, the same authors  (Pierangeli et al.,  1999) tested  human affinity- 
purified aPL from patients with the APS, in the mouse model of microcirculation that 
allows direct microscopic examination of thrombus formation and adhesion of white 
blood cells to ECs in the cremaster muscle as an indication of EC activation in vivo. 
Adhesion molecule expression on HUVECs after aPL exposure was also performed to 
confirm EC activation in vitro.  Pierangeli and colleagues demonstrated that all 6 aPL 
significantly  increased the expression  of VCAM-1,  with  one of the antibodies also 
increasing  the  expression  of  E-selectin  on  HUVECs  in  vitro.  In  the  in  vivo 
experiments,  they  showed  that each  aPL  antibody,  except from  one  preparation, 
increased  white  blood  cell  sticking  compared  with  control,  which  correlated  with 
enhanced thrombus adhesion (Pierangeli  et al.,  1999). Therefore, activation of ECs 
by aPL in  vivo may create a  prothrombotic  state on  ECs,  which  may  be the first 
pathophysiological event of thrombosis in APS.
Jankowski  and  colleagues  adapted  a  hamster  model  of  arterial  thrombosis 
(Jankowski et al., 2003). This animal model complies with the concept of thrombosis 
as  a  "double-hit"  phenomenon.  Very  mild  thrombosis  is  provoked  by  limited 
photochemically  induced  injury to the vessel  wall  ("first hit").  Three  mAbs  raised 
against human foGPI were selected on the basis of their crossreactivity with hamster 
p2 GPI.  Two of these, one with  LA activity,  5H2, and one with only aCL properties, 
11E8, were infused prior to photochemically induced vessel damage.  5H2 promoted
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thrombus formation dose dependency. The LA mAb 11E8 reactive with human p2 GPI 
exclusively, did not significantly promote thrombus formation. mAb 27A8, non-cross­
reacting with hamster frGPI and chosen as a negative control, had no clear effect.
In  another  animal  model,  Fischetti  et  al.,  (2005)  used  intravital  microscopy  to 
monitor the vascular changes that occur in rats following the intraarterial injection of 
aPL. Their results showed that human polyclonal IgG with anti-02 GPI activity triggers 
clotting  in  the  microcirculation  of  rat  mesentery  in  the  presence  of  a  priming 
proinflammatory  stimulus.  In  this  case this group did  not  induce a thrombogenic 
injury by a mechanical or photochemical damage of the vessel wall. Their approach 
was to mimic more closely the in vivo situation using a cofactor commonly occurring 
in patients with APS and unable to trigger clotting per se, such as LPS. They showed 
that the endothelial cells seem to play a critical role in the initiation of aPL antibody- 
mediated thrombosis in this model. aPL injected into LPS-treated rats targeted to the 
endothelium of the mesenteric microvessels. The binding appears to be selective for 
the  anti-p2 GPI  antibodies  because  deposits  of  IgG  were  not  observed  in  rats 
receiving aPL-positive IgG depleted of anti-p2 GPI  antibodies.  Weak deposits of IgG 
not associated  with the formation  of thrombi  were seen  in  rats treated  with  aPL- 
positive IgG  in  the absence of  LPS.  To  explain  the  increased  antibody deposition 
observed after injection of LPS and aPL the authors suggested that LPS up-regulates 
the expression  of the  ligand  for p2 GPI on  endothelial  cells  or  synergizes with the 
antibodies  in  clustering  the  ligand  capable  of  stimulating  the  endothelial  cells 
(Fischetti et al., 2005).
A  study  performed  by  Blank  and  colleagues  provides  more  direct evidence  of a 
pathogenic role of aPL in obstetric manifestations of APS. Blank et al., (1991) infused 
murine monoclonal aPL and human polyclonal IgG aPL from a patient with PAPS into 
the tail vein  of pregnant mice to evaluate the effect on fecundity,  fetal  loss (fetal 
resorption),  and  the  weight of embryos and  placentae.  They demonstrated  lower 
fecundity rate,  increased  resorption  index of embryos (equivalent to recurrent fetal 
loss), lower number of embryos per pregnancy, and lower mean weights of embryos 
and placentae in comparison to mice infused with appropriate control Igs (murine or 
human control  Ig  lacking aPL binding) (Blank et al.,  1991). Therefore, their results 
showed that aPL have direct effects on fecundity and on the outcome of pregnancy 
in this murine model.
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In  another study,  a  significantly  higher  rate of fetal  resorptions  with  a  significant 
reduction in fetal and placental weight was found in pregnant BALB/c mice injected 
with human monoclonal IgG aPL from a PAPS patient compared to mice injected with 
a  control  human  monoclonal  IgG  antibody  lacking  aPL  activity  (Ikematsu  et  al., 
1998).
Other models of APS exist,  mainly in  mice that are prone to spontaneously develop 
autoimmune disease (systemic lupus-like illness).  Hashimoto and colleagues found 
that  (NZWxBXSB)Fi  mice produce  high  titres of aCL and  develop abnormally  high 
incidence of degenerative coronary vascular disease with  myocardial  infarction and 
thrombocytopenia  (Hashimoto  et  al.,  1992).  Futhermore,  MRL/Ipr  mice 
spontaneously develop some features similar to  human APS such as high  levels of 
IgG  aCL,  thrombocytopenia  and  poor  pregnancy outcome  (Gharavi  et al.,  1989). 
Another group reported histologic evidence of central nervous system thromboses in 
M RLJlpr mice  (Smith  et  al.,  1990).  However,  there  are  differences  between  the 
models compared to human  SLE and APS.  The  marked  lymphadenopathy found  in 
MRL/lpr mice  is  not a common feature of SLE.  The autoimmune  mice with  murine 
lupus almost invariably die of severe glomerulonephritis, whereas less that 50% of 
patients with SLE develop renal involvement.
1.3.4  Mechanisms of pathogenesis in the APS
Several  hypotheses  have  been  proposed  to  explain  the  cellular  and  molecular 
mechanisms  by  which  aPL  promote  thrombosis.  The  present  hypotheses  for 
pathogenic  mechanisms  in the APS  are  summarised  in  Figure  1.3.  However,  the 
major mechanisms of hypercoagulability  in  APS  involve up-regulation  of the tissue 
factor (TF) pathway,  inhibition of the protein C pathway and the interaction of aPL 
with the endothelium.
It is known that aPL are able to recognise, injure, and/or activate cultured vascular 
ECs.  Binding  of aPL  induces  EC  activation,  as  evaluated  by  up-regulation  of the 
expression  of  adhesion  molecules  (intercellular  adhesion  molecule  1  (ICAM-1), 
VCAM-1  and  E-selectin)  and  up-regulation  of  cytokine  secretion  (George  et  al., 
1998a).
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Comparable  findings  have  also  been  reproduced  in  murine  in vivo experimental 
models of microcirculation as discussed in the section above (Pierangeli et al.,  1999, 
Pierangeli  et al.,  2000).  The  same authors  used  ICAM- 1-deficient and  ICAM-1-/P 
selectin-deficient mice to  determine whether aPL enhance thrombus formation  or 
increase leukocyte adhesion to  ECs of mouse cremaster muscle compared with the 
corresponding wild-type mice (Pierangeli et al.,  2001).  In  both  ICAM-l 7 '  mice and 
ICAM-l'^/P-selectin7'  mice,  IgG  aPL  affinity  purified  from  an  APS  patient  did  not 
increase  leucocyte  adhesion  to  ECs  nor  did  these  antibodies  enhance  thrombus 
formation (Pierangeli et al.,  2001).  In  the  in vitro studies aPL binding to ECs was 
dependent upon the presence of p2 GPI (Del  Papa et al.,  1995).  p2 GPI was found to 
adhere to human endothelial  and trophoblast cell  membranes and to offer suitable 
epitopes for circulating anti-p2 GPI  antibodies. The binding  of circulating anti-p2 GPI 
antibodies to cell adhered  p2 GPI  was  shown  to  induce functional  effects  (such  as 
increased  adhesion  moiecule  expression,  up-regulation  of cytokine  secretion  and 
arachidonic acid  metabolism)  potentially  related to the pathogenesis of the clinical 
manifestations of APS such as thrombotic events and fetal loss (Meroni et al., 2000).
TF is the physiological initiator of normal coagulation and a major initiator of clotting 
in  thrombotic  disease.  Structurally,  TF  is  a  member  of  the  cytokine  receptor 
superfamily;  it is a 47-kd transmembrane glycoprotein that serves as both  receptor 
and enzyme activator for plasma and is constitutively expressed on the surfaces of 
various cell types (e.g.  ECs and monocytes) in  response to various stimuli including 
bacterial LPS, immune-complexes, IL-1 and TNF (Dobado-Berrios et al., 2001). Data 
obtained from a number of studies suggest that increased TF activity is an important 
cause  of  hypercoagulability  in  the  APS  [reviewed  in  (Roubey,  2000)].  Potential 
mechanisms  contributing  to  upregulation  of  the  TF  pathway  include  increased 
expression  of TF due to  increased transcription,  increased functional activity of TF 
molecules due to de-encryption and decreased activity of TF pathway inhibitor. Anti- 
p2 GPI  autoantibodies  have  been  specifically  implicated  in  the  antibody-mediated 
enhancement of TF activity.
The protein C pathway is an important feedback mechanism for controlling thrombin 
formation,  and  thus  has  an  anti-thrombotic  effect.  Protein  C  is  a  vitamin-K- 
dependent serine proteinase, a heterozygous deficiency of which results in recurrent 
thrombotic  disease  (Mackworth-Young,  2004).  Activated  protein  C  combines  with 
another cofactor,  protein  S,  in  the  presence of PL to  catalyse the degradation  of
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factors Va and Villa of the coagulation pathway.  For this to occur, protein C is first 
converted to its active form by thrombin in the presence of thrombomodulin, an EC- 
derived cofactor.  Protein C is a  potential target for antibodies in  APS.  It has  been 
shown that aPL can  interfere with the protein  C system  by different mechanisms, 
which include the inhibition of thrombin formation, decrease of protein C activation 
by the thrombomodulin thrombin complex, inhibition of protein C complex assembly, 
inhibition  of protein  C activity directly or via  its cofactor protein  S, and  binding to 
factors Va  and  Vila  in  a  manner that protects them from  proteolysis by activated 
protein  C  (de  Groot  et  al.,  1996).  It  has  been  described  that aPL  isolated  from 
patients can  inhibit protein  C  activity. To  investigate if aPL are directed  against a 
combination of PLs and  protein  C or protein S, Oosting and colleagues studied IgG 
fractions from the 30 patients, of whom 26 had aPL and 23 had thrombosis (Oosting 
et al.,  1993).  The authors  found  that the antibodies  responsible for  inhibiting Va 
degradation  were  directed  against PL-bound  protein  C or  protein  S.  Other groups 
have  also  demonstrated  that  aPL  derived  from  patients'  serum  impairs  the 
degradation of factor V by protein C in vitro (Marciniak and Romond, 1989, Borrell et 
al., 1992).
The  pathogenic  mechanisms  contributing  to  obstetric  complications  are  not  fully 
understood  either.  Originally  aPL  were thought to  cause  pregnancy  morbidity  by 
placental  thrombosis  but  recently there  has  been  more compelling  evidence of a 
direct effect  upon  maternal  and fetal  cells.  For  instance,  it  has  been  shown  that 
purified  aPL  can  bind  specifically  to  placental  antigens,  providing  a  potential 
mechanism for nonthrombotic placental damage and  impaired  foetal  blood  supply. 
Donohoe  and  colleagues  developed  an  immunofluorescent  technique  to  detect 
human aPL binding to human placenta and demonstrated binding to the placenta by 
affinity purified aPL from five of six patients with the APS (Donohoe et al.,  1999). 
They have also  performed  preliminary sodium dodecyl  sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting studies that demonstrated that aPL 
bind a number of placental  proteins (Donohoe et al.,  1999).  aPL and antibodies to 
p2 GPI  have also  been  found to  modify trophoblast  proliferation  and differentiation 
(Chamley et al., 1998).
Defective endovascular trophoblast invasion,  rather than  intervillous thrombosis,  is 
the  most  frequent  hostological  abnormality  in  PAPS-positive  associated  early 
pregnancy  loss  (Sebire  et  al.,  2002).  Sebire  and  colleagues  examined  placental
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histopathology  in  patients  with  a  history  of recurrent  miscarriage,  both  with  and 
without  PAPS.  They  confirmed  that  the  major  pathophysiologic  mechanism  is 
uteroplacental  vasculopathy,  such  as  placental  infarction  and  preeclampsia.  In 
addition,  in  this  study  only  one  case  of  fetoplacental  vascular  thrombosis  was 
identified;  this  occurred  in  a  clinically  uncomplicated  PAPS-positive  pregnancy 
delivered at 38 weeks. Their findings therefore do not support the hypothesis that 
pregnancy complications in  PAPS are related to intraplacental thromboses, although 
this could occur in failed pregnancies as opposed to those successfully treated and 
resulting in live birth (Sebire et al., 2003).
While antigenic epitopes recognised by aPL are important in the pathogenesis of the 
APS,  there is emerging  evidence that the complement pathway may mediate fetal 
damage (Salmon et al., 2002).  Holers et al., (2002) used a murine model of APS in 
which  pregnant  mice  are  injected  with  human  IgG  containing  aPL to  investigate 
whether  these  antibodies  activate  complement  in  the  placenta,  generating  split 
products that mediate placental injury and lead to fetal loss and growth retardation. 
They found that inhibition of the complement cascade in vivo blocks fetal  loss and 
growth retardation and mice deficient in complement C3 were resistant to fetal injury 
induced  by aPL  (Holers  et  al.,  2002).  Similarly,  (Girardi  et al.,  2003)  also tested 
complement activation  in  pregnant mice that received  human  IgG containing  aPL. 
They  identified  complement component C5  (and  particularly  its  cleavage  product 
C5a) and neutrophils as key mediators of fetal injury and showed that antibodies that 
block C5a-C5a receptor interactions prevent pregnancy complications.
Despite the multiple ways by which aPL could cause pathology, many individuals with 
high IgG aPL levels do not develop features of APS. This may be due to the particular 
pattern  of antibody specificities  in their serum.  However,  it appears that for  many 
people other factors may be needed for the expression of the APS, i.e. a 'second hit' 
is  required.  aPL  would  be  responsible for a  hypercoagulable  state and  a  second 
stimulus,  such as other thrombotic risk factors,  infections, or drugs, would  lead to 
the development of thrombosis.
1.3.5  The role of T cells and cytokines in the APS
Cytokine abnormalities have been implicated in the pathogenesis of fetal loss, one of 
the major manifestations of the APS.  Interleukin-3 (IL-3) is an important factor that 
aids  in  embryo  implantation  and  placental  development.  IL-3  was  found  to  be
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decreased both in pregnant women with APS compared with a control group, and in 
animal models of APS (Shoenfeld et al.,  1998). In another study, where primary APS 
was  induced following  immunisation of BALB/c mice with a human  monoclonal aPL 
antibody (H-3), analysis of the cytokine profile of the mice with the APS indicated low 
production of IL-2, IL-3 and granulocyte-macrophage colony-stimulating factor (GM- 
CSF)  (Fishman et al.,  1993). The authors concluded that administration  of murine 
recombinant  IL-3  led  to  a  dramatic  reduction  in  the  fetal  resorptions  rate  and 
thrombocytopenia associated with the experimental APS was also corrected following 
IL-3 administration (Fishman et al., 1993).
To examine antigen recognition profiles and Th cell activity in p2 GPI reactive T cells. 
Arai  et al.,  (2001) generated  14 CD4+ T cell  clones specific to  p2 GPI from  three 
patients  with  APS.  At  least  four  distinct T cell  epitopes  were  identified,  but  the 
majority of the foGPI  specific T cell  clones  responded to a  peptide encompassing 
amino acid residues 276 to 290 of p2 GPI containing the major PL binding site. Ten of 
12 p2 GPI specific T cell clones stimulated peripheral blood B cells that produced anti- 
p2 GPI  antibody  in  the  presence of recombinant  p2 GPI.  Th  cell  activity  was  found 
exclusively  in T cell  clones  capable of producing  IL-6.  In vitro anti-p2 GPI antibody 
production induced by T cell clones was inhibited by either anti-IL-6 or by the anti- 
CD40  ligand  mAb.  In  addition,  exogenous  IL-6  augmented  anti-p2 GPI  antibody 
production in cultures of B cells with T cell clones lacking IL-6 expression. The results 
of this study indicate that p2GPI specific CD4+ T cells in APS patients preferentially 
recognise the antigenic peptide containing the major PL binding  site and  have the 
capability to stimulate B cells to produce anti-p2 GPI antibody via expression of IL-6 
(Arai et al., 2001).
T cells appear to  play a  major part in the pathogenesis of APS since autoantibody 
production  by B cells generally requires T cell  help.  Experimental  primary APS was 
induced  in  mice following  active immunisation  with  aPL  mAb and T cells from the 
APS  mice  were  infused  into  BALB/c  recipients  (Blank  et  al.,  1995).  The  authors 
observed  high  serum  titers  of aPL  and  clinical  features  of  primary APS,  including 
thrombocytopenia and a  high frequency of fetal  resorptions. T cell-depleted  bone 
marrow cells did  not transfer the disease (Blank et al.,  1995).  In addition, another 
group treated  BALB/c  mice with  anti-CD4  mAb either  before or after  induction  of 
experimental APS and  SLE (Tomer et al.,  1994). The treated  mice did  not develop
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proteinuria,  had fewer episodes of fetal  resorption and  significantly lower levels of 
antibodies to dsDNA, histones, CL, and PS.
1.3.6  The importance of fc-Glycoprotein i in APS
p2 GPI,  an  abundant  glycoprotein  in  human  plasma  found  at  a  concentration  of 
approximately 20(Vg/ml,  is synthesized  mainly  in  the  liver  but also  by other cells 
such  as trophoblasts (Li and  Krilis, 2003).  p2 GPI  is a  protein  of approximately  50- 
kDa;  it  is  a  highly  glycosylated,  single-chain  polypeptide  of  326  amino  acids 
containing  a  high  proportion  of  proline  and  cysteine  residues,  with  20%  w/w 
carbohydrate attached. The protein is a member of the complement control  protein 
or short consensus repeat (SCR) superfamily, characterised by repeating stretches of 
60  amino  acid  residues,  each  with  a  set  of  16  conserved  residues  and  2  fully 
conserved disulfide bonds and has 5 of the repeating SCR domains (also  known  as 
"sushi  domains")-  foGPI  is  highly  conserved  among  different  mammalian  species 
including humans, bovines, canines and mice (Miyakis et al., 2004).
aPL  can  recognise  p2 GPI  directly (in  the  absence  of  PL)  if the  protein  antigen  is 
present  on  microtiter  plates  at a  sufficient  density.  The  crystal  structure  of  the 
protein  has  been  solved  both  in solid and fluid  phase and  bears  relevance for the 
positioning of the domains of faGPI involved in the binding of the antibodies (Figure 
1.4) (Schwarzenbacher et al.,  1999);  its structure suggests that the protein binds to 
PL membranes via the cationic portion of its fifth SCR domain.  Domains III and  IV 
are  heavily  glycosylated  and  therefore  partially  shielded  from  protein-protein 
interactions and  may therefore  be  regarded  as linking domains for the N-terminal 
domains that are exposed most in the blood (Bouma et al., 1999).
Controversial results have been reported regarding the aPL-specific epitopes of p2 GPI 
that  are crucial  in  the  development  of APS.  Although,  short  peptides  containing 
sequences  from  domain  V  of  p2 GPI  inhibited  binding  to  human  mAbs  to  p2 GPI, 
polyclonal antibodies from human patients did not bind these peptides (Wang et al., 
1995).  Results  from  other  studies  using  truncated  p2 GPI  with  various  domain 
deletions indicated that the binding epitopes were not on domain V in most cases but 
on domain IV (George et al., 1998b).
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Figure 1.4 Structure of p2-glycoprotein I
(A)  Schematic drawing  of the domain  structure of p2-glycoprotein  I.  Domain  V 
is  involved  in  the  binding to  anionic  phospholipids while domain  I  contains the 
binding epitope for anti-(32GPI  antibodies.  (B)  Space-filling  model  of the crystal 
structure of p2-glycoprotein I. The antibody recognition site in domain  I and the 
phospholipid-binding  site  in  domain  V  are  indicated.  Adapted  from  (de  Groot 
and Derksen, 2005)
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Using anti-frGPI antibody from patients with APS and different p2 GPI domain-deleted 
mutants, Iverson and colleagues have reported that domain I (DI) is essential for the 
binding of APS antibodies to  PzGPI  (Iverson et al.,  1998).  Seven different domain- 
deleted  mutants  of  human  p2 GPI,  and  full-length  human  p2 GPI  (wild-type),  were 
used in competition assays to inhibit the autoantibodies from binding to immobilized 
wild-type p2 GPI. Only those domain-deleted mutants that contained DI inhibited the 
binding to immobilized  wild-type p2 GPI from  all  of the  patients.  In  a  recent study 
using anti-p2 GPI antibodies from patients with APS with Dl-mutated p2 GPI, another 
group confirmed  the finding  that DI  of p2 GPI  contains significant epitopes for the 
anti-p2 GPI antibodies found in APS (Reddel et al., 2000).  Recently it was suggested 
the positively charged arginine at position 43 and glycine at position 40 on  DI are 
important in the binding of anti-p2 GPI antibodies (Iverson et al., 2002, de Laat et al., 
2006).  de  Laat  et  al.,  (2005)  tested  the  specificity  of anti-p2 GPI antibodies with 
patients with PAPS and SLE by using eight deletion mutants of p2 GPI (comprising DI, 
DI-II,  DI-III,  DI-IV,  DII-V,  DIII-V,  DIV-V and  DV)  and  three  recombinant  p2 GPI 
molecules  with  different  point  mutations  in  DI  (aspartate to  alanine  mutation  at 
position  8,  glycine-glutamate  mutation  at  position  40,  and  an  arginine to  glycine 
mutation at position 43). The authors have shown that anti-p2 GPI antibodies directed 
at DI (recognizing epitopes at position 40 and 43) cause lupus anticoagulant activity 
and strongly associate with thrombosis (de Laat et al., 2005).
The precise physiological role of p2 GPI has not been resolved; in vitro, p2 GPI binds to 
negatively charged PLs, such as CL and phosphatidylserine (PS), as well as inhibiting 
contact  activation  of  the  intrinsic  coagulation  pathway,  platelet  prothrombinase 
activity,  and adenosine diphosphate (ADP)-mediated  platelet aggregation and  also 
aids clearance of oxidized  low-density lipoproteins (LDL) (Miyakis et al.,  2004).  In- 
vivo, p2 GPI is involved in the clearance of apoptotic bodies (Pittoni et al., 2000) and 
liposomes as well as interfering with the protein C pathway (Roubey,  1996).  p2 GPI 
adheres to resting human ECs.  p2 GPI, dimerised after binding of circulating aPL, has 
an increased affinity for cells, such as platelets, ECs and monocytes leading to their 
activation (Del Papa et al.,  1997). In addition, frGPI appears to promote clearance of 
certain  products of oxidation and  prevent thrombus formation  (review in  (Inane et 
al.,  1997)). Therefore, binding of aPL to epitopes on p2 GPI may interfere with these 
functions, and therefore promote thrombosis.
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1.4  The generation of diversity in immunoglobulins
1.4.1  Organisation of immunoglobulin genes
The  structure  of  antibodies  has  been  discussed  in  section  1.1.3.1.  It  has  been 
estimated  that  the  mammalian  immune  system  can  generate  more  than  101 1  
different antibodies and  is capable of specifically  recognising  and  responding to a 
limitless array of foreign antigens (Berek and  Milstein,  1988).  For several  decades, 
immunologists sought to  visualise a  genetic  mechanism  that might generate  such 
diversity. One of the theories that emerged is the germline theory, which maintained 
that the  genome contributed  by  the germ  cells  contains  a  large  repertoire  of  Ig 
genes.  In  contrast,  the  somatic-mutation  theory  maintained  that  the  genome 
contains  a  small  number  of  Ig  genes,  from  which  a  large  number  of  antibody 
specificities are generated in the somatic cells by mutation or recombination.
Dreyer and Bennett suggested another model which combined elements of the two 
theories; that two separate genes encode a single Ig H or L chain, one gene for the 
V  region  and  one  for  the  C  region  (Dreyer  and  Bennett,  1965).  Moreover,  they 
proposed  that  a  large  number  of  V  region  genes  were  carried  in  the  germline, 
whereas only  single  copies of C  region  class  and  subclass  genes exist.  Although 
Dreyer and  Bennett provided  a  good theoretical  model,  further validation  of their 
hypothesis  has  been  achieved  with  major  technological  advances  in  molecular 
biology with the use of restriction enzyme analysis and Southern  blotting. The first 
direct  evidence  was  provided  by  the  work  of  Hozumi  and  Tonegawa  in  1976. 
Chromosomal DNA from embryonic cells and adult myeloma cells was first cut with a 
restriction  enzyme,  and  the  DNA  fragments  containing  particular V and  C  region 
sequences were identified by hybridization with radiolabeled DNA probes specific for 
the relevant DNA sequences (Hozumi and Tonegawa,  1976). What their experiments 
showed  is that in germline DNA (in embryonic cells), the V and C region sequences 
identified by the probes are on separate DNA fragments.  However, in DNA from an 
antibody-producing  B cell these V  and  C  region  sequences are on  the same  DNA 
fragment,  showing  that  a  rearrangement  of the  DNA  has  occurred  (Hozumi  and 
Tonegawa, 1976). These results are important since they show that the Ig genes are 
rearranged in cells of the B-lymphocyte lineage, but not in other cells.
Subsequently, cloning and sequencing of the L and H chain  DNA was accomplished 
and  showed that the k and X L chains and the H chains are encoded  by separate
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multigene families each containing several gene segments. Tonegawa et al., (1978) 
cloned the germline DNA for the mouse Vx and determined its complete nucleotide 
sequence. The k V region is encoded by two fused gene segments in the order V-J 
(V-joining)  (Tonegawa  et  al.,  1978).  Furthermore,  Sakano  and  colleagues 
determined the entire nucleotide sequence for mouse Ig k chain gene and as in the 
k  multigene family, the VK   and  JK  gene  segments encode the V  region  of the k L 
chain (Sakano et al., 1979).
The organisation of the Ig H chain genes is similar but more complex. Schilling et al., 
(1980) determined the complete V  region  sequences from ten  antibodies and two 
myeloma proteins binding alpha-1,3  dextran  and  found that the VH  gene segment 
encodes amino acids 1 to 94 and the JH  gene segment was found to encode amino 
acids 99 to  107. The most striking feature of their data  is the extensive sequence 
variability of a  region  that corresponded  to amino acids 95 to  97  of the  H  chain, 
which  they denoted the  D (diversity)  segment (Schilling et al.,  1980).  From  these 
results, the authors proposed that a third germline gene segment is located at the 
junction  between  the V  and  3  segments  in  the  centre  of the third  hypervariable 
region and must join the VH  and JH  gene segments to encode the entire V region of 
the H chain. The existence of Dh gene segments was later confirmed by Kurosawa 
and Tonegawa  (1982). They located the D gene segments within  mouse germline 
DNA  with  a  cDNA  D-region  probe,  which  hybridized  with  a  stretch  of  DNA  lying 
between the VH  and JH  gene segments (Kurosawa and Tonegawa, 1982).
DNA sequencing studies revealed the presence of conserved sequences flanking each 
germline V,  D,  and J gene segment. The conserved  heptamer/nonamer sequences 
have been termed recombination signal sequences (RSSs) and function as signals for 
the recombination  process that rearranges the genes. These conserved palindromic 
heptamers (CACTGTG) and conserved nonamer sequences (GGTTIITGT) are located 
3' to each V gene segment, 5' to each 3 gene segment, and on both sides of each D 
gene segment and are separated  by an intervening sequence of 12 or 23 bp.  Early 
and colleagues observed that these intervening 12 and 23 bp sequences correspond, 
respectively, to one and two turns of the DNA helix (one-turn  recombination  signal 
sequences and  two-turn  signal  sequences)  (Early et al.,  1980).  Signal  sequences 
having a one-turn spacer can only join with sequences having a two-turn spacer (the 
one-turn/two-tum joining rule). This ensures that a VH ,  Dh,  Jh segments join  in the
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proper order and that segments of the same type do not join together (for example a 
VH  segment does not join to another VH  segment).
This  work was  ail  carried  out  in  mice.  Matthyssens  and  Rabbits  cloned  the  first 
human  VH  gene,  which  has  been  isolated from  human fetal  liver  DNA  by  using  a 
cDNA  plasmid  probe containing  a  mouse VH  sequence (Matthyssens and  Rabbitts, 
1980).  The  human  JH   and  the  first  Dh  genes  were  subsequently  cloned  and 
sequenced (Ravetch et al.,  1981, Siebenlist et al.,  1981). When the VK  (Bentley and 
Rabbits, 1980), Vx (Brockly et al.,  1989), JK  (Hieter et al.,  1980) and Jx (Vasicek and 
Leder,  1990) genes were also cloned, it was found that the same principle applied to 
human  gene segments as  well  as  mice, confirming the  presence of RSSs  and the 
one-turn/two-tum joining rule.
1.4.2  The mechanism of rearrangement of immunoglobulin genes
The  recombination  of  V  region  gene  segments,  is  a  site-specific  recombination 
process that occurs only in developing lymphocytes and only in between Ig and TCR 
gene segments flanked by RSSs (Bassing et al., 2002). The complex of enzymes that 
act synergistically to mediate V(D)J recombination is termed the V(D)J recombinase. 
The products of the two genes RAG-1 and  RAG-2 (recombination-activating genes) 
comprise the lymphoid-specific components of the recombinase.
V(D)J  recombination  is a  multistep enzymatic process in which the first reaction  is 
recognition of RSSs by recombinase enzymes and alignment of two signal sequences 
together with the adjacent coding sequence (Schatz, 2004). RAG-1 and RAG-2 make 
two  single-strand  DNA breaks at sites just 5' of each  RSS,  leaving  a  free  3'  -OH 
group at the end of each coding  segment.  This 3' -OH group then  hydrolyzes the 
phosphodiester bond on the other strand, sealing the end of the dsDNA to create a 
'hairpin'  structure  at  the  cut  end  of  the  coding  sequence  and  a  flush,  5' 
-phosphorylated, double-strand break at the signal sequence (Janeway et al., 2001). 
The DNA hairpin is nicked open by a single-stranded break at various points for the 
addition of P-region nucleotides, followed by the trimming of a few nucleotides from 
the  coding  sequence  by  a  single-strand  endonuclease.  Terminal  deoxynucleotidyl 
transferase (TdT) allows the addition of N-region nucleotides.  Double-strand  break 
repair (DSBR) enzymes then catalyse the ligation of the coding sequences with each 
other and the signal sequences with each other (Goldsby et al., 2000).
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Although  the  double-strand  DNA  breaks  that  Initiate  V(D)J  rearrangement  are 
introduced  precisely  at the junctions  of  signal  sequences  and  coding  sequences, 
there is variation in the enzymatic processes in the subsequent joining of the coding 
sequences (Schatz et al.,  1992).  This  imprecision  in the joining  process  seems to 
create diversity by contributing to the hypervariability of the antigen-binding  site. 
Another consequence of imprecise joining  is  nonproductive  rearrangement,  where 
the resulting VJ or VDJ unit will  lose or gain nucleotides at the junctions such that 
the triplet reading frame for translation is interrupted (Schatz et al., 1992). When the 
gene segments are joined in phase, the reading frame is maintained. This generates 
a  productive  rearrangement  with  the  resulting  VJ  or  VDJ  unit  translated  in  its 
entirety, yielding a complete antibody. If one allele rearranges non-productively, a B 
ceil may still be able to rearrange the other allele productively.
B  cells,  like all  somatic cells,  are diploid  and  contain  both  maternal  and  paternal 
chromosomes  (Albert et al.,  2002).  In  fact,  however,  each  B  cell  expresses  the 
rearranged  H  chain genes from only one chromosome and  the  rearranged  L chain 
genes from only one chromosome. This process, termed allelic exclusion is essential 
for the antigenic specificity of the B cell since it ensures that functional B cells never 
contain  more  than  one  VhDhJh  and  one  VL JL   unit  and  accounts  for  their 
monospecificity (Mostoslavsky et al.,  2004).  It is apparent that once a  productive 
VhDhJh  rearrangement  and  a  productive  VL JL   rearrangement  have  occurred, 
recombination  stops,  so  that  the  H  and  L  chain  genes  on  the  homologous 
chromosomes are not expressed.
A  model  proposed  to  explain  allelic  exclusion  suggests  that  once  a  productive 
rearrangement is attained, its encoded protein is expressed and its presence acts as 
a  signal  to  prevent  further  gene  rearrangement  (Yancopoulos  and  Alt,  1986). 
According to this model, the presence of  H chains signals the maturing B cell to 
turn off rearrangement of the other H chain allele and to turn on  rearrangement of 
the  k   L  chain  genes.  If a  productive  k   rearrangement  occurs,  k   L  chains  are 
produced and then pair with \i H chains to form a complete antibody molecule. The 
presence  of  this  antibody  then  turns  off  further  L  chain  rearrangement.  If  k 
rearrangement  is  nonproductive for  both  k  alleles,  rearrangement  of the  X  chain 
genes begins. If neither X allele rearranges productively, the B cell ceases to mature 
and dies by apoptosis.
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However, Ig expression  sometimes fails to prevent further rearrangement. Some B 
cells that  have  made  productive  H  and  L chain  rearrangements will  nevertheless 
rearrange a second  L chain  locus (Prak and  Weigert,  1995). This  process is called 
receptor  editing  and  allows  a  B  cell  to  change  its  receptor  specificity.  Prak  and 
Weigert, (1995) described a mouse model which recreates a functional rearranged  k 
locus by replacing the unrearranged JK  region with a  rearranged VK -JK  gene. This  L 
chain replacement (VK R) simulates the genotype of a normal B cell with a functional 
VK -JK   L  chain  gene  on  one  allele.  The  VK R  models  illustrate  that  a  productively 
rearranged  L  chain  can  either  terminate  further  rearrangement  or  allow  further 
rearrangement.
1.4.3  Generation of antibody diversity
Antibody diversity is generated in four main ways. Two of these are consequences of 
the recombination process described above. The third is due to the different possible 
combinations of a  H  and  a  L chain  in the complete  Ig  molecule.  The fourth  is  a 
mutational  process that occurs  in  mature  B cells,  acting  only on  rearranged  DNA 
encoding the V regions.
The gene rearrangement that combines gene segments to form a complete V region 
generates diversity in two ways (Maizels,  2005).  First,  there are  multiple different 
copies of each type of gene segment. Human germline DNA contains 44 VH  (Matsuda 
et al.,  1998), 27 D (Corbett et al., 1997), 6 JH  (Ravetch et al.,  1981), 40 VK  (Schable 
and Zachau, 1993), 5 JK , 30 Vx (Williams et al.,  1996) and 4 3k gene segments (these 
numbers  apply  to  functional  genes,  discussed  in  more  detail  in  section  1.4.5). 
Different combinations of gene segments  can  be  used  in  different  rearrangement 
events,  however,  not all gene segments are used at the same frequency and some 
are more common than others. This combinatorial V(D)J diversity is responsible for a 
substantial part of the diversity of the H and L chain V regions.
Second, junctional flexibility is introduced at the joints between the different gene 
segments. As described above,  recombination  involves  both the joining of RSSs to 
form  a  coding joint  and  the joining  of coding  sequences to  form  a  coding joint. 
Although  the  signal  sequences  are always joined  precisely, joining  of the  coding 
sequences  is  often  imprecise.  Junctional  flexibility  leads  to  many  nonproductive 
rearrangements,  but it also several  produces productive combinations that encode
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alternative amino acids at each coding joint. The third hypervariable region (CDR3) 
falls between the V-D and the D-J joints.  In  both  H  and  L chains, the diversity of 
CDR3  is  significantly  increased  by  the  addition  (P-addition  and  N-addition)  and 
deletion  of nucleotides  in the formation of the junctions between  gene segments. 
Since CDR3 makes a major contribution to antigen binding by the antibody molecule, 
amino acid changes generated by junctional flexibility can make a major contribution 
to antibody diversity.
A  third  source  of  diversity  is  also  combinatorial,  arising  from  the  many  possible 
different combinations of H  and  L chain  V regions that  pair to  form the antigen- 
binding site in the Ig molecule. Although it is difficult to calculate with  precision the 
number of different antibody combining sites the immune system can generate, the 
number is very  large.  Nevertheless,  it is not likely that all VH  and  VL  will  pair with 
each  other.  Finally,  somatic  hypermutation  (discussed  in  more  detail  in  the  next 
section)  introduces  point  mutations  into the  rearranged  V  region  genes,  creating 
further diversity that can be selected for enhanced binding to antigen.
1.4.4  Somatic hypermutation
All of the antibody diversity mechanisms discussed so far occur during the formation 
of V regions by gene rearrangement in the pre-B cell (early B cell precursor that does 
not express functional membrane-bound Ig and is therefore not sensitive to antigen). 
Following  antigen  exposure,  activated  B cells  migrate  into  the  primary follicles  of 
peripheral  lymphoid  organs  where  they  undergo  intense  proliferation  and  form 
germinal centres, which appear towards the end of the first week after exposure and 
provide the location for both  hypermutation and antigen  selection  (Neuberger and 
Milstein,  1995).  Somatic hypermutation occurs only within germinal  centers and  is 
targeted to rearranged V regions located within a DNA sequence which includes the 
whole  of  the  VJ  or  VDJ  segment  (Wagner  and  Neuberger,  1996).  Somatic 
hypermutation occurs at a frequency approaching 10‘3 per base pair per generation, 
a  rate which is a hundred thousand-fold higher that the spontaneous mutation rate 
in other genes and is unique to B cells (Neuberger and Milstein, 1995).
The  mechanism  of  somatic  hypermutation  is  poorly  defined.  The  mutations 
introduced are predominantly single nucleotide substitutions (rather than  insertions 
or deletions).  The  base changes are distributed throughout the V  region,  but not 
completely  randomly;  there  are  certain  'hotspots'  of  mutation  that  indicate  a
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preference  for  characteristic  short  motifs  (A/G-G-C/T)  (Rogozin  and  Kolchanov, 
1992). Gearhart and Bogenhagen (1983) examined six rearranged VK 167 genes from 
hybridoma  and  myeloma  cells.  The  sequences  were  compared  to  the  germline 
sequence  of the VK 167  gene,  the JK   genes,  and  the  C*  gene to  identify  sites  of 
mutation.  Four  of  six  rearranged  genes  had  extensive  mutation  which  occurred 
exclusively in a region of DNA centered around the V-J gene. Mutations were mostly 
due to nucleotide substitutions and their location  around each  gene  indicates that 
they occur in clusters at random sites (Gearhart and Bogenhagen, 1983).
Experimental evidence demonstrating the importance of somatic hypermutation was 
obtained  from  a  series  of experiments  on  the  response  to  the  phOx  hapten  (2- 
phenyl-5-oxazolone) in mice by Berek and Milstein, (1988). They coupled the hapten 
to  a  protein  carrier,  immunised  mice  with  the  phOx-carrier and  used  the  mouse 
spleen cells to prepare hybridomas secreting mAbs specific for the phOx hapten. The 
12  hybridomas obtained from  mice seven days after a  primary  immunisation,  had 
very  similar  sequences  to the  mouse  germline V  genes.  However,  14  days  after 
primary  immunisation, all of the hybridomas included one or more  mutations from 
the  germline  sequence.  The  number  of  mutations  in  the  anti-phOx  hybridomas 
progressively increased following primary, secondary, and tertiary immunisations, as 
did the overall affinity of the antibodies for phOx (Berek and Milstein, 1988).
The process of somatic hypermutation generates antibodies with varying affinity for 
antigen.  Following exposure to antigen, those B cells with  higher affinity  receptors 
will  be preferentially selected for survival because of their greater ability to  bind to 
the antigen, a process called affinity maturation which takes place within  germinal 
centers.  Mutations at some positions in the sequence will either adversely affect the 
basic structure of the antibody  molecule or  reduce  its affinity for antigen.  B cells 
expressing antibodies with the highest affinity for the driving  antigen are likely to 
become  initially  the  dominating  population.  These  cells  consequently  proliferate 
faster thus eventually dominating the germinal centre. This is termed antigen-driven 
clonal  expansion  (Berek and  Milstein,  1987).  Schlomchik et al.,  (1987)  studied  a 
panel of IgG rheumatoid factor autoantibodies derived from the autoimmune MRL/Ipr 
mouse and provided evidence for antigen-driven clonal expansion. Sequence analysis 
showed that these antibodies were derived from a small number of expanded clones. 
Clonally  related  antibodies  were  recognised  by  possession  of  identical  VDJ  joint 
sequences. The authors noted that a high  replacement (alters amino acid sequence
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of antibody) to silent (does not alter amino acid sequence of antibody) mutation ratio 
occurs in the CDRs but not the FRs.  Since the V region CDRs mainly determine the 
structure of the antigen-binding site, replacement mutations in CDRs are more likely 
to  alter antigen  binding  properties  indicating  that the development of a  particular 
antibody sequence was antigen-driven (Shlomchik et al., 1987).
Statistical  analysis  can  be  applied  to  the  distribution  of  replacement  and  silent 
mutations  in  an  antibody sequence to determine whether this  pattern  of somatic 
mutation  is  a  consequence of antigen-drive.  Chang  and  colleagues  performed an 
evaluation  using a  binomial distribution  model equation  (Chang  and Casali,  1994). 
The binomial method involves the use of a mathematical formula for calculating the 
probability that a  particular  pattern  of mutations (in the Ig  V gene CDRs or  FRs) 
could  have developed by chance only,  in the absence of antigen drive (Chang and 
Casali,  1994).  However, this model  is inappropriate for Ig genes in which mutations 
have four different distribution possibilities (replacement and silent mutations in the 
CDR and/or FW regions of the gene). Lossos and colleagues proposed a multinomial 
distribution model for assessment of antigen selection (Lossos et al., 2000). Side-by- 
side application of multinomial and binomial models on 86 previously established Ig 
sequences disclosed 8 discrepancies, leading to opposite statistical conclusions about 
antigen selection. Therefore, the use of the multinomial model is thought to be more 
accurate (Lossos et al., 2000).
After  antigenic  stimulation  of a  B  cell,  the  H  chain  DNA  can  undergo  a  further 
rearrangement in which the VH W H  unit can combine with any C h gene segment, a 
process called class switching. It is a DNA recombination reaction specific to the Ig H 
chain  (IgH)  locus that increases antibody versatility  by  associating  a given  IgH  V 
region  with  one  of  several  different  C  regions.  The  C m -  region  is  replaced  by 
downstream C y  ,  Ce  ,  or Ca  segments to generate IgG,  IgE,  and  IgA antibodies, 
respectively. There seems to be a  link between  hypermutation and class switiching 
since they occur at a  similar point in cell development and  IgG antibodies tend to 
carry more somatic mutations than IgM of the same specificity (Tillman et al., 1992). 
Furthermore,  Huang  and  Stollar  (1993)  carried  out  study  to  determine  whether 
similar  Ig  gene  segment  usage  occurs  in  normal  human  adult  peripheral  blood 
lymphocytes.  They found  that 48  of  77  IgM  clones  (62%)  shared  99%  or  more 
identity with known germline VH  segments, and  most of these had  no  mutations  in 
the CDR3 portion of the Jh segment. In contrast, only two of 28 rearranged VH  genes
83Chapter One Introduction
from the IgG library showed this degree of homology. Therefore, they concluded that 
IgG-encoding sequences had more mutations than IgM-encoding sequences (Huang 
and Stollar, 1993).
It  has  recently  been  discovered  that  deficiency  in  the  enzyme  called  activation 
induced  cytidine  deaminase,  blocks  the  accumulation  of  somatic  hypermutations 
(Seising, 2006,  Nussenzweig and Alt,  2004). The mechanism  by which this enzyme 
contributes to  hypermutation  is  unknown.  Interestingly,  deficiency of this enzyme 
also  abrogates  the  rearrangement  of  C-region  genes  that  underlies  the  Ig  class 
switching seen in activated B cells.
A key research question which I have attempted to answer in this thesis is:  do the 
somatic mutations that accumulate in the CDRs of rearranged Ig sequences account 
for  changes  in  the  binding  properties  of  antibodies?  The  binding  properties  of 
antibodies  depend  on  the  sequences  of their  V  regions,  particularly  the  CDRs. 
Antibodies with pathogenic properties may have a tendency to utilize the same VH  or 
VL  genes or develop the same somatic mutations  under the influence of the same 
antigen.  For  this  reason,  it  is  crucial  to  have  full  understanding  of the  germline 
human V region repertoire.
1.4.5  TTie repertoire of human variable region genes
To  understand  the  origin  and  behaviour  of  the  human  immune  repertoire  it  is 
important to  have the complete  structure of the  human  VK ,  Vx  and  VH   locus.  In 
humans, the Ig molecule is encoded by three independent gene loci, namely IgK  and 
Igx  genes  for the  L  chain  and  IgH  genes  for the  H  chain,  which  are  located  on 
chromosome 2 (Malcolm et al., 1982, McBride et al., 1982), chromosome  22 (McBride 
et  al.,  1982,  Erikson  et  al.,  1981),  and  chromosome  14  (Croce  et  al.,  1979), 
respectively.
1.4.5.1  Human VH  locus
A  complete  map  of  the  functional  VH   locus  at  chromosome  14q32.3  has  been 
produced (Matsuda et al.,  1993). The complete nucleotide sequence of the human Ig 
VH  region locus is 957-kb in length. The region  contains 123 VH  segments classifiable 
into seven different families,  of which 79 are pseudogenes. A VH  segment is defined 
as  functional  if  it  contains  an  open  reading  frame  (ORF),  an  intact  exon-intron
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structure and  is arranged  in  a functional  Ig gene (functional VDJ  rearrangement). 
Pseudogenes are nucleotide sequences that are stable components of the genome 
but  are  incapable  of  being  expressed.  Pseudogenes  are  thought  to  have  been 
derived by mutation of active ancestral genes (Goldsby et al., 2000). Of the 44 VH  
segments with an ORF, 39 are expressed as H chain proteins and  1  as mRNA, while 
the remaining 4 are not found  in  Ig  cDNAs (Matsuda et al.,  1998).  Eight VH  were 
identified  on  chromosome  15 and  sixteen  on  chromosome  16,  however these are 
unlikely to be functional since chromosomes 15 and  16 have no D, J or C segments 
(Cook and Tomlinson, 1995).
Human VH  segments can be classified into seven families, VH 1  - VH 7 on the basis of 
sequence homology, which are interspersed throughout the locus.  Different members 
of the same family are at least 80% homologous at the nucleotide sequence level 
and  some  families  are  more  highly  related  (Vh4)  than  others,  which  are  more 
divergent (VH 5).  In terms of the number of functional VH  segments, the VH 3 family 
makes the largest contribution to the functional repertoire, followed by the VH 1 and 
Vh4 families (Cook and Tomlinson, 1995).
The  exact  dimensions  of  the  VH   locus  and  number  of  functional  segments  vary 
between individuals and VH  genes display a certain amount of polymorphism.  Under 
these circumstances, the question arises whether differences between expressed and 
germline  sequences  are  true  somatic  mutations  or  arise  because  of a  difference 
between alleles of the same gene.  Certain genes occur in  some people but not in 
others as a result of insertion/deletion polymorphism with 75% of people having an 
extra group of genes located between segments 3-30 and 4-31 which are listed in V- 
BASE, a sequence directory containing the complete human Ig gene repertoire that is 
constantly being updated with new alleles (Tomlinson et al., 1996). This database of 
published alleles as well as data from direct sequencing of the same gene in different 
individuals (Sanz et al.,  1989) show that the majority of alleles differ by one or two 
nucleotides.  For this  reason,  it  is  logical  to  assume  that  most  of the  differences 
expressed  and  germline  sequences  result  from  mutation  rather  than  from 
polymorphism.
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1.4.5.2 Human Dh locus
The complete nucleotide sequence of the human IgD segment locus on chromosome 
14q32.3 was determined and a total of 27 D segments were identified (Corbett et al., 
1997). These can be grouped into seven families based on sequence homology.  Six 
of these families (DXP,  DA,  DK,  DN,  DM and  DLR) (Ichihara et al.,  1988)  have at 
least four members,  whilst the seventh  is the  unique DHQ52  segment.  Nucleotide 
sequences of Dh genes belonging to different families diverge greatly,  while those 
belonging  to  the  same families  are  well  conserved.  Other than  these  typical  Dh 
genes,  however,  Ichihara  et al.,  (1988)  described  another  Dh  gene  (which  they 
termed  DIR) the spacer lengths of whose neighbouring signals were irregular.  The 
DIR gene  appeared  to  be  involved  in  DIR-C^  or  Dh-DIR joining  by  inversion  or 
deletion.  Nevertheless, VhCDR3 vary greatly due to versatility of the  Dh segments. 
Various  other  hypotheses  had  been  proposed  to explain  this  extensive  versatility 
such as the DD recombination (regardless of the 12/23  rule) (Sanz,  1991), inverted 
D segments, or the use of minor D segments found on chromosome  15 (Cook and 
Tomlinson, 1995).
However,  a  systematic  analysis  which  compared  the  complete  sequence  of  the 
human Ig D segment locus with a database of rearranged sequences to identify all 
the germline D segments and any other sequences that contribute to the extreme 
diversity  of  VH CDR3  showed  no  evidence  to  suggest  that  any  of  the  above 
hypotheses took  place (Corbett et al.,  1997).  In  previous  studies,  the criteria  for 
assigning VhCDR3  sequences  to their germline  D  segments  appear to  have  been 
more  lenient.  For example,  others  have  taken  five  nucleotides  of  identity  or  six 
nucleotides with one mismatch as their minimum cut-off for matching an expressed 
sequence to a  germline  D gene (Brezinschek et al.,  1995).  Corbett et al.,  (1997), 
however, applied more stringent criteria whereby at least ten consecutive nucleotides 
of identity were generally required to confidently assign a D segment to its germline 
match, with the precise threshold depending on the CDR3 length.
1.4.5.3 Human JH  locus
The human JH  locus contains nine J-like gene segments, six of which appear to be 
functional (designated JH 1 to JH 6) and account for most of the known human H chain 
amino acid sequences whilst three are pseudogenes (Ravetch et al., 1981).
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1.4.5.4 Human kappa (k) locus
The human  k   L chain locus has been mapped to chromosome 2pll-12 and contains 
approximately 40 functional VK  and five JK  genes with  no D gene segments (Schable 
and Zachau,  1993). The total number of VK  genes is 76. The 40 functional VK  genes 
are arranged  into seven families, two of which are very small (VK IV and VK VII) and 
are interspersed throughout the locus amongst 36 pseudogenes. Additional VK  genes 
are located  upon chromosomes  1 and 22 although these are pseudogenes (Schable 
and Zachau,  1993). Allelic polymorphism is rare and where present, alleles differ by 
only one or two nucleotides (Tomlinson et al.,  1996).  There  is only one human  Q 
gene segment (Hieter et al.,  1980) therefore no alternative isotypes of the k chain 
exist.
1.4.5.5 Human lambda (X) locus
The  human  X  locus  lies  on  chromosome  22qll.2.  There  are  30  functional  Vx 
(Williams et al., 1996) and four functional 3k genes (Vasicek and Leder, 1990). Ten Vx 
families exist,  spread amongst three distinct Vx gene clusters.  The  1,  2  and  3 
families  comprise  more  than  half  of  all  the  genes  and  are  more  commonly 
expressed in humans.  Once again, allelic polymorphism is relatively rare and where 
present, alleles differ by only one or two nucleotides just as in the human VH  and VK  
loci (Williams et al., 1996).
The 3k and C k loci are also located upon chromosome 22. There are seven C regions 
however C k  1, 2,  3, and 7 are active genes while Q 4,  5, and 6 are pseudogenes. 
They are organized in a tandem array, and each is preceded by a single 3k region of 
which 3X 2 and 3k3 are identical. As a result, mAb sequences can include only one of 
three different \  sequences (Vasicek and Leder,  1990). The presence of different Ck  
genes means X chains like H chains can exist as one of several isotypes.
1.4.5.6 How is the repertoire defined in the expressed monoclonal antibodies?
The  recognition  that certain  VH ,  Vx,  and  VK  genes and  families are  preferentially 
rearranged  is  important  in  interpreting  sequences  of  human  mAbs  specific  for  a 
particular antigen.  Certain genes  might be rearranged  more often than others and 
some genes may be present in several copies (Dorner and Lipsky, 2001).
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It has been demonstrated using  in situ  hybridization  studies that overexpression of 
Vh3 genes persists in the adult (Zouali,  1992).  Huang and Stollar,  (1993)  made an 
IgG H chain cDNA library from peripheral blood lymphocytes (PBL) of healthy adults 
and  have shown  that there was  preferential  use of certain  genes  within  the VH 3 
family,  particularly V3-23 and V3-30.  Furthermore,  Brezinschek et al.,  (1997)  have 
amplified genomic DNA from peripheral B cells expressing surface IgM using using a 
single  cell  PCR technique  that  permits  the amplification  of  both  productive  and 
nonproductive VH   rearrangements.  They  showed  that  genes  from  the  VH 3  family 
were  more  likely to  be  used  in  productive  rearrangements,  with  VH -23  being  the 
most  commonly  rearranged  gene  accounting  for  13%  of  all  productive 
rearrangements.
Cox  et al.,  (1994)  sequenced  37  human  germline VK  segments from  the genomic 
DNA of a single individual and compiled a comprehensive directory of all germline VK  
segments. Comparison with 236 rearranged sequences revealed about 11 sequences 
(02, 08, L8, L12 and A20 from the VJ family, A3 and A17 from the VJI, L2, L6 and 
A27 from the VJII, and B3 from the VJV) were used frequently and accounted for 
90%  of  the  expressed  repertoire.  These  results  suggest  that  the  expressed  VK  
repertoire is mainly derived from a limited number of segments.
The expressed human Ig Vx repertoire also demonstrates a strong bias in the use of 
individual \  segments. By hybridisation of 7600 cDNA clones from peripheral  blood 
lymphocytes  Ignatovich  et al.,  (1997)  have  shown  that  the  use  of Vx  families  is 
heavily  biased  in the expressed  repertoire.  Indeed,  of the ten families,  only three 
(VjJ,  Vx2  and  Vx3) are used to any significant extent.  Furthermore,  by sequencing 
532 K cDNA clones they have now shown that this bias in family use is mainly due to 
biases in the use of individual Vk segments.  Indeed, of the 30 functional segments 
three (2a2,  le and  2c) encode  half the expressed Vx  repertoire (Ignatovich et al.,
1997).
1.5  Sequence  Analysis  of  Human  Monoclonal  Anti-DNA  and 
Antiphospholipid Antibodies
The antigen-binding site of an antibody is determined by the V region of the H chain 
and  the  L chain.  Within  VH   and  Vl,  the CDRs show  particularly  high  variability  of
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sequence and  have  been  shown  by  crystallography  to  contain  most of the  sites 
where antigen and antibody make contact. Sequence changes which affect the CDRs 
are therefore particularly important in determining affinity and specificity of antigen- 
antibody interactions. The aim of sequence analysis is to identify sequence features 
that are found commonly in anti-DNA antibodies or aPL which can cause disease, but 
rarely in antibodies which are not associated with disease. Sequence analysis studies 
that differentiate these two groups,  may  provide some evidence of links  between 
sequence and pathogenicity,
1.5.1  Sequence analysis of murine anti-DNA antibodies
The  sequences  of  over  300  murine  anti-DNA  mAbs  have  been  published.  The 
antibodies  were  derived  from  two  types  of  SLE  murine  models.  The  first  are 
autoimmune  strains  such  as  MRLJlpr and  (NZB/W)Fi  that  spontaneously  develop 
autoimmune disease closely paralleling the symptoms of human  SLE.  The  MRL/Ipr 
mice display the most dramatic symptoms, developing widespread lympadenopathy, 
a  range of autoantibodies (including anti-dsDNA and  aPL)  and glomerulonephritis. 
(NZB/W)Fi  mice  develop  a  lupus-like  illness  characterised  by  the  presence  of 
autoantibodies and glomerulonephritis. The second type of SLE murine models are 
normal mice that have experimentally induced autoimmune disease similar to human 
SLE through immunisation with proteins/DNA complexes or antibodies some of which 
carry public idiotypes associated with autoantibodies (Radic and Weigert,  1994).  Of 
the  283  VH  sequences studied,  183  belong to the J558 VH   gene family,  61  to the 
7183  VH   gene family  and  39  are  members of other families  (Radic and  Weigert, 
1994).  VL  gene use in anti-DNA antibodies is more diverse that VH  gene  use.  Most 
notable among the recurrent L chains are 8A and  8B,  both  derived from VK  genes 
(Radic and Weigert, 1994).
Sequence analysis of anti-DNA antibodies from various murine models has led to the
identification of recurrent characteristics amongst them. Firstly, it has highlighted the
importance  of  clonal  expansion  and  antigen  driven  accumulation  of  somatic
mutations  in  determining the ability of these antibodies to  bind  dsDNA.  Secondly,
sequence analysis of these murine anti-DNA antibodies has led to the assumption
that certain amino acids are present in the CDRs of anti-DNA antibodies at a higher
frequency than  in antibodies with other antigen specificities.  Marion and colleagues
analysed  the  sequences  of  117  monoclonal  anti-DNA  antibodies  from  (NZB/W)Fi
mice  (Marion  et al.,  1992).  In some cases,  IgG  produced  by a  single mouse were
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derived from the same expanded B cell clone whereas the majority of IgM were not. 
Within a single clone, the IgG carried more mutations than the IgM,  particularly in 
the  CDRs.  An  increase  in  the  number  of  mutations  led  to  increased  affinity  for 
dsDNA.  The  mutations that led  to  high  avidity  binding to dsDNA were those that 
increased the number of arginine residues in the CDRs, especially VH CDR3 (Marion et 
al.,  1992).  Radic  et  al.,  (1994)  also  re-iterated  that the accumulation  of somatic 
mutations has led to higher frequencies of certain basic residues,  including arginine, 
asparagine and lysine being present at various positions in the CDRs of murine anti- 
DNA mAbs. Arginine and lysine are positively charged and it has been suggested that 
these  amino  acids  could  therefore  interact  with  the  anionic  sugar-phosphate 
backbone of the DNA double helix. The presence of uncharged asparagine residues 
also appears to enhance binding to DNA by forming hydrogen bonds with adenine in 
the major groove and guanine in the minor groove (Seeman et al., 1976).
1.5.2  Sequence analysis of murine aPL
In  the  case  of  aPL  produced  from  animal  models,  the  animals  show  consistent 
serological features of the syndrome, with either the obstetric or thrombotic clinical 
features but not both (Radway-Bright et al.,  1999). MRL//pr mice frequently produce 
aPL.  Kita and  colleagues analyzed the VH  and  VK  genes of aPL from  MRl/lpr mice. 
Sequence analysis showed that different antibodies from a single mouse tended to 
be clonally related. 67% used the VH  gene of the J558 family, and 43% used the VK  
gene of the VK  23 group (Kita et al.,  1993). The same authors analysed the usage of 
VH  and VK  genes of aPL in (NZW x BXSB)Fi mice. The (NZW x BXSB)Fi mouse may be 
a better autoimmune model of APS since both male and female mice produce serum 
aPL of IgG isotype and enhanced binding to CL in the presence of p2 GPI. Also, male 
mice  develop  thrombocytopenia  and  vascular  disease,  features  characteristic  of 
human  APS.  Sequence  analysis  of  VH   and  VK   genes  of  aPL  showed  that  the 
"pathogenic" aPL, which  induced thrombosis when  injected into mice,  had VH  J558 
and  VK   21  or  VK   23  genes,  whereas  the  other "non-pathogenic" antibodies  used 
mainly the 7183 VH  family and the random VK  gene group (Kita et al., 1994).
However, the role of gene and family preference in mouse anti-dsDNA and aPL may 
not  be applicable to  human  antibodies,  because the  mouse  and  human  Ig  gene 
repertoires are very different (Goldsby et al., 2000). Mice have much larger numbers 
of VH  and VK  genes than humans; whereas there are only about 44 functional human
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VH  genes,  there  may  be  up to  1000  in  the  mouse.  Mice very  rarely  rearrange 
genes;  approximately 40%  of human antibodies but only  5% of murine antibodies 
carry  k  chains  (Goldsby  et  al.,  2000).  It  is  therefore  important  to  study  human 
monoclonal anti-DNA and aPL since murine antibodies are generated from mice that 
have a disease that is only similar but not identical to human disease.
1.5.3 Sequence analysis of human anti-DNA antibodies
Far fewer human than mouse mAbs have been produced.  Whereas laboratory mice 
can  be produced in large numbers to obtain splenocytes for use in the production of 
mAbs,  large numbers of human splenocytes are rarely available. The sequences of 
66  human antibodies  have  been  published  [reviewed  by  (Rahman  et al.,  2002a)]. 
However,  most of these are  polyreactive  IgM antibodies that  bind  DNA  with  low 
affinity and relatively  few  human  IgG  anti-DNA antibodies  have  been  sequenced. 
Most human IgG anti-DNA antibodies use genes of the VH 3 or VH 4 families and the 
most commonly utilized gene is V3-23,  which  is  known  to  be the  most commonly 
rearranged gene in the VH  repertoire (Rahman et al., 2002a).
Amongst the 66 antibodies human anti-DNA antibodies reviewed  by Rahman et al., 
(2002),  52  have known  L chain sequences (34 have  k   chains and  18  have lambda 
chains). Certain  k  genes (including A27, 02/012, L2, L12, L6, B3, 08/018 and A30) 
and k genes (such as 2a2, 2b2, 2c, lb, le, lc and 3h) are used more frequently than 
other L chain genes. A27 is the most commonly rearranged gene in the VK  repertoire 
according to the results of Cox and colleagues (Cox et al.,  1994). A single \  gene, 
2a2, encodes five k chains shown to occur in  IgG anti-DNA antibodies (Rahman et 
al.,  2002).  2a2  is the most commonly used gene in  productive k rearrangements in 
normal adults (Ignatovich et al.,  1997). One of the IgG mAbs studied in this thesis, 
B3,  was  derived  from  an  SLE  patient  and  is  encoded  by  the  most  commonly 
rearranged  human  VH  and  Vx genes,  V3-23  and  2a2  respectively  (Rahman  et al., 
2001).
1.5.4 Sequence analysis of human aPL
Fifty-one human monoclonal aPL were reviewed by Giles et al., (2006). Twenty-eight 
IgG aPL were identified. Eleven were derived from patients with SLE (four of whom 
had APS) and  12 were produced from patients with  PAPS.  Most of the monoclonal
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IgG  aPL  showed  specificity  for  PL  or  p2 GPI.  The  functional  activities  of  13  IgG 
monoclonal aPL  have  been  examined  in  various  biological  assays and  eight were 
shown to  be pathogenic compared to control  mAb.  When the monoclonal aPL  516 
was  injected  into  mice,  the  mice  displayed  a  significantly  higher  rate  of  fetal 
resorption and a significant reduction in fetal and placental weight (Ikematsu et al.,
1998). Similarly, another group has shown that CIC15, an aPL derived a patient with 
PAPS,  induced  a  significantly  higher  rate  of  fetal  losses  following  intravenous 
injection into pregnant BALB/c mice (Lieby et al., 2004). In addition, five aPL derived 
from  patients  with  PAPS  (IS2,  IS3  and  IS4)  and  SLE/APS  (CL15  and  CL24)  were 
found to be thrombogenic in an in vivo model of thrombosis (Pierangeli et al., 2000).
The commonest VH  genes were found to be V3-23, V3-30, V3-07, V4-34, V4-39, V4- 
59,  Vl-18,  Vl-69  and  V5-51  encoding  15  of  the  published  IgG  aPL.  The  most 
commonly used gene amongst IgG aPL is V3-23. All IgG aPL used VL  genes which are 
members of the three largest and  most commonly expressed  VK   (I-III)  or Vx (1-3) 
families. The most commonly rearranged VK  genes include A3, A17, A20,  02/12,  L8, 
L12,  L6, A27,  L2, and  B3 while commonly rearranged Vx genes include  lb,  lc,  le, 
2a2, 2b2, 2c, 3h and 3r.
1.5.5  The importance of somatic hypermutation and charged residues in 
the CDRs of anti-DNA antibodies and aPL?
Each  V  region  sequence  of an  antibody  can  be  aligned  to  the  closest  germline 
equivalent in the V-Base directory using  DNAplot software. This allows subsequent 
analysis of nucleotide homology and distribution of somatic mutations. According to 
the multinomial distribution  model for assessment of antigen  selection proposed  by 
Lossos  et al.,  (2000),  a  P value of less than  0.05  is  evidence for  a  non-random 
distribution  of  mutations.  Statistical  analysis  of IgG  anti-DNA antibodies  and  aPL 
strongly  supports  the  idea  that antigen  drive  was  responsible for the  pattern  of 
mutation in the majority of cases (Giles et al., 2006, Rahman et al., 2002a).
The CDRs form most of the contact between antibody and antigen.  Comparison of 
the Ig V region genes expressed in six human hybridomas secreting IgG anti-dsDNA 
antibodies derived from three SLE patients with known germline genes showed that 
the VH  and  VL  sequences are somatically mutated  particularly in the CDRs and the 
pattern and extent of the observed somatic mutations are suggestive for an antigen-
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driven  selection  (Winkler  et  al.,  1992).  MacCallum  and  colleagues  showed  that 
certain  residues within CDRs of the H  and  L chains are more likely than  others to 
contact antigens (MacCallum et al.,  1996). Giles et al., (2006) studied the sequences 
of fifty-one human monoclonal aPL and reported that there is an excess of mutation 
to arginine,  lysine and asparagine in the contact sites of the IgG aPL in comparison 
to aspartic acid or glutamic acid. IgM aPL also show some evidence of accumulation 
of arginine, asparagine and lysine at the contact sites. These amino acids are mostly 
encoded  in  the  germline  in  IgM  and  derived  from  somatic  mutation  in  IgG. 
Pathogenic aPL have a tendency to  bind  negatively charged  PLs and  foGPI, which 
has a potential epitope rich  in  negatively charged residues within DI. Therefore the 
presence of arginine,  asparagine, and  lysine  residues in the contact regions of aPL 
may increase the affinity of binding via electrostatic interactions and hydrogen bonds 
with negatively charged epitopes on PLs and DI of frGPI.
This finding also holds true for anti-DNA antibodies. Sequence analysis of murine and 
human anti-DNA antibodies has shown that somatic mutation leads to an increase of 
the amino acid residues arginine, asparagine and  lysine (discussed in sections  1.5.1 
and  1.5.4).  Rahman et al., (2002) by systematic analysis of all published sequences 
of anti-DNA antibodies to date also confirmed a statistically significant accumulation 
of somatic mutations encoding these amino acids, particularly in the CDR1 and CDR2 
areas of the IgG H and  k   L chains of human IgG anti-DNA antibodies.  It has been 
postulated that the presence of positively charged residues might enhance binding to 
DNA, which carries an array of negative charges. Somatic mutations to arginine are a 
common feature of high-affinity, anti-dsDNA antibodies and  have been predicted to 
be particularly important in the binding to DNA (Radic et al., 1993).
It is important to note that not all antibodies with arginine residues  in their CDRs 
bind  dsDNA  since  it  is  the actual  positions  of the  arginine  residues  within  the  V 
region of the H and H chains that determine the binding affinity of the antibody. The 
results  obtained  by  Stevenson  et al.,  (1993)  using  two  antibodies  RT-79  and  D5 
derived from the gene, VH 4-34,  support this argument. The VH  CDR3 sequences for 
both the antibodies had a predominance of basic amino acids, with RT-79 having five 
and D-5 two arginine residues respectively.  Despite the fact that RT-79 contains five 
arginine residues in VH  CDR3, it only binds ssDNA. Conversely, D5 contains only two, 
but binds dsDNA with  high affinity (Stevenson et al.,  1993). Arginine residues that
93Chapter One Introduction
have arisen  as a  result of somatic  mutation  are  present  in  human  IgG  anti-DNA 
antibody, B3 and aPL, IS4 which were studied in this thesis.
1.6  Three-dimensional images  of anti-DNA  and antiphospholipid 
antibodies
The importance of individual amino acid residues in determining the binding affinity 
of an antibody cannot be determined by sequence analysis.  For this reason, various 
groups have produced three-dimensional images of antibodies interacting with their 
antigen, using X-ray crystallography or computer-generated modelling, to predict the 
specific amino acid  residues in the antigen-binding site of individual antibodies that 
are  most likely to  make contact with the antigen.  Crystal  structures and computer 
models  enable  hypotheses  to  be  proposed  and  it  is  necessary  to  test  these 
hypotheses  by expressing  mutated forms of the Ig cDNA to create slighltly altered 
molecules and examining the effects upon their ability to bind antigen.
1.6.1  X-ray crystallography of anti-DNA antibodies
Few  crystal  structures  of  anti-DNA  antibodies  have  been  published,  because  of 
difficulties in purifying sufficient quantities of a single mAb for X-ray crystallography 
analysis (Kalsi and  Sutton,  1997).  Co-crystals show the precise  locations at which 
amino  acid  residues  of the  antibody  make  contacts  with  the  antigen  as  well  as 
changes in conformation of an antibody on binding to an antigen. The only published 
co-crystal involving an anti-DNA antibody, has been made by Herron et al., (1991) of 
an autoantibody BV04-01, with specificity for ssDNA in the presence and absence of 
a trinucleotide of deoxythymidylic acid, d(pT)3. When complexed with d(pT)3, BV04- 
01  undergoes conformational changes in order to incorporate the trinucleotide. The 
co-crystal  also  showed  that  the trinucleotide  is  held  in  a  large  irregular  groove 
between the VH   and  VL   regions on  the  surface of the antibody and that all three 
CDRs of the H and L chains contribute to this binding site (Herron et al.,  1991). An 
arginine residue, which was present in VhCDR2 at position 52, was seen to form an 
electrostatic contact with the phosphodiester backbone of the trinucleotide.  Despite 
the fact that other arginine and lysine residues were present in the binding site, they 
were unable to directly interact with the antigen due to either participating  in  ionic 
bonds in order to stabilise the topography of the antigen binding site or due to not 
being  in  the  appropriate  locations to  contact the  phosphodiester  backbone.  This
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finding highlights the fact that arginines are important but it is their precise position 
that determines the interaction with the antigen.
1.6.2  Computer-modelling of anti-DNA antibodies and aPL
It is difficult to purify sufficient quantities of a single mAb to make crystals. Therefore 
to  predict  the  antibody-antigen  interaction,  sequence  data  can  be  employed  in 
computer modelling to produce three-dimensional structures of anti-DNA antibodies 
and  aPL  and  therefore  provide  information  as  to  which  amino  acid  groups  may 
enhance or reduce binding to antigen. Computer modelling program create models of 
the predicted structures of antibody molecules from their VH  and VL  sequences.
This  approach  has  been  used  to  model  several  human  anti-dsDNA  mAbs.  The 
computer model of B3 (Kalsi et al.,  1996), shown in  Figure  1.5,  revealed a binding 
groove along the VH -VL  axis, which was flanked by three arginines at positions R27a 
(VL  CDR1) and R54 (VL  CDR2) of the L chain, and position  R53 (VH  CDR2) of the H 
chain.  Two of these arginine residues, VLR27a and VH  R53, were derived by somatic 
mutation.  Interactive docking of the dsDNA  helix  in  the  binding groove confirmed 
that these arginines are present at antibody-antigen contact sites and might stabilise 
the binding of B3 to dsDNA.  Further models have been produced,  by replacing B3VL  
with 33H11Vl and UK4VL  as shown in Figures 1.6 and  1.7 respectively. According to 
the computer model shown  in  Figure  1.6, B3Vh/33H11Vl is likely to  bind  DNA. The 
model  predicts  that this  interaction  is  stabilised  by  the  presence  of  an  arginine 
residue at position 92 in 33H11VL.  In contrast, the computer model shown in Figure 
1.7 predicts that B3Vh/UK4Vl is likely to be a poor binder to DNA.  One explanation 
for this prediction could  be that the groove in the B3Vh/UK4Vl model  is blocked  by 
various  residues from the light chain  including  a  bulky  positively charged arginine 
residue at position  94.  In  addition,  the serine  residue at position  29  introduces a 
possible destabilising electrostatic interaction with the phosphate backbone of DNA.
Barry et al.,  (1994) modelled six murine anti-DNA mAbs. Three of these antibodies
were  derived  from  autoimmune  mice,  whereas  the  others  were  prepared  by
immunisation  of  mice  with  the  respective  nucleic  acid  polymer.  This  procedure
allowed the authors to compare autoimmune and induced antibodies on the basis of
both  sequence  and  structure  to  determine  whether  there  were  any  obvious
differences between the antibodies obtained from these two sources. Comparison of
three  of  the  models  with  the  respective  crystal  structures  indicated  that  the
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differences between the two at the majority of sites were within O.lnm. In  general, 
ssDNA-specific antibodies  have deep clefts where the antigen  might bind, whereas 
dsDNA-specific antibodies present a relatively flat surface.  In addition, on the basis 
of both sequence and structure, there is little to distinguish autoimmune antibodies 
from those produced by immunisation (Barry et al., 1994).
The computer model of the IgG aPL IS4 shown in Figure 1.8, supports the idea that 
arginine residues are important at the binding sites of this aPL.  IS4  is likely to  be 
representative of pathogenic aPL since it was isolated from a patient with PAPS and 
was  shown  to  be  pathogenic  in  a  murine  model.  In  addition,  IS4  shows  P2GPI 
dependent binding to CL and  contains  numerous somatic  mutations  in  an  antigen 
driven  pattern.  Overall  the  H  chain  CDRs  of  IS4  display  an  accumulation  of 
predominantly  arginine  and  asparagine  residues  compared  to  acidic  residues.  In 
particular, IS4VhCDR3 is 15 amino acids long with a very high content of five arginine 
residues, four of which are a  result of somatic mutation.  The model  in  Figure  1.8 
shows these four arginine  residues  in  IS4VH CDR3  are  surface exposed  and  could 
therefore  be  important  in  contributing  to  CL-binding  specificity.  Conversely, IS4VL  
shown  in  Figure  1.8  has  no somatic mutations to arginine but contains a  germline 
encoded arginine at position 54.
Computer models such as these have been  used to identify particular amino acids 
that  potentially affect the  antibody-antigen  interaction.  These  residues  need  not 
always  be  in  the  binding  site  itself.  Certain  hidden  residues  may  control  the 
interaction between different loops of the V region. Alterations in such residues could 
change the three-dimensional structure of the whole molecule in  such a way as to 
enhance or inhibit its binding ability. Computer models provide a hypothesis and then 
expression experiments need to  be carried  out to test the hypothesis and  produce 
variant forms of the antibodies in which these key residues are altered. The effects 
of wild-type and altered antibodies can be compared upon binding and/or pathogenic 
properties  of  the  antibody.  A  number  of  different  systems  to  express  antibody 
sequences as whole Ig molecules have been developed and are discussed in the next 
section.
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dsDNA
Figure 1.5 Computer generated model of B3Vh/B3Vl with dsDNA
B3Vh  is  shown  in  light  blue  whilst  B3VL   is  shown  in  dark  blue.  The 
double  helix  of the  DNA  molecule  is  shown  in  the  centre  of the figure. 
The three arginine residues at the  periphery of the site  R27a (VL  CDR1) 
and  R54 (VL  CDR2)  of the  light chain,  and  R53  (VH   CDR2)  of the  heavy 
chain,  predicted  by  this  model  to  stabilise  the  interaction  with  the 
dsDNA  helix,  are  shown  in  yellow.  R27a  and  R53  are  derived  from 
somatic mutation.  Modelled by Dr S. Nag I.
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Figure 1.6 Computer generated model of B3VH/33H11VL with dsDNA
The  computer  model  predicts  that  33H11VL  is  able  to  create  a  DNA 
binding  site  in  combination  with  B3VH.  B3VH  is  shown  in  light  blue 
whilst  33H11VL  in  dark  blue.  The  VL  residues  that  differ  from  those 
found  at  the  same  positions  in  B3VL  are  shown  in  red.  Unlike  B3VL, 
33H11VL does  not  have  an  arginine  residue at  27a  in  CDR1,  it  has the 
germline-derived  serine  (27a).  However,  the  presence  of  an  arginine 
residue at position 92  (R92) in  33H11VL CDR3 may compensate for this, 
since  the  model  predicts  that  R92  can  interact  with  the  backbone  of 
dsDNA.  Modelled by Dr S. Nagl.
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UK4VL
Figure 1.7 Computer generated model of B3Vh/UK4Vl
B3Vh  is  shown  in  light  blue  whilst  UK4VL   is  shown  in  dark  blue.  The  VL  
residues that differ from those found at the same positions in  B3VL  are shown 
in  red.  No  complex  with  DNA  could  be  modelled.  The  model  predicts  that 
UK4Vl is unable to bind  DNA in combination with  B3VH  due to steric hindrance 
resulting from the introduction  of an arginine residue at position 94 (R94) and 
a  serine residue at  position  29  (S29)  in  UK4VL  by somatic mutation.  Modelled 
by Dr S. Nag I.
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Figure 1.8 Models of IS4VH  and IS4VL
(A) Spacefill  model of the heavy chain of IS4. The four arginines (96,  R97, 
RlOO and  RIOOg)  in the large CDR3  loop region of IS4VH  are predicted to 
importantly  contribute  to  cardiolipin-binding  specificity.  (B)  Secondary 
structure model of the  heavy chain of IS4. (C) Secondary structure model 
of the light chain of IS4.  Modelled by Dr S. Nagl.
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1.7  Expression systems for antibodies
Further  investigation  of  the  structure/function  relationship  of  antibodies  can  be 
achieved by in vitro expression of the antibodies from cloned DNA. The totai yield of 
Ig  from  in  vitro  expression  of  cloned  DNA  is  often  poor  in  comparison  to  that 
produced  by hybridoma cell  lines.  However,  human  hybridomas are often  unstable 
and  may lose the ability to secrete antibody (Barnes et al.f  2003).  Therefore,  it is 
necessary  to  develop  recombinant  monoclonal  anti-DNA  antibodies  using  such 
expression systems to test hypotheses regarding the effects of sequence changes on 
their binding and functional  properties. The great advantage of in vitro expression 
systems is that the sequence of the DNA being expressed can be controlled whereas 
the sequence of an antibody from a  hybridoma cannot be changed.  It is therefore 
possible to  use  site-directed  mutagenesis  to  produce an  antibody  with  a  precise 
amino acid  sequence.  Monoclonal  anti-DNA antibodies from  patients with  SLE and 
APS as well as murine models with the disease have been expressed in such systems 
to test various hypotheses ranging from the effects of single point mutations to the 
effects of exchanging entire H or L chains.
In vitro expression from cloned  DNA involves cloning VH  and/or VL  sequences of a 
selected antibody into an expression vector containing the appropriate Ch and/or CL  
as well as the components required to enable the plasmid vector to express Ig once 
transfected  into either a  bacterial or eukaryotic cell.  Whole Ig molecules have been 
produced using expression systems.
1.7.1  Bacterial expression systems
The disadvantage of bacterial  expression of eukaryotic  proteins  is bacteria do  not 
possess  all  the  enzymes  necessary  for  post-translational  modifications  such  as 
glycosylation and the molecules may not be folded properly. This misfolding applies 
particularly  to  IgG  molecules  as  it  has  not  been  possible  to  express  a  stable, 
functional whole antibody molecule in  bacteria (Persic et al.,  1997).  However, since 
the antigen-binding  site  of an  antibody  is  encoded  by only the V  region,  smaller 
fragments of antibodies, such as single chain Fv molecules (scFv) or Fab molecules 
[which contain the whole L chain (VL  and CL ) covalently bound to half of the H chain 
(VH  and CH 1)], have been expressed that still bind to antigen.
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scFv are the simplest of the expression products (Figure 1.9). They are composed of 
two domains, an antibody VL  amino acid sequence tethered to a VH  sequence by a 
designed  peptide that links the carboxyl terminus of the VL  sequence to the amino 
terminus  of the VH   sequence (Bird et al.r  1988).  The flexibility of the  polypeptide 
linker, which  is usually rich in glycine and serine, enables the VH  and VL  domains to 
adopt various conformations to produce an antigen-binding site. One disadvantage is 
that because scFV molecules have no C region cDNA and consist of only V regions, 
the structure of scFvs does not resemble any molecule occurring in nature.
In  order to  study the contribution  of the H  or  L chain of the  Ig  molecules to the 
binding and pathogenic properties of anti-p2 GPI, Blank and colleagues converted the 
anti-faGPI  mAbs  into scFV,  replaced  H  and  L chains  between  the  pathogenic and 
non-pathogenic anti-faGPI  scFV, and  studied  their contribution  in vitro and  in  vivo 
(Blank et al.,  1999).  The authors  showed  that  in  most  cases  replacement of the 
pathogenic VH  domain with the non-pathogenic VH  decreased the binding affinity of 
the scFv to p2 GPI and completely abrogated the anticoagulant activity.  BALB/c mice 
were immunised with the anti-p2 GPI  scFv and  developed clinical  manifestations of 
APS such as thrombocytopenia, prolonged activated partial thromboplastin time, and 
increased  fetal  resorptions (Blank et al.,  1999).  Their  results  showed  that scFv of 
pathogenic antibodies are capable of inducing the same clinical manifestations as the 
whole antibody molecule upon active immunisation. Brigido and collegues carried out 
a similar study where they used a plasmid scFv expression vector to express VH  and 
VL  from the  murine monoclonal anti-Z-DNA antibody Z22  (Brigido et al.,  1993).  Z- 
DNA is a form of DNA in which the double helix winds to the left in a zig-zag pattern 
(instead of to the right, like the more common B-DNA form). scFV containing both VH  
and VL  of Z22 bound Z-DNA but not B-DNA or ssDNA which were the same binding 
properties shown by whole Z22 molecules.  Replacement of either VH  or VL  by other 
mouse VH   or  VL  genes  prevented  binding  to  Z-DNA  in  most cases  (Brigido  et al., 
1993).  These experiments suggested  that  both  VH   and  VL were  important  in  this 
antibody.
In  some  scFv  expression  systems the VH   and  VL  DNA are  ligated  into  phagemids 
rather than  plasmid  vectors  (Rahman  et al.,  1998a).  These  vectors  are  modified 
bacteriophages (viruses which  infect bacteria). The scFvs are expressed linked to a 
surface protein on a  phage particle,  which is produced by the transfected bacteria. 
This technique  is  known  as  phage display.  If a  library of VH   and  VL  sequences  is
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cloned Into a phagemid, a library of different phage particles that display a repertoire 
of different Vh/Vl combinations is produced. This process is called repertoire cloning.
An alternative to scFvs is to express Fab fragments (Figure  1.10). The Fab can  be 
free in  solution or displayed on the surface of a  phage, allowing  repertoire cloning 
(McCafferty et al.,  1990).  Bacterial expression of Fab fragments gives  lower yields 
than  svFv.  However,  Fab  maintain  the  structure of an  antibody  binding  site,  and 
therefore are the most appropriate fragments to  be  used  in  crystallisation  studies, 
particularly if they can be produced and purified from large scale bacterial cultures. 
Kumar et al., (2004) investigated the binding characteristics of human autoantibodies 
B3  and  UK4  in  their  IgG  and  cloned  Fab  formats.  Although  B3  did  not  show 
convincing binding to Sm, it exhibited moderate binding to La or Ro and high binding 
to RNP.  UK4 bound little to Ro and weakly to Sm, La and RNP. The results obtained 
show  that the  relative  binding  pattern  against  nuclear antigens  exhibited  by  the 
cloned Fab fragments of B3 and UK4 was in general comparable to that observed for 
these molecules in their IgG format (Kumar et al., 2004).
Studies using  bacterial expression systems also illustrate the importance of not just 
the  presence  but  the  precise  position  of  residues  such  as  arginine,  lysine  and 
asparagine on DNA-binding. Mockridge et al., (1996) showed that human mAb D5 VH  
and  Vl could  be  expressed  as  phage  bound  Fab,  which  bound  both  ssDNA  and 
dsDNA. When the D5 H chain was replaced with one with no mutations and no basic 
residues in CDR3,  DNA binding activity was lost completely (Mockridge et al.,  1996). 
This study showed that somatic  mutations  in  the  FRs,  CDR1  and  CDR2  of D5 VH 
were not as essential in binding to DNA whereas the basic residues in VH  CDR3 were 
more crucial.
The  advantage  of  bacterial  expression  systems  is  that  bacteria  are very  easy to 
culture and relatively inexpensive. Therefore, it is possible to produce large amounts 
of  antibody  fragments  (Verma  et  al.,  1998).  In  addition,  by  using  libraries  of 
expression vectors, large numbers of combinations of VH   and  VL  sequences can  be 
rapidly screened for the ability to  bind a  particular antigen.  However,  because Fab 
and scFv molecules lack C region domains, they are both  unsuitable for use in the 
investigation of the binding properties affecting the pathogenicity of these antibodies 
in  vivo.  Whole  IgG  molecules  are  required  and  can  be  produced  by transfecting 
cultured eukaryotic cells.
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1.7.2  Eukaryotic expression systems
Expression  of whole,  fully glycosylated  antibodies  in  mammalian  cells is the  ideal 
expression system.  The overall yield of antibody  however  is lower than  in  bacteria 
because it is difficult to grow mammalian cells in such  large quantities. Although Ig 
molecules can be expressed by yeast and insect cells, these methods have not been 
used to produce anti-DNA antibodies or aPL (Hasemann and Capra,  1990, Horwitz et 
al.,  1988). Lieby et al., (2004) expressed human monoclonal aPL in insect cells by a 
baculovirus  expression  system.  Among  5  monoclonal  aPL,  all  originating  from  a 
single patient with APS, only  1 (CIC15) induced fetal  losses when passively injected 
into pregnant mice.  Its antiphospholipid activity was dependent on annexin A5, and 
its  V  regions  contained  3  replacement  mutations.  To  elucidate the  role  of these 
mutations in the pathogenicity of the antibody, they were reverted to the germline 
configuration (replacing 3 asparagine residues by serine in CDR1 of VK ). The resulting 
"germline" antibody reacted with multiple self-antigens (human thyroglobulin, human 
myoglobin, ssDNA) and only partially lost its reactivity against CL, but it was no more 
dependent on annexin A5 and, more importantly, was no more pathogenic (Lieby et 
al., 2004). This study illustrates that the in vivo antigen-driven maturation process of 
natural autoreactive B cells can be responsible for pathogenicity.
There are two types  of expression  of antibodies  in  mammalian  cells  [reviewed  in 
(Rahman et al., 2002b)].  In transient expression, the foreign genes inserted on the 
plasmid vector are not integrated  into the genome of the cell. Therefore, they are 
active for a short period, 3 to 6 days, after which no more antibody is produced. Only 
small  amounts  of  Ig  are  produced  in  this  way,  but  selection  of  cells  for  drug 
resistance markers and long-term maintenance of cell lines are not required, allowing 
rapid screening of large combinations of different antibodies. In stable expression, a 
small minority of cells will retain the transfected foreign genetic information for many 
generations  since  it  has  been  integrated  into  the  genome  of the  host cell.  It  is 
essential however to select those cells that have successfully integrated the DNA and 
that  are  expressing  the  highest  amount  of  antibody.  By  incorporating  genes 
conferring  drug  resistance  into  the  expression  plasmid,  this  minority  of  high 
producing cells can be isolated since only those that have taken up the plasmid will 
survive in the selective media used (Fann et al., 2000).
The  H  chain  expression  vectors  used  in  both  transient  and  stable  eukaryotic 
expression  systems,  contain  the VH   DNA  sequence  5' to  the  appropriate  Ch  DNA
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sequence (i.e.  encoding the entire H  chain C region and the hinge region).  The L 
chain expression vectors contain the VL  DNA sequence 5' to the appropriate k or K CL  
DNA sequence.  A number of techniques have been described for the transient and 
stable expression of antibodies in mammalian cells and these fall into three groups: 
the  simultaneous transfection  of separate  H  and  L  chain  expression  vectors  into 
eukaryotic cells to express whole fully glycosylated Ig molecules (Figure 1.11A); the 
transfection  of a  single  expression  vector (supervector)  containing  both  H  and  L 
chain  sequences  (VH /  Ch,  Vl  and  Q.  DNA  sequences)  (Figure  1.11B);  and  the 
transfection of H chain vector into hybridoma cells which only secrete L chains (a H 
chain  loss  variant)  [reviewed  in  (Rahman  et  al.,  2002b)].  The  advantage  of 
transfection using a supervector is that more cells may acquire the DNA required to 
make  both  chains  therefore  increasing  the  yield  of  Ig  produced.  However,  the 
simultaneous transfection of separate H and L chain expression vectors does make it 
easier to produce a wide range of Igs with different H/L chain combinations.
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Figure  1.11  Production  of  whole  immunoglobulin  molecules  using  eukaryotic 
expression systems
A) Transfection  of separate  heavy and  light chain  expression  vectors  into  eukaryotic 
cells  (B) Transfection  of  single  expression  vectors  containing  both  heavy  and  light 
chain cDNA into eukaryotic cells
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1.7.2.1  Transient expression of whole IgG molecules in eukaryotic cells
Various  groups  have  demonstrated  transient  expression  of  human  and  murine 
antibodies by transfecting both the H and L chain expression vectors into a cell type, 
which  secrete no endogenous  Ig.  COS-7  cells,  an  immortal African  green  monkey 
kidney cell line, have been used for transient expression of anti-DNA antibodies and 
a PL. They are permissive for the replication of many plasmids that contain a short 
sequence (340 bp) including the replication origin of the monkey papova virus, SV40 
(Simian Virus 40) (Gluzman, 1981). The SV40 origin is not found in these COS-7 cells 
but any plasmid vector containing  it will be actively replicated  in COS-7 cells. Once 
the COS-7 cells are transfected, foreign DNA cloned into these plasmids is expressed. 
Transient  expression  in  COS-7  cells  is  the  most  widely  used  of  all  eukaryotic 
expression systems.
Zack et al.,  (1995)  achieved  transient  expression  of whole  murine  IgG  anti-DNA 
antibody, 3E10 in COS-7 cells and examined  in detail the binding to DNA. The IgG 
produced bound ssDNA and dsDNA. There is only one arginine present in the CDRs 
of the mAb 3E10 H chain and mutagenesis studies presented by the authors showed 
that a change in the arginine at position 95  removed  DNA reactivity.  On the other 
hand, gain of an asparagine in CDR1 at residue 31  increased binding to both ssDNA 
and dsDNA (Zack et al., 1995). However, the authors also showed that several other 
residues, especially serine and tyrosine, are of equal importance in the DNA binding 
of this molecule and the L chain as well as the H chain was found to be critical for 
binding DNA.
Members of our group have  previously  used  a  similar system  in  which  VH   and  VL  
cDNA from  human anti-DNA antibodies (B3  and WRI176) and aPL (IS4 and  CL24) 
were cloned into separate vectors which allowed their expression as whole H and  L 
chains respectively (Rahman et al., 1998b, Giles et al., 2003). By cotransfecting COS- 
7  cells with  pairs of H  and  L chain  vectors  it was  possible to  produce  whole IgG 
molecules from different Vh/Vl combinations. The yield of IgG produced  by in vitro 
expression  was  low  but  it was  possible to show  binding  to  DNA and CL.  Arginine 
residues play important roles in binding to dsDNA and CL however different patterns 
of mutation to arginine are associated with binding to each of these antigens.
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1.7.2.2  Stable expression of whole IgG molecules in eukaryotic cells
Establishing  a  stable  expression  system  can  be  difficult  and  time-consuming 
however,  it  has  the advantage  of producing  higher quantities  of antibodies.  The 
yields  obtained  enable  researchers to  purify  the expressed  antibodies.  Moreover, 
fuctional studies in mice or certain affinity assays such as BIAcore (surface plasmon 
resonance),  which  require  the  use  of  purified  antibody  can  be  performed,  to 
determine the pathogenic properties of sequence alterations in antibodies.
Experiments using H chain loss variants (HCLVs) have been carried out to study the 
importance of sequence changes  particularly arginine and  other  basic  residues  in 
VhCDR3.  Radic et al., (1993) studied the H chain of a  murine IgG anti-dsDNA mAb, 
3H9 that contains three somatic mutations in CDR2, one of which creates an arginine 
residue and there is a single arginine in CDR3. Initially they transfected 3H9 VH  into a 
number of different HCLVs and showed that it could produce anti-DNA antibodies in 
combination  with  several  different  VL   sequences.  Mutagenesis  of  the  3H9  VH  
sequence  to  revert  the  arginine  at  position  53  in  CDR2  to  serine  has  led  to  a 
dramatic reduction of affinity for dsDNA.  Similarly, when the arginine in CDR3 was 
changed to glycine, the ability to bind DNA was abolished. However, reversion of the 
other somatic mutations in CDR2 that did not involve basic residues had little or no 
effect.  Furthermore, introduction of an extra arginine in 3H9 VH  at sites where they 
were  known  to  occur  in  other  murine anti-DNA  mAb CDRs,  led  to an  increase  in 
affinity  for  both  ssDNA  and  dsDNA  by  between  5  and  10-fold.  If two  or  more 
arginines were added to the same chain then binding was increased by up to 70-fold 
showing the effects of the mutations can  be additive. These data however, do not 
imply that every arginine will always react with  DNA. A case in  point is arginine at 
position  64,  which  did  not  bind  detectably to  DNA.  The authors  proposed  that a 
neighbouring aspartic acid at position 65, the product of a somatic mutation  in 3H9 
VH ,  reacts  with  R64  by formation  of a  salt  bridge,  in  a  way that  precludes  DNA 
binding. Therefore the nature of amino acid residues as well as the precise position is 
important in affecting  binding affinity. Furthermore, Guth and colleagues found that 
purified 3H9 binds chromatin and specifically a complex of H2A/H2B/dsDNA, but not 
dsDNA in  solid  phase or in  solution (Guth et al., 2003).  When  used in the form of 
culture  supernatant  or  as  a  standard  protein  G  preparation,  3H9  binds  dsDNA, 
apparently due to nuclear proteins in the preparation that assemble on target DNA.
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The H  chains of the murine anti-DNA antibody D42 and the anti-phosphorylcholine 
antibody 6G6 are both encoded by the same VH 11 germ-line gene (Pewzner-Jung et 
al.,  1996).  The  two  antibodies  differ  at  two  sites  in  VH   CDRs  1  and  2  due  to 
replacement mutations in D42. There are three arginines in CDR3 of D42 VH  whereas 
6G6 VH  does not have any arginines. Pewzner-Jung et al., (1996) transfected D42 VH  
and  6G6 VH   into  HCLVs. Their results indicated that the major contribution to DNA 
binding affinity  is provided by the particular H/L chain  pairing and the structure of 
the  VH  CDR3  gene segment.  They found  that only transfection  into  loss variants 
secreting the D42 L chain produced anti-DNA binding, which was only possible if the 
transfected  DNA  contained  D42  VH   CDR3.  The  presence  of the two  replacement 
mutations  increased  the  DNA  binding  affinity of  D42  and  one of these  mutations 
abolished  phosphorylcholine  binding  of 6G6,  but did  not convert it to an  anti-DNA 
antibody. HCLVs are not well suited to studying the effects of changes in the L chain. 
Some  information  can  be deduced  by transfecting the  same H  chain  into variants 
secreting different L chains but this does not allow for the design of point mutations 
in the L chain itself.
To evaluate the role of somatic mutations in DNA binding, Wellmann and colleagues 
subjected  human  IgG  anti-dsDNA  antibody  33.C9  and  33.F12  to  side-directed 
mutagenesis, reverting amino acid substitutions to the germline sequence. The Ig V 
gene segments from genomic DNA from 33.C9 and 33.F12 hybridomas were cloned 
into expression vectors and the resulting  plasmids were used as a template for the 
site-directed mutagenesis. The variants produced were expressed in myeloma cells. 
Geneticin  and  puromycin  were  used  for  neomycin  selection  and  double-resistant 
clones were screened for IgG production in ELISA. The germline revertants of the V 
regions of 33.C9 and  33.F12 exhibited no detectable ssDNA or dsDNA binding. The 
authors showed that arginines enhance antibody affinity for DNA in the case for the 
human antibody 33.F12.  For the antibody 33.C9, however, none of the three amino 
acid  exchanges  that  are  essential  and  sufficient to  create  a  high-affinity-dsDNA 
antibody are arginines.  In  addition,  33.C9 with germline-reverted V genes showed 
strong to CL, creating an antibody with specificity to PLs (Wellmann et al., 2005).
In  another  similar  study,  Katz  et  al.,  (1994)  used  site-directed  mutagenesis  to 
produce a  range of antibody variants of the VH  sequence of the  murine anti-DNA 
antibody R4A.  Mutants were generated with amino acid substitutions in CDR2, CDR3 
and  FR3 that alter the charge of the V  region  and tested for binding to  DNA and
112Chaoter One Introduction
deposition  in the kidneys of SCID mice.  Although  mutation of an arginine in CDR3 
was found to reduce binding, a single amino acid substitution (arginine to serine) in 
CDR2  resulted in  higher binding than  R4A to dsDNA, showing that an arginine may 
be lost within a CDR without a resulting decrease in dsDNA binding. In addition, the 
glutamic acid to glutamine replacement in FR3 showed a modest increase in dsDNA 
binding,  demonstrating that FR substitutions can also alter DNA binding. The most 
dramatic  finding  of  this  study  is  that  a  very  few  amino  acid  substitutions  can 
completely  abrogate  pathogenicity  or  alter  the  in  vivo target  of  a  pathogenic 
autoantibody.  They  injected  young  SCID  mice  intraperitoneally  with  either  R4A 
hybridoma cells or one of the HCLVs expressing whole IgG with the altered  R4AVH  
(Katz et al.,  1994). All  mice carrying the R4A hybridoma developed proteinuria with 
glomerular deposition of the antibody in the kidneys. The mutant cell line producing 
antibody  that  gave  the  highest  dsDNA  binding,  described  above,  showed  some 
glomerular deposition but deposited to a greater extent in the tubules. However, the 
change in affinity for dsDNA may also be associated with the acquisition of a  novel 
antigenic cross-reactivity. The localisation of renal deposition  raises the question of 
whether DNA binding is central or ancillary to the pathogenicity of these antibodies. 
In conclusion, these results indicate that changes in the ability to bind dsDNA do not 
necessarily predict changes in the pathogenic properties of an antibody.
HCLVs  have  not  been  used  to  express whole  human  anti-DNA antibodies.  Human 
monoclonal  anti-DNA  antibodies  have  only  previously  been  stably  expressed  in 
eukaryotic cells by one group (Li  et al.,  2000).  In this system  F3B6  human/mouse 
heteromyeloma  cells  were  transfected  simultaneously  with  expression  vectors 
containing  H  or  L  chain  DNA  of  the  human  IgA  monoclonal  anti-DNA  antibody 
412.67. The antibody was expressed as IgG rather than IgA, because the expression 
vector contained a cloned Q sequence (not Ca).  Neomycin was used as a selecting 
agent as the L chain vector carried a neomycin resistance gene neo. Therefore only 
those cells successfully transfected with the L chain expression vector survived the 
neomycin  treatment.  Those cells expressing  both  H  and  L  chain  whole  IgG  were 
detected  by  ELISA and  the IgG  purified  by ammonium  sulphate  precipitation  and 
then on a column. The quantities of whole Ig produced were far greater than those 
produced by transient expression systems thus enabling further binding assays to be 
carried  out,  such  as  inhibition  assays  (ssDNA  inhibited  antibody  binding to  solid- 
phase  DNA)  which  require a  greater yield  of Ig  than  that  produced  by transient 
expression.  Li  et al.,  (2000)  used  this  stable expression  system  to  show that for
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412.67 to bind dsDNA the presence of two VH  CDR3 arginine residues was essential 
although the presence of either arginine singly was sufficient for ssDNA binding.
1.8  Conclusion:
In conclusion  it appears that high affinity anti-dsDNA and aPL IgG are  particularly 
important in  patients with SLE and APS respectively.  Sequence analysis has shown 
antigen-driven accumulation of multiple somatic mutations in the VH  and VL  CDRs of 
these  antibodies.  Overall  the  findings  from  various  experiments,  using  different 
expression systems support the importance of basic amino acids, particularly arginine 
residues in VH  CDR3 at the antigen  binding  site. The importance of these residues 
has been highlighted using site-directed mutagenesis and tested for binding affinity.
Human monoclonal anti-DNA antibodies and aPL may well be representative of those 
antibodies most closely related to disease pathogenesis in patients with SLE and APS 
especially if they are of the IgG  isotype. As the pattern of Vh/Vl gene usage is not 
significantly different  in  patients with  SLE and APS  in  comparison to that seen  in 
healthy individuals, it is likely that representative anti-DNA antibodies and aPL for all 
SLE and APS patients are those in which both the VH  and VL  sequences are encoded 
by the most commonly rearranged genes.
The  human  monoclonal  anti-DNA  antibody  B3,  which  I  studied  in  this thesis was 
derived by members of our group from a patient with active SLE (Ehrenstein et al., 
1993a). B3 is relevant to studying SLE for a number of reasons. It has an IgG isotype 
and a high  affinity for dsDNA. The VH  and  VL  of B3 are encoded  by the two  most 
commonly  rearranged  human  VH   and  Vx  genes,  V3-23  and  2a2  respectively. 
Furthermore,  when  injected  into  SCID  mice,  B3 deposited  in the  kidneys and the 
mice developed proteinuria (Ehrenstein et al.,  1995,  Mason et al., 2005).  The other 
mAb  that  I  studied  is  an  aPL  IS4,  derived from  a  patient with  PAPS (Zhu  et al.,
1999).  IS4 possesses  multiple features  likely to make this antibody relevant to the 
pathogenesis  of  APS  and  representative  of  pathogenic  aPL  found  in  many  APS 
patients.  It  is  of  IgG  isotype,  binds  with  high  affinity  to  anionic  PL  only  in  the 
presence of p2GPI  and can bind to pzGPI alone.  Moreover, it has been shown to be 
thrombogenic  in a  murine in vivo pinch-induced thrombosis model and to cause in 
vitro and in vivo EC activation (Pierangeli et al., 2000). There have been few studies 
of the relative importance of H and L chain sequence changes in the binding of aPL
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to PL-p2 GPI. Several groups have studied murine aPL however human aPL are more 
likely to demonstrate the direct relevance to APS in humans.
The  computer-generated  model  of  the  B3/dsDNA  complex  (Kalsi  et  al.,  1996) 
suggests that binding  is stabilised  by the interaction  of dsDNA with three arginine 
residues on the periphery of the binding site (R27a [VL  CDR1] and R54 [VL  CDR2] of 
the L chain, and R53  [VH  CDR2] of the H chain). One of the arginine residues (R27a 
in VL  CDR1) is the product of a somatic mutation of the germline gene, 2a2 and has 
been previously studied by our group (Rahman et al., 2001). The arginine residue in 
VH  CDR2  (R53)  is the product of a  somatic mutation of the germline gene, V3-23. 
The  computer  model  of  IS4  VH   predicts  that four arginine  residues  are  surface- 
exposed, and therefore potentially important in  binding to PL. These are in CDR3 at 
positions 96, 97, 100 and lOOg.
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1.9  Aims of this thesis
The general alms of my thesis were to examine which sequence features in B3 and 
IS4 H chains are important in determining their ability to bind antigen by expressing 
whole  antibodies  using  a  transient and  stable  expression  system.  Experiments  to 
produce variant forms of antibodies using site directed mutagenesis were also carried 
out and their effects upon antibody binding to different antigens examined. In more 
detail I aimed to:
1.  produce variant forms of the VH  chain region of B3 and IS4 by replacing the 
arginine  residues  in  B3VH   CDR2  and  IS4VH   CDR3  using  site-directed 
mutagenesis.
2.  develop a  COS-7 transient expression system to express different H/L chain 
combinations  as  whole  IgG  molecules  and  determine their  ability  to  bind 
dsDNA, nucleosomes, a-actinin, CLf frGPI, DI of p2 GPI and PS.
3.  develop  a  system  for  the  stable  expression  of  cloned  antibody  DNA 
sequences, derived from  human monoclonal aPL and anti-dsDNA antibodies, 
as whole IgG molecules in Chinese hamster ovary cells (CHO) which lack the 
dihydrofolate reductase (dhfr) gene.
4.  purify the expressed  antibodies  produced  from  the CHO  stable expression 
system and test their binding affinities to dsDNA, nucleosomes, a-actinin, CL, 
p2 GPI, DI of P 2GPI and PS.
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CHAPTER TWO.
MATERIALS AND METHODS
2.1 Materials
2.1.1  Chemicals and reagents
All chemicals used in this project were supplied by BDH, Lutterworth, Leicestershire, 
UK with the following exceptions:
Absolute Alcohol & Propan-2-ol  (Hayman Ltd, Witham, Essex, UK)
Methotrexate (M7X) / Amethopterin  (A6770,  Sigma,  Poole,  UK)
Dimethyl Sulfoxide (DMSO)  (D-5879,  Sigma,  Poole,  UK)
Trypan Blue solution (0.4%)  (T8154,  Sigma,  Poole,  UK)
5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside  in  dimethylformamide  (Xgal), 
Isopropyl-p-thiogalactopyranoside (IPTG)  (Insight Biotechnology,  Wembley, U.K) 
All  solid chemicals were dissolved  in  ddH2 0,  adjusted  to the correct pH  with  0.1M 
HCL, glacial acetic acid or 0.1M NaOH and autoclaved or filter sterilised with 0.22[xm 
syringe driven filter units (Millipore, Bedford, MA, USA) unless otherwise stated. 
Deoxynucleotide Triphosphates (dNTPs)-  lOOmM (pH 7.5) set of dATP, dCTP, dGTP, 
dTTP (Promega, Southampton, UK) were stored at -20°C.
2.1.2  General materials and equipment
15ml and 50ml sterile tubes  (#91015T, Helena Biosciences, Sunderland, U.K) 
Bijou tubes  (#39740, Bibby Sterilin Ltd, Staffordshire, U.K)
Sterilin tubes  (#30593, Bibby Sterilin Ltd, Staffordshire, U.K)
1.5ml and 0.5ml microfuge tubes  (Anachem, Luton, Bedfordshire, U.K)
1.5ml thin-walled microfuge tubes  (Eppendorf AC, Hamburg, Germany)
Centrifuges:  (Kendro Laboratory Products Ltd, Herts, U.K)
Sorvall Biofuge Pico (and refrigerated version Fresco),
Sorvall  RT-7 Plus and 
RC26 Plus
PCR Cycler Machine  (Eppendorf Mastercycler, Hamburg, Germany)
Gene Pulser II Electroporator  (Bio-Rad Laboratories Ltd, Herts, U.K)
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Gene Pulser II Cuvettes 0.4cm  (#165-2088, Bio-Rad Laboratories Ltd)
Centricon-YM30 centrifugal concentrators  (Amicon Bioseparations,  Millipore, UK)
Spectrophotometer  (BioRad laboratories, CA, USA)
2.1.3  Enzymes
Xhol 
Hind III 
Age I 
Sail 
BamHI 
EcoRI
RNase-free, Dnase I 
Taq DNA Polymerase 
PfuTurixP DNA Polymerase
T4 DNA Ligase
All enzymes were stored at -20°C.
(#R6161, Promega, Southampton, UK) 
(#R6045, Promega, Southampton, UK) 
(#R7251, Promega, Southampton, UK) 
(#R6051, Promega, Southampton, UK) 
(New England Biolabs(NEB), Hertfordshire, UK) 
(#R6017, Promega, Southampton, UK) 
(776 785, Roche, Lewes, East Sussex, UK) 
(#M1665, Promega, Southampton, UK) 
(Quikchange™ Site-directed mutagenesis kit 
Stratagene, California, USA) 
(# M1801, Promega, Southampton, UK)
2.1.4  Reaction buffers
a)  lOx PfuTurbo  DNA  polymerase  reaction  buffer  in  Quikchange™  Site-directed 
mutagenesis kit  (Stratagene, California, USA)
- lOOmM KCI
- lOOmM (NH4)2 S04
- 200mM Tris-HCI (pH 8.8)
- 20mM MgS04
-1% Triton® X-100
- lmg/ml nudease-free bovine serum albumin (BSA)
b) DNA ligase buffer  (Promega, Southampton, UK)
- 300mM Tris-HCI
- lOOmM MgCI2
- lOOmM dithiothreitol (DTT)
- lOmM adenosine triphosphate (ATP)
c) Buffer D- for restriction enzymes Xho I and Sal I  (Promega, Southampton, UK)
- 60mM Tris-HCI (pH 7.9)
- 1.5M NaCI
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- 60mM MgCI2
- lOmM DTT
d) Buffer E- for restriction enzymes Hind III and BamH I
(Promega, Southampton, UK)
- 60mM Tris-HCI (pH 7.5)
- 1M NaCI
- 60mM MgCI2
- lOmM DTT
e) Buffer H- for restriction enzyme EcoR I  (Promega, Southampton, UK)
- 900mM Tris-HCi (pH 7.5)
- 500mM NaCI
- lOOmM MgCI2
f) Buffer K- for restriction enzyme Age I  (Promega, Southampton, UK)
- lOOmM Tris-HCi (pH 7.4)
- 1.5M KCI
- lOOmM MgCI2
g) Thermophilic DNA Polymerase lOx Buffer B supplied with separate MgCI2
(Promega, Southampton, UK)
- 20mM Tris-HCI (pH 8.0 at 25°C)
- lOOmM KCI
- O.lmM EDTA
- ImM DTT
- 50% glycerol
- 0.5% Tween 20
- 0.5% Nonidet®-P40.
All reaction buffers were stored at -20°C.
2.1.5  Agarose gel electrophoresis materials and buffers
Agarose  and  low  melting  point  agarose  were  supplied  by  Gibco  BRL,  Life 
Technologies, Paisley, Scotland, UK.
Molecular weight markers:
- 1Kb DNA MW marker  (Invitrogen, Paisley, UK)
- Lambda/Hindlll DNA MW marker  (Promega, Southampton, UK)
- lOObp DNA MW marker  (Promega, Southampton, UK) 
Loading Buffer:
The following components were added to 8.45ml autoclaved distilled water:
120ChaDter Two Materials and Methods
- 25mg xylene cyanole
- 1.5g Ficoll 400 (Pharmacia, Biotech, Uppsala, Sweden)
2.1.6 General buffers and solutions
a) Trls Acetate EDTA (TAE buffer)
A stock solution of 50 times working strength TAE buffer was made by dissolving the 
following components in 1L of distilled water:
- 242g/LTris base
- 57.1ml glacial acetic acid
- 100ml 0.5M EDTA (pH 8.0)
Dilution to a working strength gave a final concentration of 40mM Tris acetate and 
ImM EDTA.
b) Tris-EDTA (TE buffer) (pH 7.5)
- lOmM Tris-HCI (pH 7.5)
- ImM EDTA
c) Phosphate buffered saline (PBS) (pH 7.4)
One PBS tablet (Gibco, Paisley, UK) was added per 500ml distilled water.
To make PBS/0.1% Tween, 1ml 'Tween 20" detergent was added to 1L PBS.
2.1.7  Specific buffers and solutions
a)  Plasmid DNA purification from bacterial cultures
The following buffers were supplied with Qiagen (Crawley, West Sussex, UK) plasmid 
purification kits:
- Buffer PI (Resuspension Buffer)  50mM Tris-CI (pH 8.0)
- Buffer QC (Wash Buffer)
- Buffer P2 (Lysis Buffer)
- Buffer P3 (Neutralisation Buffer)
- Buffer QBT (Equilibriation Buffer)
lOmM EDTA 
lOOpg/ml RNase A 
200mM NaOH 
1% SDS
3.0mM potassium acetate (pH 5.5) 
750mM NaCI 
50mM MOPS (pH 7.0) 
15% isopropanol 
0.15% Triton ®X-100 
1.0M NaCI
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50mM MOPS (pH 7.0) 
15% isopropanol
- Buffer QF (Elution Buffer for maxiprep kit)  1.25M NaCI
50mM MOPS (pH 7.0) 
15% isopropanol
- Buffer N3 (Neutralisation Buffer)  3.0mM potassium acetate (pH 5.5)
- Buffer EB (Elution buffer for miniprep kit)  lOmM Tris-HCI (pH 8.5)
b) Buffers for production of "super" competent DH5a E.coli cells:
Transformation buffer 1:  lOmM MES (pH 5.8)
lOOmM RbCI2  
lOmM CaCI2  
50mM MnCI2
Transformation buffer 2:  lOmM PIPES (pH 6.5)
75mM CaCI2  
lOmM RbCI2  
15% v/v glycerol
c) Western Blot reagents
Perfect Protein™ Western Markers  (Novagen, Nottingham, UK)
Anti-human IgG (y-chain specific) Peroxidase Conjugate  (A8419, Sigma, Poole, UK) 
Anti-Domain I  Monoclonal Antibody (kind gift from  Dr M.  Iverson and Dr M.  Linnik, 
La Jolla Pharmaceuticals (UP), San Diego, USA)
Peroxidase-Conjugated  Goat Anti-Mouse Immunoglobulins (P0447,  Dako,  Glostrup, 
Denmark)
d) Nucleosome preparation buffers
Dounce buffer:
- lOmM HEPES-NaOH (pH 7.9)
- 1.5mM MgCI2
- lOmM KCI
- 0.5mM Phenylmethylsulphonylfluoride (PMSF)
-1:100 protease inhibitor cocktail
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All reagents made up in ddH2 0 except PMSF, which is dissolved in isopropanol and 
mixed at 55°C until the crystals dissolved. Aliquots of 1ml were frozen and stored at - 
20°C.
Digestion buffer: 
lOmM Tris-HCI (pH 7.4)
ImM CaCI2
ImM Phenylmethylsulphonylfluoride (PMSF)
2.1.8  ELISA Reagents and buffers
Bovine serum albumin (BSA)
Goat anti-human IgG (Fc fragment specific)
Cardiolipin
p2-Glycoprotein I  (#B2G1-0001, Haematologic Technologies Inc, U.S.A)
Purified human IgGx 
a-actinin from chicken gizzard 
Goat anti-human \  alkaline phosphatase conjugate 
Goat anti-human IgGy alkaline phosphatase conjugate 
p-nitrophenyl phosphate tablets 
Sample, enzyme and conjugate dilution buffer (SEC)
- lOOmM Tris-HCI (pH 7)
- lOOmM Sodium chloride
- 0.02% Tween 20
- 0.2% BSA
Bicarbonate  buffer (BIC) (pH 9.6)
- 0.5M Sodium bicarbonate
- 0.05M Sodium dihydrogencarbonate
2.1.9  Bacterial Strains
- £ co// of strain DH5a were supplied by Gibco, Paisley, U.K.
- E coli XLl-Blue Supercompetent cells were supplied with Quikchange™ Site- 
directed mutagenesis kit by Stratagene, California, USA.
2.1.10  Bacterial growth media
Media were made in ddH2 0 and sterilised by autoclaving.
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(#A9776, Sigma, Poole, UK) 
(#A2094, Sigma, Poole, UK) 
(#A3150, Sigma, Poole, UK) 
(#104-105, Sigma, Poole, UK)
(#A7030, Sigma, Poole, UK) 
(#18885, Sigma, Poole, UK) 
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Luria-Bertani (LB) medium:
-1% (w/v) Bacto-tryptone 
- 0.5% (w/v) Bacto-yeast extract
(Duchefa, Haarlem, The Netherlands) 
(Duchefa, Haarlem, The Netherlands)
-1% (w/v) Sodium chloride
The pH was adjusted to pH 7.0 using NaOH.
For LB agar plates 1.5% (w/v) agar (Duchefa, Haarlem, The Netherlands) was added 
to the LB medium.
When antibiotic was added to the medium, the final concentration used was SOpg/ml 
ampicillin. Stock solutions of ampicillin at 50mg/ml in sterile water were kept at -20°C 
in light-tight containers.
NZY+ Broth:
-1% (w/v) NZ amine (casein hydrolysate)  (Sigma, Poole, UK)
- 5% (w/v) Bacto-yeast extract  (Duchefa, Haarlem, The Netherlands)
- 5% (w/v) NaCI
This was made up to 1L with distilled water, the pH adjusted to pH 7.5 using Sodium 
hydroxide and then autoclaved. The following supplements were added to the media 
prior to use:
-1.25%  1 M MgCiz 
-1.25% 1M MgS04 
-1% 2M Glucose solution
2.1.11  Human monoclonal antibodies
B3,  33H11,  UK4 and  IS4 are all  human IgG  mAbs produced from  peripheral  blood 
lymphocytes (PBL) of four different patients.
B3, 33H11, and UK4 were isolated by fusion of PBL from patients with SLE with cells 
of the  mouse  heteromyeloma  line  CB-F7.  33H11  is  specific  for  dsDNA,  B3  binds 
ssDNA,  dsDNA,  nucleosomes and  histones.  UK4 binds  negatively charged  (but not 
neutral) PL in the absence of p2 GPI and does not bind DNA.
IS4 was derived from a patient with PAPS by EBV transformation of peripheral blood 
mononuclear cells and fusion with the human-mouse heterohybridoma K6H6/B5 cell 
line. IS4 binds to CL in the presence of bovine and human p2 GPI and to human p2 GPI 
alone.
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B3 and  UK4 were produced  by our group at UCL in  London.  33H11 was a kind gift 
from Dr Thomas Winkler (Erlangen, Germany). The hybridoma cell lines of IS4 were 
produced  and  kindly donated  by  Dr P.  Chen,  Department of Medicine,  Division  of 
Rheumatology, University of California at Los Angeles, Los Angeles, USA.
2.1.12  Eukaryotic cell lines
COS-7  cells  and  CHOdhfr  were  both  kind  gifts  from  Mrs  Alison  Levy,  AERES 
Biomedical, MRC Collaborative Unit, Mill Hill, London.
The COS-7 cells were originally derived from American Type Culture Collection,  Ref 
No. CRL 1651.
CHO  dhfr  cells used are from the cell  line DXB11 originally derived from CHO-K1  in 
1978  by  Professor  Lawrence  Chasin  (Professor  of  Biological  Sciences,  Columbia 
University, USA). These CHO-K1 cells were derived from Ted Puck and Fa-ten Kao at 
the Eleanor Roosevelt Cancer Institute in  Denver, Colorado,  USA in  1970.  One dhfr 
allele  was  deleted  in  DXB11  and  the  other  allele  carries  a  mis-sense  mutation 
resulting in a single amino acid substitution.
2.1.13  Growth media and solutions for maintenance of eukaryotic cell 
lines
- Pre-Electroporation COS-7 Growth Medium 1
Dulbecco's Modified Eagle Medium (DMEM)  (41966-029,  Invitrogen, Paisley, UK)
Supplemented with:
10% (v/v) Fetal calf serum (FCS)  (10099-133, Invitrogen, Paisley, UK)
580pg/ml L-glutamine  (25030-024,  Invitrogen, Paisley, UK)
lOOOOUnits/ml penicillin/lOOOOpg/ml streptomycin
(15140-122, Invitrogen, Paisley, UK)
- Post-Electroporation COS-7 Growth Medium 2
Dulbecco's Modified Eagle Medium (DMEM)  (41966-029,  Invitrogen, Paisley, UK)
Supplemented with:
10% (v/v) Ultra low IgG FCS  (16250-078,  Invitrogen, Paisley, UK)
580pg/ml L-glutamine  (25030-024,  Invitrogen, Paisley, UK)
lOOOOUnits/ml penicillin/lOOOOpg/ml streptomycin
(15140-122, Invitrogen, Paisley, UK)
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- CHOdhfr (Non-selective) Growth Medium A
MEM a-Medium(a-MEM) with ribonucleosides and deoxyribonudosides
(32571-028, Invitrogen, Paisley, UK)
Supplemented with:
10% (v/v) FCS (10099-133, Invitrogen, Paisley, UK) 
lOOOOUnits/ml penidllin/lOOOOpg/ml streptomycin
(15140-122, Invitrogen, Paisley, UK)
- CHOdhfr  (Selective) Growth Medium B
MEM a-Medium (a-MEM) without ribonudeosides and deoxyribonudosides
(32571-029, Invitrogen, Paisley, UK)
Supplemented with:
10% (v/v) Dialysed FCS (Hyclone, UK) 
lOOOOUnits/ml penicillin/10000Mg/ml streptomycin
(15140-122, Invitrogen, Paisley, UK)
- Hank's Balanced Salt solution, containing no magnesium and no calcium (HBS)
(14175- 053, Invitrogen, Paisley, UK)
- Trypsin-EDTA (lx) in HBSS w/o CA&MG, liquid - 0.25% Trypsin ImM EDTA*4Na
(25200-056, Invitrogen, Paisley, UK)
2.1.14  Expression constructs
The expression vector (neSLE122H45.4) that encodes a  human VH 3-23,  D6-25, JH5 
IgH  chain  (CDR3:  DGGGYSSSFDP)  was  a  kind  gift  from  Dr  H.  Wardemann,  The 
Rockefeller University, New York, USA. It comes from a non-DNA-reactive, non-self­
reactive germline IgM antibody from a naive B cell originally associated with a Vk3- 
15,  Jk2  light chain.  The vector  has an  Amp  resistence cassette and the VDJ  was 
cloned into the vector using a 5’ Age I  restriction site and a 3' Sal I site. The VDJ was 
originally amplified from a single cell using nested PCR.
pGlDl, pGlD210, pLNlO and pLNlOO are expression vectors and were all kind gifts 
from Dr C.A.  Kettleborough and Dr T. Jones at AERES Biomedical, MRC Collaborative 
Unit,  Mill  Hill,  London.  Each expression vector contains the human cytomegalovirus 
(HCMV)  promoter to drive transcription  of the  recombinant immunoglobulin  gene, 
the SV40 origin of replication to give high  levels of transient expression  in  COS-7 
cells and either the bacterial neo gene (in pLNlO and pLNlOO) or mouse dhfr gene 
(in pGlDl or pGlD210) coding sequences driven by the SV40 early promoter to act
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as  dominant  selectable  markers during  stable transformation. The SV40  promoter 
however  that  drives  the  dhfr  is  crippled  by  the  presence  of  a  defective  SV40 
promoter-enhancer  sequence  so  that  expression  is  poor  thus  allowing  for  the 
selection of high expression level clones using comparatively low levels of MIX. Each 
vector also contains an ampicillin resistance gene driven  by an internal promoter to 
enable  it to  be cultured  in  E.coli.  In the recombinant expression vectors  pGlD210 
and pLNlOO, the CMV IEI  promoter contains a regulatory sequence intron A, which 
has  been  shown  to  increase the levels of expression of glycoprotein from  vectors 
containing this additional sequence.  Plasmids pGlDl and pLNlO are "old" versions of 
PG1D210 and pLNlOO respectively which lack intron A.
2.1.14.1  Heavy chain expression vectors
Recombinant  expression  vector  pGlDl  and  pGlD210  containing  human  Ig  VH  
(B3Vh/pGlDl  and  B3Vh/ pG1D210  respectively)  cDNA  was  constructed  by  Drs  A. 
Rahman and J.  Haley. The construct IS4Vh/ pG1D210 was constructed by Dr I. Giles. 
The vector map of pGlD210 is shown in Figure 2.1.
pGlDl contains a human cDNA version of the gamma-1 constant region (Human CH ), 
5'  to  which  is  a  multiple  cloning  site  (MCS)  allowing  the  insertion  of a  variable 
domain  gene  immediately  followed  by  a  splice  donor  site.  The  human  CH   is 
immediately preceded by a splice acceptor site hence the DNA between the variable 
(V) domain and constant (C) region is treated like a V::C intron by mammalian cells. 
The CH  is followed  by a termination  sequence to  prevent read  through.  The CH   is 
followed by a termination sequence to prevent read through.  The promoter driving 
the  dhfr gene  is  crippled  so  that  expression  is  poor  making  selection  by  MTX 
amplification during stable transfection possible. pGlD210 is identical to pGlDl apart 
from for the removal of the V::C intron and the replacement of the multiple cloning 
site (MCS) with a  new  sequence which also encodes the last few amino acids of a 
heavy chain J  region,  i.e.  GTLVTVSS. VhDh sequences can be cloned into the vector 
directly adjacent to CH  and in frame with it.
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2.1.14.2 Light chain expression vectors
The following expression constructs were prepared  by  Dr A.  Rahman:  B3Vi/pLN10, 
33H11Vl/ pLN10  and  UK-4Vi/pLN10  (Figure 2.2).  The construct  ISWpLNlOO  was 
constructed by Dr I. Giles.
The  light  chain  expression  vectors  pLNlO  (Figure  2.2)  and  pLNlOO  (Figure  2.3) 
contain a human cDNA version of the X-2 constant region sequence DNA (CJ, 5'  to 
which  is  a  MCS  allowing  the  insertion  of  a  variable  domain  gene  immediately 
followed  by a splice donor site. The constant region cDNA is immediately preceded 
by  a  splice  acceptor  site  hence  the  DNA  between  the V  domain  and  C  region  is 
treated like a V::C intron  by mammalian cells and not represented  in the expressed 
light chain  peptide.  A termination  sequence follows the  human  Q. to  prevent  read 
through.  Each of the V* region sequences were ligated into expression vector pLNlO 
5'  to  the  Q  human  DNA  sequence  to  produce  the  constructs,  B3Vl/ pLN10, 
33H11Vl / pLN10 and UKWpLNlO.
2.1.14.3 Supervectors
The  three  supervectors  IS4VH 8dS4Vl/PGlD210,  IS4VH&B3VL/PG1D210  and 
IS4Vh&UK4Vl/PG1D210  were  made  by  Dr  I.  Giles.  The  four  supervectors 
B3Vh&B3Vl / pG1D1,  B3VH &B33Vt/pGlDl,  B3VH&B3(R27aS)VL/pGlDl  and 
B3Vh&BUVl/pG1D1  were  made  by Drs 1  Haley and  L.  Mason. The  method  used  is 
outlined in Figure 2.4.
2.1.15  Hybrid Vl chain constructs
Each hybrid VL  chain construct contained the CDR1 of one of the human monoclonal 
IgG  antibody  and  the  CDR2  and  CDR3  of  a  different  antibody.  These  hybrid 
sequences were named by combining the names of the parent antibodies such that 
the first letter represented the antibody from which the CDR1  was derived and the 
last letter represented the antibody from which both the CDR2 and 3 were derived. 
Thus,  hybrid  B33  contains  CDR1  from  B3  and  CDR2  and  3  from  33H11  whereas 
hybrid BU contains CDR1 from B3 and CDR2 and 3 from UK4. The hybrid VL  chain BU 
had previously been made by Dr 1 Haley (Haley et al., 2004), and B33 was made by 
a similar method by Dr L. Mason.
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Pvu I 621
AmpR pro
AmpR sig Xho I 5921
AinpR
Human CH
Hind III 5875
MCS pG!D210
SV40 origin
7268 bp
HCMVi promoter
dhfr
SV40 poly A sequence
EcoR I 4293
Figure 2,1  Plasmid map of expression vector pG1D210
Abbreviations:  -  HCMVi -   improved  human cytomegalovirus  promoter containing  intron 
A;  Human  CH  -  cDNA  version  of the  gamma-1  constant region;  MCS  -  multiple cloning 
site;  AmpR  pro -  ampicillin  internal  promoter;  AmpR  sig  -  ampicillin  signal  sequence; 
AmpR  - Ampicillin  resistance gene; dhfr -  dihydrofolate reductase gene.
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Figure 2.2  Vector  map  of  recombinant  light  chain  expression  vector  pLN10 
containing VL  cDNA
The VL  region  sequences of B3,  UK4 and 33H11  were each  cloned  separately into 
expression  vector  pLNlO  5'  to  the  Q.  human  DNA  sequences  to  produce  the 
constructs, BSVt/pLNlO,  UK4Vl / pLN10 and 33H11VL/PLN10.
pLNlO  contains  the  human  cytomegalovirus  (HCMV)  promoter  to  drive 
transcription  of the  recombinant Ig  gene,  the  SV40  origin  of  replication  to  give 
high  levels  of  transient  expression  in  COS-7  cells  and  the  bacterial  neo  gene 
coding  sequence  driven  by  the  SV40  early  promoter  to  act  as  a  dominant 
selectable  marker during  stable transformation.  pLNlO also contains an  ampicillin 
resistance gene (AmpR) driven  by an  internal  promoter to enable it to be selected 
in  E.  coli.  The  Ig  V  region  sequence  is  immediately  followed  by  a  splice  donor 
(SD)  site  whilst  the  Ig  C  region  sequence  is  immediately  preceded  by  a  splice 
acceptor (SA)  site.  The  purpose of these splice sites was to facilitate the transfer 
of the  V  region  cassette  (V  region  sequence  and  Ig  leader  sequence)  into  the 
expression vectors.
130Chapter Two Materials and Methods
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EcoR I 2294
Pvu I 2920
Figure 2.3 Plasmid map of expression vector pLN100
Abbreviations:  -  HCMVi -   improved  human cytomegalovirus  promoter containing  intron 
A;  Human  CL  -  cDNA  version  of the  human  lambda-2  constant  region;  MCS  -  multiple 
cloning  site; V::C intron - region of plasmid DNA between variable (V) domain insert and 
constant  (C)  region  treated  like  a  V::C  intron  by  mammalian  cells;  AmpR  pro  -  
promoter  for  ampicillin  resistance  gene;  AmpR  sig  -   signal  sequence  for  ampicillin 
resistance gene; AmpR  - ampicillin  resistance gene;  NeoR pro -  promoter for neomycin 
resistance gene;  NeoR -  neomycin resistance gene.
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Figure 2.4  Cloning method used to construct the supervectors by combining the L 
chain and H chain expression vectors
(a)  EcoRI  restriction  sites  in  recombinant  L  chain  expression  vector,  pLNlO 
containing Vx cloned DNA sequences
(b) EcoRJ-d igested L chain cassette containing HCMV promoter, Ig leader sequence, 
L chain V region DNA sequence and C region DNA sequence
(c) Ligation of L chain cassette into EcoR /-linearised  B3Vn/pGlDl  H chain vector to 
produce the final supervector, containing all components required to produce whole 
IgGl.
The  four  supervectors  B3 Vh&B3Vl/ pG 1D1,  B3VH&B3(R27aS)VL/pGlDl,
B3VH &B33Vi/pGlDl and  B3Vh&BUVl/pG1D1 were constructed using EcoR I digested 
L chain fragments from  pLNlO containing  B3VL  or B3(R27aS)VL  or VL -hybrid  B33 or 
VL -hybrid  BU.  The  other  three  supervectors  IS4Vh&IS4Vl/pG1D210, 
IS4Vh&B3Vl/pG1D210 and IS4Vh&UK4Vi/pG 1D210 were constructed in the same way 
using  the appropriate  EcoR  I  digested  light chain  fragments  from  IS4Vl/pLN100, 
B3Vi/pLN10 and UK4Vi/pLN10 leading to slight variations in the overall plasmid size.
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2.2  Small-scale extraction of recombinant Vh/Vl vectors
DH5a-strain  E.coli containing  the recombinant  Vh/V l  vectors  was  stored  in  media 
containing  15%  (v/v)  glycerol  at  -80°C.  Under  sterile  conditions  (i.e.  next  to  a 
Bunsen  burner flame), a  sterilised wire loop was used to streak the glycerol-stored 
cultures onto a  Luria-Bertani (LB) agar plate supplemented with  50ng/ml  ampicillin 
and  incubated at 37°C in a dry  incubator overnight. The plates were transferred to 
the  refrigerator  and  kept  at  4°C.  5ml  LB  medium  supplemented  with  lOOjxg/ml 
ampicillin in a 50ml falcon tube was inoculated with a colony using a sterile wire loop 
and  incubated  at  37°C  in  a  shaking  incubator  overnight.  5ml  of  LB  medium 
(supplemented  with  100ng/ml  ampicillin)  that  had  not  been  inoculated  were also 
incubated  under the  same  conditions.  This  aliquot  was  a  control  to  ensure  that 
irrelevant bacteria did not contaminate the LB medium.
Recombinant vector was extracted from overnight £  coli bacterial cultures using the 
QIAGEN  QIAprep®  Miniprep  kit  (Crawley,  West  Sussex,  UK)  according  to  the 
manufacturer's instructions. A bacterial pellet was obtained by centrifugation (Sorvall 
RT-7)  at  3000rpm  for  10  minutes  at 4°C  and  dried  by  inversion.  The  pellet  was 
resuspended  in  250^1 of buffer PI and transferred to a 0.5ml  microfuge tube. Then 
250jil of buffer P2 was added and the tube inverted six times. Following this 350jaI of 
buffer  N3  was added,  mixed  by inversion  and then  centrifuged for  10  minutes.  All 
subsequent centrifugation  steps were carried out at 13000rpm  in a  microcentrifuge 
(Biofuge Pico) for one minute at room temperature (RT).  Supernatant from this step 
was  decanted  into  a  QIAprep  spin  column  and  centrifuged.  DNA  bound  to  the 
QIAprep  spin  column  was washed  by adding  0.75ml  of Buffer  PE and  centrifuged. 
Flow through was discarded and the column centrifuged.  After placing the QIAprep 
spin column in a clean  1.5ml microfuge tube recombinant DNA was eluted by adding 
50\i\  of autoclaved  water to the centre of each QIAprep column,  which  was  left to 
stand for one minute before being centrifuged. Eluted DNA was then stored at -20°C.
2.2.1  Restriction  digest  of  recombinant  vectors  containing  VH /VL 
fragments
B3Vh and IS4VH  were digested with  Hind III/Xho I.  B3VU  33H11Vh,  33H11Vl,  IS4Vl 
and  UK4Vl  were  digested  with  Hind  III/BamH  I.  VH 3-23/neSLE122H45.4  was 
digested with Sal 1/Age I and VH 3-23/pGlD210 was digested with Hind III/Xho I. For 
the confirmation digests lp-g of plasmid DNA and 10 units of each restriction enzyme
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were usually  incubated  in a total volume of 20^1 for one hour with the appropriate 
buffer, at 37°C as recommended by the manufacturer (Promega, Southampton, UK).
The recipe for a typical small-scale restriction digest would be as follows:
2.2.2  Separation of DNA fragments by agarose gel electrophoresis
In order to separate the DNA fragments resulting from the above restriction digests, 
the products were run on a  1% agarose gel.  One litre of TAE buffer was prepared, 
lOOmls  of  which  were  then  removed  and  mixed  with  lg  of  low  melting  point 
agarose.  The  solution  was  heated  in  a  microwave oven  until  all  the  agarose  had 
dissolved  and then  allowed  to cool  until  hand  hot when  2^1  of  lOmg/ml  ethidium 
bromide was added.  Ethidium  bromide molecules intercalate  between  base pairs in 
the  DNA double helix  rendering  it fluorescent when viewed  under  ultraviolet (UV) 
light.
The open  ends of a  gel  tray (Bio-Rad)  were closed  off with tape and the agarose 
solution  poured in.  Plastic combs were then placed in the gel tray to create wells in 
the agarose as it solidified and any air bubbles were removed. Once the gel had set 
the  comb  and  tape  were  carefully  removed  and  the  gel  tray  placed  in  an 
electrophoresis tank  (Bio-Rad)  to  which  the  remaining  900mls of TAE  buffer  was 
added.
To each  10^1 of sample to be loaded onto the gel 2^1 of loading buffer were added. 
This buffer contains  Ficoll  which  increases the density of the sample,  ensuring the 
DNA in each  sample sinks evenly into the well.  The buffer also colours the sample 
with  a  dye (xylene  cyanole)  that  moves towards the anode at a  predictable  rate, 
allowing  progress through  the gel  to  be  monitored.  Between  5  and  10^1  of each 
sample  were then  added  to each  well  and  a  voltage of  100 Volts applied  for one 
hour. The gel was then removed from the electrophoresis tank and examined  under 
UV  light.  The  position  of the band  is visualised to assess the size and the  relative 
intensity of each band which reflects the amount of DNA present by comparison with
ddH20
Plasmid DNA
Enzyme 
lOx Buffer
S[l\ (ltxg DNA) 
IjaI (10u/nl) 
2|aI
to 20\i\
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a  standard  DNA  molecular  weight  marker  (1Kb  DNA  ladder  and  the  X/Hind III 
marker) loaded into another well in the same gel. Photographs of the gel were taken 
using the Genesnap programme (Syngene, Cambridge, UK) and printed onto paper.
2.2.3  Ethanol Precipitation of DNA
In the presence of salt (monovalent cations such as Na+) and at a temperature of - 
20°C or  less,  absolute  ethanol  efficiently  precipitates  nucleic acids.  Therefore  0.1 
volume of 3M Sodium Acetate, pH 5.2 and 2.5 volumes of 100% ethanol were added 
to the DNA preparation in a 1.5ml microcentrifuge tube. This tube was then placed in 
a -80°C freezer for one hour to precipitate the DNA.
To  collect  the  precipitate  the  preparation  was  firstly  spun  in  a  microcentrifuge 
(Biofuge  Fresco)  for  10  minutes  at  13000rpm  at  4°C.  Supernatant  was  then 
discarded and the  pellet washed  with  1ml  70%  ice-cold ethanol.  The solution  was 
centrifuged again for  10 minutes in a microcentrifuge at 13000rpm at 4°C and then 
air dried on the bench for 10-30 minutes. Care was taken to ensure that no ethanol 
remained  as this could  affect  subsequent  procedures  such  as  ligations,  restriction 
digests or transfections.
Plasmid  DNA  intended  for  transfection  into  eukaryotic  cells  was  resuspended  in 
sterile autoclaved ddHzO  at a  concentration  of 2|xg/|xl  under sterile conditions  in  a 
tissue culture hood and stored at -20°C.
2.3  Cloning of VH3-23 sequence into pG1D210 Vector
2.3.1  Amplification of Vh by PCR
In this step,  template  DNA encoding the VH 3-23  is selectively amplified  by specific 
PCR primers.
At the 5' end the following primer was used to create a Hind III site:
5' GAGCTAAGCTTGCCGCCACCATGGGTTGGTCATGTATCATCCTT 3'
At the 3' end the following primer was used to create a Xho I site:
5'  GGTCGACGCTCTCGAGACGGTGACCAG 3'
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The following  reaction  mixture was  made  in  a thin-walled  PCR tube:  lpl  template 
DNA,  10(^1 DNA Polymerase lOx Buffer B, 8(xl 25mM MgCI2/  M  of a mixture of dATP, 
dCTP,  dGTP  and  dTTP  containing  each  dNTP  at  a  concentration  of  25mM,  l\i\ 
forward  primer  (final  concentration  l^M),  1(aI  reverse  primer  (final  concentration 
l(xM), autoclaved ddH20 to 80\i\ and M  (5u/|xl) Taq Polymerase.
As  a  negative control  no template  DNA was added to one  reaction  mixture.  Each 
mixture was then pulse spun and placed into a PCR machine programmed as follows: 
Initial denaturation at 95°C for 10 minutes 
Then 30 cycles as follows:
94°C for 1 minute
Annealing temperature at 42°C for one minute 
72°C for one minute
Then a final elongation phase at 72°C for 5 minutes.
The presence of PCR product of the expected length (420-440bp) was confirmed  by 
gel electrophoresis through a 2% agarose gel (see section 2.2.2).
2.3.2  Purification of amplified Vh DNA from agarose gels
PCR sample was purified from agarose gel using the QIAquick gel extraction (Qiagen, 
Crawley, West Sussex, UK) kit. An excised band of DNA of up to 0.4g was placed in a 
1.5ml microfuge tube and  1ml of buffer QG added. The mixture was then  incubated 
at  55°C for  10  minutes  until  all  agarose had dissolved.  700^1  of this solution  was 
then  added to a  spin  column  placed  in  a  collection tube and  centrifuged  (Biofuge 
Pico) at 13000rpm for  10 seconds.  Flow through was discarded from the collection 
tube  and  the  procedure  repeated  until  all  of the  initial  mixture  had  been  passed 
through  the  spin  column.  A  further  500*xl  of buffer  QG  was  added  to  each  spin 
column  and  centrifuged  at  13000rpm  for  10  seconds.  After  discarding  the  flow 
through the column  was washed  twice with  500(aI  of buffer  PE and centrifuged as 
above.  Each  column  was then  placed  into a fresh  1.5ml  microfuge tube and  dried 
under a  lamp for  5  minutes.  Elution  of DNA from each  column  was  performed  by 
addition of 50|xl of solution EB (lOmM Tris-HCI pH 8.5), allowing the column to stand 
for 1  minute followed  by centrifugation as above. The product was then stored at - 
20°C.
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2.3.3 Ligation of amplified DNA into pG1D210 Vector
Purified  PCR product from step 2.3.2 was then ligated  into (50ng)  pGlD210 Vector 
by TA cloning at a range of 3:1 to 1:3 insert:vector molar ratios. To 10\i\ of pGlD210 
Vector:  purified  PCR product mix, 2^1 of lOx ligase buffer, 7.4^1 of autoclaved water 
and 0.6|il (3u/yJ) of T4 DNA ligase were added.  Samples were incubated for 3 hours 
at RT or overnight at 4°C.  The  ligation  product was  used to transform  DH5a cells 
made competent by the following method.
2.3.4 Production of fresh competent DH5a-strain E.coli cells
Bacterial  cultures  were  prepared  from  glycerol  stocks  of  DH5a-strain  E.coli as 
described  in  section  2.2  except that  no antibiotic was added  to  agar  plates  or LB 
medium. This culture was then grown  overnight in a shaking incubator (250rpm) at 
37°C.  lOOfil  of this  overnight culture  were  added  to  100ml  LB  medium  in  a  2.5L 
sterile  (autoclaved)  conical  flask  and  then  returned  to  the  shaking  incubator 
(250rpm) for approximately three hours.
After 2  hours and then  every 30  minutes after that, the growth  of the cell  culture 
was checked. The 100ml culture was removed from the incubator when the culture 
was in the exponential log phase of the growth curve (i.e. clouds of bacteria swirling 
in the medium were just visible when held up to the light and when the absorbance 
reading of the culture when  measured on the spectrometer at 600nm was between 
0.3 and 0.8).
The culture was then  divided  between two 50ml sterile falcon tubes,  placed on  ice 
for five minutes and centrifuged at 3000rpm for 10 minutes in a Sorvall RT-7 Plus at 
4°C. The supernatant was discarded and the pellet in each tube was resuspended in 
20mls ice-cold transformation buffer 1 and incubated on ipe for 5 minutes. Each tube 
was  again  centrifuged  at  3000rpm  for  10  minutes  at  4°C  and  the  supernatant 
discarded.  Each  pellet was then  resuspended  in  1ml of transformation  buffer 2 and 
incubated on  ice for  15 minutes.  100^1 of this suspension  were then aliquoted  into 
pre-chilled  1.5ml  microcentrifuge  tubes  and  stored  at  -80°C or  used  directly  for 
transformations.
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2.3.5  Transformation of competent E.coli cells
5^1 of ligation mixture was added to lOOy.1 of competent E.coli cells and incubated on 
ice for 30 minutes. A heat shock at 42°C for 60 seconds was then applied, following 
which  the  cells  were  incubated  in  800y,l  of  LB  at  37°C  for  one  hour.  The  cell 
suspension was then centrifuged (Biofuge Pico) at 3000rpm for 10 minutes, most of 
the supernatant poured off and the pellet resuspended in the remaining supernatant. 
This  suspension  was then  spread  on  an  appropriate antibiotic  containing  LB agar 
plate.  After drying  on the  bench for  15 minutes the plates were then  incubated  at 
37°C overnight and finally stored at 4°C. The following day antibiotic resistant clones 
were picked, grown in 5ml  LB with appropriate antibiotic and miniprep plasmid DNA 
produced as in section 2.2.
2.4  Site directed PCR mutagenesis
The  QuikChange  site-directed  mutagenesis  kit  (Stratagene)  was  found  to  be  a 
convenient method to produce the following:
Arg to Ser mutations-
at position 53 in B3VH  CDR2
at 96, 97,100 and lOOg in IS4VH  CDR3
at position 94 in UK4VL
Arg to Asp mutation-
at position 53 in B3VH  CDR2
Arg to Lys mutation-
at position 53 in B3VH  CDR2
Ser to Arg mutation-
at position 53 in VH 3-23 CDR2
The basic procedure requires a dsDNA vector containing an insert of interest and the 
design of two specific oligonucleotide primers containing the desired  mutation.  The 
oligonucleotide primers,  each complementary to opposite strands of the vector, are 
extended during temperature cycling by PfuTurbo DNA polymerase. This enzyme has 
a 6-fold higher fidelity in DNA synthesis than  Taq DNA polymerase;  hence has a low 
potential  for  generating  further  mutations  during  PCR.  Incorporation  of  the 
oligonucleotide primers generates a  mutated  plasmid.  Following  PCR the product is 
treated with  Dpnl, an endonuclease specific for methylated DNA produced by DH5a 
E.coli,  which thus digests the parental  DNA template but not the mutated  plasmid.
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Vector  DNA  containing  the  desired  mutations  is  then  transformed  into  XLl-Blue 
supercompetent cells.
The  mutagenic oligonucleotide  primers  were designed  according  to  manufacturers 
specifications.  Primers  were  between  25  and  45  bases  in  length  with  a  melting 
temperature (Tm ) greater than or equal to 78°C. The formula used to calculate Tm  is: 
Tm  = 81.5 + 0.41(%GC) -  675/N - %mismatch
Where -  N is the primer length in  bases
Values for %GC and %mismatch are whole numbers 
% GC = the percentage of GC bases in the primer sequence 
% mismatch = the number of deletions / primer sequence x 100
The specific primers used designed according to the formula are shown in Table 2.1.
Purified  plasmid  DNA  was  obtained  as  described  in  section  2.2.  A  series  of  PCR 
reactions were then set up containing 5ng,  lOng,  20ng, and  50ng concentrations of 
plasmid  DNA  with  the  appropriate  mutagenic  primers  (Table  2.1)  and  reaction 
solutions provided in the QuikChange site-directed mutagenesis kit (Stratagene).  1^1 
(5-50ng) of plasmid  DNA was mixed with  5|xl  lOx reaction  Buffer,  ljxl of dNTP mix, 
S\i\  forward  primer  (125ng),  5\i\  reverse  primer  (125ng),  1^1 Pfu  Turbo  DNA 
Polymerase (2.5 units/nl) and autoclaved ddH2 0 to a final volume of 51^1.
As  a  negative  control  no  plasmid  DNA  was  added to  one reaction  mixture.  Each
mixture was then pulse spun and  placed into  a PCR  machine programmed  according
to the manufacturers instruction with the extension time of each  reaction calculated 
at two minutes per kb of plasmid length. Cycling parameters used were as follows: 
Initial denaturation at 95°C for 30 seconds 
Then 12 cycles as follows:
- Denaturation- 95°C for 30 seconds
- Annealing- 55°C for 1 minute
-  Extension-  68°C for  18  minutes for sample  reactions and  12  minutes for control 
reaction
The reaction was then held at 4°C until the samples were removed.
Once the PCR step had been carried out the methylated template DNA containing the 
undesired  sequence was digested  by the addition  of  1^1  (lOu) of Dpn I  restriction
140Chapter Two Materials and Methods
enzyme directly to each  amplification  reaction.  The resultant reaction  mixture was 
mixed gently by pipetting up and down several times, after which it was pulse spun 
in a bench centrifuge and incubated at 37°C for one hour.Chapter Two  __________________________________________________________________Materials and  Methods
PRIMER SEQUENCE
1. Forward 5' GCTCATATACAAACAGCG1G M III CGGCGGAGGG 3'
2. Back 5' CCCTCCGCCGAAAAACACGCTGTTTGTATATGAGC 3'
3. Forward 5' GGG1C1  CAACTATTAGTGGTAGTGGTAGTAGCACATAC 3'
4. Back 5' GTATGTGCTACTACCACTACCACTAATAGTTGAGACCC 3'
5. Forward 5' GGGTCTCAACTATTAGTOGTAATGGTAGTAGCACATAC 3'
6. Back 5'GTATGTGCTACTACCATTACCACTAATAGTTGAGACCC 3'
7. Forward 5' GGG 1C1CAACTATTAGTGGTAAGGGTAGTAGCACATAC 3'
8. Back 5' GTATGTGCTACTACCCTTACCACTAATAGTTGAGACCC 3'
9. Forward 5' CTCAGCTATTAGTGGTCGTGGTGGTAGCACATAC 3'
10. Back 5' GTATGTTGCTACCACCACGACCACTAATAGCTGAG 3'
11 Forward 5'GCGAGAGGAAGTAGTGACGTTAGTGGAGTICI I 1GGAGGGGCAGTCATGACTAC 3'
12. Back 5'GTAGTCATGACTGCCCCTCCAAAGAACTCCACTAACGTTCACTACITCCICICGC 3'
13. Forward 5' GCGAGAGGAAGTCGAGACGTTAGTGGAGTIC1  11 GGAGGGGCAGTCATGACTAC 3'
14. Back 5' GTAGTCATGACTGCCCCTCCAAAGAACTCCACTAACGT C1CGACTTCCTCTCGC 3'
15. Forward 5' GCGAGAGGACGTAGTGACGTTAGTGGAGTTCTT1  GGAGGGGCAGTCATGACTAC 3'
16. Back 5'GTAGTCATGACTGCCCCTCCAAAGAACrCCACTAACGTGACTACGTCCTCTCGC 3'
17. Forward 5' CGCGAGAGGAAGTAGTGACGTTCGGG 3'
18. Back 5' CCCGAACGTCACTACTTCCTCTGGCG 3'
19. Forward 5' CTGCGCGAGAGGAAGTCGAGACGTTCGG 3'
20. Back 5' CCGAACGTCTCGACTTCCTCTCGCGCAG 3'
21. Forward 5' CGCGAGAGGACGTAGTGACGTTCGGGGAG 3'
22. Back 5' CTCCCCGAACGTCACTACGTCCTCTCGCG 3'
23. Forward 5 'GGACGTCGAGACGTTAGTGGAG1IC I1IGGAGG 3'
24. Back 5'CCTCCAAAGAACTCCACTAACG1 C1CGACGTCC 3'
25. Forward 5'Cl 11GGAGGGGCAGTCATGACTACTTTGAC 3'
26. Back 5' GTCAAAGTAGTCATGACTGCCCCTCCAAAG 3'
Table 2.1 Sequences of primers used in site directed mutagenesis
Mutagenic  primers  with  sites  of  point  mutation  shown  in  bold.  Primers  1+2  were 
used to  mutate Arg94 to Ser in  UK4VL.  Primers 3+4 were used to  mutate Arg53 to 
Ser  in  B3VH .  Primer 5+6  were  used to  mutate Arg53 to Asn  in  B3VH .  Primers 7+8 
were used to mutate Arg53 to Lys in B3VH . Primers 9+10 were used to mutate Ser53 
to  Arg  in  VH 3-23.  Primers  11-26  were  used to  mutate Arg to  Ser  in  IS4VH   at the 
following positions;  primers 11+12 mutated Arg 96, 97, 100 and  lOOg to create VH x; 
primers  13+14  mutated  Arg  96,  100  and  lOOg to  create VH i,iii&iv;  primers  15+16 
mutated Arg 97,  100 and  lOOg to create VH ii,iii&iv;  primers  17+18 mutated Arg 96 
and 97 to create VH i&ii; primers 19+20 mutated Arg 96 to create VH i;  primers 21+22 
mutated  Arg  97  to  create  VH ii;  primers  23+24  mutated  Arg  100  to  create  VH iii; 
primers 25+26 mutated Arg lOOg to create VH iv.____________________________
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A separate 50^1 aliquot of XLl-Blue supercompetent cells was then transformed with 
l|xl of the Dpn I treated DNA from each control, sample reaction and transformation 
control plasmid supplied by Stratagene. Each reaction was kept on ice for 30 minutes 
and then a heat shock of 42°C was applied for 45 seconds with recovery on ice for a 
further two minutes;  0.5ml of NZY+  medium  preheated to 42°C was added to each 
transformation reaction and incubated at 37°C with shaking.
The purpose of the control  was to test the efficiency of mutant plasmid generation. 
The control  plasmid contains a stop codon (TAA) at the position where a glutamine 
codon  (CAA)  would  normally  appear  in  the  p-galactosidase  gene.  XLl-Blue 
supercompetent  cells  transformed  with  this  control  plasmid  appear  white  on  LB- 
ampicillin  agar  plates,  containing  IPTG  and  X-gal,  because  p-galactosidase  gene 
activity  has  been  obliterated.  The  oligonucleotide  control  primers  create  a  point 
mutation on the control plasmid that reverts the T residue of the stop codon (IAA) at 
amino acid  9 of the p-galactosidase gene to a C residue, to produce the glutamine 
codon (CAA) found in the wild-type sequence.  Following transformation, colonies can 
be screened for the p-galactosidase (p-gal+, blue) phenotype.
Colonies  were  picked  from  the sample transformation  plates  into  5ml  LB cultures 
containing 5(Vg/rnl of ampicillin and kept overnight in a 37°C shaking incubator. The 
following day glycerol stocks were made and plasmid DNA purified (see section 2.2) 
and  screened for the presence of the desired mutation  by sequencing. The primers 
used for sequencing the constructs are shown in Table 2.2.
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PRIMERS SEQUENCES
NEO A 5'CTCCATAGAAGACACCG3'
(binds to pGlDl and pLNlO 30bp 5' of insert)
HCMVI 5' GACTAACAGACTGTTCC3'
(binds to pG!D210f pLNlOO and pKNIOO  50bp  5m
of insert)
HUG1 5'TTGGAGGAGGGTGCCAAG3'
(binds to pGlD210 90bp 3'  of insert)
DONOR 5' CAAAGTTCTGCCCTTGG3'
(binds to pLNlOO BObp 3'  of insert)
T M i 2.2 Prim m  und In nqueneing of mutations
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2.5  Large scale extraction of DNA for transfection into COS-7 cells
The yield  of plasmid  DNA from a  miniprep was  insufficient for electroporation  into 
COS-7  cells  therefore  large-scale  extraction  to  produce  100-500ng  of  DNA  per 
preparation  was carried out using the Qiagen  Plasmid  Maxi  purification  buffers and 
protocol.  A single colony of recombinant DNA in final expression  vector was picked 
from  a  freshly  prepared  LB/Ampicillin  plate  to  inoculate a  starter  culture  of  5ml 
LB/Ampicillin  medium.  This culture was incubated for approximately eight hours at 
37°C with vigorous shaking at 300rpm. One ml of the starter culture was then diluted 
into  500ml  of LB/Ampicillin  medium and  incubated at 37°C for  16  hours overnight 
with vigorous shaking at 300rpm.  Following which  bacterial cells were harvested  by 
centrifugation at 9000 rpm in a Sorvall RC26 Plus (SLA 3000 rotor) for 15 minutes at 
4°C. Supernatant was discarded and the bacterial pellet resuspended in  lOmls of ice 
cold buffer PI and  lOmls of buffer P2 was added. After mixing and incubation at RT 
for 5 minutes lOmls of chilled buffer P3 was added. The mixture was kept on ice for 
20 minutes then centrifuged at 12000rpm in a Sorvall RC26 Plus (SS-34 rotor) for 30 
minutes at 4°C. Supernatant containing plasmid DNA was promptly removed and re­
centrifuged for 15 minutes at 4°C.  A Qiagen tip 500, containing DNA binding resin, 
was  equilibrated  by  the  addition  and  free  gravity  flow  of  lOmls  Buffer  QBT. 
Supernatant was then applied to the Qiagen tip and allowed to enter and  bind  DNA 
to the resin by free gravity flow while all other components pass through. The DNA 
was then washed  by  passing  30  ml of buffer QC through the tip twice and eluted 
with  15  ml  of  buffer  QF.  To  precipitate  the  DNA  10.5  ml  (0.7  volumes)  of  RT 
isopropanol was added to the eluted DNA,  mixed and then centrifuged at 3000rpm 
(in  a  Sorvall  RT7  Plus)  for 45  minutes at 4°C.  Following  which  supernatant  was 
carefully decanted  and  the  DNA  pellet washed  with  5  ml  of RT 70%  ethanol  and 
centrifuged  at  3000rpm  (in  a  Sorvall  RT7  Plus)  for  15  minutes  at  4°C.  Then 
supernatant was discarded,  the  pellet dried  under a vacuum for  2-5  minutes  and 
then redissolved in 1ml of autoclaved water.
2.5.1  Quantification of dsDNA concentration
dsDNA concentrations were quantified in two ways;  either by running the linearised 
DNA samples alongside molecular weight markers of known DNA concentration on an 
agarose  gel  and  comparing  the  intensity  of  the  bands  or  by  using  ultraviolet 
absorbance  spectrophotometry.  The  amount  of  ultraviolet  light  absorbed  by  a 
solution  of  DNA  is  directly  proportional  to  the  amount  of  DNA  in  the  sample.
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Absorbance was  measured at 260nm, at which wavelength an absorbance (A26o)  of 
1.0 corresponds to 50ng of double-stranded DNA per ml.
Ultraviolet  absorbance  was  also  measured  at  the  wavelength  280nm  in  order to 
check the purity of the DNA preparation. The ratio of the absorbance at 260nm and 
280 nm  (Awq/Aq s q ) of a  pure sample of DNA would  be 1.8. A ratio of less than  1.8 
indicated that the preparation was contaminated with protein.
2.6  Tissue culture
AH  tissue culture preparation  was carried  out  in a  sterile tissue culture hood.  Any 
buffers, solutions and  materials  required  were kept in the tissue culture laboratory 
and  solely  used  for  this  work.  All  plastic  ware  was  supplied  by  Nunc,  VWR 
International,  Leicester,  UK.  All  protocols  used  for tissue  culture and  transfection 
were obtained from AERES Biomedical, Mill Hill, UK.
2.6.1  Transient Expression System in COS-7 cells
COS-7 cells are immortal  monkey kidney cells,  which express the T antigen of the 
human polyoma virus SV40 constitutively. The T antigen binds to the SV40 origin to 
stimulate replication. Plasmids used in this study all contain the SV40 origin (which is 
not otherwise present in COS-7 cells) hence will be replicated actively in COS-7 cells 
and achieve a high copy number. This expression system is thus ideal for achieving 
efficient transient expression of heavy and light chains.
2.6.2 Defrosting COS-7 cells aliquots stored in liquid nitrogen
When using COS-7 cells in a transient expression system, efficiency is optimised  by 
transfecting the cells at as low a  passage number as possible. Therefore a  master 
cell bank of the COS-7 cell line stored in liquid nitrogen was essential.
Aliquots of these cells were frozen  in growth  medium  1 containing  10%  DMSO (D- 
5879, Sigma, Poole, UK) which is cryoprotective during freezing but toxic to the cells 
once  they  have  thawed.  Therefore  once  defrosted  at  37°C,  the  cell  aliquot  was 
immediately added to  10ml  fresh,  pre-warmed  COS-7  growth  medium  1  and  spun 
down  at  700rpm  (in  a  Sorvall  RT7  Plus)  for  10  minutes  at  RT.  The  medium  was
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discarded whilst the pellet was  resuspended  in  10ml COS-7 growth  medium  1  and 
transferred to an 80cm2 culture flask containing a further 10ml of the same medium.
2.6.3 Maintenance of COS-7 cells in culture
COS-7 cells were maintained in a continuous culture by changing the growth medium 
1 every 3-4 days. All solutions and  media to be used were initially placed in a 37°C 
water bath for 10 minutes. The 80cm2 or 175cm2 tissue culture flask containing COS- 
7 cells was removed from the incubator. Old medium was removed by aspiration and 
the remaining cells adherent to the floor of the flask washed by adding  lOmls sterile 
HBS to remove any remaining fetal calf serum.  HBS was then  removed and 3mls of 
Trypsin-EDTA solution added. The flask was shaken gently to allow Trypsin-EDTA to 
fully cover the floor of the flask. Trypsin-EDTA was then left in contact with the cells 
for two minutes in a 37°C incubator to release all cells adherent to the floor of the 
flask. At the end of this time the flask was tapped and viewed under the microscope 
to  make  sure  at  least  80%  of the  cells  had  become  detached.  lOmls  of growth 
medium  1 were then added to the flask and gently shaken to inactivate the Trypsin- 
EDTA solution. This mixture was then split from an 80cm2 to a  175cm2  flask or from 
one  175cm2   to  three  new  175cm2 flasks  and  growth  medium  1  added  to  a  final 
volume of 20ml for an 80cm2 flask or 25ml for a  175cm2  flask. The flasks were then 
placed  horizontally in a  37°C  incubator in  which the concentration of CO 2  was  5% 
and checked daily to assess growth.
2.6.4 Freezing down COS-7 cells for storage in liquid nitrogen
To  create  a  cell  bank,  cells  of a  low  passage  number growing  in  an  exponential 
phase were trypsinised as above then spun at 700 rpm (in a Sorvall RT7 Plus) for 10 
minutes at RT.  Following a cell count (carried out as described below) the cells were 
resuspended in the appropriate volume of growth medium  1 containing  10% DMSO, 
to give a concentration of 1 x  107 cells/ml.  1.5ml aliquots were then put in cryovials, 
immediately placed at -80°C overnight and then transferred to liquid nitrogen.
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2.6.5 Preparation of COS-7 cells for electroporation
The  COS-7  cell  line  was  maintained  as  detailed  in  section  2.6.3  and  used  in  a 
transfection at as low a  passage number as possible. The cells were split 24 hours 
prior to transfection to ensure exponential growth as follows:
24 hours prior to the electroporation, the COS-7 cells were split from one 175cm2  to 
two  new  175cm2  flasks,  as described above. The cells were incubated overnight at 
37°C  in  5%  CO 2.  The  number  of flasks  of  COS-7  cells  that  were  prepared  was 
dependent on the number of electroporations that were planned (approximately one 
175cm2  flask per electroporation).
The following day the cells in each flask were washed with  HBS and trypsinised as 
described  above.  Ten  mis  of warm  medium  1  were  added  to  each  flask  and  the 
entire contents then transferred to a sterile 50ml centrifugation tube. The cells were 
then  centrifuged  at  700rpm  (in  a  Sorvall  RT7  Plus)  for  five  minutes  at  RT.  The 
supernatant was discarded and the pellet of COS-7 cells resuspended in 20-50 mis of 
autoclaved  PBS according to the size of the cell  pellet.  A cell count was performed 
upon a 200^1 aliquot of the suspension to estimate the number of cells present.
2.6.6 Trypan blue viable cell count
Trypan blue is one of several stains that can be used in dye exclusion procedures for 
viable cell counting. This method is based on the principle that live (viable) cells do 
not take  up certain  dyes whilst dead  (non-viable)  cells do.  The following  protocol 
derived from Sambrook et al. (2001) was used:
The cells were re-suspended in HBS.  0.5ml of 0.4% Trypan blue solution (w/v) was 
transferred to a 5ml bijou tube. 0.3ml of HBS and 0.2ml of the cells suspension were 
then added to the bijou, therefore producing a dilution factor of five. The preparation 
was mixed thoroughly and then allowed to stand for 5 to  15  minutes.  (If cells are 
exposed  to Trypan  blue for extended  periods of time,  viable cells as well  as  non- 
viable cells may begin to take up the dye).
A haemocytometer was used to count the cells.  Each square of the haemocytometer 
with the cover slip in place represented a total volume of 0.1mm3 or  10‘4cm3.  Since
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lcm3   is equivalent to  1ml,  the subsequent cell  concentration  per  ml  and the total 
number of cells were determined as follows:
CELLS  per  ml  =  the  average  count  per  square x  dilution  factor x  104  (count  10 
squares)
TOTAL CELLS = cells per ml x the original volume of fluid from which cell sample was 
removed
This procedure was repeated in order to ensure accuracy.
The remainder of the suspension was again centrifuged at 600rpm for 10 minutes at 
RT.  Supernatant was carefully removed by aspiration and the cell pellet resuspended 
in the appropriate volume of PBS to give a final concentration of 1 x 107  cells per ml.
2.6.7  Transfection of COS-7 ceils with  recombinant expression vectors 
by electroporation
Recombinant expression vector DNA was removed from storage at -20°C and thawed 
at RT.  10[iQ of H chain and  lOjxg of X . L chain expression vector DNA were added to 
a  Gene  Pul ser® (0.4cm gap) disposable electroporation cuvette.  Alternatively,  20jxg 
of  single  expression  vector  containing  both  the  H  and  L  chain  sequence 
("supervector")  was  added  to  a  cuvette.  A  separate  cuvette  was  used  for  each 
supervector or combination of heavy and light chain vectors.  7 x 106 washed COS-7 
cells  (700|xl)  were then  added  to  each  and  gently  mixed  with  the  DNA  by  slowly 
pipetting  the contents  up and  down  three times.  To  ensure that  no arcing  could 
occur during the electroporation, it was ensured that there was neither liquid on the 
side of the cuvette nor air bubbles nor clumps of cells in the cuvette.  Using the Bio- 
Rad Gene Pulser® apparatus a  1.9kV and 25fiFarad capacitance pulse was delivered 
to each cuvette. A negative control cuvette containing COS-7 cells only and no DNA 
was prepared and subjected to an electroporation pulse in exactly the same way.
The  transfected  COS-7  cells  were allowed  to  recover  at  RT for  10  minutes.  The 
contents of each cuvette were then  gently transferred  into a  10cm diameter tissue 
culture dish containing 8ml of fresh pre-warmed (post-electroporation) COS-7 growth 
medium 2. The cells were incubated in 5% CO 2 at 37°C for 72 hours.
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2.6.8 Treatment of COS-7 cell supernatants with DNase / (RNase -free)
After 72  hours  post-electroporation the supernatants were  removed  from the cells 
and transferred to sterile 15ml falcon tubes. The supernatants were centrifuged for 
10 minutes at 2000rpm in a Sorvall RT7 Plus at RT in order to pellet all the cell debris 
present.  Following  centrifugation,  the  COS-7  cell  supernatants  were  immediately 
transferred  to  fresh  15ml  falcon  tubes  and  treated  with  RNase-free  DNase  I as 
follows:
DNase I (RNase-free) was added to the COS-7 cell  supernatants to produce a final 
concentration of 7.5u DNase I per ml of supernatant (i.e. M  of 10u/|il DNase I was 
added to 8ml  supernatant). The tubes were inverted to  mix and then  incubated  at 
37°C in a dry incubator for one hour. After the one-hour incubation, EDTA (pH 8.0) 
to a final concentration of 15mM was then added to inactivate the enzyme plus 5\i\ 
of 1M sodium azide solution (Final concentration 0.5mM).  The function of the EDTA 
is to chelate the magnesium ions in the solution required by the DNAse I to function. 
Sodium  azide  was  added  to  the  supernatants  to  prevent  fungal  growth.  The 
supernatants were then stored at 4°C for testing by ELISA.
The treatment of the  supernatants with  DNase I  (RNase-free)  was essential  since 
80% of cells die during electroporation, thus releasing their contents (including DNA) 
into the supernatant.  Whole IgG antibody molecules that were produced due to the 
transfection  may  then  have  bound  this  DNA,  forming  immune  complexes.  Thus 
making  them  undetectable  by  whole  IgG  ELISA  (see  section  2.7.1)  as  had  been 
demonstrated previously by (Rahman et al.,  1998). Therefore the DNase I was used 
to digest this  DNA thus breaking down the immune complexes leaving the antibody 
molecules free to be detected by ELISA.
2.6.9  Concentration of whole IgG in cell supernatants
Due to the relatively low concentrations of IgG produced by the transient expression 
system, the IgG  levels in the COS-7 supernatants were concentrated  prior to ELISA 
analysis.  The supernatants were concentrated  by  using Centricon-YM30 centrifugal 
concentrators (30 000 MW cut-off) according to the manufacturer's instructions. Two 
mis of supernatant were added to each sample reservoir coupled with its filtrate vial 
and  centrifuged  at  5000rpm  in  a  Sorvall  RC26  Plus  (SS-34  rotor)  at  RT  for  30 
minutes.  Further  supernatant  was  then  added  to  the  sample  reservoir  and
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subsequent  centrifugation  steps  performed  for  40-50  minutes.  This  process  was 
repeated  until  all  but  the  final  one  ml  of  supernatant  had  passed  through  the 
membrane of the sample reservoir. A retentate vial was then placed over the sample 
reservoir the unit inverted  and centrifuged at 3000rpm for 2  minutes in  a  Sorvall 
RC26 Plus (SS-34 rotor) to transfer concentrated antibody from the membrane into 
the remaining supernatant. Concentrated samples were then stored at 4°C.
2.7  Analysis of COS-7 supernatant IgG by immunoassays
In all of the different ELISAs performed the 96 well  plates were supplied  by Nunc, 
VWR International,  Leicester,  U.K.  and  OD  measured  by  the  Genios  plate  reader 
(Tecan, Reading, U.K.). Each plate was marked vertically to divide it into two halves; 
the test half and the control  half.  The 36 wells at the edge of the plate were  not 
used and henceforth all descriptions of the plate refer to the inner 60 wells only.
2.7.1  Detection of total whole IgG molecules in COS-7 supernatants by 
ELISA
A "Sandwich" ELISA (Enzyme-linked  Immunosorbent assay) was used to detect the 
total whole IgG  molecule concentration of each  supernatant.  Goat anti-human  IgG 
(Fc fragment specific) was dissolved  in  bicarbonate (BIC) buffer to give a  working 
concentration  of 400ng/ml.  50jaI  of  this  solution  were  added  to  each  well  of  a 
Maxisorp plate in the left (test) half of the plate. 50|xl of BIC buffer alone were added 
to the wells in the right (control) half of the plate. Each plate was then covered and 
incubated  overnight  at  4°C.  After this  the  plates  were  washed  three  times  with 
PBS/0.1% Tween and  100^1 of PBS containing 2% BSA were added to each well to 
block non-specific  binding  of Ig  to the  plastic. The plates were  incubated for one 
hour at 37°C and then washed three times with PBS/0.1% Tween.
In order to dilute COS-7 cell  supernatant in SEC buffer serially,  such that for each 
well  in the test half of the plate there was a well in the control  half containing the 
same supernatant at the same dilution the following procedure was performed.  50^1 
of SEC  buffer was  added  to each  well  in  both  halves  of the  plate except the top 
wells.  100|xl of neat COS-7 cell supernatant was added to the top well and diluted 
down  the  column  such  that  each  well  contained  supernatant  at  half  the
151Chapter Two Materials and Methods
concentration  of  the  well  above.  Purified  human  IgC^  of  known  concentration 
(lOOng/ml or  lOng/ml) was loaded and diluted serially in the same way upon each 
plate to allow the construction of a standard curve relating optical density (OD) to Ig 
concentration. The  plates were  incubated for one hour at 37°C and then  washed 
three times with PBS/0.1% Tween.
To detect bound antibody,  50^1 goat anti-human X . alkaline phosphatase conjugate 
(diluted 2500-fold in SEC dilution buffer) was added to the wells and  incubated for 
one  hour  at  37°C.  After  one  hour,  the  plates  were  washed  three  times  with 
PBS/0.1% Tween and once with BIC buffer. One tablet of p- nitrophenyl  phosphate 
substrate was dissolved  in  5ml  BIC  buffer supplemented  with  10^1 of 2mM MgCI2. 
50(xl of this solution was added to each of the wells on the plate.  The plates were 
then incubated at 37°C to allow a yellow colour to develop in each well. The optical 
density of the reaction was read after 60 minutes at 405nm. The final  reading was 
calculated by subtracting the OD value of each control well from the OD value of the 
same sample in the corresponding test well. This ensures that only conjugate bound 
directly to IgG in the supernatant that had been captured by the anti-Fc IgG, would 
contribute to the result.
The binding of the whole IgG molecules in the supernatants to the plate depended 
on the  presence of the Fc region  whereas detection  by the alkaline  phosphatase 
conjugate depended on the presence of the k light chain, therefore this method only 
detected whole IgGk antibodies.
2.7.2  Detection of anti-dsDNA activity in COS-7 supernatants by ELISA
Direct ELISAs were used to detect the anti-dsDNA activity of the whole IgG antibody 
molecules in the supernatant.
To prepare the pure DNA, calf thymus DNA (Sigma, Poole, UK) was dissolved in TE 
buffer (pH 7.5) on a rotator at RT overnight. The DNA solution was then subjected to 
a  phenol:  chloroform:  isoamyl alcohol  (25:24:1) extraction and ethanol-precipitated 
(as before, see section 2.8.3). The dried pellet of DNA was resuspended in TE buffer 
(pH 7.5) and then sonicated at high frequency for one minute. ssDNA was removed 
by  passing  the  solution  through  a  0.45jxg  Millex-HA filter that contained  methyl- 
cellulose esters. The sonication of the DNA produces a more reproducible coating of
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the plate whilst there  Is  less chance of the  binding  detected  being due to ssDNA 
rather than dsDNA.
A 96 well Maxisorp ELISA plate was marked vertically Into two halves, the test half 
and the control  half.  The test half of the plate was coated  with  50y,l  of  lOmg/ml 
purified dsDNA dissolved in PBS, pH 7.4, whilst the control half was coated with PBS, 
pH  7.4 only.  The  plates were  incubated  overnight at 4°C and  then  washed three 
times  with  PBS/0.1%  Tween.  Non-specific  binding  to  the  plate  was  blocked  by 
adding  lSOyJ of 2%  casein  in  PBS to each well. The plates were then  incubated at 
37°C for one hour. The plates were washed three times with PBS/0.1% Tween.
The  concentrated  COS-7  supernatants  were  serially  diluted  in  SEC  buffer  and 
identical concentrations of supernatant added to each half of the plate. As a positive 
control for experiments described  in  this thesis,  human  serum  (known  to  contain 
anti-dsDNA  IgG)  was  serially diluted  from  1/400 to  1/32000  onto  the  plate.  The 
plates  were  incubated  for  one  hour  at  37°C  and  then  washed  six  times  with 
PBS/0.1% Tween.
To detect bound antibody,  a  goat anti-human  IgG alkaline  phosphatase conjugate 
(A3150, Sigma, Poole,  UK) was diluted to  1/1000 in SEC buffer and  50^1 were then 
added  to  each  well.  The  plates  were  incubated  for  one  hour  at  37°C  and  then 
washed  three  times  with  PBS/0.1%  Tween  and  once  with  BIC  buffer.  Bound 
antibodies were detected  using the same substrate as described for the human IgG 
ELISA (section 2.6.1).
2.7.3  Detection of anti-cardiolipin antibodies in COS-7 supernatants by 
ELISA
Wells in the test half of a Polysorp ELISA plate were coated with 50|xl of CL (diluted 
to 50{xg/ml in ethanol) and 50^1 of ethanol alone were added to wells in the control 
half. The plates were  incubated  uncovered overnight at 4°C.  Each  plate was then 
washed three times with  PBS  and  lOOjxl  of PBS containing  10%  FCS (Invitrogen) 
were  added  to  each  well  to  block  non-specific  binding  of Ig  to  the  plastic.  After 
incubation at 37°C for one hour, plates were washed three times with PBS.
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Each  concentrated  COS-7  supernatant  to  be  tested  was  serially  diluted  in  PBS 
containing  10%  FCS.  An  identical  concentration of supernatant was  loaded  into a 
well in the test half and a corresponding well  in the control half of the plate.  Serum 
containing polyclonal antibodies known to bind CL was loaded as a positive control to 
each plate. The total volume in each well was 50|xl.  Plates were then incubated for 
90 minutes at 37°C after which they were washed three times with PBS. Goat anti­
human IgG alkaline phosphatase conjugate was diluted  1000 fold  in PBS containing 
10%  FCS and  50^.1 of this solution added to each well. After one hour at 37°C the 
plate  was  washed  four  times  with  PBS  and  once  with  BIC  buffer.  Addition  of 
substrate and  incubation  were  carried  out as  in  section  2.7.1  with  additional  OD 
measurements taken at 30 minutes.
The standard CL ELISA was modified to remove p2GPI from the assay by replacing 
10% FCS in each relevant step with 10% BSA.
2.7.4  Detection of anti-a-actinin antibodies in COS-7 supernatants by 
ELISA
A 96 well Maxisorp ELISA plate was marked vertically into two halves, the test half 
and the control  half. The test half of the plate was coated with  50|xl of 20|xg/ml a- 
actinin dissolved in BIC, pH 9.6, whilst the control half was coated with  BIC,  pH 9.6 
only. The plates were incubated overnight at 4°C and then washed three times with 
PBS/0.1% Tween.  Non-specific binding to the plate was blocked by adding  150^1 of 
2% (w/v) BSA in  PBS/0.1% Tween to each well. The plates were then incubated at 
37°C for one hour. The plates were washed three times with PBS/0.1% Tween.
The concentrated COS-7 supernatants were serially diluted  in the PBS/0.1% Tween 
and  identical  concentrations of supernatant added to each  half of the plate.  As  a 
positive control for experiments described  in this  project,  human serum (known to 
have  anti-a-actinin  activity)  was  serially  diluted  from  1/400  to  1/32000  onto the 
plate. The plates were incubated for one  hour at 37°C and then  washed six times 
with PBS/0.1% Tween.
To detect bound antibody,  a  goat anti-human  IgG alkaline  phosphatase conjugate 
(A3150, Sigma, Poole, UK) was diluted to 1/1000 in SEC buffer and 50fxl were then 
added  to  each  well.  The  plates  were  incubated  for  one  hour at  37°C  and  thenChapter Two Materials and Methods
washed  three  times  with  PBS/0.1%  Tween  and  once  with  BIC  buffer.  Bound 
antibodies were detected  using the same substrate as described for the human IgG 
ELISA (section 2.7.1).
2.7.5 Detection of anti-fcGPI antibodies in COS-7 supernatants by ELISA
A Maxisorp ELISA plate was coated with  50^1 of fcGPI (SCIPAC), diluted to 10^g/ml 
in  PBS,  on wells  in  the test half and  50^1 of PBS alone on the control  half.  Plates 
were covered and incubated overnight at 4°C. Following that each plate was washed 
three  times  with  PBS.  In  order  to  block  non-specific  binding  50fxl  of  0.25% 
gelatin/PBS was added to each  well.  After  incubation at 37°C for one hour plates 
were washed three times with PBS.
Antibody samples were serially diluted in 0.1% BSA/PBS and then loaded upon each 
half of the plate, as well as a  positive control  of serum containing  polyclonal anti- 
P2GPI  antibodies  leaving  a  final  volume  in  each  well  of  50|il.  Plates  were  then 
incubated for two hours at 37°C after which they were washed three times with PBS. 
Goat anti-human IgG alkaline phosphatase conjugate was diluted  1000 fold  in  PBS 
containing  0.1%  BSA/PBS  and  50jxl  of  this  solution  added  to  each  well.  A  final 
incubation for one hour at 37°C was performed and the plate washed four times with 
PBS and  once with  bicarbonate buffer.  Addition  of substrate and  incubation  were 
carried  out  as  in  section  2.7.1  with  additional  OD  measurements  taken  at  30 
minutes.
2.7.6 Detection of monoclonal aPL binding to purified recombinant hiS6- 
tagged Dl
DI of human  p2 GPI with a C-terminal  hise-tag  was expressed  in  bacteria  by  Dr Y. 
Ioannou.  By virtue of the incorporated  C-terminal  hise-tag,  a direct ELISA could  be 
performed  by  recombinant  DI  binding  to  a  nickel-coated  microwell  plate.  This 
process would orientate DI correctly and allow binding to various aPL to be assayed 
(Iverson et al., 1998).
Recombinant hiss-tagged  DI  was diluted  to a  concentration  of 75|Ag/ml  using  PBS 
and 50|xl added to the wells of a nickel chelate-coated microwell plate. The test half 
was coated with  DI and the control half with  PBS.  Plates were incubated at RT for
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two hours and then washed three times with PBS, blocked with  IOOjaI 0.25% geiatin 
(Sigma, Poole, UK) in PBS, incubated for a further one hour at RT and washed three 
times with PBS.
Each monoclonal aPL sample to be tested, either affinity purified antibody or derived 
from  CHO  supernatant,  was  serially  diluted  in  SEC.  An  identical  concentration  of 
primary antibody was loaded into a well in the test half and a corresponding well in 
the control  half of the plate.  Serum containing  polyclonal antibodies known to bind 
CL and  p2 GPI was diluted  lOOx with  SEC buffer and loaded as a positive control to 
each plate. The total volume in each well was  50(aI.  Plates were then incubated for 
one  hour at 37°C after which they were washed three times with  PBS.  Goat anti­
human IgG alkaline phosphatase conjugate was diluted  1000 fold in SEC buffer and 
50(xl  of this  solution  added  to  each  well.  After  one  hour  at  37°C  the  plate  was 
washed  three times  with  PBS  and  one time with  BIC.  Addition  of  substrate  was 
carried out as  in  section  2.7.1, the  plates  incubated at RT and  OD measurements 
taken at 30 minutes and one hour.
2.7.7  Detection of monoclonal aPL binding to PS or PC
Wells in the test half of a  Polysorp ELISA plate were coated with  50^1 of PS or PC 
(diluted  to  50|xg/ml  in  methanol  and  chloroform  4:1)  and  50^1  of  methanol  and 
chloroform alone were added to wells in the control half. The plates were incubated 
uncovered overnight at 4°C.  Following that, the plates were washed twice with PBS 
and blocked with  10CVI of 10% FCS/ PBS at RT for one hour. The plates were then 
washed twice with PBS. Test samples were serially diluted with  10%  FCS/ PBS. An 
identical concentration of supernatant was loaded into a well in the test half and a 
corresponding well  in the control half of the plate.  Polyclonal serum was applied to 
each plate as a standard. The total volume in each well was 50|xl. The plates were 
then  incubated for 90 minutes at RT and washed with  PBS three times.  Goat anti­
human IgG alkaline phosphatase conjugate (Sigma A3150) was diluted  1  in  1000 in 
10% FCS/PBS, 50jxl of this solution added to each well and incubated for 1  hour at 
RT.  The  plates were  washed  with  PBS  three times  and  once  with  BIC.  SO^I/well 
substrate of 1 tablet PNP in 5ml  BIC and  lOul 2M  MgCI2 was applied per plate and 
incubated at 37°C. Plates were read at 405nm at 15,30,45 and 60 minutes.
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2.7.8 Detection of anti-PS-PT antibodies by standard ELISA
Each well of a Polysorp ELISA plate was coated with 30|xl of PS (diluted to 50|xg/ml 
in  methanol.-chloroform 4:1) and the plates were incubated  uncovered overnight at 
4°C.  Following  that,  the  plates  were washed  with  TBS/Tween  0.05%/5mM  CaCI2  
three times and blocked with 150^1 of TBS containing 1% BSA and 5mM CaCI2  (BSA- 
Ca) at RT for one hour. The plate was washed with TBS/Tween O.Q5%/5mM CaCI2  
three times.  SOjxl human  PT (10ixg/ml) in  BSA-Ca was added to the test half of the 
plate and BSA-Ca alone to the control  half and the plate incubated for one hour at 
37°C. The plates were then washed three times with TBS/Tween 0.05%/5mM CaCI2  
and test samples were  serially diluted  in  BSA-Ca,  50nJ/well.  Polyclonal  serum  was 
applied to each plate as a standard. The plates were incubated for 60 minutes at RT 
and washed three times with TBS/Tween  0.05%/5mM CaCI2.  Goat anti-human  IgG 
alkaline phosphatase conjugate (Sigma A3150) was diluted 1 in 1000 in BSA-Ca, 50^1 
of this solution added to each well and  incubated one hour at RT. The plates were 
then  washed  with TBS/Tween  0.05%/5mM  CaCI2 three times  and  once  with  BIC. 
50|xl/well substrate of 1 tablet PNP in 5ml BIC and  lOul 2M MgCI2  was applied  per 
plate and incubated for 30-60 minutes at RT.  Plates were read at 405nm at 15, 30, 
45 and 60 minutes.
2.8 Stable expression system in CHOdhfr  cells
The  CHO  cell  line  used  lacks  a  functional  dhfr gene.  The  enzyme dihydrofolate 
reductase  is  responsible  for  the  intracellular  reduction  of  dihydrofolic  acid  to 
tetrahydrofolic acid, which  is an  important co-factor in the synthesis of nucleic acid 
precursors.  To  survive  the  CHO  dhfr  cell  line  required  exogenous  hypoxanthine 
(adenine),  glycine,  proline  and  thymidine  for  survival.  All  of  these  nutritional 
requirements were provided via non-selective medium.
If  however,  these  CHO  dhfr  cells  were  successfully  transfected  with  expression 
vectors (e.g.  a  supervector) containing  a functional  dhfr gene the cells  would  be 
transformed to a dhfr+ phenotype. Thus, allowing them to grow in selective medium 
that was depleted of ribonucleosides and deoxyribonucleosides (but not proline as all 
CHO cells are proline-dependent even  in the presence of dhfr gene). Consequently 
CHO  dhfr  cells  were  used  to  provide  an  expression  system  in  which  the  genes 
required to produce IgG could be co-transfected with the dhfrgene.
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MTX  is  a  competitive  inhibitor  of the  intracellular  activity  of the  DHFR enzyme. 
Progressive selection of cells that are resistant to increasing concentrations of MTX 
leads  to  amplification  of the  dhfr gene,  with  concomitant  amplification  of  IgG- 
encoding  sequences  that  flank  the  dhfr  sequences  (Schimke,  1984).  In  those 
resistant cells where amplification has occurred, there is not only sufficient free dhfr 
enzyme to generate  intracellular tetrahydrofolate required for cell  biosynthesis but 
also these resulting cell lines express high levels of Ig.
2.8.1  Maintenance of  CHOdhff cells prior to electroporation
The  CHOdhfr  cells  were  grown  in  pre-warmed  non-selective  growth  medium  A 
(described in section 2.1.13) in 175cm2  flasks prior to transfection and split every 3 -  
4 days keeping their passage number to a  minimum prior to transfection. A master 
cell bank was created and the cells were defrosted and frozen down as described in 
section 2.6.2 and 2.6.4 using growth medium A containing 10% DMSO.
2.8.2 Preparation of CHO cells for electroporation
The cells were  split  24  hours  prior to transfection  to  ensure exponential  growth. 
Flasks  containing  confluent CHO  cells  were  trypsinised  and  then  divided  equally 
between three 175cm2 flasks,  each containing 25ml of fresh,  pre-warmed CHO  dhfr 
(non-selective) growth medium A. One flask was required for each supervector to be 
tested. The cells were incubated overnight at 37°C in 5% CO*
The following  day the cells  in  each  flask  were  washed,  trypsinised,  pelleted  and 
resuspended in sufficient autoclaved PBS to give a final concentration of 1 x 107  cells 
per ml.
2.8.3 Transfection of recombinant expression supervector into CHOdhfr 
cells
The CHOdhfr cells were electroporated (using the same method as that used for the 
COS-7  cells,  see  section  2.6.7).  A  700|xl  aliquot  of  the  washed  CHO  dhfr  cell 
suspension was pipetted into a disposable electroporation cuvette to which 20|xg of 
thawed recombinant supervector was added.  A 1.9kV and 25nF capacitance pulse 
was  then  delivered  to  each  experimental  transfection  and  a  control  containing 
CHO  dhfr cells only,  using a Bio-Rad Gene Pulser® II electroporator. The cells were
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then  allowed  to  recover  at  RT for  10  minutes  and  the contents  of each  cuvette 
transferred  to a  separate  10cm  tissue culture dish  containing  8ml  of pre-warmed 
medium A. Each dish was then incubated overnight in 5% CO 2 at 37°C.
2.8.4  Selection of transfected CHOdhfr' cells post electroporation
From this point onwards the cells were  maintained  in  selective growth  medium  B 
(described  in  section  2.1.13)  that  lacks  ribonucleosides and  deoxyribonucleosides, 
which are absent from dialysed FCS. Thus only those cells which contain supervector, 
hence a functional dhfr gene will then be able to grow.
Following overnight growth of the transfected CHOdhfr' cells in non-selective medium 
A the cells in each  10cm dish were washed with  lOmls of HBS, trypsinised and then 
pelleted at 700rpm  (in a  Sorvall  RT7  Plus) for five minutes at RT.  Cells from each 
transfection  and  control  were  resuspended  separately  in  lOOmls  of  prewarmed 
selective medium B before being divided equally between ten  10cm diameter tissue 
culture dishes.
Incubation of the cells at 37°C in  5% C02 then took place for  10-14 days changing 
the selective medium  B every 3-4 days.  After  10-14 days the cells on the no DNA 
control dish were all dead and discrete foci of transfected cells were clearly visible on 
all the test culture dishes without the aid of a microscope. In order to pick these foci 
they were visualised under a microscope and using a sterile pipette tip 200^1 of foci 
plus medium was aspirated under direct vision and transferred into individual wells of 
a 24 well tissue culture plate containing 0.5ml of prewarmed medium B. A total of 48 
foci  were  picked  from  each  transfection  (ten  plates).  The  picked  cells  were  then 
grown  in  the  selective  medium  B  until  almost  confluent  (between  7-14  days), 
changing the media every seven days.
Once almost confluent, the  medium from the individual wells of each 24 well  plate 
was tested for whole IgG antibody production  by ELISA (see section 2.6.1).  Those 
clones  producing  the  highest  levels  of  antibody  were  selected  for  expansion  in 
CHO  dhfr  (selective) growth medium B until the cells were growing in  175cm2  tissue 
culture flasks.
159Chapter Two Materials and Methods
2.8.5 Assay of antibody production in transfected CHOdhff cells
Following growth of the selected cells to just below confluent level in selective media 
in  175cm2  flasks the  cells  were washed  with  10ml  HBS,  trypsinised  with  Trypsin- 
EDTA and  pelleted at 700rpm (in a Sorvall  RT7  Plus) for five minutes at RT.  Each 
clone of cells was  resuspended  in  20ml  of prewarmed  selective  medium  B  and  a 
viable cell count performed (as in section 2.5.6). The cells were then pelleted again 
(as above) and resuspended in sufficient prewarmed medium B to produce a viable 
cell  count of  1x10s cells/ml.  One  ml  of this  solution  was then  added  to  a  10cm 
diameter tissue culture dish containing 9ml of prewarmed  medium  B and  incubated 
at 37°C  in  5% CO 2 for three days. After three days, the supernatant of these cells 
was  collected  from  each  10cm  dish  and  the  concentration  of  intact  whole  IgG 
antibody assayed using an ELISA, as described in section 2.7.1. Cells in each  10cm 
dish  were  washed  with  5ml  HBS,  trypsinised  (2ml  Trypsin-EDTA)  and  pelleted  at 
700rpm (in a Sorvall RT7 Plus) for five minutes at RT.  Following this the cells were 
resuspended  in  one  ml  of  prewarmed  medium  B  and  a  viable  cell  count  was 
performed as above.
From  the  new  viable  cell  count  and  the  antibody  concentration  in  the  decanted 
supernatants,  the  level  of antibody  production  was  calculated  and  expressed  as 
ng/106 cells/day. A cell bank of the clones with the highest antibody production rates 
was created by suspending  1 x 107 cells/ml in medium B containing 10% DMSO and 
stored  in  liquid  nitrogen  (as  in  section  2.6.4)  for  further  selection  using  MTX 
amplification.
2.8.6  Amplification  of  transfected  CHO dhff  cells  following 
electroporation and selection
Following the growth of the selected CHOdhfr  cells in CHOdhfr  (selective) growth 
medium B in a  175cm2 flask, the cell lines producing the highest levels of IgG were 
trypsinised and centrifuged at 700rpm for two minutes at RT in a Sorvall RT7 Plus. 
The cells were resuspended  in CHOdhfr  (selective) growth  medium  B to produce a 
final viable cell count of 1 x 10®  cells/ml. 0.5ml (i.e. 5 x 105 cells) of this solution was 
diluted  in  a  further  49.5ml  of  pre-warmed  1  x  10'®M  amplification  medium  (i.e. 
CHOdhfr  (selective)  growth  medium  B  supplemented  with  1  x  10'8M  MTX).  The 
resulting culture was then divided equally between five lOcm-diameter tissue culture
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dishes, (i.e.  1 x 105 cells/culture dish). This dilution was required in order to produce 
pure foci that could be easily identified from one another on the plate.
The  cells  were  incubated  at  37°C  in  5%  CO 2  for  10-14  days.  The  amplification 
medium  (supplemented  with  the appropriate concentration  of  MTX)  was  changed 
every 3-4 days. After 10-14 days, foci of transfected cells were easily visible in most 
of the culture dishes.
Approximately 24 foci  were picked for  each  transfection  (as in  section  2.8.4)  and 
were then transferred into individual wells of a 24-well tissue culture plate containing 
lml  of pre-warmed  CHO dhfr  amplification  medium.  These  cells  were  allowed  to 
grow  in the amplification  medium  until  almost confluent (usually after 7-14 days), 
whilst the medium was changed every 7 days or as required. Once almost confluent, 
the medium from the individual wells was tested for antibody production as before, 
using the whole IgG ELISA (see section 2.7.1).
Those clones producing the highest levels of antibody were selected for expansion in 
CHO  dhfr  (selective)  growth  medium  B  with  MTX  until  the  cells  were  growing  in 
175cm2  tissue culture flasks. The antibody production rates of individual clones (see 
section 2.8.5) were then determined. A cell bank of selected amplified cell lines was 
created. When creating a cell bank, selective pressure was maintained when freezing 
cells i.e. concentration of MTX was kept the same on freezing as that used in culture.
2.9  SDS~Polyacrylamide Gel Electrophoresis (PAGE)
Each gel  consisted of 3mIs  5%  stacking  gel  layered on top of 5mls  15%  resolving 
gel. The resolving gel was  poured and  immediately layered with  isopropanol.  After 
the gel had set, the isopropanol was removed and the stacking gel added to form the 
upper layer. A suitable comb was added  prior to the polymerisation of the stacking 
gel. The composition of the resolving and stacking gels is described in Table 2.3.
Total protein samples were separated into polypeptide units by SDS-PAGE according 
to the  method  of (Laemmli,  1970).  Protein  samples were added  in  a  1:1  ratio to 
sample buffer (2% (w/v) SDS, 50mM Tris-HCI pH6.8, 0.1% bromophenol  blue,  10% 
(w/v)  glycerol,  lOOmM  dithiothreitol  (DTT) and  denatured at  100°C  for  3  minutes 
immediately before loading on to the gel.  20^1 of sample or 5^1 of molecular weight
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protein  marker  (Prestained  Protein  Marker,  Broad  Range,  NEB,  Herts,  UK  or 
Rainbow™  Coloured  Protein  Molecular Weight Markers,  AmershamBio,  Bucks,  UK) 
were  loaded.  SDS-PAGE  gels  were  prepared  in  a  vertical  gel,  one-dimensional, 
electrophoresis system (Gibco-BRL, Paisley, UK) and run in lx running buffer (25mM 
Tris,  250mM glycine and 0.1% (w/v) SDS pH  8.3) at 40mA/gel at RT until the dye 
reached the bottom of the plate.
lOmls 10% Resolving gel 8mls 5%Stacking gel
ddH20 2.3mls 5.5mls
30% acrylamide mix1 5.0mls 1.3mls
1.5M Tris, pH 8.8 2.5mls -
1.0M Tris-HCI, pH 6.8 - 1.0ml
10% SDS 0.1ml 0.08ml
10% AmPS2 0.1ml 0.08ml
TEMED3 0.004ml 0.008ml
Table 2.3. Composition of resolving and stacking gels for SDS-PAGE
Acrylamide bis  =  N,N'-Methylene-bis-acrylamide.  AmPS  =  ammonium  persulfate. 
*TEMED = NNNN-tetramethylethalinediamine.
2.9.1  Coomassie Stain
This stain was used to visualise the protein bands run on an SDS-PAGE gel. The gel 
was  transferred  from  the  electrophoresis  apparatus  to  a  plastic  container  and 
covered with  0.2%  Coomassie gel stain  (0.2%  (w/v) Coomassie,  7.5% acetic acid, 
40%  methanol,  dH2 0  to  a  volume  of  1L)  for  eight  minutes.  The  gel  was  then 
destained with Coomassie destain (7.5% acetic acid and  5%  methanol  made up to 
1L with dH20) for three hours. The gel was then dried on a gel dryer at 60-80°C for 
30 minutes and kept as a permanent record.
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2.9.2 Transfer of protein to nitrocellulose and western blotting
Protein  separated  on  SDS-PAGE  gels  were  transferred  to  Hybond  C  membranes 
(Amersham,  Bucks,  UK)  using  a  wet-transfer  method  described  by Towbin,  1979. 
The gel and the nitrocellulose membrane were pre-soaked  in transfer buffer (50mM 
Tris, 180mM glycine, 0.1% (w/v) SDS and 20% methanol) and blotted over one hour 
at  400mM  /  RT  in  a  Trans-blot™  Cell  (Bio  Rad)  according  to  manufacture's 
instructions.  An  ice-block  was  placed  in  the  cell  to  avoid  over-heating.  The 
membrane was subsequently removed and dried.
2.9.3 Immunodetection of proteins on western blots
The  membrane  was  blocked  in  PBS/0.1%  polyxyethylene  sorbitan  monolaurate 
Tween  20/5%  (w/v) skimmed  milk for one hour at RT on a  shaking  platform.  The 
primary  antibody  solution  (in  PBS/0.1%  Tween  20/5%  milk)  was  added  and 
incubated for a further one hour, shaking at RT. The unbound primary antibody was 
then  rinsed  off  by  two  10-minute  washes  with  PBS/0.1%  Tween  20,  and  the 
appropriate anti-IgG  horseradish  peroxidase (HRP)  conjugated  secondary antibody 
(in  PBS/0.1% Tween  20/5%  milk) added for one hour,  RT on  a  shaker.  Unbound 
secondary  antibody  was  then  rinsed  off  with  two  washes  of  10  minutes  with 
PBS/0.5% Tween  20. The bound  HRP was then detected  using chemiluminescence 
(ECL™, Amersham,  Bucks,  UK) and the resultant light emissions  exposed  to X-ray 
film for one second to one hour, depending on the strength of the signal.
2.10  Nucleosome preparation
Jurkat cells  were grown  in 40  ml  medium  until  70%  confluent (7 X  107   cells  are 
needed for the nucleosome preparation). The cells were pelleted  in a  50  ml  Falcon 
by centrifugation at 700rpm (Sorvall RT7 Plus) at RT for 8 minutes. The supernatant 
was discarded and gently resuspended in  10 ml ice cold  PBS. The cells were again 
centrifuged at 700rpm for 8 minutes the supernatant discarded and resuspended in 2 
ml  ice cold  Dounce buffer (adding fresh  protease inhibitor at 1:100 each time) and 
transferred to Dounce tube. The cells were incubated in the Dounce tube on ice for 
10  minutes. The cell membrane was disrupted using a fine tissue homogenizer that 
enables  release of the  nucleus  without destroying  it.  The  cells  were assessed  to 
identify  those  with  a  disrupted  membrane from  which  nuclei  could  be  released. 
When sufficiently homogenized, the vast majority of cells stain blue with trypan blue,
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with the nucleus only remaining. The homogenised cells were transferred into  1.5ml 
eppendorf tubes and the nuclei were pelleted by centrifugation at 3000rpm (Biofuge 
Fresco), 4°C for 10 minutes. Nuclei were resuspended in a minimal volume of lOmM 
Tris-HCI buffer, pH 8.0, with 50mM NaCI, 5mM MgCI2. The nuclei were either stored 
in  50%  glycerol  at  -80°C  or  directly  processed  as  described  below  to  produce 
oligonucleosomes or mononucleosomes.
Stored  nuclei were rapidly thawed in a  37°C water  bath  and  a  minimal  volume of 
digestion  buffer was added, spun  at 3000rpm  (Biofuge  Fresco) for 20 mins at 4°C 
and the supernatant was discarded. The wash and cetrifugation steps were repeated, 
the nuclei were gently resuspended by flicking the tube, and  IOOjaI ice-cold digestion 
buffer was added.  The DNA concentration was checked by taking an aliquot in  2% 
SDS  (ultra-pure  quality)  and  measuring  absorbance  at  260nm  (A2 6 o)  on  a 
spectrophotometer.  Further digestion buffer was added until the DNA concentration 
was approximately 5yg/nl.
The  suspension  was  quickly  warmed  to  RT and  micrococcal  nuclease  was  added 
(Worthington Biochem, USA) to a final concentration of 200 units/ml.  Digestion was 
continued for 45-60  minutes on  a  rotator.  Digestion was terminated  by  making  up 
the suspension to a concentration of 2mM in EDTA (pH 8.0). Nuclei were pelletted by 
centrifugation in an eppendorf centrifuge at lOOOrpm for 5 minutes at 4°C and the 
supernatant was transferred  to a  fresh  tube on  ice without disturbing  the  pellet. 
Products of this procedure were then confirmed to give the ladder of bands expected 
from oligonucleosomes on a gel.
2.11  Reproducibility of direct binding assays
In  the  results  chapters  to  follow,  single  representative  graphs  from  ELISA 
experiments are presented. All experiments were carried out in triplicate in separate 
occasions to demonstrate reproducibility and diluted serum from a  patient was run 
on every plate as a positive control and cells transfected with no DNA, as a negative 
control.  As  an  example,  Figure  2.5  illustrates  duplicate  experiments  carried  on 
separate  occasions.  Overall,  OD  values  vary  in  repeat  experiments  however,  the 
same pattern of binding with the different antibody combinations is observed.
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Figure 2.5 Binding of purified human IgG molecules to nucleosomes
In  order  to  confirm  the  findings  of  the  first  experiment  (A),  this  experiment  was 
repeated  on  a  separate  occasion  (B).  Further  discussion  on  the  binding  of  the 
antibodies shown in this figure is detailed in Chapter 5.
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CHAPTER THREE.
THE IMPORTANCE OF SEQUENCE FEATURES OF THE HEAVY 
CHAIN OF B3 AND THE LIGHT CHAIN OF UK4 IN BINDING TO 
DIFFERENT ANTIGENS
3.11ntroduction and aims of this chapter
The  human  monoclonal  IgGl  anti-DNA antibody  B3,  derived  from  a  patient  with 
active SLE, is known to be pathogenic in vivo in SCID mice and contains VH  and VL  
encoded by the two most commonly rearranged human Vx and VH  genes, Vx2a2 and 
Vh3-23.  Therefore,  it  is  likely to  be  representative of those  antibodies  related to 
disease pathogenesis in patients with SLE.
Sequence  analysis  of  both  murine  and  human  monoclonal  anti-DNA  antibodies, 
suggests that  high  affinity  for  dsDNA  is  associated  with  the  presence  of certain 
amino acid residues within the CDRs, notably arginine, asparagine and lysine, which 
frequently arise at sites of somatic mutation.  Expression and modification of murine 
and  human  anti-DNA  antibodies  in  vitro  has  shown  that  substitution  of arginine 
residues, especially those in VH CDR3, often leads to a decrease in affinity for dsDNA.
The original computer model of the B3/dsDNA complex, previously published by our 
group (Kalsi et al., 1996) (shown in Figure 1.5) suggests that the dsDNA double helix 
lies in a groove on the surface of B3 between the VH  and VL  and that this interaction 
is  stabilised  by  the  presence  of  three  arginine  residues  at  the  periphery  of the 
antigen-binding  site (R27a and  R54 of the L chain and  R53 of the H chain).  Since 
R53 in B3Vh is to be found in the CDR2 region, it is important to determine whether 
replacing arginine by another amino acid would this hinder or block DNA binding. In 
this chapter, site-directed  mutagenesis was used to determine whether the arginine 
residue  at  position  53  (R53)  in  B3VH   CDR2,  which  is  the  product  of  a  somatic 
mutation of the VH  germline gene V3-23, is important in enabling B3 to bind DNA, as 
predicted by the model. The hypothesis is that mutation of R53 will reduce binding to 
DNA. Which leads to another interesting question: can binding be 'created7  by adding 
this  arginine?  To  investigate  this  question,  a  construct  that  has  the  wild-type
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sequence of the V3-23 gene was made and the serine at position 53 was mutated to 
arginine.
Previous studies  showed  that the critical arginine  residues  for  DNA  binding  in  the 
2a2-derived  L chains of human  anti-DNA antibodies  B3 and  33H11,  were those  in 
B3V|_ CDR1 and 33H11VL  CDR3, whilst an arginine in UK4VL  CDR3 appeared to block 
DNA binding of this aPL (Rahman et al., 2001). This latter finding was predicted by 
the computer model  (shown  in  Figure  1.7)  because the groove  in the B3Vh/UK4Vl 
model  is blocked  by various  residues from  the L chain  including a  bulky positively 
charged arginine residue at position 94 (R94). This finding leads to the question:  if 
the arginine  in  UK4VL   CDR3 is  replaced  by  another amino acid,  would  it exhibit a 
positive effect on binding to DNA? To answer this question, a mutant form of UK4VL  
was created by site-directed mutagenesis and tested for binding to DNA.
The principal aim of the experiments described  in this section was to use a COS-7 
transient expression system to produce a variety of IgGl molecules and test: (1) the 
effect of the mutations created by site-directed mutagenesis in the H chain of B3 in 
order to investigate the contribution of the arginine residue in VH CDR2 to the binding 
properties of the antibody;  (2) the effect of the  mutation  created  by site-directed 
mutagenesis in the VH 3-23 construct in order to investigate the role of the arginine 
residue introduced by mutagenesis in VH CDR2;  and (3) the effect of the mutation of 
the L chain  of UK4.  The effect of the B3VH   mutation  on  binding to other clinically 
relevant antigens such as nucleosomes, a-actinin, and CL was tested, since previous 
studies  have  suggested  cross-reactivity  between  DNA  and  these  antigens.  Two 
groups have reported that pathogenic murine anti-DNA monoclonals bind directly to 
a-actinin (Deocharan et al., 2002, Mostoslavsky et al., 2001).
However,  the  quantities  of IgG  produced  by the  transient expression  system  are 
insufficient  to  affinity  purify  the  antibodies  and  determine  their  pathogenic 
properties. This chapter describes the production of four stable cell lines expressing 
some  of  the  H/L  combinations  reported  previously  in  the  transient  expression 
system.
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3.2  The  importance  of sequence  features of B3VH  in  binding  to 
dsDNA, nucleosomes, cardioiipin and alpha-actinin
3.2.1  Transfer of Vh3-23  cloned  PCR fragment from neSLE122H45.4 to 
PG1D210
As  explained  in  more  detail  in  section  2.3,  the  appropriate  VH 3-23  cloned  PCR 
fragment was transferred from the original expression vector neSLE122H45.4, to the 
vector pGlD210 containing CH  sequence. Through the design  of specific primers, a 
Hind III and a Xho I  site was introduced into VH 3-23/neSLE122H45.4 so that the VH 3- 
23 region DNA sequence could be extracted from neSLE122H45.4 and transferred to 
PG1D210 with  Hind III and Xho I.  The VH 3-23 sequence was successfully amplified 
as shown in Figure 3.1 and once ligated  into pGlD210, a  Hind III/Xho I restriction 
digest was used to verify the presence of VH 3-23 DNA sequence in the new vector. 
Successful ligation of VH 3-23 into pGlD210 produced two bands of 7217 and 434 bp 
in  length  when digested with  Hind III/Xho I upon gel electrophoresis, as shown  in 
Figure  3.2.  DNA  sequencing  ensured  that  no  additional  mutations  had  been 
introduced  into  the  sequence  due  to  PCR  error  and  Figure  3.3  shows  the 
representative sequencing plot.
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1  2  3
< 5— 1500bp
4-1000bp
<—  600bp
4 —  500bp
4 — 400bp
< J —   300bp
4 -   200bp
Lanes
1  = Control (PCR mix without template cDNA)
2 = Template VH 3-23 cDNA
3 =  lOObp DNA Ladder
Figure 3.1  PCR amplification of VH 3-23 sequence cDNA
The Vh3-23  region  DNA  sequence was  extracted  from  neSLE122H45.4 and amplified
by  using  specific  PCR  primers (see section  2.3.1).  A 430bp  band  of cDNA consistent
with VH 3-23 is seen in lane 2 and no band is seen in the control lane 1.
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1500bp
500bp— t> 
400bp— >
200bp— >
<1— 7217bp
— 430bp
Lanes
1  =  Lambda DNA/Hind III marker
2  = Hind III/Xho /digested VH3-23/pGlD210
Figure 3.2 Confirmation Hind III/Xho I restriction digest of vector pG1D210 containing 
Vh3-23 insert
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Figure 3.3 Sequencing plot confirming the cloning of VH 3-23 sequence into the pG1D210 plasmid
The sequence of the VH 3-23  insert into  pGlD210 was confirmed  by automated sequencing. The chromatograph trace 
is shown here with the black arrows indicating the beginning and the end of the VH 3-23 insert.Chapter Three The importance of sequence features of the heavy chain of B3 and the light chain of UK4
3.2.2  Sequences of heavy chains and light chains expressed and results 
of site-directed mutagenesis
The  amino  acid  sequence  of  B3VH ,  B3(R53S)VH ,  B3(R53N)VH ,  B3(R53K)VH /  the 
corresponding germline gene, V3-23 and VH 3-23(S53R) are displayed  in Figure 3.4A 
(highlighted in red are the arginines mutated). B3VH  has a single somatic mutation to 
arginine in CDR2. Figure 3.4A shows the amino acid sequence of three variant forms 
of B3Vh  produced  by  mutagenesis,  where the arginine at position  53  in the CDR2 
region was converted into a serine, asparagine or lysine. The H chain VH3-23(S53R) 
shown in the figure, was derived from the V3-23 gene, by site directed mutagenesis, 
where the serine at position 53 in the CDR2 region was converted into an arginine.
Amino acid sequences of B3Vl, B3(R27aS)VL, 331-IIIVl,  UK4VL  and the corresponding 
germline gene,  2a2 are shown  in  Figure 3.4B.  B3VL  contains two adjacent arginine 
residues  in  CDR1  both  produced  by  somatic  mutations.  33H11VL   contains  two 
arginine residues in CDR3, neither of which is germline encoded. One is the result of 
a somatic mutation whilst the other is formed by the junction between 2a2 and Jx2. 
UK4Vl has a single somatic mutation to arginine in CDR3. Figure 3.4B also shows the 
amino acid sequence of a variant form of B3VL  produced by mutagenesis converting 
the arginine at position 27a into a serine in the CDR1 region. The L chain B3(R27aS) 
shown  in  the  figure,  was  derived  from  B3VU  by  site-directed  mutagenesis.  All  L 
chains expressed are encoded  by the same germline gene,  2a2,  but differ in their 
pattern of somatic mutation.
Plasmid  DNA  of  the  appropriate  size  was  confirmed,  post  transformation,  by  a 
Hindlll/Xhol digest (Figure 3.5).  This plasmid  DNA was then  sent for sequencing 
analysis  (MWG-Biotech).  The  results  of site-directed  mutagenesis of the germline 
Vh3-23 and its variant VH 3-23(53) and of the VH  CDR2 of the wild type B3VH  and its 
variants B3(R53S)VH ,  B3(R53N)VH ,  and  B3(R53K)VH  were confirmed  by sequencing 
and are shown in Figure 3.6.
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FRl  CDRl  FR2  CDR2  FR3  CDR3  J H
31  36  40  52abc 53  60  70  82  90  100  101
I  I  I  Iabc
3 g| c 3-23  EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGfGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK  YFDYWGQGTLVTVSS
3-23* EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGRGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK  YFDYWGQGTLVTVSS
B3    V------------------ T-----T-T------------------- T---- |-S-----G— Q-----L----- S---------------------- PNVGSGW  S— S------ L-T__
B3-1    v-------------------T-----T-T------------------- T---- S-S--G— Q -   L-------- S  PNVGSGW  S— S------ L-T__
B3-2    V-------------------T-----T-T------------------- T---- N-S-----G— Q-----L----- S  PNVGSGW  S— S------ L-T__
B3-3    V------------------ T-----T-T------------------- T---- K-S--G— Q -   L-------- S---------------------- PNVGSGW  S— S______ L-T__
B  V L
FRl  CDRl  FR2  CDR2  FR3  CDR3  J*
1  20  24 27  34 35  40  50  60  70  80  89  94  100
I   I   I  l a b c   I I I   I   I   I   I   I I I
2a2  QSALTQPASVSG.SPGQSITISC TGTSSDVGGYNYVS WYQQHPGKAPKLMIY EVSNRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC SSYTSSST WFGGGTKLTVLG
S3    .-------- P§----- F-----------------------H------ T---A--- S----------------------- S-TTR-------------   £
B3-4    .-------- RS----- F-----------------------H------ T---A--- S----------------------- S-TTR-------------
UK  4    .-------- SN--S----------L--E---- L—   DAIK------------ E------------------ G-------- n|. .  -F-----------
UK4*    .-------- SN--S--------- L--B---- L—   DAIK-------------E— --------------- G-------- NS. .  -F-----------
33H11    .-----------1----------------- L-----D— T-------------------------------------     R--R----------
Figure 3A Sequence alignment of expressed VH  and VL  regions
(A) Sequences of expressed VH  regions compared to 3-23. (B) Sequences of expressed VL  regions compared to 2a2. The 
amino acids altered by site-directed mutagenesis are highlighted in red.  The amino acids are numbered according to Kabat 
(Wu and Kabat, 1970). A dash indicates homology with the corresponding germline sequence. Abbreviations: FR -  
Framework region; CDR -  Complementarity determining region; 3-23* -  VH 3-23(53); B3-1 -  B3(R53S)VH  ;  B3-2 -  
B3(R53N)Vh ;  B3-3 -  B3(R53K)VH ; B3-4 -  B3(R27aS)VL; UK4* -  UK4(R94S)VL .Chapter Three The importance of sequence features of the heavy chain of B3 and the light chain of UK4
lOOOObp
3000bp— >  
2000bp— £> 
lSOObpr^ 
lOOObp-—-C >
500bp— >
Lanes
1  =  lkb DNA ladder
2 = Hind III/Xho I digested
3 = Hind III/Xho I  digested
4 = Hind III/Xho I digested
5 = Hind III/Xho I digested
6 = Hind III/Xho I digested
7 = Hind III/Xho I digested
B3Vh/ pG1D210
B3(R53S)Vh/ pG1D210
B3(R53N)Vh/ pG1D210
B3(R53K)Vh/ pG1D210
VH3-23/pGlD210
VH3-23(53)/pGlD210
Figure 3.5 Hind III/Xho I restriction digest of pG1D210 vector containing B3VH  and B3VH  
variant constructs, VH 3-23 and VH 3-23(53) variant construct on 1% agarose gel
B3Vh/pG1D210,  B3(R53SVh/pG1D210,  B3(R53N)VH /pGlD210/  B3(R53K)VH /pGlD210/ 
VH 3-23/pGlD210  and  VH 3-23(53)/pGlD210  were  digested  with  Hind III and Xho 1  
and  the fragments  separated  on  a  1%  agarose gel. The actual  agarose gel  is shown 
above,  indicating  the  expected  band  sizes.  It  can  be  seen  from  the  gel  that  DNA 
bands of 7222 and 431  bp are present in each.
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5' TCA ACT ATT AGT GGT CGT GGT AGT AGC ACA TAC 3' 
Arginine
jiS S C T S S  A G   t s q 6 t c t C « aCT < »   t  t  «   .   j - 5 q t  «  f t   - 5 6  T  >6T »  f t   C  «   C  * T  »CT»CGC*G &   CT_CCGT&C «0 5SCC00'' TC *
Serine
It *   m  13*  M *  19*  1W
A G  TGGGTC rC**C T* T  T   A  G  TGGTAATGG7AGTAGC ACA TAC  7  A  COCA G  GC TCCG 7  G  C  A  G   G
Asparagine
*« » v r>
GAG TGGGTC TCAAC T A  T  TAGTGGTAAGGGTAOTAGCACATACTACGCAGGC TCCGTGCA
Lysine
Figure  3.6  (A)  The  sequences  of  the  B3VH   variants  were  confirmed  by  automated 
sequencing (see over for legend)
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3' GTA TGT GCT ACC ACC ACT ACC ACT AAT AGC TGA 5'  VH 3-23 CDR2
Serine
Arginine
Figure  3.6  (B)  The  sequence  of  the  VH 3-23  variant  was  confirmed  by  automated 
sequencing
The amino acids  mutated  in  the wild-type and  germline sequences are  highlighted 
in  green.  In  the  wild-type  B3VH   sequence,  a  single  amino  acid  alteration  was 
introduced to  produce 3 different variants and  in  the case of the germiline VH 3-23, 
one  variant  was  produced.  The  chromatograph  traces  represented  in  this  figure 
show  the  sequences  of  (1)  B3(R53S)VH ,  (2)  B3(R53N)VH/  (3)  B3(R53K)VH   and  (4) 
VH 3-23(S53R).  The  mutation  introduced  in  these  sequences  is  indicated  by  blue 
arrow  pointing  to the single amino  acid  alteration.  Sequences  (A),  (B)  and  (C)  are 
5' to 3' and sequence (D) is 3' to 5'.Chapter Three The importance of sequence features of the heavy chain of B3 and the light chain of UK4
3.2.3  Transient expression of whole lgG1 molecules in COS-7 cells
Table 3.1 displays the H/L chain combinations expressed in COS-7 cells. The L chains 
were all similar in that they were derived from the germline gene 2a2, but contained 
different somatic mutations. The transfection of the COS-7 cells was carried out as 
described in section (2.6.7), and after 72 hours the supernatants from the cells were 
DNase  I treated  and  concentrated  (2.6.9).  Three  expression  experiments  were 
carried out for each combination. The whole IgG yields for each  Vh/Vl combination 
were similar between  each of the expression  experiments. The B3  L chain variant, 
B3(R27aS)VL,  was  generated  by  Dr A.  Rahman  using site-directed  mutagenesis of 
arginine 27a to serine in B3VL  CDR1 (see figure 3.4B).
The concentration of IgGl  in each COS-7 cell supernatant was determined  by IgGl 
ELISA,  described  in  section  2.7.1.  IgG  was  obtained  in  the  supernatant  for  all 
combinations.  Each  combination  was  expressed  in  three  separate  occasions  and 
similar yields of antibody were produced. The range of IgG concentrations obtained 
are shown in Table 3.2.
In  each  experiment,  the  negative  control  sample  in  which  COS-7  cells  were 
electroporated without any plasmid DNA contained no detectable IgGl. Combinations 
containing  UK4VL   produced  noticeably  higher  yields  of  whole  IgG  than  the  other 
combinations. There is no clear reason for the variable expression seen with different 
VH  and VL  combinations and the differences in antibody levels produced and this is 
well  documented  in  this  and  other  expression  systems  (Rahman  et  al.,  1998, 
Rahman et al., 2001). This variation could  have occurred for a number of reasons, 
such as variable post-electroporation COS-7 cell growth, or transfection efficiency.
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B3Vh  Vh3-23
UK4Vl
■ B3Vl  CZZH EZ~3 B3Vl
I B3(R27aS)V  IZ7 1 [ZZ I B3(R27a)VL
]E Z Z l3 3 H llV L   EZZZ3 EEH 33H11VL
I  UK4Vl
B3(R53S)Vh
B3Vl
B3(R27a)VL  
IH I3 3 H 1 1 V L  
M M  uk4Vl
Vh3-23(53)
IB3Vl
]B3(R27a)VL
I   1EZZH33H11VL 
2UUK4VL
B3(R53N)Vh
UZZIUZD B3(R27aS)VL  
I  1 CZZ 1 33H11Vl 
n Z J E Z l  UK4Vl
B3(R53K)Vh
CZZDCZZ] B3(R27aS)V 
I  I E ~ 133H11Vl 
■ I  UK4Vl
Table 3.1 The heavy/light chain combinations expressed in COS-7 cells
This schematic diagram  illustrates the six groups of Vh/Vl combinations in 
which a different H chain is paired with the four 2a2-encoded VL  chains.
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Heavy Chain 2a2-derived Light Chain IgG concentration (ng/ml)
B3 B3 3-18
B3 B3(R27aS) 3-25
B3 33H11 3-20
B3 UK4 62-92
B3 (R53S) B3 80-120
B3 (R53S) B3(R27aS) 90-120
B3 (R53S) 33H11 75-95
B3 (R53S) UK4 225-250
B3 (R53N) B3 415-425
B3 (R53N) B3(R27aS) 415-425
B3 (R53N) 33H11 420-600
B3 (R53N) UK4 485-495
B3(R53K) B3 800-850
B3 (R53K) B3(R27aS) 800-850
B3 (R53K) 33H11 800-950
B3 (R53K) UK4 875-900
VH3-23 B3 13-17
VH3-23 B3(R27aS) 57-60
VH3-23 33H11 57-60
VH3-23 UK4 475-485
VH3-23(53) B3 12-15
VH3-23(53) B3(R27aS) 42-45
VH3-23(53) 33H11 42-45
VH3-23(53) UK4 35-40
No DNA No DNA 0
Table  3.2  The  range  of  IgG  concentrations  in  ng/ml  for  each  heavy/light  chain 
combination during the COS-7 transient expression experiments
Three  variant  forms  of  B3VH   were  produced  by  mutagenesis,  B3(R53S)VH , 
B3(R53N)Vh, and B3(R53K)VH , where the arginine at position  53 in the CDR2 region 
was  converted  into  a  serine,  asparagine  or  lysine  respectively.  The  H  chain  VH 3- 
23(S53R) was derived from the V3-23 gene, by site-directed mutagenesis, where the 
serine at position 53 in the CDR2 region was converted into an arginine. Each value 
in the table was derived,  by reference to a standard curve of human IgG of known 
concentration, after the background OD values had been subtracted.
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3.2.4  Results  of  anti-nucleosome  and  anti-dsDNA  ELISA  with  COS-7 
supernatants
Binding  of each  of the  H/L chain  combinations to  nucleosomes  is shown  in  Figure 
3.7A and to dsDNA in  Figure 3.7B.  In each case, similar binding results were seen 
from each  of the expression experiments and the figures  show  results of a  single 
representative  experiment.  The  negative  control  sample  in  each  case  was 
supernatant from  COS-7  cells  to  which  no  plasmid  DNA  had  been  added  during 
electroporation and contained neither anti-DNA activity nor anti-nucleosome activity 
on testing  by ELISA. The positive control in each case was polyclonal serum from a 
patient  with  SLE  known  to  bind  dsDNA  and  nucleosomes.  The  same  aliquot  of 
polydona! serum was used for all the anti-dsDNA and anti-nucleosome EUSAs.
The strongest binding to both antigens was seen with the combinations containing 
the wild-type sequence of B3VH  when  paired with  B3VL  or 33H11VL  (B3Vh/B3Vl and 
B3Vh/33H11Vl). Both of these H/L chain pairs produced very small amounts of whole 
IgG yet clearly bound to both these antigens. The introduction of the single R to S 
mutation  in  CDR1  led  to  a  reduction  in  binding  to  nucleosomes  or dsDNA (i.e. 
B3VH/B3(R27aS)VL ).  The  results  of  the  DNA  ELISA  were  consistent  with  those 
obtained  in  previous studies of expression studies of these combinations  in COS-7 
cells (Rahman et al., 2001, Giles et al., 2003, Haley et al., 2004).
Despite being tested at a range of concentrations much higher than those that gave 
maximal  nucleosome  and  DNA  binding  for the  other wild-type  combinations,  the 
variant forms of B3VH  showed  no  binding to  nucleosomes or dsDNA.  Also,  none of 
the  other  combinations  containing  VH 3-23  or  VH 3-23(53)  or  UK4VL   showed  any 
binding nucleosomes or dsDNA at all.
3.2.5 Anti-alpha-actinin binding of expressed whole IgG molecules
The a-actinin binding ability of each of the Vh/Vl combinations was tested by ELISA
and is shown in Figure 3.8.  From the three expression experiments, similar results
were seen. Figure 3.8 shows the a-actinin binding results of a single, representative,
experiment.  The negative control  sample in each  case contained  neither IgGl  nor
anti-a-actinin  activity  on  testing  by  ELISA.  The positive control  in  each  case  was
polyclonal serum from a patient with SLE known to bind a-actinin. The same aliquot
of  polyclonal  serum  was  used for all  the  a-actinin ELISAs.  B3Vh/33H11Vl  was  the
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only combination that bound a-actinin. All  other combinations did not bind, despite 
being tested at a range of concentrations higher than those that gave binding with 
the B3Vh/33H11Vl combination.
3.2.6  Anti-cardiolipin binding of expressed whole IgG molecules
Binding of each of the H/L chain combinations to CL is shown in Figure 3.9. In each 
case,  similar  results  were  seen  from  each  of the expression  experiments and the 
figure  shows  results  of a  single  representative  experiment.  The  negative  control 
sample contained  neither IgGl  nor anti-CL activity  in  an  ELISA test.  The  positive 
control in each case was polyclonal serum from a patient with APS known to bind CL. 
The same aliquot of polyclonal serum was used for all the CL EUSAs.
The strongest  binding  was seen with the B3Vh/B3Vl (wild-type) chain combination. 
The reversion of the arginine residue to a serine residue at position 27a (R27aS) in 
V |_  CDR1  led  to  a  reduction  in  binding  to  CL.  The  introduction  of a  mutation  at 
position  VH   CDR2  (R53S,  R53N  and  R53K)  completely  abolished  binding  to  CL 
irrespective of the L chain it was paired with.
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Figure 3.7  (A) Effect of point mutation in B3VH  and VH 3-23 in binding to nucleosomes (See figure legend)
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Figure 3.7 (B) Effect of point mutation in B3VH  and VH 3-23 in binding to dsDNA (See figure legend)Chapter Three The importance of sequence features of the heavy chain of B3 and the light chain of UK4
Figure 3.7 Effect of point mutation in B3VH  and VH 3-23
The graphs show  binding of IgG  in COS-7 cell  supernatants containing each  H/L 
chain  combination  to  (A)  nucleosomes  and  (B)  dsDNA.  Diluted  serum  from  a 
patient with SLE was run on every plate as a positive control. The negative control 
in each case was supernatant from COS-7 cells to which no plasmid DNA had been 
added during electroporation and contained no IgG and no anti-nuclesome or anti- 
dsDNA activity.
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Figure 3.8 Results of anti-a -actinin ELISA
The graph shows binding of IgG in COS-7 cell supernatants containing each H/L chain combination to a-actinin (20^g/ml).S'
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Figure 3.9 Results of anti-cardiolipin ELISA
The graph shows binding of IgG in COS-7 cell supernatants containing each H/L chain combination to CL 
(5(Vg/ml).
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3.3  The  importance  of sequence  features of UK4VL   in  binding  to 
dsDNA
3.3.1  Results  of  site-directed  mutagenesis  for  production  of  UK4Vl 
variant
The amino acid  sequence of UK4Vl,  UK4(R94S)VL/ and the corresponding germline 
gene, 2a2 are displayed in Figure 3.4B (highlighted in red is the mutated arginine). 
To study the contribution of arginine at position 94 in CDR3 of UK4VL  in  binding to 
dsDNA,  a  variant  of  UK4VL  was  made  by  site-directed  mutagenesis and  germline 
reversion of the arginine at position 94 (R94) to a serine (S).
Plasmid DNA of the appropriate size was confirmed,  post transformation, by a Hind 
III/Bam  HI digest  (Figure  3.10).  This  plasmid  DNA was then  sent for sequencing 
analysis (MWG-Biotech) and the mutation was confirmed. The sequencing  plots are 
represented in Figure 3.11.
3.3.2 Transient expression of whole lgG1 molecules in COS-7 cells
The following L chains were expressed in combination with the B3 H chain in COS-7 
cells;  UK4Vl  and  UK4(R94S)VL . Three expression  experiments were carried out for 
the  two  combinations  and  a  negative  control  sample  of  COS-7  cells  that  were 
electroporated  without  plasmid  DNA  and  contained  no  detectable  IgGl  in  their 
supernatant. The whole IgG yields for each Vh/Vl combination were similar between 
each  of the expression  experiments.  The  mean  yields obtained  were  75ng/ml for 
B3Vh/UK4Vl and llOng/ml for B3Vh/UK4(R94S)Vl.
3.3.3 Results of anti-dsDNA binding of expressed whole IgG molecules
The dsDNA binding ability of each of the combinations were tested by ELISA and are 
shown  in  Figure  3.12.  Each  expression  experiment  (i.e.  electroporation  and 
subsequent human IgG, and anti-dsDNA ELISAs) was carried out three times and  in 
each  case,  similar results were seen  in  each.  Figure 3.12  shows the DNA binding 
results  of a  single,  representative  experiment.  As  shown  previously,  B3Vh/UK4Vl 
showed  no  binding  to  dsDNA.  In  addition,  the  combination  containing  the 
UK4(R94S)Vl CDR3 did not bind to dsDNA.
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lOOOObp
3000bp 
2000bp— £> 
1500bp— £>
lOOObp— -£> 
500bp— >
Lanes
1  =  lkb DNA ladder
2  = Hind III/BamH I  digested UKW pLNlO
3 - 4 = Hind III/BamH I  digested UK4(R94S)Vl/pLN10
Figure  3.10  Hind IH/BamH I restriction  digest of pLN10 vector containing  UK4VL  
and UK4(R94S)Vl variant construct on 1% agarose gel
UK4Vl/pLN10  and  UK4(R94S)Vl/pLN10 were digested  with  Hind III and BamH 1 
and  the  fragments  separated  on  a  1%  agarose  gel.  The  actual  agarose  gel  is 
shown  above,  indicating  the  expected  band  sizes.  It can  be seen  from  the gel 
that DNA bands of 7091 and 355 bp are present in each.
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TCA TAT ACA AAC AGG GTG TTT TTC GGC GGA  Wild type UK4VL  CDR3
i
Arginine
Serine  Mutant UK4(R94S)VL  CDR3
Figure 3.11 The sequence of UK4VL  variant was confirmed by automated sequencing
The  chromatograph  trace  represented  in  this  figure  shows  the  sequence  of 
UK4(R94S)Vl  CDR3.  The  mutation  introduced  in  the  sequence  is  indicated  by  an 
arrow pointing to the single amino acid alteration.
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B3VH/UK4VL
B3VH/UK4(R94S)VL
Total whole IgG concentration (ng/ml)
Figure 3.12 Effect of point mutation in UK4VL
The  graphs  show  binding  of  IgG  in  COS-7  cell  supernatants  containing  B3VH  
paired with  UK4VL  and  UK4VL   R94S to  dsDNA.  Diluted  serum from a  patient with 
SLE  was  run  on  every  plate  as  a  positive  control.  The  negative  control  in  each 
case was supernatant from COS-7 cells to which  no plasmid  DNA had  been added 
during electroporation and contained no IgG or anti-dsDNA activity.
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3.4  Stable expression of whole IgG molecules in CHOdhfr  cells
There are two main difficulties with the use of IgG in COS-7 cell supernatants. The 
first is that the total amount of IgG produced from transient expression is small so 
that it is not feasible to purify the IgG. The second is that the concentration of IgG in 
COS-7  supernatants from  cells transfected  with  different  H/L combinations  varies 
widely so that it is difficult to test all the combinations at the same concentration. 
Both  these  problems  can  be  overcome  by  creating  stably  transfected  CHO  cells, 
which secrete the H/L combinations of interest.
3.4.1  “Supervectors” expressing both VH  and Vl
The two supervectors (SV), SV-B3Vh/B3Vl and SV-B3Vh/B33Vl were originally made 
by Drs J. Haley and L.  Mason as described in section 2.1.14.3. The single expression 
vectors were combined to produce "supervectors".  From the plasmid vector pLNlO, 
an EcoRI fragment containing the promoter, the X C region gene and the X V region 
gene was transferred into the vector pGlDl/B3VH .  From the two supervectors SVBL 
and SVB33, I  produced four new variants by site-directed mutagenesis. Two of the 
variant supervectors had an arginine to serine mutation at position  53 in the B3  H 
chain and were paired with  B3 L chain (SV-B3(R53S)Vh/B3Vl) and B33  L chain  (SV- 
B3(R53S)Vh/B33Vl).  The  other two  variant  supervectors  both  had  the same  B3  L 
chain  but  a  different  H  chain,  one  with  an  arginine  to  asparagine  (SV- 
B3(R53N)Vh/B3Vl)  and  the  other  with  an  arginine to  lysine (SV-B3(R53K)Vh/B3Vl) 
mutation at position  53  in  B3  H chain.  SV-B3(R53S)Vh/B33Vl was included because 
previous experiments  had  shown that the chimeric  L chain  B33VL  (i.e.  B3VL  CDR1 
and  33H11Vl CDR2  and  CDR3)  confers  stronger anti-dsDNA and anti-nucleosome 
activity than the wild type L chain B3Vl, and we wanted to see if that effect would 
overcome the negative effect of the R53S change in the H chain.
Using an EcoRI restriction digest, plasmid DNA of the appropriate size was confirmed 
by the presence of a 6917bp band and a 2260bp band when run on an agarose gel. 
The incorporation of the mutation in the H chain of the supervectors was verified by 
sequencing analysis (MWG-Biotech).
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3.4.2  Transfection  of  CHOdhfr"  cells  with  supervectors  and 
methotrexate amplification of the transfected CHO cell lines
CHOdhfr  cells  were transfected  with  the four  supervectors  by electroporation.  In 
addition,  two aliquots of CHOdhfr cells were also electroporated  (under the same 
conditions as the expression vectors), one with an empty pGlD210 expression vector 
(i.e.  contains no H  or L chain V region  DNA sequences) and one without any DNA. 
Following  10-14  days  of  culture  in  growth  medium  lacking  ribo  and 
deoxyribonucleosides, all the cells in the "no DNA" negative control dish were dead 
and foci of cells were clearly visible in the dishes containing cells transfected with the 
four supervectors and the empty  pGlD210 expression vector.  The amount of IgG 
produced was measured from which the IgG production rate was determined for a 
number of clones of each supervector. The production rates of the highest producers 
are shown in Table 3.3. The two controls produced no detectable IgGl.
Supervector IgG production rate
(ng/106 cells/day)
SV-B3(R53S)Vh/B3Vl 413
SV-B3(R53S)h/B33Vl 52
SV- B3(R53N)Vh/B3Vl 670
SV- B3(R53K)Vh/B3Vl 670
Table 3.3 Human IgG production rates of CHO cells transfected with the supervectors
Different amounts of IgG were obtained from each cell line after one round of MTX 
amplification.  However,  MTX amplification did  not increase the yield  of IgG  in the 
case of these four stable cell  lines. The variable expression from CHO cells is well 
documented  in both our hands and others (Kim et al.,  1998, Rahman et al., 2002). 
This phenomenon occurs during sub-cloning in successive amplification steps;  when 
cells  can  increase  the  copy  number  of  the  dhfr  gene  without  increasing  their 
production  rate. Thus, cells that do not produce an exogenous protein will  usually 
have a higher growth rate and take over the culture thereby reducing the chance of 
selecting a high producer cell.
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3.5  Discussion
The results described  In  this chapter show that whole human  IgGl  molecules that 
bind  dsDNA,  nucleosomes  alpha-actinin  and  CL  can  be  produced  through  the 
transient expression of cloned autoantibody DNA sequences in eukaryotic cells. The 
total yield of IgGl varied between 3ng/ml to 950ng/ml depending on the H/L chain 
combination. Zack et al. (1995) have reported low yields of expressed IgGl, through 
the use of a  similar expression system  in COS-7 cells.  Kettleborough et al.,  (1991) 
have  previously  used  this  expression  system  to  humanise a  mouse  mAb  by  CDR 
exchange and have seen that the yield of IgG varied between different constructs.
B3Vh/B3Vl (wild type) bound dsDNA,  nucleosomes and CL, which is consistent with 
the previously reported properties of this mAb, (Ehrenstein et al.,  1995, Giles et al., 
2003, Mason et al., 2005) as well as the computer model of the interaction between 
a dsDNA helix and  B3,  shown  in  Figure  1.5 (Kalsi et al.,  1996).  Although VH  CDR3 
plays a major role in antigen binding of a number of other murine and human anti- 
dsDNA antibodies described in the past (Radic and Weigert,  1994,  Li et al., 2000), I 
believe it is  unlikely to play a major role in the interaction of B3 with antigen. The 
computer model of the B3/dsDNA complex shows no major sites of contact between 
dsDNA  and  VH   CDR3  and  this  CDR3  sequence  is  short  and  contains  no  arginine, 
asparagine  or  lysine  residues  (sequence  shown  in  Figure  3.4)  The  results  of the 
ELISA tests correlated with the predictions of the computer model in  showing that 
the ability of B3 to  bind dsDNA is dependent upon the arginine residues present at 
critical positions (position 53 in B3VH  and positions 27a and  54 in B3VL ) that enable 
the antibody to form a specific electrostatic interaction with the phosphate backbone 
of  dsDNA.  This  interaction  is  completely  lost  by  mutation  to  serine  (R53S), 
asparagine (R53N) or lysine (R53K), thus leading to a loss in DNA binding ability by 
the variant H chain when compared to the wild type. In contrast, in B3 L chain, this 
interaction is critically reduced but not lost by mutation to serine (R27aS), therefore 
leading  to  a  reduction  in  DNA  binding  ability.  The  precise  location  of  arginine 
residues has been shown to be important in the binding of both murine and human 
anti-dsDNA  antibodies  to  DNA  (Radic  et  al.,  1993,  Radic  and  Weigert,  1994). 
33H11Vl contains a serine at position 27a rather than an arginine, however, despite 
this fact it is able to bind DNA when in combination with B3 H chain. The computer 
model of the B3Vl/33H11Vl combination  predicts that the arginine at position 92 in 
the CDR3 is able to interact with the dsDNA backbone. Therefore it is possible that 
the presence of the arginine residue in CDR3 of 33H11VL could compensate for the
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absence  in  CDR1.  In  conclusion,  the  results  shown  here  suggest  that  in  a  2a2 
encoded L chain such as B3VL  and 33H11Vl, which has undergone extensive somatic 
mutation,  DNA-binding  ability  is  determined  by  the  pattern  of  these  somatic 
mutations. Also, the presence of the H chain of B3 plays a dominant role in  binding 
dsDNA,  nucleosomes and CL.  B3VH   binds nucleosomes and  DNA with  3 of the 4 L 
chains tested  (Figure  3.8).  Single  amino  acid  changes can  affect  DNA  binding  of 
these antibodies, especially where these changes involve arginine residues that have 
been predicted by the computer models to directly interact with the dsDNA helix. The 
arginine residues critical to  DNA binding are those in  B3VH  CDR2,  B3VL  CDR1  and 
33H11VlCDR3 which may have an additive effect in enhancing binding to DNA whilst 
an arginine in UK4VL  CDR3 blocks DNA binding (computer models shown in  Figures 
1.5,  1.6 and  1.7)  (Haley et al.,  2004).  Replacement of this arginine residue with 
serine  did  not  introduce  DNA  binding  suggesting  that  the  arginine  is  not  solely 
responsible for blocking DNA binding.
To  identify  the  features  of  B3VH   that  are  responsible  for  conferring  DNA  and 
nucleosome  binding  ability,  I  focused  on  the germline VH 3-23.  The  position  53  is 
occupied  by  serine  so  I  produced  the  opposite  effect,  which  was  addition  of an 
arginine to investigate if this amino acid will re-introduce binding to nucleosomes and 
DNA.  However,  there  was  no  binding  observed  with  the  variant form  of VH 3-23 
(Figure 3.7). Thus introducing the S53R mutation alone into this germline gene is not 
sufficient to  engender  binding  to  these  antigens.  This  finding  suggests  that the 
arginine  is  not  solely  responsible  for  binding  of  B3VH   to  nucleosomes  or  DNA. 
Therefore, other somatically mutated amino acids present in the sequence of B3VH  in 
combination with this arginine must also play a role in conferring the binding ability 
of this antibody.
UK4Vl is very similar to B3Vl, however there is a serine rather than a glycine present 
at position 29 in CDR1 and an asparagine at position 27a rather than an arginine. As 
predicted by the computer model of B3Vh/UK4Vl (Figure 1.7), the pattern of somatic 
mutations in UK4VL  prevents any binding to DNA, even when  paired with  B3  heavy 
chain.  From the computer model,  it was  hypothesized that the introduction of the 
arginine residue at position 94  in  addition to the changes at positions 27a and  29 
prevent DNA binding. This finding  is in agreement with  previous  studies that have 
also  shown that it  is not the mere presence of arginine residues  in the CDRs that 
confers  the  ability  to  bind  DNA  but  their  precise  positions  (Guth  et  al.,  2003,
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Stevenson et al.,  1993).  I had hypothesised that the blocking arginine at position 94 
prevents the binding to DNA in the case of B3Vh/UK4Vl combination. Mutation of this 
arginine to serine however, did not introduce binding to DNA. The reason for the lack 
of any DNA binding might involve other blocking amino acids in UK4Vl, and mutation 
of  multiple  residues  might  be  required  to  produce  an  effect.  Therefore,  this 
hypothesis needs to  be further investigated since the mutation  introduced alone is 
not sufficient to free the binding cleft.
Various groups have previously used computer models to produce three-dimensional 
images of anti-DNA antibodies (mainly murine)  interacting with DNA and to predict 
sites of contact  between  dsDNA and  certain  amino  acid  residues at the antigen- 
binding site (Radic and Weigert,  1994). They have followed a method similar to our 
group,  where  they  used  site-directed  mutagenesis  to  test  the  validity  of  these 
predictions.  In many cases the targets of mutagenesis have been arginine residues 
and as in our system the number of arginine residues did not always strictly correlate 
with the ability of the antibody to bind DNA (Radic et al.,  1993). For example, Radic 
et al (1993) examined the effects of amino acid substitutions on DNA binding where 
they  reverted  three  somatic  mutations  in  the  H  chain  of  a  murine  anti-dsDNA 
antibody 3H9.  Their results showed that arginine 53  eliminated virtually all  dsDNA 
binding and this agreed with my findings shown in this chapter. Mutation of a leucine 
in 3H9Vh CDR2 to an arginine (L64 to R64), completely eliminated binding to ssDNA 
and dsDNA. The authors suggested that this may be due to the formation of a salt 
bridge of R64 with a neighbouring aspartic acid (D65) producing an Ig conformation 
incompatible with  DNA binding  (Radic et al.,  1993).  Wellmann  et al.,  (2005)  used 
human  monoclonal  anti-DNA antibodies that were systematically subjected to site- 
directed  mutagenesis reverting  amino acid substitutions to the germline sequence, 
and tested  the  antibody  reactivity  against dsDNA.  They  have shown  that for  the 
human antibody 33.F12, arginines enhance antibody affinity for DNA. In the case of 
another antibody however, asparagine and lysine residues in the L chain of 33.C9 are 
involved in the contact to DNA.
Katz et al.,  (1994) used site-directed mutagenesis to change amino acid residues in 
the H chain of the pathogenic R4A anti-dsDNA antibody to look for alterations in DNA 
binding and pathogenicity. Their results showed that single amino acid substitutions 
in  both  CDRs  and  FW  regions  reduced  DNA  binding.  However,  in  contrast to  the 
results  of  Radic  and  colleagues  and  my  findings,  this  group  showed  that the  VH
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sequence  that  resulted  in  the  highest  ability  to  bind  DNA  contained  two  fewer 
arginine residues than  R4A,  highlighting the fact that charge interaction  is  not the 
sole determinant of  binding  to  DNA.  These two arginines  were  both  replaced  by 
serine  in  R4AVH   FR3,  suggesting  that  FW  regions  not only  perform  a  scaffolding 
function  but  also  affect  binding  specificity.  Furthermore,  Radic  et  al.,  (1994) 
predicted from a  computer model  of a  murine anti-dsDNA antibody that VH  FR3  is 
positioned so as to contribute contacts with the minor groove of the DNA.
Members of our group have used a  bacterial expression system to  produce Fab of 
three autoantibodies described  in this chapter (B3/33H11, anti-DNA;  UK4, aPL) and 
six related hybrids (Kumar et al., 2000, Kumar et al., 2001). The system described by 
Kumar et al., (2000)  involved the transformation of £  coli with  plasmid expression 
vectors containing the appropriate Vl-Cl and Vh-Ch DNA for each antibody.  Following 
culture of the bacteria,  Fab were harvested from the periplasm of the £   coli and 
then purified. SDS-PAGE and Western blot confirmed that the purified Fab was of the 
correct  size and  assembled  form.  Protein  expression  levels  of  5-9mg  per  litre  of 
culture were achieved.  The comparative DNA/CL-binding analysis of the nine Fabs 
demonstrated  that  B3  and  33H11  L  chains  possess  both  anti-DNA  and  anti-CL 
activities (Kumar et al., 2001). These results are consistent with the binding  results 
and computer generated models of these H and L chain combinations expressed  in 
eukaryotic systems, as presented previously by our group (Haley et al., 2004) and in 
this chapter.
The amount of whole IgG produced by transient expression in COS-7 cells described 
in  this  chapter  was  too  small  to  allow  purification  of  the  antibodies  or  for 
experiments  on  pathogenicity  to  be  carried  out.  It  was  therefore  necessary  to 
establish  a  stable  expression  system  for  production  of  recombinant  B3  and  its 
variants in CHO cells to allow for more extensive in vitro and in vivo characterisation 
of the binding of the human IgG. The results described in this chapter also show that 
I  have successfully developed a stable expression system to produce whole human 
recombinant anti-nucleosome  IgGl  molecules from  cloned  PCR  products encoding 
anti-nucleosome  antibody  sequences.  This  system  has  the  potential  to  produce 
significant amounts of antibody whose sequence-related functional properties can be 
studied both in in vitro and in vivo assays. The total yield of IgGl varied between 52 
and 413 ng per 106 cells per day depending on the H/L chain combination expressed. 
The yield of these antibodies, however, was not increased by further selection of the
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stable  cell  lines  in  selective  growth  media  containing  MTX.  The  process  of  MTX 
amplification  selects  the  clones  of  cells  with  a  higher  dhfr copy  number  and 
consequently a higher copy number of IgG cDNA flanking the dhfr gene.
A number of groups have previously described stable expression of murine anti-DNA 
antibodies from cloned cDNA (Katz et al.,  1994, Radic et al.,  1993, Pewzner-Jung et 
al.,  1996).  In  most  cases,  expression  was  achieved  using  HCLVs,  which  are 
hybridoma cells that have lost the ability to secrete H  chains.  By transfecting  such 
variants with  expression  vectors encoding various different H  chains,  Radic  et al., 
(1993),  Katz  et  al.,  (1994)  and  Pewzner-Jung  et  al.,  (1996)  were  all  able  to 
demonstrate that altering the numbers of arginines in CDRs of the H chains altered 
the ability of murine mAbs to bind DNA.  Of these groups, only Katz and colleagues 
went on to test the ability of the altered antibodies to cause pathogenic changes in 
mice. They produced antibodies based on the murine monoclonal anti-DNA antibody 
R4A. All these antibodies had the L chain of R4A, but the H chains were variants of 
the R4A VH  sequence. They found that the antibody with strongest binding to dsDNA 
did  not  have  more  CDR  arginines  than  wild-type  R4AVH .  This  antibody  actually 
showed  less glomerular binding but more tubular binding to mouse kidneys in vivo 
than the wild-type R4A.
Only  one  group  has  previously  reported  stable  expression  of whole  human  anti- 
dsDNA molecules (as opposed to Fab or single chain  Fv fragments) in vitro.  Li  and 
colleagues expressed the V region  sequences of the human IgA anti-DNA antibody 
412.67  in  F3B6 human/mouse heteromyeloma cells (Li et al.,  2000).  The products 
were whole IgG molecules, since the expression vectors contained  rather than a, C 
regions. This group showed that reversion of two arginines in 412.67 VH  CDR3 totally 
removed the ability to bind ssDNA or dsDNA. All somatic mutations outside VH  CDR3 
in either VH  or VL  of this antibody, however, could be reverted with no effect on DNA 
binding.  No data were presented regarding the effect of these sequence changes on 
pathogenicity,  and  it  is  not  known  whether the  original  IgA  antibody  412.67  is 
pathogenic in mice. The stable expression of antibody B3 described here, therefore, 
is only the second report of stable expression of a whole human anti-dsDNA antibody 
in vitro.
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CHAPTER FOUR 
Somatic mutations to arginine residues affect the 
binding of different human aPl derived heavy and light 
chains to cardlellpin, (>?-glycepretein I and 
phosphatidylserfne
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CHAPTER FOUR.
SOMATIC MUTATIONS TO ARGININE RESIDUES AFFECT THE 
BINDING  OF  DIFFERENT HUMAN aPL DERIVED  HEAVY AND 
LIGHT  CHAINS  TO  CARDIOLIPIN,  p2-GLYCOPROTEIN  I  AND 
PHOSPHATIDYLSERINE
4 .1 1ntroduction and aims of this chapter
Sequence analysis of human  monoclonal aPL has shown that IgG aPL often contain 
large numbers of somatic mutations in their H and L chain V region sequences (Giles 
et  al.,  2003b).  The  distribution  of  these  somatic  mutations  suggests  they  are 
antigen-driven  (Shlomchik et  al.,  1987).  Arginine,  asparagine  and  lysine  residues 
tend to accumulate in the CDRs of these monoclonal aPL and arginine residues have 
been shown to play an  important role in the CDRs of some murine monoclonal aPL 
(Cocca et al., 2001, Kita et al., 1993).
Our group has  previously described  a  system for  in  vitro expression  of whole IgG 
molecules from cloned VH  and VL  sequences of human monoclonal aPL (Giles et al., 
2003a). This system  was  used  to test the  binding  properties  of different  H  and  L 
chain combinations derived from a  range of antibodies. One of these is the human 
monoclonal IgG antibody IS4, which was derived from a patient with PAPS and binds 
to anionic (but  not neutral)  PL in the presence of the cofactor p2 GPI. This human 
mAb  is  pathogenic  in  a  murine  model,  therefore  it  is  likely to  be  relevant  in  the 
pathogenesis  of  APS  (Pierangeli  et  al.,  2000).  Our  group  has  shown  that  the 
sequence of IS4VH  was dominant  in  conferring the ability to  bind CL whilst the VL  
that was paired with was important in determining the strength of CL binding (Giles 
et al., 2003a).
Modelling  studies  have  shown  that multiple surface-exposed arginine  residues are 
prominent features of the H chain of IS4 that conferred the highest ability to bind CL 
in earlier experiments (Giles et al., 2003a). The hypothesis is that in the arginine rich 
CDR3 of IS4Vh, four out of five arginine residues [at positions 96, 97, 100,  lOOg (Wu
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and Kabat, 1970)] are surface exposed and therefore potentially important in binding 
to  CL. Therefore,  the aim  of  my  experiments as described  in this chapter was to 
define the contribution of individual arginine residues within CDR3, in binding to CL, 
p2 GPI  and  PS.  To  investigate this,  patterns  of CDR3  arginine  residues  in  the  VH  
sequence were altered  by  site-directed  mutagenesis.  The altered  sequences were 
expressed transiently in COS-7 cells and stably in CHOdhfr  cells. The binding of the 
different H and L combinations expressed was then assessed by direct ELISAs.
4.2 The importance of sequence features of IS4VH in binding to CL
4.2.1 Sequences of heavy chains and light chains expressed
The VL  sequences  of IS4VL  and  B3VL  are  both  encoded  by  the  same germline Vx 
gene,  2a2,  but  differ  in  their  patterns  of  somatic  mutation.  The  amino  acid 
sequences are displayed  in  Figure 4.1A. As described  in the previous chapter, B3VL  
contains  two  adjacent  arginine  residues  in  CDR1,  both  produced  by  somatic 
mutations. In CDR3 of IS4VL  a serine residue is replaced  by asparagine. The amino 
acid  sequences of IS4VH  and the corresponding germline gene are shown in  Figure 
4. IB.  IS4Vh  contains an  asparagine  residue  in  CDR2 that was  created  by  somatic 
mutation and multiple arginine residues in CDR3. The four surface exposed arginine 
residues that were altered by site-directed mutagenesis are shown in bold.
4.2.2  Results of site-directed mutagenesis
Six mutant forms of IS4VH  were generated in which particular arginine residues were 
mutated to serine. Serine was chosen  because it is a non-polar amino acid residue. 
Germline reversion could  not be performed, as our group could not align IS4 DH  to 
the germline Dh gene using DNAplot, which has strict alignment criteria described in 
Corbett et al.,  (1997).  Four  mutants,  named  IS4VH i,  IS4VH ii,  IS4VH iii  and  IS4VH iv 
contained  single  mutations of arginine residues at positions 96,  97,  100 and  lOOg 
respectively. The remaining  mutants contained two arginine to serine mutations at 
positions 96 and 97 (IS4VH i&ii) and at all four positions in IS4VhX.  Figure 4.2 shows 
the sites of site-directed mutagenesis in the VH  CDR3 of the wild type IS4VH  and its 
six variants  IS4VH i,  IS4VH ii,  IS4VH iii,  IS4VH iv,  IS4VH i&ii  and  IS4VhX.  The  mutations 
were confirmed by sequencing analysis.
2011-03
IS4
(A)Vl
FRl  CDR1  FR2  CDR2  FR3  CDR3  Jx
1  20  24 27  34  35  40  50  60  70  80  89  100
|   I   I   l a b c   I I I   I   I   I   |   |   |
2a2  QSALTQPASVSG.SP6QSITISC TGTSSDVGGYNYVS WYQQHPGKAPKLMIY EVSNRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC SSYTSSST WFGGGTKLTVLG
IS4    .---------     A -I-S— S----- HL------- 1—   D— S----------------F----------P__________c  TIN- W___________
B3    •-------------  **----p— -----------------  H-------T---A----S-------------------- --S-TTR-------------
(B)Vh
FRl  CDR1  FR2  CDR2  FR3  CDR3  JH   r s i
30 31  36  40  50  60  70  82  90  100  101  °
I  I  I  I   I   I  I  labc  I  I  I
QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYAMH WVRQAPGQRLEWMG WINSGNGNTKYSQKFQG RVTITRDTSASTAYMELSSLRSEDTAVYYCAR  YFDYWGQGTLVTVSS
  F---------------------F— S----FL---------- GP------------------ N------S--------W -------G----------- GRRDVRGVLWRGRHD  F--------1---
Figure 4.1 Sequence alignment of expressed VL  and VH  regions
(A) Sequences of expressed VL  regions compared tx> 2a2. (B) Sequence of expressed VH  region compared to 1-03. The amino acids altered 
by site-directed  mutagenesis are shown  in  bold. The amino acids  are  numbered  according to  Kabat  (Wu  and  Kabat,  1970).  A dash 
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96  97  98  99  100  a  b e d   e  f  g
Wild type IS4VH  CDR3  AGA GGA CGT CGA GAC GTT CGG GGA GTT CTT TGG AGG GGC AGA CAT GAC
m   a
Arginine  Arginine  Arginine
Mutant IS4VH i CDR3  AGA GGA AGT CGA GAC GTT CGG GGA GTT CTT TGG AGG GGC AGA CAT GAC
.i Serine
Mutant IS4VH ii CDR3  AGA GGA CGT AGT GAC GTT CGG GGA GTT CTT TGG AGG GGC AGA CAT GAC
A Serine
Mutant IS4VH iii CDR3  AGA GGA AGT CGA GAC GTT AGf GGA GTT CTT TGG AGG GGC AGA CAT GAC
Se^ie
Mutant IS4VH iv CDR3  AGA GGA CGT AGT GAC GTT CGG GGA GTT CTT TGG AGG GGC AGT CAT GAC
Sertfe
Mutant IS4VH i&ii CDR3  AGA GGA AGT AGT GAC GTT CGG GGA GTT CTT TGG AGG GGC AGA CAT GAC
y
Serine
Mutant IS4Vhx CDR3  AGA GGA AGT AGT GAC GTT AGT GGA GTT CTT TGG AGG GGC ACT CAT GAC
4   . & rine  Serine  Serine
Figure 4.2 Production of IS4VH  variants
This figure illustrates the results of the site-directed  mutagenesis of IS4VH   producing  6 
new  variant  constructs.  The  amino  acids  mutated  in  the  wild-type  sequence  are 
highlighted in yellow.
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4.2.3 Transient expression of whole IgG in COS-7 cells
A total  of  14 H/L chain  combinations were expressed  in  COS-7 cells.  At least two 
expression  experiments  were  carried  out  for  each  combination.  Each  of the  six 
mutant forms of IS4VH   was  paired  with  IS4VL  and  B3VL.  IgG  was  obtained  in the 
supernatant for all the combinations and the range of concentrations in COS-7 cell 
supernatants from each of the 14 H/L chain combinations is illustrated in Table 4.1. 
In  each  experiment,  the  negative  control  sample  in  which  COS-7  cells  were 
electroporated without any plasmid DNA contained no detectable IgG.
4.2.4  Results of anti-cardiolipin  ELISA and the  importance of arginine 
residues in IS4Vh
For each  H/L  chain  combination  that  bound  CL,  the  linear portion  of the  binding 
curve for absorbance against antibody concentration was determined empirically by 
dilution  of the COS-7  supernatant over a  wide  range of concentrations.  For each 
combination,  similar  patterns  of  binding  were  observed  from  repeated  expression 
experiments,  hence  representative  results from  a  single  experiment are  shown  in 
Figure 4.3.  A  H/L chain  combination  was  not considered to  bind  CL  if its  binding 
curve gave an absorbance at 405nm, less than 0.1 in the anti-CL ELISA.
Very weak binding was seen with  native IS4 (IS4Vh/IS4Vl) and this binding was lost 
when variant forms of IS4VH  were paired with  IS4VL.  Pairing  with  B3VL  however is 
more informative. IS4Vh/B3Vl displayed high binding to CL, which was altered by the 
replacement of some or all of the four surface-exposed arginines in IS4VH  CDR3 to 
serine.  Substitution  of all  four arginine with  serine residues  (IS4Vhx) abolished  CL 
binding  completely.  This effect seems  likely to  be due entirely to the changes at 
positions 100 and  lOOg since the H chain combinations containing arginine to serine 
at these positions (IS4VH iii and IS4VH iv) showed approximately 50% weaker binding 
to  CL  in  combination  with  B3VL   than  the  wild-type  IS4Vh/B3Vl combination.  In 
contrast, the H chains containing arginine to serine mutations at position 96 (IS4VH i), 
position 97 (IS4VH ii) or both (IS4VH i&ii) dispayed no reduction in CL binding.
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Heavy Chain Light Chain IgG concentration (ng/ml)
IS4 B3 5-14
IS4VH i B3 24-54
IS4VH ii B3 30-34
IS4VH iii B3 30-34
IS4VH iv B3 28-30
IS4VhX B3 32-34
IS4VH i&ii B3 32-47
IS4 IS4 24-368
IS4VH i IS4 50-56
IS4VH ii IS4 65-70
IS4VH iii IS4 48-90
IS4VH iv IS4 48-90
IS4VhX IS4 78-94
IS4VH i&ii IS4 74-80
Table  4.1  The  range  of  IgG  concentrations  in  ng/ml  produced  for each  heavy/light 
chain combination during the COS-7 transient expression experiments
The IS4Vh  mutants VH i,  VH ii,  VH iii  and VH iv contain  single arginine to serine point
mutations at  positions  96,  97,  100  and  lOOg  respectively;  whilst VH i&ii contains
arginine to serine mutations at positions 96 and 97; and VH x has arginine to serine
mutations at all four positions.
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Figure 4.3 Effect of arginine to serine point mutations in IS4VH  CDR3
CL binding of IgG in COS-7 cell supernatants containing wild type or mutant forms of IS4 H chain  with wild type IS4 or B3 L chains. 
The IS4Vh  mutants VH i, VH ii, VHiii and  VHiv contain  single Arg to Ser point mutations at positions 96,  97,  100 and  lOOg  respectively; 
whilst VH i&ii contains Arg to Ser mutations at positions 96 and 97; and VH x has Arg to Ser mutations at all four positions.Chapter Four Somatic mutations to Arg residues affect aPL derived H and L chains to CL, jnGPI, PS
4.3  Stable expression of whole IgG molecules in CHOdhfr  cells
4.3.1  Transfection  of  CHOdhfr  cells  with  supervectors  and 
methotrexate amplification of the transfected CHO cell lines to increase 
the yield of IgG
CHOdhfr  cells were transfected with the thirteen supervectors by electroporation as 
described in section 2.8. The three supervectors SV-IS4Vh/B3VL/ SV-IS4Vh/IS4Vl and 
SV-IS4Vh/UK4Vl were made by Dr I. Giles. I produced the remaining 10 supervectors 
by  introducing  mutations  in  these  three  supervectors,  using  site-directed 
mutagenesis. Two control lines underwent the same procedures and stresses as the 
supervector cell lines but they did not secrete IgG. This was achieved by transfecting 
the CHOdhfr  cells with an  expression vector that contained a functional  dhfr gene 
but no cloned VH  cDNA or Vx cDNA (the "empty vector").  Consequently, these cells 
were not able to express whole IgG. This control cell line was treated (i.e.  selected 
and  amplified  with  MTX)  exactly  as  the  IgG  producing  cell  lines.  Another 
electroporation was carried out on CHO  dhfr  cells,  without the addition  of DNA as 
another control. After 24 hours the cells were plated out in selective CHOdhfr growth 
medium as described in section 2.8.  Following  10-14 days of culture, all the cells in 
the "no DNA" negative control dishes were dead and foci of cells were clearly visible 
in the dishes containing cells transfected with the supervectors.
From the twenty-four foci picked from each electroporation stable cell line and tested 
for human IgG production (as described  in section 2.8), six clones with the highest 
IgG  production  were  selected  for  further  expansion.  Of  these  six,  the  highest 
producer was selected for further expansion and  MTX amplification. Thirteen stable 
cell lines were produced from a single round of selection in growth medium B lacking 
ribo  and  deoxyribonucleosides  (see  section  2.1.13).  The  human  IgG  production / 
1x10s cells / day of each  clone, shown in Table 4.2, was measured as described in 
section 2.8.5.
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Supervector IgG production rate 
(ng/106 cells/day)
SV-IS4Vh/IS4Vl 700
SV-IS4VH i&ii/IS4VL 1056
SV-IS4VH iii/IS4VL 5152
SV-IS4VH iv/IS4VL 3145
SV-IS4VH iii&iv/IS4VL 4103
SV-IS4VhX/IS4Vl 1458
SV-IS4Vh/B3Vl 1 0 0
SV-IS4VH i&ii/B3VL 293
SV-IS4VH iii&iv/B3VL 2242
SV-IS4VhX/B3Vl 4333
SV-IS4Vh/UK4Vl 1 0 0
SV-IS4VH i,iii&iv/B3VL 4103
SV-IS4VH ii,iii8uv/B3VL 293
Table 4.2 Human IgG production rates of CHO cells transfected with the supervectors
The IS4Vh  mutants VH i,  VH ii,  VH iii  and  VH iv contain  single arginine to serine point 
mutations at  positions  96,  97,  100 and  lOOg  respectively;  whilst VH i&ii  contains 
arginine to serine mutations at positions 96 and 97; and VhX has arginine to serine 
mutations at all four positions.
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4.3.2 Binding of IgG produced by CHO cells to CL
The supernatants from  CHO  cell  cultures  producing  each  of the human  aPL were 
tested for binding to CL by ELISA.  Figure 4.4 shows the results of a representative 
experiment (carried out three times). The negative controls used in the ELISAs were 
CHO  dhfr  media  and  also  supernatant from the CHO  (empty pGlD210 vector) cell 
lines.  Neither contained  IgG  nor anti-CL activity on testing  by  ELISA.  The positive 
control in each case was serum from a patient with APS, containing anti-CL IgG. The 
same  positive  control  was  used  for all  the  PL  ELISAs and  the SD of the  positive 
control between the OD readings of the three experiments was always less than 0.1.
The IgG produced by the cell lines containing native IS4VH  (SV-IS4Vh/B3Vl and SV- 
IS4Vh/IS4Vl) were shown to bind CL with SV-IS4Vh/B3Vl being the strongest binder. 
With the higher concentration of IgG obtained from the stable cell  lines, there was 
binding to CL,  which  was  not evident with  my previous experiments with the IgG 
amounts obtained from the COS-7 expression system. From the results of the COS-7 
expression  system,  IS4Vh/IS4Vl  appeared  to  be  a  weak  binder  whereas  SV- 
IS4Vh/IS4Vl  binds  well  to CL.  Mutation  of the arginines at  positions 96 and 97 to 
serine in IS4VH , only has a slight effect on the binding of CL when paired with B3VL  
(SV-IS4VH i&ii/B3VL )  and  when  paired  with  IS4VL   the  binding  to  CL  is  abolished. 
Mutations at positions  100 and  lOOg  have a greater influence on the binding to CL 
with  binding significantly reduced when  paired with  B3VL  and completely lost when 
paired with IS4VL.  Mutation of three arginines in IS4VH  (96,  100 and  lOOg / 97,  100 
and lOOg) reduces the binding even further. I observed weak binding to CL with SV- 
IS4VH iv/IS4VL, which I was unable to show in the COS-7 transient expression system.
4.3.3 Binding of igG produced by CHO cells to fcGPI and PS
The anti-0 2GPI  and  anti-PS  binding  activity  of  the  IgG  expressed  by  the  stably 
transfected CHO  dhfr  cells  is shown  in  Figure 4.5 and  4.6  respectively,  which  are 
representative results of three experiments. The positive and negative controls used 
were the same as those used in the CL ELISA. A combination was not considered to 
bind p2 GPI  if its binding curve gave an absorbance of less than 0.1 (at 405nm) for 
the concentration tested in the anti-frGPI ELISA. The strongest binder to both faGPI 
is  SV-IS4Vh/B3Vl.  Another  four  combinations  show  weak  binding  to  p2GPI.  I 
successfully demonstrated weak binding of SV-IS4Vh/IS4Vl to p2GPI, something that 
I  had  been  unable to show with the concentrations of antibody obtained previously
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from the COS-7 expression system. This combination was described as a weak binder 
to p2 GPI  by the original authors (Zhu et al.,  1999). The combination containing the 
mutation at position  lOOg  and  IS4VL  (i.e.  SV-IS4VH iv/IS4VL )  also  bound  p2 GPI  and 
the  binding  was  slightly  stronger  than  the  wild-type  SV-IS4Vh/IS4Vl.  Two  other 
combinations gave similar weak binding to p2 GPI in combination with IS4Vl, one has 
the mutation at position  100 and the other has the mutation at positions 96 and 97 
in  IS4Vh. Any mutation  in  IS4VH   in  combination with  B3VL  abolishes the binding to 
p2GPI.
The results obtained from the anti-PS ELISA are much clearer (Figure 4.6). Only two 
combinations bind PS. SV-IS4Vh/B3Vl is a strong binder and mutation of arginines at 
positions 96 and  97  shows a  marked  reduction  in the binding to  PS.  None of the 
other combinations bind PS at the concentrations tested.
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Figure 4.4 Results of aCL ELISA
CL  binding  of  IgG  in  CHO cell  supernatants containing  supervectors with  wild  type or  mutant forms of IS4  H  chain 
with wild type IS4, B3 and UK4 L chains.C M
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Figure 4.5 Results of anti-feGPI ELISA
p2 GPI  binding of IgG  in CHO cell  supernatants containing  supervectors with  wild type or mutant forms of IS4 H chain  with 
wild type IS4, B3 and UK4 L chains.
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Figure 4.6 Results of anti-PS ELISA
PS  binding of IgG  in CHO cell  supernatants containing  supervectors with wild type or mutant forms of IS4 H chain with wild 
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4.4  Discussion
Computer  models and  previous experiments  performed  by our group  have shown 
that  IS4Vh  contains  multiple  non-germline  encoded  surface  exposed  arginine 
residues, which may be important in creating a CL binding site (Giles et al., 2003a). 
The results described in this chapter support this hypothesis as well as showing that 
it is  not just the  presence  but also the precise location of arginine residues in the 
CDRs that is important in determining the ability to bind CL.
The experiments described report the use of an in vitro eukaryotic expression system 
to produce whole human IgG  aPL. The great advantage of this transient expression 
system  is that  it allows  rapid testing  of large numbers of H/L chain  combinations. 
One  of  the  light  chains  that  I  expressed  was  derived  from  aPL  (IS4VL )  whereas 
others were derived from an anti-DNA antibody (B3VL ).  The links between aPL and 
anti-DNA antibodies  are a  source  of some  interest since they share a  number of 
sequence characteristics.  It has been shown that a murine anti-PC antibody can lose 
specificity for PL and become an anti-DNA antibody (Diamond and Scharff, 1984). By 
studying  the  properties  of  various  combinations  of  these  chains,  I  aimed  to 
distinguish sequence features important in binding to PL.
Site-directed mutagenesis of specific arginine residues at sites of antigen contact, in 
IS4VH  CDR3, was performed to assess the contribution of individual arginines to CL 
binding. The  low  binding  of IS4Vh/IS4Vl was abolished  by  inclusion of any one of 
these mutations.  This  phenomenon of loss of binding was not observed,  however, 
when these IS4VH  mutants are paired with B3VL . In this case the arginine residues at 
positions  100  and  lOOg  confer  a  greater  effect  on  CL  binding  compared  to  the 
arginine  residues  at positions  96  and  97.  Substitution  of all  of these IS4VH   CDR3 
arginine  residues was  sufficient to abolish completely all  binding to CL.  It may be 
concluded  that  the  effect  of  these  arginine  residues  on  binding  to  CL  is  highly 
dependent  on  the  positions  that  they  occupy  in  the  sequence.  Krishnan  and 
colleagues (Krishnan et al., 1996, Krishnan and Marion, 1998) demonstrated a strong 
correlation between the position of arginine residues in VH  CDR3 and the specificity 
for dsDNA. They reported that the frequency of arginine expression among murine 
anti-dsDNA  antibodies  was  highest  at  position  100  which  suggests  that  the 
importance of this residue in binding to dsDNA lies in its position at the centre of the 
Vh CDR3 loop in the structure of the antigen combining site (Krishnan et al., 1996).
214Chapter Four Somatic mutations to Arg residues affect aPL derived H and L chains to CL, feGPI, PS
In the previous chapter,  I have shown the importance of an  arginine residue at a 
specific position in the VH  of an anti-DNA antibody, B3. Many other groups have also 
expressed antibodies in  vitro,  altering  the VH   or  VL  sequence  by  mutagenesis and 
shown that altering the numbers of arginine residues in the CDRs of these antibodies 
can  lead to significant changes in  binding to DNA.  Several groups have shown that 
arginines in VhCDR3 often play a particularly important role in binding to DNA (Li et 
al.,  2000,  Radic et al.,  1991,  Mockridge et al.,  1996).  In the case of aPL, different 
groups have reported  important contributions from the H and the L chain. Cocca et 
al., (2001) studied a murine antibody, 3H9 that has dual specificity for PLs and DNA 
and showed that reversion of an arginine in the H chain V region reduced binding to 
these  antigens.  In  another  study  also  by  the  same  group  (Cocca  et  al.,  2002), 
arginine residues were introduced into the VH  region at positions known to mediate 
DNA  binding  and  they  observed  enhanced  binding to  PS-fcGPI  complexes and  to 
apoptotic cell debris.
The amount of whole IgG  produced by transient expression  in COS-7 cells was too 
small to allow purification or for experiments on pathogenicity to be carried out.  It 
was therefore  necessary to establish  a  stable expression  system for production  of 
recombinant IS4 and its variants in CHO cells to allow for more extensive in vitro and 
in  vivo characterisation  of  the  binding  of  the  human  IgG.  In  this  chapter  I  also 
describe the successful development of a stable expression system to produce whole 
human  recombinant  aPL  IgG  molecules  from  cloned  PCR  products  encoding  aPL 
sequences. Furthermore, the stable cells lines were amplified using MTX.
The  total  yield  of  IgGl  varied  between  6   and  5152  ng  per  106  cells  per  day 
depending on the H and L chain expressed. With the larger amounts of IgG produced 
using  MTX  amplification,  binding  to  CL  as  well  as  frGPI  and  PS  was  clearly 
demonstrated. The results demonstrating weak binding to foGPI in the absence of CL 
shown in Figure 4.5 confirm the observation of the original authors (Zhu et al., 1999) 
who found that IS4 secreted by hybridoma cells bound better to CL than to fcGPI.
My results show that there are different patterns of binding to different antigens. It is 
possible that the effects of the CDR3 arginine residues on binding to anionic PL are 
due to charge interactions between different antigens and different antibodies. It is 
also likely that the conformation of the cofactor, p2GPI, exposes different epitopes to 
different PL. The binding of human monoclonal aPL IS4 to p2 GPI is further evidence
215Chapter Four Somatic mutations to Arg residues affect aPL derived H and L chains to CL, fcGPI, PS
that  studying  this  antibody  is  relevant  to  increasing  our  understanding  of  the 
pathogenesis  of APS  given  that  p2 GPI  is  recognised  as  an  important  cofactor for 
pathogenic aPL.  This  aPL  is  likely to  be typical  of pathogenic aPL found  in  other 
patients with APS.  Pewzner-Jung et al., (1996) is the only group that have described 
a  stable expression  system to produce a  murine monoclonal anti-phosphorylcholine 
antibody (6 G 6 ) as whole IgM  molecules. The stable expression of IS4 and variants 
that I  have described in this thesis is the first report of stable in vitro expression of 
whole human IgG aPL.
In summary, I have demonstrated the relative importance of certain surface exposed 
arginine  residues at critical  positions within the  heavy chain  CDR3 of aPL (IS4)  in 
conferring the ability to  bind CL  in  a direct ELISA.  After expression  of the altered 
antibodies  in  larger  quantities  obtained  from  stably  transfected  cells,  it  is  now 
important to test the effects of sequence changes involving these amino acids on 
pathogenic functions.  More accurate information about changes in affinity of variant 
forms of IS4 for CL or p2 GPI could be obtained by testing larger quantities of purified 
antibodies.
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CHAPTER FIVE 
Investigation of the relationship between antibody 
sequonco and binding properties of purified human 
monoclonal antibody B3 and its variants
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CHAPTER FIVE.
INVESTIGATION  OF  THE  RELATIONSHIP  BETWEEN 
ANTIBODY  SEQUENCE  AND  BINDING  PROPERTIES  OF 
PURIFIED  HUMAN  MONOCLONAL  ANTIBODY  B3  AND  ITS 
VARIANTS
5 .11ntroduction and aims of this chapter
When purified under rigorous conditions, Guth and colleagues have shown that some 
murine anti-dsDNA antibodies actually  bind chromatin  rather than dsDNA (Guth  et 
al.,  2003).  This  finding  suggests  that  they  may  actually  be  anti-nucleosome 
antibodies, which only appear to bind dsDNA when they are incompletely dissociated 
from nudeosomes.
In order to obtain large quantities of purified human IgG secreted from the CHO cell 
lines produced  and described  in  more detail  in Chapter Three, they were grown  in 
their selective amplification  medium  in a  large volume commercial culture system. 
The human  IgG was then  purified from the supernatant using a  protein A column 
and dialysed  into PBS. The product was then analysed for purity by SDS-PAGE and 
quantified by spectrophotometry. This large-scale culture and purification was carried 
out  by  Chemicon  Europe  Ltd,  Hampshire,  UK.  With the  large amounts of purified 
antibody  generated  using  this  method,  it  was  possible  to  obtain  more  accurate 
information regarding binding affinities to different clinically relevant antigens.
The aims of this chapter are to report the results of testing the purified antibodies to 
investigate whether the human mAb B3 is actually an anti-nucleosome antibody and 
also  to  investigate further the  properties  of the  mutations  introduced  into  B3,  in 
binding to nudeosomes, ssDNA, a-actinin, CL, p2GPI, Domain I of p2GPI, PS and PS- 
PT.
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5.2 Results of binding of purified human IgG molecules to clinically 
relevant antigens
5.2.1  Assembly of purified antibodies
Microgram quantities of recombinant human IgG were produced from  each of the 
CHO  cell  lines  'wild-type7  B3Vh/B3Vl,  B3VH /B3(R27aS)VL/  B3Vh/B33Vl  (B3Vh  co­
expressed  with  B3Vl  CDR1  and  33H11VL CDR2  and  CDR3),  B3Vh/BUVl  (B3Vh  co­
expressed  with  B3VL   CDR1  and  UK-4VL   CDR2  and  CDR3),  B3(R53S)Vh/B3Vl, 
B3(R53S)Vh/B33Vu  B3(R53N)Vh/B3Vu  B3(R53K)Vh/B3Vl.  The  human  IgG 
concentration  of each  antibody  was  verified  using  the  whole  human  IgG  ELISA, 
described in section 2.7.1.
5.2.1.1  Results of anti-dsDNA ELISA
Figure 5.1 shows binding of purified IgG from the four H/L combinations B3Vh/B3VL/ 
B3VH /B3(R27aS)VL/  B3Vh/B33Vl and  B3Vh/BUVl tso dsDNA under different conditions. 
Similar results were obtained in repeated ELISA assays. Figure 5.1A shows that when 
the samples are not treated with DNase after being simply diluted in SEC buffer, the 
combination B3Vh/B33Vl binds dsDNA but the other three do not. Figure 5. IB, shows 
the effect of DNase I treatment of the purified antibodies, diluted in SEC buffer, prior 
to testing  in  the dsDNA  ELISA.  None of these combinations binds dsDNA and the 
DNase I treatment appears to  have abolished the binding of the purified SVB33 to 
dsDNA. In order to investigate whether a 'cofactor7 was necessary for DNA binding, 
which  might  be  present  in  cell  culture  supernatant  but  which  may  have  been 
removed  by  purification,  the  purified  antibodies  were  also  tested  for  binding  to 
dsDNA after dilution in supernatant from COS-7 cells that had been electroporated in 
the absence of plasmid. The antibody/COS-7 supernatant solutions were pre-treated 
with  DNase  I,  prior  to  testing  in  the  dsDNA  ELISA.  The  addition  of  the  COS-7 
supernatant  allows  the  binding  of  the  three  combinations  -  B3Vh/B3Vl, 
B3VH /B3(R27aS)VL ,  B3Vh/B33Vl -  to  dsDNA  (Figure  5.1C),  despite treatment  with 
DNase.  The  strength  of  binding  increased  in  the  order  B3VH/B3(R27aS)VL   < 
B3Vh/B3Vl<  B3Vh/B33Vl.  The same order was seen  previously by expressing these 
combinations  transiently  in  COS-7  cells  (Haley  et  al.,  2004).  The  combination 
B3Vh/BUVl  does  not  bind  dsDNA  in  ELISA  under  any  conditions,  which  also 
corresponds to results obtained previously (Haley et al., 2004).
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Figure 5.1 Binding of purified human IgG molecules to dsDNA
For legend see over
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Figure 5.1  Binding of  purified human IgG molecules to dsDNA
The  purified  human  IgG  antibodies  were  tested  by  ELISA for  their  binding  to 
dsDNA. Diluted serum from a patient with SLE was run on every plate as a positive 
control.  The  standard  deviation  (S.D) of the standard  serum  OD value  between 
plates  was  +/-0.07.  ODs  in  the control  wells containing  no antigen  were always 
lower than  0.068.  In order to confirm the findings of the experiments, they were 
repeated on a separate occasion.
(A) The dsDNA binding of the purified antibodies when diluted in SEC buffer but not 
treated  with  DNase I.  The standard deviations were as follows:  SD  <  0.121  OD 
units for all points on the curve B3Vh/B33Vl and SD < 0.002 for all points on curves 
B3Vh/B3Vl, B3Vn/B3(R27aS)VL  and B3VH/BUVL.
(B) The dsDNA binding of the purified antibodies when diluted  in SEC buffer, and 
treated with DNase I  prior to testing in the ELISA. The SD for all points on all four 
curves was less than 0.002 OD units.
(C) The dsDNA  binding of the  purified  antibodies diluted  in  supernatant derived 
from  non-transfected COS-7 cells and treated with  DNase I prior to testing in the 
ELISA. The standard deviations were as follows:  SD < 0.176 OD units for all points 
on  the curve  B3Vh/B33Vl,  SD  <  0.185  for all  points  on  curve  B3Vh/B3Vl,  SD  < 
0.185 for all  points on  curve  B3VH/B3(R27aS)VL  and  SD  <  0.01  for ail  points on 
curve B3Vh/BUVl.
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5.2.1.2 Results of anti-nudeosome and anti-ssDNA ELISA
Figure  5.2  shows  binding  of the  eight  purified  antibodies to  nudeosomes,  in the 
absence of COS-7 cell  supernatant.  The combinations B3Vh/B3VL/  B3Vh/B33Vl, and 
B3VH /B3(R27aS)VL )  are  good  nucleosome  binders.  Strength  of  binding  to 
nudeosomes  was  similar  for  the  three  combinations.  There  is  a  tendency  to 
increased  strength  of  binding  in  the  order  B3VH/B3(R27aS)VL   <  B3Vh/B3Vl< 
B3Vh/B33Vl.  B3(R53S)Vh/B33Vl  is  a  weak  binder to  nudeosomes.  The  other four 
combinations B3(R53S)Vh/B3Vu B3(R53N)Vh/B3Vu B3(R53K)Vh/B3Vl, and  B3VH /BUVL  
do not bind nudeosomes. Thus mutation of R53 to either S, N or K abolishes binding 
of B3 to nudeosomes (when paired with B3VL ) even when the antibodies are purified 
and  tested  at  high  concentrations.  Similar patterns of binding  were obtained  with 
each antibody from repeated experiments hence representative results from a single 
experiment  are  shown  in  Figure  5.2.  I  also  tested  the  antibodies for  binding  to 
ssDNA.  There  was  no  binding  to  ssDNA  for any  of the eight  purified  antibodies 
despite good binding of the positive control in the anti-ssDNA ELISA.
5.2.1.3 Addition of nudeosomes allows the reinstatement of dsDNA binding of the 
purified antibodies
Since the  same three combinations which  bound dsDNA on the addition  of COS-7 
supernatant  (Figure  5.1C)  also  bound  nudeosomes  (Figure  5.2),  I  carried  out 
experiments  to  test  whether  addition  of  purified  nudeosomes  (rather than  cell 
supernatant) would  have the same effect on binding of these antibodies to dsDNA. 
Figure  5.3  shows that  binding  of  B3VH/B3(R27aS)VL  to  dsDNA  is  reconstituted  by 
adding purified nudeosomes at a concentration of 10pg dsDNA/ml. This effect was 
also seen for this H/L combination at a nucleosome concentration of 2.5^g dsDNA/ml 
(though the OD achieved was lower) but not at nucleosome concentrations of 1.5pg 
dsDNA/ml or 20pg dsDNA/ml.  I was unable to demonstrate reconstitution of binding 
of  purified  B3Vh/B3Vl,  B3Vh/B33Vl  or  B3Vh/BUVl to  dsDNA  at  any  of these  four 
concentrations of nudeosomes (1.5,2.5,10 or 20^g dsDNA/ml).
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Figure 5.3 Binding to dsDNA of purified antibodies containing nudeosomes
Binding  to  dsDNA of purified  DNase I  treated  antibodies diluted  in  SEC containing  nudeosomes  at a  concentration 
of 10pg dsDNA/ml.  At this concentration  of nudeosomes only B3VH /B3(R27aS)VL  binds to dsDNA.  The same results 
were obtained  when  the experiment was  repeated  at a concentration  of 2.5pg  dsDNA/ml  except that the  peak OD 
for the  B3VH/B3(R27aS)VL  curve was  lower (OD values was  0.2.  At  nucleosome concentrations of  1.5pg  dsDNA/ml 
or 20pg dsDNA/ml, none of these H/L combinations bound dsDNA.
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Binding to  dsDNA of purified  DNase I  treated  antibodies diluted  in  SEC containing  nudeosomes  at a  concentration 
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were obtained  when  the experiment was  repeated  at a  concentration  of 2.5pg  dsDNA/ml  except that the  peak OD 
for the  B3VH /B3(R27aS)VL  curve was  lower (OD values was  0.2.  At  nucleosome concentrations of  1.5pg  dsDNA/ml 
or 20^g dsDNA/ml, none of these H/L combinations bound dsDNA.
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5.2.1.4 Results of a-actmin ELISA
Figure  5.4 shows  binding of the eight purified  antibodies to a-actinin.  In complete 
contrast to  the  results  of the  anti-nucleosome  ELISA,  the  presence  of the  R53S 
mutation  enhances  binding  to  a-actinin.  The wild-type combination  B3Vh/B3Vl  did 
not bind a-actinin in this experiment.  However,  B3(R53S)Vh/B3Vl did  bind a-actinin. 
Both  B3Vh/B33Vl and  B3(R53S)Vh/B33Vl  bind  a-actinin  but the  latter  binds  more 
strongly,  again  showing that the  R53S  mutation  enhances  binding to this antigen. 
The B33 light chain appears to confer stronger binding to a-actinin than B3VL , just as 
was  previously  seen  for  binding  to  dsDNA  and  nucleosomes.  None  of the  other 
combinations  binds  a-actinin.  In  particular,  the  other  mutations  at  position  R53 
(R53N and R53K) did not enhance binding.
5.2.1.5 Results of binding to whole fcGPI and Domain I of fcGPI
Figure 5.5 shows binding of the eight purified antibodies to p2GPI.  Binding was only 
seen at concentrations  1 0  times higher than those which gave binding of the wild- 
type  B3Vh/B3Vl  to  nucleosomes.  As  with  a-actinin,  the  introduction  of the  R53S 
mutation enhances binding to p2GPI. Similarly, B3(R53S)Vh/B33Vl binds p2 GPI better 
than  B3Vh/B33Vl.  Interestingly,  on  this occasion  the  R27aS  mutation  in  B3VL  also 
enhances binding. The loss of this L chain arginine has not previously been found to 
enhance binding to any antigen (Haley et al., 2004, Rahman et al., 2001). B3VH /BUVL  
does  not bind  p2 GPI  even  at an  IgG concentration of  lO^g/ml  but it is difficult to 
reach  any firm  conclusions about the other combinations because I  could  not test 
them  at  concentrations  above  l^g/ml  (at  which  only  B3(R53S)Vh/B33Vl  showed 
binding).  In  particular,  it is impossible to tell from  Figure 5.5 whether mutation  of 
R53 to N or K would have the same effect as R53S.
If we consider Figure 5.6, it becomes clear, that the mutation R53S in B3VH  has an 
effect on  binding to DI of p2GPI, which is not shared  by R53N or R53K. This figure 
shows  binding  of  all  eight  purified  antibodies  to  DI  over  the  same  range  of 
concentrations up to a peak of l^g/ml.  Only B3(R53S)Vh/B3Vl shows any significant 
binding  to  DI  at these  concentrations.  Here,  B3(R53S)Vh/B33Vl  binds  much  less 
strongly than  B3(R53S)Vh/B3Vl  showing  that  the  B33  L  chain  does  not  enhance 
binding to DI, contrary to its effects on binding to nucleosomes and a-actinin.
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Figure 5.4 Results of anti-a-actinin ELISA
This  figure  shows  the  binding  of the eight  purified  antibodies  in  direct  ELISA  assay  to  a-actinin.  Diluted 
serum from a patient with SLE was run as a positive control.C
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Figure 5.5 Results of anti-fcGPI ELISA
This figure shows the binding of the eight  purified  antibodies in direct ELISA assay to  |32GPI.  Diluted  serum 
from a patient with APS was run as a positive control.
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Figure 5.6 Results of anti-Domain I ELISA
This figure  shows the  binding  of the eight  purified  antibodies  in  direct  ELISA assay to  DI  of  |32GPI.  Diluted 
serum from a patient with APS was run as a positive control.Chapter Five Investigation of relationship between sequence and binding of purified  B3 and variants
5.2.1.6 Results of anti-cardiolipin ELISA
Figure 5.7 shows results of the ELISA to detect binding to CL in the presence of FCS, 
containing  bovine  p2GPI.  With  the  exceptions  of  combinations  B3Vh/B3Vl  and 
B3(R53S)Vh/B33VL/ binding is either absent or weak and only present above lug/ml. 
Surprisingly, the combination B3(R53S)Vh/B3Vl did  not bind CL despite binding well 
to p2 GPI and DI at the same concentrations of IgG. In many cases human anti-p^PI 
antibodies bind CL, using p2 GPI as a cofactor. One possible explanation was that the 
strong binding of B3(R53S)Vh/B3Vl to  human  p2 GPI and  DI  is species-specific since 
there  are  11  amino  acid  differences  between  human  and  bovine  DI  of  p2GPI, 
represented in Figure 5.8. This hypothesis would predict that this combination would 
bind CL  in the presence of human  but not bovine p2GPI. Therefore,  I  replaced the 
FCS  in  the CL ELISA with  human  serum to test this hypothesis.  Figure 5.9  shows 
weak binding  of the  purified antibody  B3(R53S)Vh/B3Vl to  CL was  restored  in  the 
presence of human  serum  and was similar to that seen with a  human  monoclonal 
aPL (IS4Vh/IS4Vl).  To confirm the species-specificity still  further,  B3(R53S)VH /B3VL  
was tested for binding to bovine p2 GPI in a direct ELISA and did not bind.
5.2.1.7 Results of anti-phosphatidylseriiie ELISA
Figure 5.10 shows the results of the ELISA to detect binding to PS in the presence of 
FCS,  containing  bovine  p2GPI.  There  is  weak  binding  with  the  combination 
B3(R53S)Vh/B3Vl,  but since the ODs are very low, it is difficult to reach to any firm 
conclusions.  None of the other combinations bound PS.  However,  it can be argued 
that binding of B3(R53S)Vh/B3Vl to PS may be enhanced by replacing the FCS with 
human  serum  (since  we  have  proved  above  that  B3(R53S)Vh/B3Vl  is  species- 
specific).
5.2.2  Reproducibility of results
Figures  5.1  to  5.10  (except  Figure  5.8)  all  show  representative  ELISA  curves. To 
confirm reproducibility of the findings we tested each antibody against each antigen 
in triplicate at a fixed IgG concentration of l^g/ml. Figures 5.11 and 5.12 show these 
results with error bars (mean  +/- S.D) and confirm the different patterns of binding 
seen against different antigens. These results show that the presence or absence of 
R53  in  the VH  sequences of these eight H/L combinations has  profound effects on 
binding to  multiple clinically relevant antigens  but has different effects on different 
antigens.
229B3VH/B3VL 
— B3VH/B33VL
B3VH/B3(R27aS)VL 
— h—  B3(R53S)VH/B3VL 
B3(R53S)VH/B33VL 
— B3(R53N)VH/B3VL 
—h-B3(R53K)VH/B3VL 
  B3VH/BUVL
10  100  1000  10000 
Total whole IgG concentration (mcg/ml)
Figure 5.7 Results of anti-cardiolipin ELISA
This figure shows the binding of the eight purified  antibodies in  direct ELISA assay to CL.  Diluted  serum from 
a patient with the Antiphospholipid syndrome was run as a positive control.
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1  5  10
Human  NH2-Gly-Arg-Thr-Cys-Pro-Lys-Pro-Asp-Asp-Leu-Pro-Phe-Ser-Thr-Val
Bovine  NH2-Gly-Arg-Thr-Cys-Pro-Lys-Pro-Asp-Gly-Leu-Pro-Phe-Ser-Thr-Val
16  20  25
Human  Val-Pro-Leu-Lys-Thr-Phe-Tyr-Glu-Pro-Gly-Glu-Glu-Ile-Thr-Tyr
Bovine  Val-Pro-Leu-Lys-Arg-Thr-Tyr-Glu-Pro-Gly-Glu-Gln-Ile-Val-Phe
31  35  40
Human  Ser-Cys-Lys-Pro-Gly-Tyr-Val-Ser-Arg-Gly-Gly-Met-Arg-Lys-Phe
Bovine  Ser-Cys-®fii-Pro-Gly-Tyr-Val-Ser-Arg-Gly-Gly- Ile-Arg-Arg-Phe
46  50  55
Human  Ile-Cys-Pro-Leu-Thr-Gly-Leu-Trp-Pro-Ile-Asn-Thr-Leu-Lys-Cys-Thr
Bovine  Thr-Cys  -Pro-Leu-Thr-Gly-leu-Trp-Pro-Ile-Asn-Thr-Leu-Lys-Cys-Mei
Figure 5.8 Amino acid sequence of Domain I of human and bovine feGPI
There are  11  amino acid differences  between  the sequence of Domain  I  of human 
and  bovine p2GPI. These are highlighted  in yellow (in the case of human) and  blue 
(in the case of bovine).
231Chapter Five Investigation of relationship between sequence and binding of purified B3 and variants
0.25
0.2
E
5
3
B3(R53S)VH/B3VL
n
a
o
aPL purified 
antibody 0.1
0.05  -
10 100 1000 10000
Total whole IgG concentration (ng/ml)
Figure 5.9 Results of anti-cardiolipin ELISA in the presence of human serum
This figure shows that antibody B3(R53S)Vh/B3Vl binds CL as well as a human 
monoclonal aPL in the presence of human serum.
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Figure 5.10 Results of anti-phosphatidylserine ELISA
This figure shows the binding of the eight purified antibodies in direct ELISA assay 
to PS.  Diluted serum from a patient with APS was run as a positive control. A 
combination was not considered to bind PS if its binding curve gave an 
absorbance of less than 0,1 (at 405nm) (represented by the dotted line) for the 
concentration tested in the anti-PS ELISA.
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Figure 5.11 Summary of binding to nucleosomes and a-actinin
The  chart  represents  the  binding  of the  eight  purified  antibodies  to  nucleosomes 
(equivalent  to  a  concentration  of  lCVg/ml  dsDNA)  and  a-actinin  (20^g/ml).  All 
antibodies were tested at a concentration  of  l^g/ml  in triplicate and the error bars 
represent mean +/- S.D.
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Figure 5.12 Summary of binding to cardiolipin, fcGPI and Domain I
The chart represents the binding  of the eight purified antibodies to CL (5(Vg/ml), 
p2 GPI (lO^ig/ml) and DI  (5pg/ml). All antibodies were tested at a concentration of 
lua/ml in triplicate and the bars reoresent mean +/- S.D.
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5.3 Discussion
The results that I obtained from  ELISA using the purified antibodies show that the 
wild-type antibody B3Vh/B3Vl only binds to dsDNA when the antibody is complexed 
with a component that is present in the supernatant of transfected COS-7 cells. This 
complex dissociates  when  the  antibody  is  purified  causing  the  binding  to  be  lost. 
When  the  COS-7  cell  supernatant  is  added  back,  the  ability  to  bind  dsDNA  is 
restored.  The  same  is  true  of  B3VH/B3(R27aS)VL,  but  binding  is  weaker.  The 
combination  B3Vh/B33Vl  binds  more  strongly  to  dsDNA  with  the  addition  of  the 
supernatant.  However,  in  the case of  purified  B3Vh/B33Vl,  the  complex  does  not 
dissociate  fully  during  purification  and  when  diluted  in  SEC  buffer  alone,  this 
combination  binds  dsDNA.  This  binding  is  lost  following  treatment  with  DNase 
suggesting  that  the  component  complexed  with  B3Vh/B33Vl  is  a  bridging 
nucleoprotein,  which  is  essential  for  binding  of  this  antibody  to  dsDNA.  This 
hypothesis is based on the assumption that if only a small quantity of cofactor was 
bound  to  the  purified  SVB33,  DNase  I digestion  of  the  DNA  component  might 
dissociate the complex and prevent binding to DNA via the histone component. This 
theory is potentially  supported,  by the abrogation of the  binding of B3Vh/B33Vl to 
dsDNA by DNase I treatment. If the complexed component were dsDNA alone, then 
digestion  with  DNase I would  increase binding to dsDNA on  the  plate  rather than 
decreasing it. The results obtained after addition of the cell supernatant concur with 
the  findings  obtained  using  the transient  expression,  of  separate  H  and  L  chain 
vectors on COS-7 cells, showing the same pattern of binding (Haley et al., 2004).
This interpretation of my results, obtained using  human antibodies is very similar to 
the  arguments  of  Kramers  et al.,  (1996)  and  Guth  et al.,  (2003),  following their 
experiments  using  murine  antibodies.  Kramers  and  colleagues  showed  that 
purification  of  monoclonal  murine  antibodies  from  hybridoma  supernatant  using 
DNase and high salt conditions prior to loading on a protein A column was necessary 
to produce non-complexed antibodies. These antibodies would bind to nucleosomes 
but  not  dsDNA  whereas  if  high  salt  and  DNase  were  not  used  the  antibodies 
remained complexed to nucleosomes, and would  bind dsDNA.  Guth and colleagues 
studied antibodies 3H9 and SN5-18 derived from two different autoimmune mouse 
strains  and  obtained  similar  results.  Both  antibodies  bound  chromatin,  but  not 
histones or dsDNA, when highly purified whereas unpurified  hybridoma supernatant 
or standard Protein G preparation of 3H9 did bind dsDNA and SN5-18 supernatant or 
Protein  G  preparation  bound  histones.  When  cell  culture  supernatant from  SP2/0
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cells was added to highly purified 3H9,  its ability to bind dsDNA was restored and is 
similar to  our finding  that addition  of COS-7  supernatant  restores  binding  of the 
purified antibody B3 to DNA. The conclusion was that incomplete purification of such 
antibodies  can  lead  to the  interpretation  that they  bind  dsDNA  whereas  the true 
antigen  is nucleosomes (a complex of dsDNA,  histone 2A and histone 2B) (Guth et 
al., 2003).
There is another possible explanation of my results. Treatment with DNase may alter 
DNA in  solution  in  such a way that it acts as a  competitive  inhibitor of binding of 
antibody  to  dsDNA  on  the  plate.  When  DNase  I   is  added  to  an  incompletely 
dissociated complex of dsDNA with  B3Vh/B33Vl it may generate small fragments of 
DNA or perhaps ssDNA. These fragments may remain associated with the antibody, 
or may gain access to the combining site, and act as efficient competitors of binding 
to dsDNA.  The supernatants of the dying COS-7 cells could release other nucleases 
cleaving  the  phosphodiester  bonds  between  the  nucleotide  subunits  of  DNA. 
However, this theory does not explain why B3Vh/B3Vl and B3VH/B3(R27aS)VL  do not 
bind dsDNA in the absence of  COS-7 supernatants even in the absence of DNase I, 
but will bind it when these supernatants are added.
During electroporation of COS-7 cells, approximately 70% of the cells are believed to 
die. The supernatant collected from these cells is therefore rich in debris from dying 
cells.  Nucleosomes are part of this  material  and contain  DNA.  Nucleosomes might 
well be the cofactor from the COS-7 supernatant that binds the expressed antibodies 
and enables them to bind dsDNA in  ELISA.  For this assumption to  be correct, then 
the  purified  DNase treated antibodies should  bind  nucleosomes.  Results shown  in 
Figure 5.2 confirm this assumption. The combinations B3Vh/B3Vl,  B3VH/B3(R27aS)VL, 
and  B3Vh/B33Vl  bind  nucleosomes,  without  requiring  the  addition  of  cell 
supernatant. Guth et al., (2003) showed that arginine to serine mutations in VH  CDR3 
of SN5-18 eliminates binding to chromatin. The single arginine to serine mutation in 
B3(R27aS)VL   did  not  remove  binding  to  nucleosomes  but  reduced  it  slightly. 
Replacement of CDR2 and CDR3  of B3VL  by those of 33H11  or UK4 gave different 
effects  on  binding to  nucleosomes,  even  though  these three L chains are derived 
from the same germline gene and differ only at positions of somatic mutations (see 
Figure 5.2).  In particular, the combination  B3Vh/BUVl does not bind  nucleosomes at 
all.
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It was confusing that addition of purified nucleosomes could reconstitute the binding 
of  B3VH/B3(R27aS)VL   to  dsDNA  but  not  that  of  combinations  B3Vh/B3Vu  or 
B3Vh/B33Vl, which  bind  nucleosomes at least as well as B3VH/B3(R27aS)VL  in direct 
ELISA.  However,  it  is clear from the experiments with  B3Vh/B3(R27aS)VL  that the 
concentration  of nucleosomes  is critical  to their ability to act as a  cofactor  in the 
binding of this antibody to dsDNA.  This finding  may well  also  be the case for the 
other  two  combinations.  Perhaps  some  non-nucleosome  component  of  the 
supernatant,  such  as a  nuclease,  which  removes a  competitive  inhibitor from the 
binding site, is playing a role in promoting the binding of B3Vh/B3Vl and B3Vh/B33Vl 
to dsDNA. Alternatively, these two H/L combinations may require the presence of a 
nucleoprotein cofactor, which is not found in our nucleosome preparation, in order to 
bind dsDNA.
My  results from  the  binding  studies  described  in  this  chapter  show  that a  single 
change from arginine to serine in VH  CDR2 causes a  dramatic  shift in  the  binding 
properties  of the  human  monoclonal  IgG  antibody  B3.  Arginine  at  position  53  is 
critical for binding to dsDNA and  nucleosomes.  Changing this arginine to serine,  in 
the absence of any other change in sequence in either the H or L chain, abolishes 
binding to those two antigens but creates binding to a-actinin, whole p2 GPI and DI. 
Other groups  have  previously shown  simultaneous decreases  in  binding of human 
anti-dsDNA antbodies  to  dsDNA  and  nucleosomes  (Wellmann  et  al.,  2005)  or  to 
dsDNA and  PLs  (Cocca  et al.,  2001)  after  loss  of  particular  arginine  residues  by 
mutagenesis.  In this thesis I  have  reported  dramatic shifts of binding  in  opposite 
directions to different clinically relevant antigens caused by a single arginine to serine 
mutation and to my knowledge this finding  has not been  reported  in the literature 
thus far.
Mostoslavsky and  colleagues  studied  a  panel  of  15  monoclonal  murine anti-DNA, 
anti-histone and  anti-nucleosome antibodies  and  have  shown  that their  ability  to 
cause  nephritis  was  closely  associated  with  their  ability  to  bind  a-actinin 
(Mostoslavsky et al.,  2001). a-actinin  is an  important structural  protein  in the renal 
podocyte  and  the  theory  that  anti-a-actinin  antibodies  are  important  in  lupus 
nephritis has been supported by experiments in another murine model (Deocharan et 
al., 2002, Zhao et al., 2005) and in a clinical study (Mason et al., 2004). This thesis 
describes an analysis of the effects of somatic mutations in anti-dsDNA antibodies on
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ability to  bind  a-actinin  and  to  my  knowledge,  this  has  not  been  reported  in the 
literature thus far.
Anti-nucleosome antibodies are thought to cause glomerulonephritis by the formation 
of  nucleosome/anti-nucleosome  complexes,  which  interact  with  HS  in  the  GBM 
(Kramers et al.,  1994, van Bruggen et al.,  1997).  Wellmann et al., (2005) recently 
showed that two  somatic  mutations  in the  L chain  and  one in  the  H  chain of the 
human  monoclonal anti-dsDNA antibody 33.C9  were essential for binding to either 
dsDNA  or  nucleosomes.  In  summary,  there  is  convincing  evidence  that  anti- 
nucleosome antibodies are important in the pathogenesis of lupus nephritis and that 
somatic mutations are important in controlling affinity for nucleosomes.
Cocca  et al.,  (2001) showed that reversion  of an  arginine at  position  53  in the  H 
chain of the murine anti-dsDNA antibody 3H9 to serine reduces binding to DNA, PL, 
(3 2 GPI and apoptotic cells. They suggested that some autoantibodies are produced in 
response to autoantigens derived from apoptotic cell debris and that some somatic 
mutations could therefore enhance binding to several such antigens. Accumulation of 
further mutations might then be expected to increase the affinity of the antibody for 
one autoantigen while reducing its affinity for others.  My results could suggest that 
the wild-type B3 antibody which contains some somatic mutations (94% homology to 
the germline gene V3-23) had high affinity for nucleosomes,  but the introduction of 
the H chain  germline reversion  R53S created an antibody with  specificity and  high 
affinity  for  a-actinin  and  p2GPI.  My  experiments  showed  that  B3Vh/B3Vl  binds 
nucleosomes  at  much  lower  antibody  concentrations  than  the  concentrations  of 
B3(R53S)Vh/B3Vl required to bind a-actinin and  p2 GPI. The computer model of the 
B3/dsDNA complex  (Figure  1.5)  showing  an  interaction  between  dsDNA and  R53 
supports the idea that R53 is important in affinity maturation of the antibody (Kalsi et 
al.,  1996). Although some previous authors had  shown that an increase of arginine 
residues  in  CDRs  led  antibodies to develop first  binding to ssDNA then  binding to 
dsDNA (Li et al., 2000, Wellmann et al.,  2005),  in  my experiments none of the H/L 
chain combinations bound ssDNA.
One strength of my work compared to previous studies is that I compared the effects 
of mutations to differently charged amino acids (R53S,  R53N and  R53K).  I did this 
comparison because several authors have noted a prevalence of R, N and K residues 
at the antigen-binding sites of human and murine anti-dsDNA antibodies (Radic and
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Weigert, 1994, Winkler et al., 1992, Rahman et al., 2002). Using a different approach 
(Collis et al., 2003) reviewed the sequences of 1875 antibodies in the Kabat database 
and showed that both  R and  N,  but not K, are significantly over-represented  in the 
combining  sites  of  antibodies  that  bind  nucleotide  antigens,  in  comparison  to 
antibodies binding other types of antigen.  Lysine, like arginine, is positively charged 
and could potentially interact with  negatively charged antigens. Arginine, asparagine 
and  lysine can  all form  hydrogen  bonds with dsDNA.  Therefore, this might lead to 
the hypothesis that the R53N and R53K mutations would have less adverse effect on 
binding to dsDNA and  nucleosomes than R53S but I did not find this to be the case 
in  my  study.  It  seems  likely  that  a  property  of  arginine  apart  from  charge  or 
hydrogen bond formation  is crucial to its interaction with dsDNA.  Perhaps the length 
and  shape of the arginine  side chain  are  important.  In  contrast  R53S,  R53N  and 
R53K had very different effects on interaction with a-actinin, and DI.
The  production  of an  antibody,  B3(R53S)Vh/B3Vl  which  was  found  to  distinguish 
human from  bovine  p2 GPI  was  unexpected and  has  not previously  been  described 
according to my literature search. As shown  in  Figure 5.8, there are 11  amino acid 
differences between the sequence of DI of human and bovine p2 GPI, therefore it is 
likely  one  of these  differences  plays  a  role  in  the  specificity  of the antibody  for 
human p2 GPI.
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CHAPTER SIX.
ARGININE RESIDUES ARE IMPORTANT IN DETERMINING THE 
BINDING OF PURIFIED HUMAN MONOCLONAL ANTIBODY IS4 
TO CLINICALLY RELEVANT ANTIGENS
6.11ntroduction and aims of this chapter
In  Chapter Four, I  have shown that the sequence of IS4VH  conferred the ability to 
bind PL whilst the identity of the paired VL  was important in determining the strength 
of PL binding. Subsequently, I reported that specific arginine residues in IS4VH  CDR3 
were especially  important  in  conferring  the ability to  bind  CL,  p2 GPI  and  PS  and 
described the production of stable cell lines that provided an increase in the yield of 
IgG compared to the transient expression system. Thus, it was feasible to purify IgG 
and  remove apoptotic/necrotic debris from the supernatant. This large-scale culture 
and purification was carried out by Chemicon Europe Ltd, Hampshire, UK.
The  aims  of  the  work  described  in  this  Chapter  are  to  report  the  experiments 
performed with each purified H/L combination in ELISA assays for binding to anionic 
PL,  such  as CL and  PS,  as well  as  p2GPI and  PS-PT that have been  proposed as 
important targets in APS.  I have also tested the purified antibodies for binding to a 
neutral PL (PC) and dsDNA, which shares some structural similarities with anionic PL 
but  is  not involved  in  the  pathogenesis of APS.  PC  and  dsDNA were  included to 
determine whether the relationships between antibody sequence and binding that I 
observed were specific for clinically important antigen/antibody interactions.
6.2  Assembly of a  PL antibodies
6.2.1  Sequences of expressed antibody variable regions
The sequences of IS4, B3 and UK4 have all been described in the previous chapters. 
All three antibodies contain L chains encoded by the germline Vx gene 2a2. These L 
chains differ in nucleotide sequence only by 7% or less, as a result of their different 
patterns  of somatic mutation.  There are five Arg  residues  in  IS4VH   CDR3,  four  of
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which are surface exposed and were mutated to serine to create the mutant forms of 
IS4Vh (discussed in more detail in Chapter Four). The nomenclature of the mutant H 
chains is summarised in Table 6.1.
Heavy chain Position 96 Position 97 Position 100 Position lOOg
IS4VH R R R R
IS4VHiii R R R100S R
IS4VHiv R R R RIOOgS
IS4VHi&ii R96S R97S R R
IS4VHiii&iv R R R100S RIOOgS
IS4VHi,iii&iv R96S R R100S RIOOgS
IS4VHii,iii&iv R R97S R100S RIOOgS
IS4VHX R96S R97S R100S RIOOgS
Table 6.1 Patterns of Arginine (R) to serine (S) replacements in IS4VH CDR3
6.2.2  Stable expression  of whole  IgG  in  CHO  cells  and  purification  of 
antibody
A total of 13 H/L chain combinations were expressed in CHO cells, which contained 
wild type or mutant IS4VH .  Different amounts of IgG were obtained from each cell 
line after successive rounds of methotrexate amplification (detailed in Chapter Four). 
Human IgG was purified and quantified (as described in Chapter Five). Western blot 
analyses  of  the  purified  antibodies  confirmed  the  presence  of  a  strong  band 
consistent with whole IgG on non-reducing gels (Figure 6.1) with no free H chains.
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6.3  Characterisation  of the  binding properties  of monoclonal aPL 
by ELISA
6.3.1  Results of anti-cardiolipin ELISA
Figure 6.2 shows binding the degree of the thirteen purified antibodies to CL. Similar 
patterns of binding  were obtained  with  each  antibody from  repeated  experiments 
hence representative results from a single experiment with dilutions of antibody over 
a  wide  range  of concentrations  are  shown  in  Figure  6.2.  These  results  are  also 
confirmed  in  Figure 6.3, which  represents binding of each combination  in triplicate 
using a fixed antibody concentration of l^g/ml to prove reproducibility. The wild-type 
combination  IS4Vh/IS4Vl  bound  CL,  but  any  reduction  in  the  number  of  CDR3 
arginines abolished binding.  In contrast, replacement of the L chain of IS4 by B3VL  
(IS4Vh/B3Vl)  increased  binding  to  CL.  Since  the  binding  of  the  combination 
IS4Vh/IS4Vl was abolished  by substitution of any one of the four VH  CDR3 arginine 
residues, the effects of VH  CDR3 arginine to serine substitutions in combination with 
IS4Vh/B3Vl  on  binding  to  CL  are  more  informative.  The  combination  containing 
mutations at positions 96 and 97 (IS4VH i&ii/B3VL ) has actually increased the binding 
to  CL.  With  all  the  other  combinations,  binding  was  reduced,  but  not  always 
abolished  by different patterns of arginine to  serine substitutions,  therefore useful 
comparisons between the degrees of reduction caused  by substitutions at different 
positions  can  be  made.  Substitution  of  all  four  arginine  with  serine  residues 
(IS4Vhx/B3Vl)  abolished  binding to CL completely.  Substitution  of the arginines at 
positions  100 and  lOOg  (IS4VH iii&iv/B3VL )  reduced  binding  to  CL.  However,  in  the 
case of the triple mutants, either 96,  100 and  lOOg  (IS4VH i,iii&iv/B3VL ) or 97,  100 
and  lOOg  (IS4VH iii&iv/B3VL ),  binding  was  abolished.  The combination  IS4Vh/UK4Vl 
conferred weak binding to CL (Figure 6.2).
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Figure 6.1 Western blot showing the presence of whole IgG
Lane 1: COS-7 cell supernatant from electroporation without any plasmid DNA 
Lane 2: CHO cell supernatant from electroporation without any plasimd DNA 
Lane 3: Shows the presence of whole IgG in the COS-7 supernatant produced from 
the IS4Vh/IS4Vl combination 
Lane 4:  Shows the presence of whole IgG in the CHO supernatant produced from the 
IS4Vh/IS4Vl combination 
Lane 5: This band represents the positive control, whole IgG in the purified 
IS4Vh/IS4Vl (150-kDa)
The second  band obtained  in  lanes  1-4 is  likely to  be some form  of impurity  present 
in the cell  supernatant since this band  is not visible in the purified sample. This band 
was  visible  in  the  negative  control  lanes  1  and  2  ("no  DNA" control  supernatants), 
therefore it rules out the possibility that this band represents any free H or L chain. A 
marker was  not available for a  non-denaturing  gel  therefore the  size of the  band  is 
not known.
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Figure 6.2 Results of cardiolipin ELISA
The graph shows binding of purified IgG antibodies to CL in a direct EUSA when 
IS4Vh and variants are paired with A) native IS4VL  and B) B3VL  and UK4VL .
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Figure 6.3 Reproducibility of cardiolipin binding with purified IgG
Each purified Vh/Vl  combination was tested at lpg/ml in triplicate and error bars represent mean absorbance +/- SD.Chapter Six Arginine residues are important in determining binding of purified human  monoclonal IS4
6.3.2 Results of modified anti-CL ELISA
Purified  native  IS4Vh/IS4Vl  and  two  other  combinations  (IS4Vh/B3Vl  and 
IS4VH iii&iv/B3VL ) that bound CL in the standard  ELISA, bound equally well to CL in 
the modified ELISA (Figure 6.4). This result suggested a  lack of serum dependency 
of native IS4,  in contrast to the findings of Zhu and colleagues (Zhu  et al.,  1999) 
using IS4 hybridoma. Therefore, I examined the purified samples for the presence of 
contaminating p2 GPI by western blot. A faint band was visible on the blot consistent 
with the presence of bovine p2GPI at 54-kDa (Figure 6.5). This result indicates that 
the purification carried out was not sufficient to remove completely the bovine p2 GPI 
present in the FCS of the culture media used for growing the cell lines.
6.3.3 Results of anti-phospatidylserine ELISA
The results of the PS ELISA (Figure 6.6) are similar to the results of the binding to 
CL. This is confirmed  in  Figure 6.7 which represents binding  results to PS, of each 
combination  in triplicate using a fixed antibody concentration  of l^g/ml. The wild- 
type combination IS4Vh/IS4Vl bound  PS,  but any reduction  in the number of CDR3 
arginines paired with IS4VL  abolished binding as was the case with CL.
In  contrast,  replacement  of  the  L  chain  of  IS4  by  B3VL   (IS4Vh/B3Vl)  increased 
binding  to  PS.  Similar to  the  results  obtained  in  the  CL  ELISA,  the  combination 
containing mutations at positions 96 and 97 (IS4VH i8di/B3VL )  has actually increased 
the  binding  to  PS.  However,  substitution  of all  four  arginine with  serine  residues 
(IS4Vhx/B3Vl)  abolished  binding  to  PS  completely  (Figure  6.6).  There  is  a  minor 
difference between binding to PS and CL. IS4Vh/UK4Vl conferred weak binding to CL 
but did not bind PS.
The results shown in Figure 6.6 obtained using higher concentration of IgG available 
with  the  use  of  purified  antibodies  add  more  information  to  what  I  reported  in 
Chapter  Four using CHO cell  supernatant,  where only two combinations  bound  PS 
(IS4Vh/B3Vl and IS4VH i&ii/B3VL ).
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Figure 6.4 Results of modified anti-cardiolipin ELISA
The graph shows  binding of purified  IgG  antibodies to CL detected  by ELISA in 
the absence of  FCS,  when  IS4VH   and  variants  are  paired  with  A)  native  IS4VL  
and B) B3Vl.
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Lane 1:  Shows the presence of whole frGPI in the CHO supernatant produced from 
the IS4Vh/IS4Vl combination 
Lane 2:  Purified IS4VH i&ii/B3VL  at a concentration of lug/ml 
Lane 3:  Purified IS4Vh/IS4Vl at a concentration of l^g/ml 
Lane 4: Shows the positive control, whole human p2GPI at concentration 125ng/ml
Figure  6.5  Western  blot  showing  the  presence  of  whole  p2GPI  in  antibody 
preparations
Different antibody  preparations were  loaded  onto the gel  and  probed  for  presence 
of p2GPI to compare with control p2GPI.
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Figure 6.6 Results of phosphatidylserine ELISA
The graph shows binding of purified IgG antibodies to PS in a direct ELISA when 
IS4Vh and variants are paired with A) native IS4VL  and B) B3VL  and UK4VL .
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Figure 6.7 Reproducibility of phoshpatidylserine binding with purified IgG
Each purified Vh/Vl  combination was tested at l^g/ml in triplicate and error bars represent mean absorbance +/- S.D.Chapter Six Arginine residues are important in determining binding of purified human  monoclonal IS4
6.3.4 Results of anti-phosphatidylcholine ELISA
Figure  6.8  shows  the  binding  results  to  PC  where  the  wild-type  combination 
IS4Vh/IS4Vl did  not bind  PC.  However,  replacement of the L chain of IS4  by  B3VL  
(IS4Vh/B3Vl) created the ability to bind PC.  None of the other combinations bound 
PC.  It  seems  likely that all  four of these  residues  contribute to  PC  binding  since 
double mutations of either arginines 96 and 97 (IS4VH i&ii/B3VL ) or arginines 100 and 
lOOg (IS4VH iii8dv/B3VL ) also caused a complete loss of binding to this antigen.
6.3.5 Results of anti-phosphatidylserine-prothrombin ELISA
The results of the PS-PT ELISA (Figure 6.9) are similar to the results of the binding 
to PC.  IS4Vh/B3Vl displayed  strong  binding to PS-PT.  In fact, this combination was 
the only one to convincingly bind to PS-PT. Therefore,  it is clear that any pattern of 
arginine to serine substitutions in IS4VH  dramatically reduces binding to PS-PT.
6.3.6 Results of anti-dsDNA ELISA
dsDNA shares some structural similarities with anionic PL but is not involved in the 
pathogenesis of APS therefore I tested all combinations for binding to this antigen. 
None  of the  purified  antibodies  convincingly  bound  dsDNA  therefore  no  data  is 
shown.
2520.8
Purified antibodies at 1mcg/ml
Figure 6.8 Phosphatidylcholine binding with purified IgG
Each purified Vh/Vl  combination was tested at lpg/ml in triplicate and error bars represent mean absorbance +/- S.D.C
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Figure 6.9 Results of phosphatidylserine-prothrombin ELISA
The graph shows binding of purified IgG antibodies to PS-PT in an ELISA.Chapter Six Arginine residues are important in determining binding of purified human monoclonal IS4
6.3.7  Results of anti-fcGPI ELISA
Figure  6.10  shows  the  binding  of the  purified  antibodies  to  02 GPI.  I  found  that 
IS4Vh/IS4Vl  and  IS4Vh/B3Vl  bound  fcGPI  but  IS4Vh/UK4Vl did  not.  Although  this 
order of  binding was  similar to the results obtained  in  the PL  ELISAs,  the  results 
obtained  with the arginine to  serine substitutions are different.  When  paired  with 
IS4VLf single arginine to serine mutations at 100 or lOOg as well as double mutations 
at 96 or 97  or  100 and  lOOg  did  not abolish  binding when tested at the  maximal 
concentrations available.  The double mutants (IS4VH i8di/B3VL  and  IS4VH iii&iv/B3VL ) 
showed  similar  reductions  in  binding  to  p2 GPI  compared  to  IS4Vh/B3Vl  and  this 
binding was abolished altogether when any three or all four arginines were mutated.
The new  information obtained  with  higher concentration  of IgG available with the 
use of purified antibodies compared to the CHO supernatant results in Chapter Four, 
is  that  three  additional  combinations  bind  p2 GPI.  These  are  IS4VH iii&iv/IS4VL , 
IS4VH i&ii/B3VL  and very weak binding of IS4Vh/UK4Vl. Figure 6.11 represents binding 
results  to  p2 GPI,  of  each  combination  in  triplicate  using  a  fixed  antibody 
concentration  of  l^g/ml.  In  this figure IS4VH iii&iv/IS4VL   and  IS4Vh/UK4Vl,  do  not 
bind  p2 GPI. This finding  is explained  by the lower concentration  of  l|Ag/ml  used  in 
this experiment whereas the minimum concentration for these combinations to bind 
was 2.4 and  10pig/ml respectively in the serial dilution experiments shown in Figure 
6.10.
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Figure 6.10 Results of frGPI ELISA
The graph shows binding of purified IgG antibodies to p2GPI in a direct ELISA 
when IS4Vh and variants are paired with A) native IS4VL  and  B) B3VL  and UK4VL . 
A combination was not considered to bind (32GPI if its binding curve gave an 
absorbance of less than 0.1 (at 405nm) (represented by the dotted line) for the 
concentration tested in the anti-p2GPI ELISA.
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Figure 6.11  Reproducibility of foGPI binding with purified IgG
Each purified Vh/V l combination was tested at lpg/ml in triplicate and error bars represent mean absorbance +/- S.D.Chapter Six Arginine residues are important in determining binding of purified human  monoclonal IS4
6.3.8  Results of anti-Domain I ELISA
The  results  obtained  in  the anti-DI  ELISA,  shown  in  Figure  6.12,  differ from  the 
results obtained in the anti-p2GPI ELISA in both the Vh/Vl combinations that bind and 
their pattern of binding. Figure 6.13 also confirms that these results are reproducible 
by testing  each  combination  in  triplicate  using  a  fixed  antibody  concentration  of 
1 pig/ml. The strongest binder to  DI  is  IS4Vh/IS4Vl.  Substitution  of any of the four 
arginine with  serine  residues  in  combination  with  IS4Vl,  abolishes  binding  to  DI 
completely. IS4Vh/B3Vl binds DI  but removal of the arginines at positions 96 and 97 
(IS4VH i&ii/B3VL ) and  100 and  lOOg (IS4VH iii&iv/B3VL ) does not have a marked effect 
on the binding to DI.  From the serial dilution graph  (Figure 6.12B) the curves are 
very  similar  therefore  there  is  equal  contribution  to  the  binding  of each  of the 
combinations containing  B3VL.  This  is  also  the  case  with  the triple  mutants  (i.e. 
IS4VH i,iii&iv/B3VL  and  IS4VH ii,iii8dv/B3VX-  In  Figure  6.13,  the ODs obtained  by the 
different combinations are very similar if we take into consideration the error bars 
therefore I  conclude that there  is no  marked  difference  between the combinations 
containing  mutations  96  and  97  or  100  and  lOOg  and  the  native  IS4Vh/B3Vl. 
Furthermore,  if all  four  arginines  in  IS4VH   are  mutated,  when  paired  with  B3VL  
(IS4Vhx/B3Vl), this combination  loses its ability to bind  DI and this is clear in  both 
Figure 6.12 and 6.13.  There is a difference in what I  have seen  in the  binding to 
(3 2 GPI  compared  to  DI,  where  IS4Vh/B3Vl  was  the  strongest  binder  followed  by 
IS4Vh/IS4Vi_ .  In  the  case  of  DI,  however,  I  have  shown  the  reverse  order,  with 
IS4Vh/IS4Vl being the strongest, followed  by IS4Vh/B3Vl.  For IS4Vh/UK4Vl,  I  have 
shown that it is a weak binder to DI as was found with p2 GPI.
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Figure 6.12 Results of Domain I of p2GPI ELISA
The graph shows binding of purified IgG antibodies to DI in a direct ELISA when 
IS4Vh and variants are paired with A) native IS4VL  and B) B3VL  and UK4VL . A 
combination was not considered to bind DI if its binding curve gave an 
absorbance of less than 0.1 (at 405nm) (represented by the dotted line) for the 
concentration tested in the anti-DI ELISA.
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Purified antibodies at 1  mcg/ml
Figure 6.13 Reproducibility of binding to Domain I of fcGPI with purified IgG
Each purified Vh/Vl  combination was tested at lpg/ml in triplicate and error bars represent mean absorbance +/- S.D.Chapter Six Arginine residues are important in determining binding of purified human  monoclonal IS4
6.4  Discussion
In this Chapter, I have examined the binding of human monoclonal purified aPL to a 
variety of antigens. I found that the wild-type IS4Vh/IS4Vl antibody binds to CL, PS, 
P 2GPI  and  DI  of  P2GPI.  This  finding  is  consistent  with  the  hypothesis  that 
development  of  pathogenic  aPL  such  as  IS4  is  driven  by  an  antigen  which  is  a 
complex of anionic PL and p2 GPI. Therefore, specific amino acids within the VH  or VL  
sequences of IS4 that have been created  by somatic mutation in the germline gene 
and promote binding to anionic PL and p2GPI can be identified. My results show that 
arginine residues at positions  100 and  lOOg when changed to serine show reduced 
binding to CL, PS and p2 GPI. This effect was seen when the mutated VH  was paired 
with IS4Vl. However, binding to these antigens is dependent on the identity of the L 
chain with which it is paired. In the case of B3VU mutations at positions 96 and 97 in 
IS4VH  can  either enhance or  reduce  binding  to  CL and  PS depending  on  whether 
positions 100 and lOOg are occupied by arginine or serine.  In the case of 96 and 97 
mutations alone the binding to CL and  PS  is enhanced.  In the case of the 96,  100 
and  lOOg  mutations  binding  is  reduced  and  the  same  holds true for 97,  100 and 
lOOg.  My explanation for the  results obtained  by  mutating  arginine 96  and 97 to 
serine  is  that these  particular  arginines  are  concerned  primarily  with  binding  to 
(3 2 GPI.  It is also possible that these two arginine residues are particularly important 
in forming an interaction with IS4Vl, which itself has multiple antigen driven somatic 
mutations.  In that case,  it would  not be surprising that substitutions of arginine 96 
and 97 to serine reduce binding of IS4Vh/IS4Vl but not IS4Vh/B3VL to anionic PL. My 
results  suggest  that  it  is  possible  that  IS4VH   makes  contacts  with  PL  that  are 
separate  from  its  interaction  with  p2 GPI,  since  the  effects  of arginine  to  serine 
substitutions on binding to p2 GPI were markedly different to the effects on binding to 
the PL antigens tested.
DI of P 2GPI is thought to contain crucial antibody binding epitopes for aPL, which are 
critical to the pathogenesis of APS.  Recombinant DI  used  in  my experiments is an 
artificially  produced  antigen  made  by  my colleague Dr 3.  Ioannou  (Ioannou  et al., 
2006).  My explanation for the fact that some antibodies bind  DI better than whole 
p2 GPI  could  be  that  the  isolated  domain  has  greater  exposure  of  aPL  binding 
epitopes that are shielded  when  attached to the  rest of p2 GPI  when  bound to an 
irradiated  plate.  It  is likely that aPL bind  weakly to P 2GPI  in  solution than  in  solid
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phase because of the conformation  of the antigen.  Dr 3.  Ioannou  has also shown 
that DI inhibits the binding of IS4Vh/IS4Vl to DI.
There were two  limitations with  my experiments.  Firstly, the antibody preparations 
did  not remove p2 GPI completely, as I  have shown by Western blotting (see Figure 
6.1).  Therefore,  I  was  unable to demonstrate a  loss  of CL  binding  when  purified 
IS4Vh/IS4Vl was tested in the modified CL ELISA in the absence of FCS (see Figure 
6.4).  By carrying out more rigorous purification of IS4 from  hybridoma supernatant, 
Zhu et al., (1999) were able to remove p2 GPI and hence, demonstrate that IS4 does 
not  bind  CL  in  the  absence  of  p2 GPI.  Secondly,  the  concentration  of  purified 
antibodies available was limited and not all antibodies were available at 10yg/ml.
It is important that I have been able to show reactivity to PS with IS4, since it is now 
recognised as another clinically relevant antigen important in the pathogenesis of the 
APS, in addition to CL (Gharavi et al., 1987, Nash et al., 2004) and p2 GPI (McNally et 
al., 1995). Anti-PS antibodies have been shown to have a significant association with 
arterial thrombosis (Lopez et al.,  2004) and  studies  have also found a  relationship 
between anti-PT antibodies and clinical manifestations of the APS (Amengual et al., 
2003). Cocca et al., (2002) have shown that by introducing arginine residues into the 
Vh of a murine antibody, 3H9, which has dual specificity for PL and DNA, the binding 
to PS-p2 GPI  complexes and to apoptotic cells was enhanced.  dsDNA  is  negatively 
charged and similar to anionic PL, however, none of the  13 H/L chain combinations 
that I tested  bind to dsDNA.  This observation  shows that the effects of the CDR3 
arginine residues on binding to anionic PL are not simply due to non-specific charge 
interactions between antigen and  antibody and  suggests that dsDNA is not part of 
the  immunogenic  antigen  that  has  driven  the  accumulation  of  these  arginine 
residues.
IS4Vh/B3Vl  is  a  strong  binder to  a  number of clinically  relevant antigens  such  as 
(3 2 GPI and PT, and my prediction would be that it is likely to be pathogenic in  vivo. 
However, this combination also binds PC. I was not expecting IS4Vh/B3Vl to bind to 
the neutral  PC because this characteristic  is generally a feature of non-pathogenic 
aPL (Loizou et al.,  1990).  The  real  test of my prediction,  will  however come from 
experiments  testing  this  combination  in  biological  assays,  which  are  currently  in 
progress by my colleague Dr I. Giles. The aim is to study the variants of IS4 for their 
thrombogenic properties in an in  vivo pinch-induced thrombosis model developed by
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Pierangeli  et  al.,  (1999)  at the  Morehouse  School  of  Medicine  in  Antlanta,  USA. 
Native  IS4  isolated  from  hybridoma  cells  has  previously  been  shown  to  be 
thrombogenic (Pierangeli et al., 2000).  Pierangeli and colleagues injected groups of 
mice  either  with  monoclonal  Igs  isolated  from  patients  with  the  APS  or  with 
monoclonal Igs of the same isotype from healthy controls. A non-occlusive thrombus 
was induced in the femoral veins of experimental mice by a pinch injury (Pierangeli 
et  al.,  1999).  Igs  from  patients  with  APS  caused  a  significant  increase  in  mean 
thrombus  area  and  a  significant  delay  in  mean  thrombus  disappearance  time  as 
compared with normal controls.
Two groups have shown that germline reversion of certain somatic mutations in both 
murine  (Cocca  et  al.,  2001)  and  human  (Wellmann  et  al.,  2005)  anti-dsDNA 
antibodies reduced the ability of the antibodies to  bind  DNA and  nucleosomes but 
enhanced  their  PS  binding.  I  have also  shown  this  phenomenon  in  Chapter  Five 
where I  mutated an  arginine  residue  into the germline  serine  residue in  a  human 
mAb, B3 and abolished binding to dsDNA and nucleosomes but introduced binding to 
PL in the presence of human p2GPI. This abolition of binding was not demonstrated 
with any of the mutated IS4 antibodies however since none of the antibodies bound 
dsDNA regardless of reactivity to PS. Given that I have shown that purified native B3, 
an  anti-nucleosome  antibody,  did  not  bind  dsDNA  unless  supernatant  from 
electroporated  cells  was added,  it would  be  interesting  to examine these  purified 
recombinant aPL for binding to nucleosomes.  It is possible that IS4VH i&ii/B3VL  (with 
arginine 96 and 97 substituted to Ser), which binds well to anionic CL and  PS,  may 
also bind nucleosomes.
There have been very few reports investigating the relationship between sequence, 
structure and pathogenicity of aPL.  Pierangeli and colleagues have tested a range of 
aPL  in  in  vivo models of microcirculation  and  have shown  that there  is  no  simple 
relationship between  pathogenicity and  strength of binding to CL (Pierangeli et al, 
2000). Two of the antibodies tested, IS1 and IS2, contained identical VH  and their L 
chains differed from each other by only five amino acids (Chukwuocha et al., 2002). 
IS1VL  contained  a few  more mutations than  IS2VL  which  improved  its reactivity for 
antigen  but removed  its thrombogenic activity  (Zhu  et al.,  1999,  Pierangeli  et al., 
2000).  Lieby et al.,  (2004)  studied  5  monoclonal  aPL, all  originating from  a  single 
patient suffering from this autoimmune disease. They have found that for only one 
antibody (CIC15) its antiphospholipid activity was dependent on annexin A5, and its
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V region contained mainly 3 replacement mutations, which were in  vitro reverted to 
the germline configuration  (asparagines to  serine  in  VL CDR1), to demonstrate the 
role of these mutations in the pathogenicity of the antibody. The resulting "germline” 
antibody  reacted  with  multiple  self-antigens  and  only  partially  lost  its  reactivity 
against PLs, but it was no more dependent on annexin A5 and, more importantly was 
no more pathogenic.  Germline  reversion  caused the antibody to  lose its ability to 
induce fetal loss in BALB/c mice. In conclusion, somatic mutations affect the binding 
of antibodies and the effect on function requires further studies.
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CHAPTER SEVEN.
OVERVIEW AND IDEAS FOR FUTURE WORK
The work described in this thesis increases our understanding of the importance of 
somatic mutations and the critical effect that the precise position of arginine residues 
in  the  antigen-binding  site  may  have  on  the  binding  properties  of  anti-DNA 
antibodies  and  aPL.  Computer  models  for  the  human  mAbs,  B3  and  IS4  have 
provided  more insight about the likely positions of key arginine residues leading to 
the hypothesis that these residues are likely to contribute to the binding affinity of 
the antibodies. To investigate this hypothesis I have produced variant forms of B3VH  
and  IS4Vh  using  site-directed  mutagenesis,  and  have  shown  that arginines in  the 
CDRs play a major role in the binding properties of anti-dsDNA antibodies and aPL.
Both transient and stable expression of cloned cDNA from  human  monoclonal anti- 
DNA antibodies and aPL in the form of whole IgG molecules has been accomplished 
and  allowed me to test the properties of B3VH   and  IS4VH  variant forms.  In total  I 
have  produced  17  stable  cell  lines.  The  antibody  production  of  the  CHO  cells 
transfected  with  the  supervectors  was  higher  than  that  of  the  COS-7  cells  co­
transfected  with  separate  H  and  L  chain  vectors. The  main  advantage  of  the 
transient expression system  however, was that it allowed testing of a range of H/L 
combinations and  provided evidence as to which chains are essential in  binding to 
nucleosomes, dsDNA, CL, and faGPI.
It was vital  to express antibodies  stably in  CHO cells to  increase the volume  and 
concentration  of IgG expressed,  in  order to test these antibodies against a  wider 
variety of antigens at a higher dose than was possible with COS-7 cells. The larger 
amounts of antibodies  produced  from  CHO cells were crucial for purification.  This 
purification  could  not  be  carried  out  using  the  much  smaller  amounts  of  IgG 
produced by the transient system because during purification much Ig protein is lost, 
therefore requiring larger initial quantities of Ig. I have summarised and represented 
the binding results of all purified antibodies against all antigens in Table 7.1 and 7.2.
The  abolition  of  dsDNA  binding  by  the  purification  and  DNase  I  treatment  of 
antibodies, which had previously bound dsDNA when suspended in supernatant, and
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the subsequent reinstatement of dsDNA binding by reconstitution with supernatant, 
suggested that B3  might in fact recognise an  epitope comprising  both  dsDNA and 
histone,  such  as  nucleosomes.  To  determine  the  nature  of  the  factor  in  the 
supernatant that was required for dsDNA binding, pure nucleosomes were added to 
the purified and  DNase I  treated antibodies prior to assaying for dsDNA binding. In 
the  case  of  purified  B3VH/B3(R27aS)VL,  addition  of  nucleosomes  allowed  the 
reconstitution  of dsDNA binding.  In  light of the  lack of DNA  binding  by the  highly 
purified antibodies,  I also assessed the binding of these antibodies to nucleosomes 
on the solid-phase and confirmed anti-nucleosome activity. The additional binding of 
purified B3Vh/B33Vl to a-actinin suggests that it actually recognises a conformational 
epitope  that  allows  limited  cross-reactive  binding.  Thus  it  is  possible  that  anti- 
nucleosome and anti-dsDNA antibodies may bind more than one antigen.
The major achievement from my work however, is that I have shown dramatic shifts 
of binding in opposite directions to different clinically relevant antigens caused by a 
single arginine to serine mutation (refer to summary table 7.1).  In the combination 
B3Vh/B3Vl, an arginine in VH  CDR2 at position 53 is critical for binding to dsDNA and 
nucleosomes. Changing this arginine to serine, in the absence of any other change in 
sequence in  either the  H  or  L chain,  abolished  binding  to those two antigens  but 
created  binding to a-actinin, whole p2GPI  and  DI of whole  p2GPI.  In  addition, the 
production of an antibody [B3(R53S)Vh/B3VJ that distinguishes human from bovine 
p2 GPI  has  not  previously  been  described.  There  are  11  amino  acid  differences 
between the sequence of DI of human and bovine p2 GPI, therefore it is likely one of 
these differences plays a role in the specificity of the antibody for human p2GPI. Our 
group has expressed two variant forms of DI that specifically target these residues of 
interest, therefore it will be possible in future experiments to determine the binding 
affinity of B3(R53S)Vh/B3Vl to these variant forms of DI. Only the germline reversion 
R53S  (not  R53N  or  R53K)  enhanced  binding  to  a-actinin,  whole  p2 GPI  and  DI, 
supporting the  idea  that the  germline  sequence of the V3-23  gene  in  that  region 
promoted  low affinity  binding  to these antigens.  Since  I did  not produce  a  stably 
transfected  CHO  line  producing  the  germline  V3-23  sequence,  I  was  not able  to 
produce sufficient quantities of purified germline-encoded antibody to test its binding 
to a-actinin,  whole  p2GPI  or  DI.  However,  there  are  many  descriptions  in  the 
literature of polyreactive antibodies with H chains encoded by the unmutated V3-23 
gene [reviewed in (Giles et al., 2003)].
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Antibody dsDNA
(Figure 5.1)
Nucleosomes
(Figure 5.2)
a-actinin
(Figure 5.4)
CL
(Figure 5.7)
PS
(Figure 5.10)
fcGPI
(Figure 5.5)
DI
(Figure 5.6)
B3Vh/B3Vl +++ +++ - + - - -
B3Vh/B33Vl +++ +++ +++ - - + -
B3VH/B3(R27aS)VL ++ ++ - + - + -
B3(R53S)Vh/B3Vl - - +++ +++ - +++ +++
B3(R53S)Vh/B33Vl - - +++ + - + +
B3(R53N)Vh/B3Vl - - - - - - -
B3(R53K)Vh/B3Vl - - - - - - -
B3Vh/BUVl - - - - - - -
Table 7.1 Summary of the binding properties of the B3 variants
The presence of arginine at position 53 in B3VH  results in binding to dsDNA and nucleosomes. 
On the contrary, the presence of this arginine reduced  binding to alpha-actinin, p2 GPI and 
Domain I of 02GPI. Binding to these antigens was shown when the arginine was substituted 
to serine. (+++: indicates strong binding, ++: medium, +: weak and  denotes no binding)
Antibody CL PS PC PS-PT fcGPI DI
(Figure 6.2) (Figure 6.6) (Figure 6.8) (Figure 6.9) (Figure 6.10) (Figure 6.12)
IS4Vh /IS4Vl +++ ++ - - +++ +++
IS4VH iii/IS4VL - - - - + +
IS4VH iv/IS4VL - - - - + +
IS4VH i&ii/IS4VL - - - - - -
IS4VH iii&iv/IS4VL - - - - - -
IS4Vh x/IS4Vl - - - - - -
IS4Vh /B3Vl +++ +++ +++ +++ +++ +++
IS4VH i&ii/B3VL +++ +++ - - + ++
IS4VH iii&iv/B3VL ++ ++ - - + ++
IS4VH i,iiiSdv/B3VL - - - - - ++
IS4VH ii, iii &iv/B3VL + + - - - ++
IS4Vh x/B3Vl - - - - - -
IS4Vh/UK4Vl + - - - - +
Table 7.2 Summary of the binding properties of the IS4 variants
Arginine residues in IS4VH  substituted to serine, at positions 100 and lOOg reduced binding to 
all  antigens,  while  at  positions  96  and  97  reduced  binding  to  p2GPI  but  increased  or 
decreased binding to CL and PS (in combination with B3VL ). When paired with IS4Vl, arginine 
residues substituted to serine at positions  100 and  lOOg abolish  binding to CL and  PS but 
confer weak binding to p2GPI and DI. Only the IS4Vh/B3Vl combination bound PC and PS-PT. 
(+++: indicates strong binding, ++: medium, +: weak and  denotes no binding)Chapter Seven Conclusions and ideas for future work
The direct binding ELiSAs used in this thesis were sufficient to determine the binding 
ability of the purified antibodies tested however, may be possible in future to obtain 
more accurate information using assays such as surface plasmon resonance (SPR) or 
inhibition ELiSAs. SPR can be applied in the case of the two antibodies that did not 
show  any  binding  to  the  any  of  the  antigens  tested  [B3(R53K)Vh/B3Vl  and 
B3(R53N)Vh/B3VJ.  In  inhibition  ELiSAs,  the  affinity  of  Igs  in  a  test  sample  is 
determined  according to the amount of antigen  that  has to  be  added to the  test 
sample in order to inhibit binding to the same or another antigen coated to the plate. 
Alternatively the dissociation constant (Kd), as a measure of antibody affinity, can be 
determined  by incubation of the antibodies with varying concentrations of antigen 
prior to assaying in an ELISA with antigen on the solid-phase (Friguet et al. 1985). In 
this  system  the  concentration  of  antigen  must  be  in  great  excess  of  the 
concentration of antibody. Functional affinity of the antibodies can also be measured 
by addition of the chaotropic agent diethylamine (DEA) to inhibit the binding of low 
affinity antibodies to the antigen coated on the solid-phase (Devey et al  1988).  The 
higher the affinity of the antibodies tested, the smaller the shift in binding caused by 
the presence of DEA in the assay. The results are expressed in terms of the inhibition 
index, which is the reciprocal logio of the shift, thus a small shift in binding gives a 
high inhibition index for a  high affinity antibody.  In SPR the antibody affinity for an 
antigen is measured through the calculation of kinetic rate constants detected for the 
binding and dissociation of an antibody when  it is  passed  over a  chip coated with 
antigen.
In future, it is vital to assess the pathogenicity of these antibodies in vivo to correlate 
binding with functional effects.  For example, our group and others have studied the 
effects  of whole  IgG  secreted  from  hybridoma  or  CHO  cells  administered  intra- 
peritoneally to immunodeficient mice (Mason et al., 2005, Mostoslavsky et al., 2001, 
Zhao  et  al.,  2005,  Ehrenstein  et  al.,  1995,  Ravirajan  et  al.,  1998).  It  would  be 
interesting  to  compare the  effects  of the  nucleosome-binding  antibody  B3Vh/B3Vl 
and  the  a-actinin-binding antibody B3(R53S)Vh/B3Vl on  the  kidneys of such  mice. 
The use of murine models to study human diseases may be criticised especially since 
studying the role of human mAbs in normal, immunodeficient or autoimmune mice is 
clearly  complex.  Given  their  increased  availability,  it  would  seem reasonable  to 
consider  using  simpler  in  vitro  systems,  such  as  human  kidney  cells.  Using  a 
conditionally  immortalised  human  podocyte  line,  Coward  and  colleagues  recently 
showed that exposure to plasma from  patients with  nephrotic syndrome (including
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one with SLE) altered the distribution of intracellular proteins essential to  podocyte 
function  (Coward et al.,  2005). The podocyte is highly specialised and is especially 
interesting since several hereditary human nephrotic syndromes have been shown to 
be attributable to defects in podocyte specific genes including those for nephrin and 
podocin  (Pavenstadt  et  al.,  2003).  It  would  be  fascinating  to  see  if  the  anti- 
nucleosome and/or anti-a-actinin  IgG antibodies expressed  in this experiment have 
similar effects on those podocytes and if they can bind to other podocyte molecules 
such as nephrin and podocin, which have been implicated in other human nephrotic 
diseases. As well as the binding to the individual cells, antibody binding could also be 
assessed  in  the  human  glomerular  basement  membrane  assay  (Lefkowith  and 
Gilkeson, 1996) and the rat perfused kidney system (Raz et al.,  1989). The perfused 
rat  kidney  has  previously  been  used  to  measure  the  effect  of  both  murine  and 
human anti-DNA antibodies on induction of proteinuria (Raz et al., 1989).
Assays of the effects of monoclonal aPL on thrombosis (Pierangeli et al.,  1994) and 
pregnancy loss (Blank et al.,  1991)  in  mice  have  been  developed  and  it would  be 
possible to compare the effects of anti-p2 GPI antibodies such  as  B3(R53S)VH /B3VL  
with  antibodies that do  not bind p2 GPI  (e.g.  B3Vh/BUVl)  in  these assays.  IS4  has 
been shown to be highly thrombogenic and to enhance endothelial activation in the 
in vivo model of microcirculation (Pierangeli et al., 2000). As described in section 6.4, 
my colleague Dr I. Giles is currently looking at the effects of the IS4 variants upon 
thrombus formation and leucocyte adhesion  in this model.  In addition,  it would  be 
interesting to study the effects  of the  IS4 variants  upon  vascular EC activation  in 
vitro by examining the expression  of adhesion  molecules  (E-Selectin,  ICAM-1  and 
VCAM-1) which have all been shown to be up-regulated by native IS4 (Pierangeli et 
al., 2000)
TF  is a  major  initiator of coagulation  in  vivo  produced  from  EC  and  monocytes. 
Several studies have shown  both  in  vivo and in  vitro up-regulation of monocyte TF 
expression in patients with APS. aPL from APS patients, have been shown to enhance 
TF expression and procoagulant activity on normal monocytes (Kornberg et al., 1994, 
Reverter et al.,  1998).  Additionally, TF expression on monocytes from patients with 
PAPS  (compared  to  monocytes  from  normal  controls)  is  directly  involved  in  the 
pathogenesis of thrombotic complications (Cuadrado  et al.,  1997).  In  vitro studies 
have  also  shown  that  IgG  purified  from  patients  with  APS  increases  surface 
expression  of TF  in  normal  human  EC (Ferrara  et al.,  2004). Recent studies  have
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shown that aPL activate monocytes and EC through several signalling pathways such 
as  p38MAPK and  NF-kB. Having extensively characterised the binding  properties of 
IS4  (both  wild-type  and  mutant forms),  it would  be  very  interesting  to  study  its 
effects upon  monocyte and  EC expression and function of TF and characterise the 
signalling pathways involved.
It is therefore urgent to carry out this future work since it would help to elucidate the 
precise  role  of arginine  residues  in  the  binding  of autoantibodies  to  their target 
antigen and  provide better understanding of how  manipulation of antibody binding 
sites may affect their function. The long-term goal of this future research would  be 
to  design  a  more  effective  and  targeted  therapy  to  block  the  effects  of  these 
autoantibodies in patients with SLE and APS.
An attempt has made to re-educate the immune system with toleragenic therapies, 
by  administration  of  a  structure  which  contains oligovalent  B  cell  epitopes  on  a 
nonimmunogenic  molecular  framework,  lacking  T  cell  epitopes.  This  has  been 
developed  as  a  means  to  inactivate  pathological  B  ceils  in  an  antigen-specific 
manner. These types of agents,  developed  by  La Jolla  Pharmaceuticals,  consist of 
three or four identical antigenic constructs attached to a proprietary carrier platform 
made of nonimmunogenic polyethylene glycol (Merrill, 2004). Abetimus sodium (UP 
394,  Riquent) consists of four deoxyoligonucleotide epitopes selective for antibodies 
to dsDNA (Lorenz, 2002). Animal studies and clinical trials suggested that UP-394 is 
safe and well tolerated.  It has been shown to inhibit binding of DNA to anti-dsDNA 
antibodies and to reduce antibody producing cells in an immunised mouse model and 
in  controlled  trials  in  SLE,  it  can  reduce  circulating  anti-dsDNA  antibody  levels 
without causing generalized immunosuppression. Treatment with UP 394 in patients 
with high affinity antibodies seemed to prolong time to renal flare and decreased the 
number  of  renal  flares  (Lorenz,  2002).  Similarly,  another  polyvalent  antigenic 
structure has been developed for the treatment of stroke, deep-vein thrombosis and 
other conditions associated with antibody-mediated thrombosis. UP 1082 is aimed at 
crosslinking specific surface Ig and tolerising B cells to p2GPI (Merrill, 2004).
Toleragen studies have provided evidence of encouraging clinical benefit however it 
is  likely that they  can  cause  a  reduction  in  the average  affinity of the  remaining 
antibodies. If this type of therapeutic intervention results in elimination of a majority 
of high affinity B cells that specifically recognize an antigen, administration of a small
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peptide that targets arginine residues in autoantibodies would  be a  possible option. 
My findings have shown that in the two human monoclonal antibodies,  B3 and IS4, 
arginine  residues are  important in  binding to clinically  relevant antigens, therefore 
targeting these arginine residues with an inert epitope can be effective at modulating 
the immune response and would be expected to influence the amount and affinity of 
circulating antibody.
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